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Abstract 
In the UK, antiretroviral therapy (ART) is used during the vast majority of pregnancies 
among women living with HIV. This thesis aims to examine some of the consequences 
of antenatal ART use on women’s health during and after pregnancy.  
Initially, a linkage was developed between two well established studies, the UK 
Collaborative HIV Cohort (UK CHIC) Study and the UK and Ireland’s National Study of 
HIV in Pregnancy and Childhood (NSHPC). The resultant dataset was used to assess 
pregnancy incidence in women attending HIV clinical care at UK CHIC sites in 2000-
2009. The overall pregnancy incidence increased. The rate of increase did not 
significantly differ between ethnic groups, age groups or according to ART use.  
In women starting life-long cART at least one year after HIV diagnosis, those who had 
previously used short-course cART in pregnancy were more likely to experience viral 
rebound and interrupt their treatment compared to those who had never previously 
used ART.  
Levels of the liver enzyme alanine transaminase (ALT) were assessed in women on 
combination ART (cART). The risk of liver enzyme elevation (LEE) was higher during 
pregnancy than at other times in women who started ART during pregnancy and in 
women who conceived on ART. 
The risk of viral rebound (HIV-RNA >200 copies/ml) whilst on cART was higher in 
women who had recently had a pregnancy than in similar women who had not recently 
been pregnant. In post-pregnant women remaining on cART, the risk of viral rebound 
was higher in women who had started cART during their pregnancy than in women 
who had conceived on cART. 
The findings presented in this thesis contribute to the evidence-base for the 
management of pregnant women living with HIV and highlight the need for close 
monitoring of toxicity in pregnancy and additional drug adherence support following 
pregnancy.  
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Chapter 1 Introduction 
 
1.1 An overview of HIV  
 Global epidemiology  1.1.1
When starting this work, the most up-to-date estimates of the number of people living 
with HIV were from 2008. At that time there were an estimated 33.4 (95% confidence 
interval [CI] 31.1-35.8) million people living with HIV worldwide of whom 15.7 (CI 14.2-
17.2) million were women [1]. More recent data indicate that in 2015, there were 36.7 
(CI 34.0-39.8) million people living with HIV globally, of whom 17.8 (CI 16.4-19.5) 
million were women [1, 2]. The highest burden continues to be in Sub-Saharan Africa 
(Figure 1.1). In 2015, there were an estimated 19.1 (CI 17.7-20.5) million people living 
with HIV in Eastern and Southern Africa and 6.5 (CI 5.3-7.8) million in Western and 
Central Africa compared to 2.4 (CI 2.2-2.7) million in Western and Central Europe and 
North America [2]. 
 
Figure 1.1. The number of people estimated to be living with HIV, 2014 by World 
Health Organization (WHO) region  
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Globally, the number of new infections has decreased, with an estimated 2.1 (CI 1.8-
2.4) million new infections in 2015 [2, 3]. The number of deaths due to acquired 
immunodeficiency syndrome (AIDS) has also fallen, with an estimated 1.1 million (CI 
940,000-1.3 million) deaths in 2015, compared to 2.0 (CI 1.7-2.4) million in 2008. 
However, as transmission continues to occur, the number of individuals living with HIV 
worldwide continues to increase and as such HIV continues to have a huge impact on 
global health and economic systems [1]. Although the number of deaths from HIV/AIDS 
is likely to continue to fall, the WHO predicts that HIV/AIDS will remain one of the 
world’s leading causes of death by 2030 [4].   
Women and young people are disproportionately affected by HIV. In 2008, there were 
an estimated 370,000 new infections in children younger than 15 years, the majority 
due to mother-to-child transmission (MTCT), and most (90%) in sub-Saharan Africa [1]. 
This was less than in previous years [5] and, due to the successes of prevention 
programmes, the number of new infections among children has continued to fall, with 
an estimated 150,000 (CI 110,000-190,000) infections among children in 2015 [2]. 
Access to antiretroviral therapy (ART) in pregnancy for women living in low- and 
middle-income countries remains insufficient but has increased steadily since 2008 
from 40% to 73% in 2014, when the most recent data are available [2, 6] (Figure 1.2). 
  
Figure 1.2. Number of pregnant women living with HIV in low- and middle-income 
countries and the number and percentage of them receiving ART drugs for prevention 
of mother-to-child transmission (PMTCT) of HIV, 2000-2014 
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 HIV epidemiology in the UK 1.1.2
In the UK, the number of people living with HIV has continued to increase during the 
last decade. When starting this research, the most recent estimate available, from 
2008, was that there were 83,000 people living with HIV in the UK, 27% of whom were 
unaware of their infection [7, 8].  
More recent data from Public Health England (PHE) estimated that in 2014 there were 
103,700 (95% credible interval [Crl] 65,000-75,100) people living with HIV in the UK, 
17% of whom were unaware of their HIV status [9, 10] . In the UK (in people aged 15-
44 years old), the prevalence of HIV is estimated to be 2.3 (Crl 2.1-2.5) per 1000 
population overall, 1.7 per 1000 in women and 2.8 per 1000 in men (2014 estimate) [9]. 
The number of new HIV diagnoses in the UK has fallen from a peak in 2005 (n=7892), 
with 6151 people newly diagnosed in 2014 (Figure 1.3) [9], slightly higher than the 
number diagnosed in the previous year.  
The number of AIDS diagnoses and deaths among people living with HIV has 
remained low during the past decade, having greatly fallen since the mid-1990s when 
effective ART became available (Figure 1.3). Late diagnosis (a CD4 count of ≤350 
cells/mm3 at diagnosis) increases the risk of AIDS [11, 12] and the majority of deaths 
among individuals living with HIV are among people already immunocompromised at 
diagnosis [10]. 
The majority of HIV-positive individuals receiving HIV clinical care in the UK are on life-
long ART; 75% (45,953/60,805) in 2009, when this research was started, and 91% 
(76,462/85,489) in 2014, when the latest data were available. Among people on life-
long ART, 95% were virally suppressed [9]. 
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Figure 1.3. New HIV diagnoses, AIDS and deaths over time, 1999-2014 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: PHE, HIV New Diagnoses, Treatment and Care in the UK 2015 Report [9]. 
 
Figure 1.4. New HIV diagnoses in the UK by exposure group, 2005-2014 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: PHE, HIV New Diagnoses, Treatment and Care in the UK 2015 Report [9]. 
Adjustments are for missing information in case reporting. 
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In 2014, 40% (2490/6151) of people newly diagnosed with HIV had acquired their 
infection through heterosexual contact and 55% (n=3360) through sex between men. In 
the UK, in contrast to many other European countries, the number of people who are 
infected through sharing injecting drug equipment is very low (Figure 1.4). In 2014, 
there were 131 diagnoses in people thought to have acquired HIV through shared use 
of injecting drug equipment, representing 2% of diagnoses in that year [10].  
The number of people accessing HIV-related clinical care has steadily increased during 
the past decade. In 2014, 85,489 adults accessed HIV-related care: 57,347 men and 
28,142 women. Of these, 45% (n=38,432) were men infected via sex with other men; 
30% (n=25,459) were women infected heterosexually; 18% (n=15,383) were men 
infected heterosexually, 2% (n=1654) were people infected through shared use of 
injecting drug equipment and 2% (n=1709) were infected via MTCT (Figure 1.5) [9].  
 
Figure 1.5. Number of adults accessing HIV care in the UK by key prevention groups, 
2005-2014 
  
Source: PHE, HIV New Diagnoses, Treatment and Care in the UK 2015 Report [9]. 
MSM: men who have sex with men. Groups are not mutually exclusive, Black African and Young adults 
include all exposure categories, MSM and PWID include all ethnicities  
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 The history of HIV and AIDS 1.1.3
The first recognised AIDS cases 
HIV is thought to have entered the human population at some point between 1915 and 
1941 [13] but was not identified until the 1980s. Initially, the disease, which in 1982 
became known as AIDS, [14] was discovered after investigations into a number of rare 
illnesses in the US. Reports of Pneumocystis pneumonia (PCP) and Kaposi's sarcoma, 
among MSM in New York and California [15, 16] led epidemiologists to identify a new 
illness which impaired T-cell function, weakening the immune system. Further AIDS 
cases were soon identified in other groups including women, injecting drug users, 
haemophiliacs and infants, indicating that transmission could occur via a number of 
routes [14, 16-20]. 
In 1983 and 1984 the causative virus was isolated and named by two groups 
independently [21-23] and in 1986 the decision was made to call the virus the human 
immunodeficiency virus [24-26]. It later became called ‘HIV-1’ when, in 1986, a distinct 
strain of the virus, which was named ‘HIV-2’, was isolated in West Africa [27]. HIV-2 
infection results in a similar, but somewhat slower, disease progression than HIV-1 
infection [28].  
The origin of HIV  
Both HIV-1 and HIV-2 are thought to have originated from simian immunodeficiency 
viruses (SIVs). The HIV-1 genome is most closely related to that of the SIVcpz 
genome, which infects the chimpanzee species, Pan troglodytes troglodytes [29, 30]. 
There are three principal groups of HIV-1 identified through phylogenetic analysis: M, 
the main group which is found globally; O, an outlier group found mostly in Cameroon, 
Gabon and Equatorial Guinea; and N, a newer group found mostly in Cameroon. Each 
group is thought to have independently entered the human population via cross-
species transfer of a recombinant form of SIV probably from human contact with 
primate blood during hunting or butchering of chimpanzee meat [30-33].  
HIV-2, which is less widespread than HIV-1, is thought to have originated from SIVsmm 
which infects the West African sooty mangabey monkey (scientific name Cercocebus 
atys). HIV-2 is mostly found in West Africa but has spread to some parts of Europe and 
India [29].  
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 HIV transmission 1.1.4
HIV can be transmitted via a number of routes. In HIV-positive individuals, the virus is 
present in bodily fluids including blood, semen, vaginal fluids and breast milk. 
Transmission occurs when these fluids come into contact with a mucus membrane, 
damaged tissue or direct contact with the bloodstream. Globally, the most common 
routes of transmission are through sex, use of contaminated drug injecting 
paraphernalia, and from mother to child (vertical transmission). HIV can also be 
transmitted via contaminated blood, blood products, organs or tissues and through 
needle stick injuries.  
The risk of HIV transmission is dependent on numerous factors but primarily on the 
amount of circulating virus (the viral load) in the infected person. It is estimated that for 
every 1-log decrease in plasma viral load there is a 2.5 fold reduction in the risk of 
onward transmission [34]. The risk of transmission is higher for anal sex than for 
vaginal sex and is higher for receptive than for insertive anal sex [35-37]. Co-infection 
with a sexually transmitted infection (STI) increases the risk of sexual transmission 
[38].  
 
 The molecular structure of HIV  1.1.5
Virus structure and genome 
HIV is a type of retrovirus. The virion, the virus when it is outside a host cell, is 
approximately 100nm in diameter and spherical. Within the virus core are two copies of 
the single stranded ribonucleic acid (RNA) and the viral enzymes; reverse transcriptase 
(RT), integrase and protease (Figure 1.6) [29, 39].     
 
30 
 
Figure 1.6. The structure of the HIV virion 
 
 
Source: The Molecules of HIV – A Hypertextbook. Available at www.mcld.co.uk/hiv (Accessed May 2015).  
 
The HIV-1 genome contains at least ten overlapping genes (env, pol, gag, vif, vpr, tat, 
rev, vpu, and nef). The same area of the DNA codes for different proteins using 
staggered reading frames [29] (Figure 1.7).  
 
Figure 1.7. HIV-1 and HIV-2 genomes.  
 
 
Genes are shown in their respective reading frames and are flanked by long-terminal repeats  
Source: The Molecules of HIV – A Hypertextbook. Available at www.mcld.co.uk/hiv (accessed May 2015).  
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Infection of host cells 
The main host cell of HIV is the CD4+ helper T-lymphocyte. These cells, referred to as 
CD4 cells, form an important part of the immune system helping CD8+ T-lymphocytes 
destroy cells expressing foreign antigens and stimulating the production of antibodies 
[29]. Other cells which express CD4 antigens on their surface, including macrophages 
and dendritic cells, can also be infected by (and act as host cells to) HIV.   
Fusion of the virus with the host cell’s membrane allows the contents of the virus to 
enter the cell’s cytosol. The viral enzyme RT then transcribes the viral RNA into DNA 
which the integrase enzyme incorporates at random into the host cell’s genome. When 
the host cell transcribes its own DNA into messenger RNA (mRNA) it also transcribes 
the viral DNA. New virions bud off from the cell membrane eventually destroying the 
host cell (Figure 1.8).  
 
Figure 1.8. Overview of HIV virus replication cycle; binding to and entering the host 
cell; reverse transcription of viral RNA; integration of viral DNA into the host genome; 
and production and release of new virions 
 
Source: Wiess, 2001 [40]. 
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 The impact of HIV on the human immune system 1.1.6
Immune response to HIV infection 
A typical pattern of HIV infection starts with an acute or primary phase followed by a 
longer asymptomatic phase and finally a symptomatic phase. During the acute phase 
of infection, which lasts 2 to 12 weeks, there is initially a short period of around 10 days 
when the viral RNA is not detectable. Plasma viral load rapidly increases reaching a 
peak at 21-28 days after infection [41] before declining to a viral set point after 3-6 
months [41-44]. The number of CD4 cells in the blood falls by as much as half, 
returning to around normal levels (540-1120 cells/mm3) in the following months [45, 46] 
(Figure 1.9). 
 
Figure 1.9. The typical immune response to HIV infection  
 
Source: Pantaleo et al. 1993 [47] 
 
Seroconversion occurs within 1-3 months of infection with the body starting to produce 
detectable levels of antibodies and T-cells in response to the virus [42]. Many 
individuals experience seroconversion illness, acute ‘flu-like’ symptoms which can 
include fever, nausea, skin rashes and diarrhoea [48].  
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Enzyme-linked immunosorbent assays (ELISAs) that detect the presence of HIV 
specific antibodies can be used to detect HIV infection from around 20 days after 
exposure. ELISAs that detect viral antigens such as p24 can be effective from around 
15 days after infection and polymerase chain reaction (PCR) can be used to detect 
viral RNA from around 10 days after infection (Figure 1.10) [41].  
 
Figure 1.10. Assays used for detection of HIV infection  
 
Source: McMichael et al. 2010 [41] 
The term ‘viral load’ refers to the number of copies of HIV-RNA per millilitre (ml). A 
baseline viral load measurement is normally performed shortly after HIV diagnosis. If 
ART is not started straight away, viral load is also measured before starting ART, in 
order to inform decisions about which regimen to use, and is also monitored closely 
after ART initiation or if the regimen is changed, to assess how effective the regimen is. 
Among people who are stable on ART, viral load monitoring is performed at regular 
intervals, typically every 3-6 months.  
There are three main techniques used for measuring viral load. These are: branched-
chain DNA technique, nucleic sequence-based amplification (NASBA) and reverse 
transcriptase-PCR [49, 50]. For each technique, there are multiple commercially 
available assays on the market. Commercial RNA assays include, Roche COBAS®, 
Abbott RealTime, Seimens VersantTM and bioMerieux Nuclisens®. Although there is a 
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high correlation between the results produced by different assays on the same sample, 
there are small differences, since each assay has slightly different performance 
characteristics [51]. The correlation between assays is lower in blood/serum samples 
with lower levels of viral load. All commercially available assays can detect virus levels 
as low as 1000 copies/ml, many to as low as 40 copies/ml and some to as low as 20 
copies/ml [52, 53] 
AIDS 
The symptomless chronic phase of infection can last many years. During this time the 
number of CD4 cells are slowly depleted (Figure 1.9.). The immune system is gradually 
weakened until the body becomes vulnerable to common infections such as 
Candidiasis, and more serious opportunistic infections such as PCP. This is known as 
the symptomatic phase of infection. There are a number of infections and illnesses 
classified as AIDS defining, that is, if an HIV-positive individual is diagnosed with one 
or more, they are classified as having an AIDS event (Table 1.1). In the UK, the 
European AIDS case definition is used for adults aged 15 years and older [54, 55], and 
for children of less than 15 years old [56]. These are based on the uniform AIDS case 
definition published in 1982 [17]. In the absence of treatment, the median time from 
initial infection with HIV to AIDS is 10-11 years [46, 47, 57]. If untreated, many of these 
infections/illnesses can eventually be fatal [58]. 
Table 1.1. 1993 European AIDS surveillance case definition - list of indicator 
diseases [54, 55] 
 Bacterial infections, multiple or recurrent in a child under 13 years of age 
 Candidiasis of bronchi, trachea, or lungs 
 Candidiasis, oesophageal 
 Cervical cancer, invasive 
 Coccidioidomycosis, disseminated or extrapulmonary 
 Cryptococcosis, extrapulmonary 
 Cryptosporidiosis, intestinal with diarrhoea (> 1 month’s duration) 
 Cytomegalovirus disease (other than liver, spleen, or nodes) in a patient over one 
month of age 
 Cytomegalovirus retinitis (with loss of vision) 
 Encephalopathy, HIV-related 
 Herpes simplex: chronic ulcer(s) (>1 month’s duration); or bronchitis, 
pneumonitis, or oesophagitis in a patient over one month of age 
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 Histoplasmosis, disseminated or extrapulmonary 
 Isosporiasis, intestinal with diarrhoea (>1 month’s duration) 
 Kaposi’s sarcoma 
 Lymphoid interstitial pneumonia in a child under 13 years of age 
 Lymphoma, Burkitt’s (or equivalent term) 
 Lymphoma, immunoblastic (or equivalent term) 
 Lymphoma, primary, of brain 
 Mycobacterium avium complex, or M. kansasii, disseminated or extrapulmonary 
 Mycobacterium tuberculosis, pulmonary in an adult or adolescent (≥13 years) 
 Mycobacterium tuberculosis, extrapulmonary 
 Mycobacterium, other species or unidentified species, disseminated or 
extrapulmonary 
 Pneumocystis carinii pneumonia (PCP)  
 Pneumonia, recurrent 
 Progressive multifocal leukoencephalopathy 
 Salmonella (non-typhoid) septicaemia, recurrent 
 Toxoplasmosis of brain in a patient over one month of age 
 Wasting syndrome due to HIV 
 
 
 ART 1.1.7
There is currently no cure for HIV. The use of combination ART, first introduced in 
1995-1996, is now the main treatment strategy for HIV [59-64]. ART is very effective – 
to such an extent that in developed countries the life expectancy of individuals who are 
asymptomatic at diagnosis is now approaching that of non-infected individuals [65, 66].  
The aim of ART is to suppress viral replication for as long as possible in order to 
prevent damage to the immune system. The different classes of ART drugs target 
different stages of the HIV replication cycle. Drugs from different classes are used 
together, with regimens typically including a combination of three drugs from at least 
two drug classes. In 2014, there were 28 ART drugs (including fixed-dose 
combinations [FDC]) used in the European Union (EU) (Table 1.2) [67]. In addition to 
these, there are a number of drugs which were previously but no longer licensed for 
use.  
36 
 
Nucleoside reverse transcriptase inhibitors (NRTIs)  
Nucleotides form the building blocks of DNA. NRTIs and nucleotide reverse 
transcription inhibitors (NtRTIs) act as nucleoside/nucleotide analogues. The enzyme 
RT incorporates NRTIs into the new viral DNA chain instead of nucleotides resulting in 
chain termination, in other words, the construction of the viral DNA is halted [68, 69].  
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
NNRTIs inhibits the action of RT by binding to the enzyme near its active site. This 
changes the shape of the active site, decreasing the action of the enzyme [70, 71].  
Protease inhibitors (PIs)  
HIV-1 protease is an enzyme involved in processing of HIV polyproteins, precursors to 
the structural proteins and enzymes of the mature virion. PIs bind to the active site of 
the protease enzyme inhibiting its action [72].  
Use of a PI co-administered with low dose ritonavir, termed a ‘boosted PI’, can improve 
the effectiveness of the treatment and is frequently used in combination therapy. The 
first PI, saquinavir, was approved for use in 1995. There are now 6 PIs licensed for use 
in the EU (Table 1.2).  
Newer classes of ART drugs 
There are newer ART drug classes which target other parts of the viral replication cycle 
[71]. Integrase inhibitors (INIs) prevent insertion of the viral DNA into the host’s DNA by 
inhibiting the viral enzyme, integrase [71]. Raltegravir was the first INI licensed for use 
in the EU in 2008. Since then, two further drugs have been licenced (Table 1.2).  
Fusion inhibitors prevent the virus binding to host cells. Enfuvirtide (T-20) was the only 
drug of this type used in the EU. Due to its high cost and the need for it to be 
administered by injection it is no longer used in Europe and is used in the US only as a 
salvage therapy for people with multi-drug resistance. 
Drugs have been developed which bind to the CCR5 and CXCR4 co-receptors which 
are required for entry of the virus into the host cell. The only CCR5 inhibitor currently 
used is maraviroc, licensed in 2007.  
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Fixed-dose combinations (FDCs) 
FDCs are single tablets which contain two or more co-formulated drugs. Some FDCs 
need to be used in combination with an additional drug or drugs to make the full 
regimen. Others, referred to as single tablet regimens, contain the full regimen 
required. 
Adverse consequences of ART use 
Many ART drugs cause adverse side effects, either short-term or long term. These can 
vary from minor to life threatening and are either caused by a response of the body to 
the drug (allergic reaction or hypersensitivity) or as a direct effect of the drug on the 
body. Some side effects can be successfully treated with other drugs, such as anti-
nausea drugs or painkillers, and others with behavioural change, such as taking drugs 
just before sleep or with food. Some side effects cannot be treated and may require a 
change in regimen. Documented long-term side effects include diabetes, lipodystrophy, 
lipoatrophy (loss or gain of fat) [73], osteopenia (thinning bones), cardiovascular 
disease and myocardial infarction, [74] kidney problems and liver disease [75].  
38 
 
Table 1.2. ART drugs licensed for treatment of HIV in the EU - October 2014  
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Table 1.2 continued. ART drugs licensed for treatment of HIV in the EU - October 2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: NAM website [67]. 
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 Clinical care of people living with HIV in the UK  1.1.8
HIV treatment clinics 
The majority of HIV clinical care in the UK is provided by the National Health Service 
(NHS) specialist HIV services. NHS HIV services are open access; patients can 
choose where they attend care and can transfer between services or use multiple 
services. There are currently around 220 specialist NHS HIV services in the UK. Some 
hospitals and clinics which do not provide routine HIV clinical care provide antenatal 
care for pregnant women living with HIV and their infants.   
Starting life-long ART 
High viral load and low CD4 count are associated with increased risk of disease 
progression [76, 77] and are therefore used as surrogate markers for clinical 
progression of HIV. Both are traditionally measured as part of HIV clinical care. In the 
UK, in the absence of HIV-related illnesses, CD4 count has routinely been used as a 
guide for when to start life-long ART. In most circumstances, once treatment has been 
initiated it is then continued even when a high CD4 is achieved [78]. As the evidence 
has grown on the benefits of starting ART earlier i.e. with a higher CD4 count, the cut 
off at which ART is recommended has increased. Early BHIVA guidelines, published 
prior to 2008, recommended that treatment be started when the CD4 count was 200-
350 cells/mm3 and before it reached 200 cells/mm3 [79-83]. The guidelines published in 
2008 emphasised starting at 350 cells/mm3 (in asymptomatic patients without 
additional comorbidities) [78]. Guidelines, published in 2012, emphasised the 
importance of not delaying initiation if the CD4 count was approaching 350 cells/mm3 
[84] and the 2014 guidelines, recommended ART use for patients with a CD4 count 
>350 cells/mm3 who wanted to start treatment to minimise the risk of onward 
transmission [85]. The most recent BHIVA guidelines, when submitting this thesis, were 
the 2015 guidelines [86], and the 2015 European HIV Guidelines [87], published in 
October 2015. Both recommend that all adults living with HIV start ART irrespective of 
their CD4 count. These changes to the guidance were made in response to strong 
evidence that starting ART at a higher CD4 count benefits the health of the individual 
as well as reduces the risk of onward transmission [88-90], and even at CD4 counts 
above 500 cells/mm3, a lower CD4 count is associated with an increased risk of AIDS 
and death [91, 92]. This brought the UK and European guidance in line with the US 
(DHHS) [93] and WHO guidelines [94] which also recommend universal use of ART by 
people living with HIV.  
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ART use 
When starting this research, the first line treatment in the UK was typically a 
combination of one NNRTI with two NRTIs. An alternative to this was the use of NRTIs 
plus a ritonavir boosted PI (PI/r) or an NRTI only regimen. The 2015 British HIV 
Association (BHIVA) treatment guidelines [86], recommend the first line treatment for 
ART-naïve people living with HIV be two NRTIs plus either a PI/r, an NNRTI or an INI  
(Table 1.3).  
 
Table 1.3. Summary recommendations for choice of ART according to 2015 BHIVA 
treatment guidelines 
 
Source: BHIVA 2015 Treatment Guidelines [86] 
 
As well as the effectiveness of ART drugs, the choice of regimen is dependent on a 
number of other factors. These include clinical factors such as drug resistance 
(baseline resistance testing is undertaken before ART initiation), the presence of 
factors that may place individuals at higher risk of drug specific toxicities and the cost 
of the drugs. If adherence might be a problem then combinations that are more 
forgiving to poor adherence (such as PI-based regimens) or available as a single tablet 
regimen may be preferable. Drugs taken at night, such as efavirenz, might not be 
suitable for people who work at night.  
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 HIV drug resistance 1.1.9
Phenotypic resistance is the ability of a virus (or bacteria) to replicate in the presence 
of a drug which normally kills it. This can lead to drug failure and an increase in the 
viral load which puts the individual at risk of HIV-related disease and death [95-98]. 
Drug resistance develops due to mutations; random errors in the virus’s genetic code 
which occur during viral replication and which result in different amino acids being used 
in the viral proteins. HIV has a high replication rate and a high mutation rate – with 
approximately one mutation per virion [44, 99] as well as a high capacity for its proteins 
to function after multiple amino acid changes [71, 100]. Over time an HIV-positive 
individual will have many different viral variants (quasi species) which differ by one or 
more bases [101].  
 
 Genetic barrier to resistance 1.1.10
Different drugs have different genetic barriers to resistance. This is dependent on the 
number of mutations required to confer drug resistance. Some drugs require only a 
single mutation for the virus to have high-level resistance. This is the case for NVP 
[102] and EFV which both have a low genetic barrier [102, 103]. Other drugs require 
multiple mutations, and therefore have a higher genetic barrier [102, 104].  
 
Mutations can be classified as either primary or secondary. Primary mutations are 
inhibitor specific and may have an effect on the susceptibility to a drug/s. Secondary 
mutations occur after one or more primary mutations are already present - they may 
not change the susceptibility to a drug but instead affect viral ‘fitness’ [105], its ability to 
create successive generations [106].  
 
 Changes in viral profiles 1.1.11
Whereas many mutations have no effect on the virus or reduce its fitness, mutations 
which affect the proteins which are drug targets namely, RT, integrase, protease, and 
the glycoprotein gp41, can result in drug resistance. Mutations which confer resistance 
can result in a lower enzymatic efficiency and reduced viral fitness. The wild-type virus 
is therefore normally ‘fitter’ than a mutant strain and thus the predominant strain [106]. 
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However, in the presence of ART, the drug is less effective against the drug resistant 
strain which then has an advantage over the wild-type strain and can become the 
dominant strain [107]. The virus profile can change quickly following cessation of ART 
with the wild-type strain reverting back to become the main circulating strain as the 
resistant strain no longer has any advantage over the wild-type strain [108-111]. At this 
point the resistant strain may not be detectable using PCR. However, when ART is 
subsequently restarted, the resistant strain, which if it persists at low/undetectable 
levels in tissues, can again become the dominant strain [112].  
Because drugs within the same class all target the same part of the virus replication 
cycle, drug resistance to one ART drug can result in resistance to other drugs in the 
same class [113, 114].  
 
 Transmitted drug resistance (TDR) in the UK 1.1.12
Drug resistance strains of the virus can be passed on to an individual when they 
become infected including infants infected via MTCT [115, 116]. This is referred to as 
transmitted drug resistance (TDR) and means that people starting ART with no 
previous exposure to ART (ART naïve) still require a resistance test in order to select 
the most appropriate regimen [78].  
 
There is some evidence that there has been a decrease in the prevalence of TDR in 
the UK [117]. A study which used linked data from the UK HIV Drug Resistance 
Database (HDRD), the UK Collaborative HIV Cohort (UK CHIC) study and the UK 
Register of HIV Seroconverters showed that among ART naïve adults the prevalence 
of TDR peaked in 2002 when 16% of patients had resistance to any drug class (i.e. at 
least one mutation associated with TDR), 11% to an NRTI, 6% to an NNRTI and 5% to 
a PI. In 2004, prevalence had fallen to 9%, 4.6%, 4.4% and 2.1% for any drug class, 
NRTI, NNRTI and PIs respectively. The prevalence of resistance also decreased over 
time among recently infected individuals (who had seroconverted in the last 18 months) 
[117]. A study which linked data from the UK HDRD, UK CHIC and the Survey of 
Prevalent HIV Infections Diagnosed (SOPHID) found that 11% of people tested before 
starting ART in 2002-2009 had TDR. The prevalence of TDR declined from 16% in 
2002 to 10% in 2007 after which it plateaued (11% in 2009) (Figure 1.11). The extent to 
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which ART experienced and ART naïve individuals contribute to the onward 
transmission of drug resistant strains is unclear [118]. 
 
Figure 1.11. Prevalence of TDR in the UK over time by ART drug class, 2002-2009 
 
Bars show the 95% confidence intervals  
Source: UK Collaborative Group on HIV Drug Resistance, 2012 [119]. 
 
1.2 HIV and pregnancy 
 Vertical transmission 1.2.1
Vertical transmission, from mother to child, can occur during pregnancy (in utero), 
during labour and delivery (intrapartum) and during breastfeeding via breast milk or 
blood (postpartum) [120]. It is thought that around 15-20% of vertical transmissions 
occur during pregnancy, half during labour/delivery, and 30-40% during breastfeeding 
[121-123]. With no interventions to minimise the transmission risk, the rate of vertical 
transmission is approximately 25% to 48% in lower income settings and 13% to 32% in 
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high income settings [124]. Maternal HIV viral load is strongly associated with MTCT 
risk [125-128]. A UK study found that women with a viral load ≥10,000 copies/ml had a 
transmission rate of 9.2% compared to a rate of 0.05% in women with a viral load <50 
copies/ml [129]. There are a number of additional factors which increase the risk of 
MTCT including a low maternal CD4 count and younger gestational age of the baby at 
birth [130-133]. Factors which increase the risk of transmission via breast feeding 
include high viral load [134], low CD4 count [134], mastitis [135, 136], the presence of 
an abscess [135] and mixed feeding [137-139]. The risk of transmission is related to 
the length of exposure, but there is a higher risk in the first 3-6 months after birth [140].  
 
 Antenatal screening 1.2.2
The routine offer and recommendation of antenatal HIV testing was introduced in 
England in 1999-2000 with a target of 90% uptake and 80% of infections identified by 
the end of 2002 [141]. Similar policies were implemented in the rest of the UK in the 
following years. Following introduction of the policy, the uptake of testing swiftly 
increased [142] and is now over 97% [143].  
Current testing policy states that women should be offered an HIV test early on in their 
pregnancy or as soon as possible after they first attend antenatal care. Women who 
are initially negative but have a high risk of infection or women who initially decline a 
test should be offered testing later on in their pregnancy. The children of women who 
are diagnosed either before or during antenatal care and whose children are not known 
to be infected should also be tested [144].  
 
HIV testing is also recommended for all patients attending termination of pregnancy 
(TOP) services, genitourinary medicine (GUM) clinics, drug dependency services and 
services treating patients with tuberculosis, hepatitis B, hepatitis C and lymphoma as 
well as in primary care where the diagnosed prevalence of HIV is higher than 0.2% [8]. 
Self-test kits can now be purchased online (since April 2015).  
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 HIV prevalence in pregnant women in the UK 1.2.3
Unlinked anonymous testing of neonatal dried blood spots indicates that the overall 
prevalence of HIV (diagnosed and not diagnosed) among women giving birth in 
England and Scotland has gradually increased over time. In the areas covered by the 
study (64% of women giving birth in England and Scotland), 2.1 per 1000 women were 
living with HIV in 2008, the most recent data available when starting this research. As 
would be expected, the prevalence was higher in London than outside London (3.7 per 
1000 women vs. 1.5 per 1000 women, respectively) [8]. However, the prevalence 
among women living in London had fallen since 2003 and the prevalence among 
women living elsewhere in England and in Scotland had increased (Figure 1.12).  
 
Figure 1.12. HIV prevalence in pregnant women in England and Scotland 
 
Source: PHE, Health Protection Scotland (HPS) and the Institute for Child Health (ICH) [145] 
Available from: www.ucl.ac.uk/nshpc/slides (Accessed January 2016). 
 
 
 MTCT rates in the UK 1.2.4
The most recent data available (from March 2015) suggest that there have been in total 
at least 18,417 children born to HIV-positive mothers in the UK. The number of infants 
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known to have become infected with HIV is 222 (representing 1.3% of the 17,637 
infants born to women diagnosed with HIV before they delivered) [145]. The overall 
MTCT rate among HIV-positive women giving birth in the UK was 19.6% (8-33%) in 
1993, has fallen to around 0.3% (17/5946) (CI 0.2-0.4%) in 2010-14 [145] (Figure 
1.13). 
 
Figure 1.13. MTCT rates in diagnosed women, UK and Ireland 2000-2011 
 
Approximately 12,500 singleton births; decline in MTCT rate over time (p<0.001).  
Source: NSHPC website [145] (Accessed August 2015), derived from Townsend et al. 2014 [129]. 
 
 
 Preventing MTCT  1.2.5
Antenatal ART use 
There are a number of interventions used in the UK to minimise the risk of MTCT. ART 
use in pregnancy, and when breastfeeding, dramatically reduces the risk of MTCT by 
reducing the mother’s viral load [130, 131, 146, 147]. ART drugs have been used in 
pregnancy since 1994 when ZDV, administered during pregnancy, labour and to the 
infant for six weeks after birth, was found to reduce MTCT risk by 68% (there was an 
8% transmission rate in the intervention group compared to a 25% transmission rate in 
the placebo group) [148]. Later studies found that the use of combination ART reduced 
the MTCT rate further [127, 149] and in resource rich countries, such as the UK, the 
use of ZDV monotherapy (ZDVm) became restricted to women with a low viral load 
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who had not yet reached the CD4 threshold for life-long ART initiation [144]. Despite 
the effectiveness of ART at reducing the risk of MTCT, there is some evidence that 
vertical transmission can still occur even if the mother has an undetectable plasma viral 
load [129, 132, 147] since although there is correlation between the viral load in the 
plasma and in the genital tract, women can be infectious due to genital tract shedding 
despite viral suppression in the plasma [150].  
Because of its history of use in pregnancy, ZDV has typically been included in the 
short-term combination therapy regimen recommended for use in pregnancy. However, 
a study using the UK and Ireland National Study of HIV in Pregnancy and Childhood 
(NSHPC) data found that ZDV-sparing regimens are as effective at reducing vertical 
transmission as ZDV-containing regimens [151]. The ART regimens previously 
recommended for use in pregnancy are discussed in Section 1.2.8. 
Avoidance of breastfeeding 
In breast milk, the HIV virus is found in both the liquid phase and within white blood 
cells [139]. In the UK where formula feeding is safe and socially acceptable and 
practised by many mothers, avoidance of breastfeeding is recommended for all HIV-
positive women. Transmission rates are lower in infants exclusively breast fed than in 
infants mixed fed i.e. with breast milk and formula or solids [137-139], therefore 
exclusive breastfeeding (and the use of ART) plus weaning at 6 months is 
recommended in settings where exclusive formula feeding is not possible or well 
adhered to [152] and for women in the UK who choose to breastfeed.   
Caesarean section 
 
Studies indicate that pre-labour caesarean section (PLCS) is associated with a reduced 
risk of MTCT compared with vaginal delivery [153, 154]. In some studies this 
association was also seen in women with an undetectable viral load [131]. However, in 
a French cohort, PLCS was not associated with a reduced risk of transmission among 
women with a viral load <400 copies/mL who delivered at term [155]. Similarly, 
observational data in the UK indicates that PLCS is not associated with reduced 
transmission rates among women on HAART [129].  
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 HIV and fertility rates 1.2.6
In Europe, HIV diagnosis was previously associated with a reduced live-birth rate and 
an increased termination rate [156, 157]. However, with the introduction of ART leading 
to reduced rates of vertical transmission and improved prognosis for adults and 
children living with HIV, [59, 158] (including pregnant women [159]), the number of 
pregnancies among HIV-positive women has increased in Europe and elsewhere [157, 
160, 161]. A European study of HIV-positive women published in 2008 concluded that 
HIV infection did not influence women’s desire to have children [162]. A study of 
women living with HIV in the UK found that more than half said that their HIV diagnosis 
affected their fertility intentions, with 11% wanting children sooner [163].   
 
As well as possibly influencing people’s decisions whether and when to have children, 
HIV affects some biological mechanisms related to fertility. In men, HIV can reduce the 
quality and quantity of semen [164] and in women it may increase the risk of menstrual 
disorders [165]. There is some evidence that either the virus or the use of ART 
increases the risk of early menopause [166]. 
 
 HIV diagnosis prior to pregnancy 1.2.7
Since 2005, pregnancies in women already aware of their HIV infection (whether 
diagnosed in or outside the antenatal setting) have outnumbered pregnancies in 
women not yet diagnosed (Figure 1.14). At the same time, pregnancies in women 
already on ART began to outnumber pregnancies in women diagnosed but not yet on 
life-long ART. In recent years, three-quarters of diagnosed women were already on 
ART at conception [145].  
 
50 
 
Figure 1.14. Timing of maternal HIV diagnosis among HIV-positive pregnant women in 
UK and Ireland 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*All pregnancies reported by March 2015, regardless of outcome; reporting delay for recent years. **Other 
category is pregnancies lacking information on precise timing of diagnosis and/or ART use. Source: 
NSHPC website (Accessed January 2016) [145]. 
 
 
 Clinical management of pregnant women living with HIV in the UK 1.2.8
The clinical management of HIV-positive pregnant women in the UK has changed since 
the time when ZDVm was first recommended [167]. When starting this research the 
most recent BHIVA guidelines for the clinical management of HIV-positive pregnant 
women were published in 2008 [144]. Updated guidelines were subsequently published 
in 2012 [168] and in 2014 [169]. Current recommendations for antenatal ART, mode of 
delivery, infant treatment and feeding and drug resistance testing are summarised 
below. At the time of submission of the thesis, the BHIVA’s pregnancy specific 
guidelines had not yet been updated in line with changes to the general guidelines [86], 
however, the recommendation of universal ART use now eradicates the need for short-
term ART use in pregnancy. 
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ART use 
Women already receiving ART at time of conception are recommended to continue on 
therapy during and after the pregnancy. If they have an undetectable viral load and are 
tolerating the therapy well then they would normally continue on the same regimen, 
even if it contains efavirenz, which was previously not recommended for use in 
pregnancy. If the current regimen is failing then the regimen should be changed to an 
appropriate alternative. Women who conceive on ART are likely to be on drug 
combinations similar to those recommended for women starting therapeutic ART in 
pregnancy [85]. 
Pregnant women not yet on ART are now advised to start cART and remain on therapy 
after delivery. Until the September 2015 update to the BHIVA guidelines [86], only 
pregnant women with a CD4 count <350 cells/mm3 or co-morbidities were 
recommended to initiate therapy [78] (Table 1.4 and Table 1.5). Women with no HIV-
related symptoms and whose CD4 count was above 350 cells/mm3 were 
recommended a short-course of cART during the pregnancy to prevent MTCT. In order 
to reduce the risk of resistance it was important that when therapy was stopped after 
delivery, consideration was given to the half-life of each drug to avoid inadvertent 
monotherapy of the drug with the longest half-life [85]. 
The timing of antenatal ART initiation is a balance between limiting the ART exposure 
of the foetus, especially in the early stages of foetal development, with the urgency to 
start ART for the health of the mother and/or to ensure viral suppression is achieved as 
soon as possible and definitely before delivery.  
 
The latest available data on ART use in pregnancy when starting this thesis were from 
2006. At that time, the majority of diagnosed pregnant women used ART at some point 
during pregnancy (98%), most using combination therapy (95%) and only 4.4% using 
ZDVm [170]. Around half the women were prescribed a short-course of ART for 
PMTCT only [170].  
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Table 1.4. BHIVA 2012 guidelines for ART combinations used in pregnant and non-
pregnant people starting ART treatment for therapeutic and PMTCT reasons [84, 168].  
Reason for 
ART use 
Status Recommended combinations  Criteria  
Therapeutic  
Not 
pregnant 
First line regimens: 
Efavirenz + nucleoside backbone
1
  
Nevirapine + nucleoside backbone
1
  
PI/r
3
+ nucleoside backbone
1
 
  
- 
CD4 <250 cells/mm
3
 
- 
Therapeutic Pregnant 
In the absence of contraindications: 
Efavirenz + nucleoside backbone
2
  
Nevirapine + nucleoside backbone
2
  
PI/r
3
 + nucleoside backbone
2
 
 
- 
CD4 <250 cells/mm
3
 
- 
PMTCT only Pregnant 
PI/r
3
 + nucleoside backbone
2
 
Abacavir + lamivudine + ZDV 
ZDV monotherapy
4
 
- 
VL <100,000 copies/ml 
VL <10,000 copies/ml 
Therapeutic ART use refers here to life-long ART and PMTCT refers to the use of short-course ART               
PI/r: ritonavir boosted protease inhibitor; ZDV: zidovudine; VL: viral load. 
1
Nucleoside backbone combinations: tenofovir + emtricitabine; abacavir + lamivudine
 
2
Nucleoside backbone combinations: tenofovir + emtricitabine; abacavir + lamivudine; or ZDV + lamivudine 
3
Typically lopinavir or atazanavir  
4
Women on ZDVm are also given a ZDV infusion starting four hours before the caesarean [144] 
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Table 1.5. Changes over time in BHIVA guidance on when and which ART drugs to 
start in pregnancy  
 Year Recommendation  
Women not needing ART treatment for their own health 
When to start  2001 Not specified 
 
2005 Start in the 2
nd
 trimester 
 
2008 
 
Start by 28 weeks  
Start at 20-24 weeks for women with high VL wanting a 
vaginal delivery 
 
2012 
 
Start by 24 weeks  
Start at the beginning of 2
nd
 trimester if VL >30,000 
copies/ml or earlier if VL >100,000 copies/ml 
 
2014 No change from 2012 guidelines 
What to start 2001 ZDVm in women with VL <20,000 copies/ml 
Short-course cART considered as an alternative                     
(no regimen is specified but there is a suggestion that a PI-
based regimen such as nelfinavir could be used) 
 2005 PI-based cART  
ZDVm is alternative for women with VL <10,000 copies/ml 
willing to deliver by PLCS 
 2008 PI/r cART with ZDV + lamivudine nucleoside backbone if 
no contraindications 
ZDVm is alternative for women with VL <10,000 copies/ml 
willing to deliver by PLCS 
 2012 No change from 2008 guidelines 
 2014 No change from 2008 guidelines 
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Table 1.5 continued. Changes over time in BHIVA guidance on when and which ART 
drugs to start in pregnancy  
Women needing treatment for their own health  
When to start  2001 Not specified 
 2005 Not specified 
 2008 As soon as possible but preferably waiting until the 2
nd
  
trimester unless the woman has an opportunistic infection 
 2012 No change from 2008 guidelines  
 2014 No change from 2008 guidelines 
What to start   
 2001 As per adult treatment guidelines [80]    
The guidelines note that there are more data on the safety 
and effectiveness of ZDV than other drugs but that 
ritonavir and nevirapine have also been found to reduce 
vertical transmission risk 
 2005 As per adult treatment guidelines [82] 
Notes that stavudine plus didanosine should be avoided 
 2008 As per adult treatment guidelines [82, 171] 
 2012 As per adult treatment guidelines [84] 
The guidelines note that the first line therapy combinations 
typically used outside pregnancy (tenofovir/emtricitabine or 
abacavir/lamivudine) can be used as the nucleoside 
backbone in pregnancy instead of ZDV/lamivudine (for 
which there is most evidence) 
This is in combination with efavirenz or nevirapine (if low 
CD4 count) or a PI/r such as lopinavir, atazanavir or 
saquinavir  
 2014 As per 2012 guidelines 
PLCS: pre-labour caesarean section; VL: viral load  
Source: BHIVA guidelines for the management of pregnant women living with HIV published in 2001, 
2005, 2008, 2012 and 2014 [144, 168, 169, 172, 173]. 
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Mode of delivery 
Women on either life-long or short-course combination therapy with a viral load of <50 
copies/mL at 36 weeks can opt for a vaginal birth. Women on ZDVm are recommended 
to have a PLCS at 38 weeks. Women with a viral load >50 copies/mL at 36 weeks 
should have their treatment changed and are recommended a PLCS at 38 weeks. 
They should also be given intravenous ZDV starting four hours before the caesarean. 
In some cases the mother will also be given a single dose of NVP [144]. Women 
presenting in labour who are either known to be HIV-positive or are diagnosed in labour 
are given a combination containing NVP and intravenous ZDV [144].    
ART given to the infant 
Infants should be given ZDVm twice daily for 4 weeks or, an alternative monotherapy if 
the mother’s regimen does not include ZDV. If the mother has a detectable viral load or 
did not use ART in pregnancy then the infant is given triple therapy (PEP) for 4 weeks.    
Infant feeding  
It is recommended that in the UK where alternatives to breast feeding are accessible, 
all HIV-positive mothers avoid breastfeeding irrespective of their viral load, CD4 count 
or ART use. Formula-feeding is recommended as the alternative to breastfeeding. If 
women choose to breastfeed they should continue to use cART until one week after 
cessation. Infants should be exclusively breastfed until the weaning period and 
breastfeeding should be stopped by the end of 6 months.   
Resistance testing 
Women should have a baseline resistance test before their ART regimen is decided. 
When treatment is failing resistance testing should also be carried out to help identify a 
suitable alternative regimen [144].  
Current treatment guidelines state that women starting ART in pregnancy should have 
a resistance test prior to starting unless they present in late pregnancy - when ART 
should be started swiftly before the resistance results are returned. Women using 
short-course ART during pregnancy should also have a resistance test after ART is 
stopped [144].  
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Pregnancy outcome 
Use of cART, particularly during the start of pregnancy has, in some settings, been 
found to be associated with pre-term delivery [174] and pre-eclampsia [175]. The use 
of cART, and more specifically the use of protease inhibitor (PI)-containing regimens, 
have been associated with a lower birth weight [176, 177]. Use of NRTIs, including 
ZDV, have been associated with mitochondrial toxicity in infants exposed in utero [178, 
179], the risk being higher in infants exposed to NRTI combinations than ZDV 
monotherapy [179]. In utero exposure to triple therapy increased the risk of neutropenia 
in infants up to one month old [180] and cART can increase the risk of mothers 
developing anaemia [181].  
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Chapter 2 Literature review   
 
 
Whilst in Chapter 1 I gave an overall introduction to HIV and HIV within the context of 
pregnancy, the aim of this chapter is to give a more detailed account of our current 
understanding of the areas addressed in this research. These include the impact of 
pregnancy and ART use in pregnancy on disease progression, drug resistance, toxicity 
within pregnancy and the associations between pregnancy and HIV viral load. 
2.1 Methods 
This is a narrative review of topics addressed in the research. Literature searches were 
conducted primarily using PubMed1. The search terms used can be found in Appendix 
Ia. Key papers were searched for relevant references. Most of the relevant papers 
found were in English, since the majority of research with international relevance is 
published in English and since the search terms I used were in English. However, I 
also read a handful of relevant papers in Spanish. I was alerted to relevant papers 
being published via emails from Scopus2. Searches in Google3 were used to find grey 
literature and conference proceedings. Google scholar4 was used to find peer reviewed 
articles which were missed or could not be found in PubMed. Specific websites were 
searched for relevant grey literature including published statistics, reports and national 
and international treatment guidelines. These included the websites for the UK and 
Ireland National Study of HIV in Pregnancy and Childhood (NSHPC)5, the Health 
Protection Agency (HPA) (which became part of Public Health England [PHE] in 
2010)6, the Office for National Statistics (ONS)7, the World Health Organization 
(WHO)8, the British HIV Association (BHIVA)9, and the Royal College of Midwives10. I 
also read a number of PhD theses written by colleagues at UCL in order to find further 
references of relevance. 
                                               
1
 www.ncbi.nlm.nih.gov/pubmed 
2
 www.scopus.com 
3
 www.google.co.uk 
4
 www.google.co.uk/scholar 
5
 www.ucl.ac.uk/nshpc 
6
 www.gov.uk/government/collections/hiv-surveillance-data-and-management 
7
 www.ons.gov.uk/ons/index.html 
8
 www.who.int/en/ 
9
 www.BHIVA.org 
10
 www.rcm.org.uk 
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2.2 Pregnancy and disease progression 
Some early studies indicated that pregnancy may have a deleterious effect on HIV 
progression [182-185]. A meta-analysis of 7 studies published in 1983-1996 found a 
weak association between pregnancy and disease progression [186]. However, 
numerous studies have found no such association [187-193] (Appendix Ib: Table 1 and 
Table 2). Many of the studies which examined disease progression after pregnancy, 
including those which found an association and those which did not, had limited 
statistical power due to the small number of women included in the analysis. For 
example, a Swiss study which found no association between pregnancy and time to 
AIDS or death included only 32 pregnant women [182]. Since most were observational 
studies they were subject to the methodological limitations of observational studies i.e. 
they could not adjust for unmeasured confounders. This is particularly important within 
the context of pregnancy because women who have a pregnancy may have different 
demographic and clinical characteristics from women who do not. Many of the studies 
assessed outcomes which, certainly within the UK, are now relatively rare events 
among women living with HIV such as death, AIDS, symptomatic disease or a CD4 
count <200 cells/mm3.  
More recent studies have either found no association between pregnancy and disease 
progression [147] or a lower risk of progression to AIDS or death (hazard ratio [HR] 
0.40, 95% confidence interval [CI] 0.2-0.79) [194] in women with a pregnancy than in 
women without. Again, these differences are likely to be a result of existing differences 
in the health and immune status of women in the two groups rather than a 
consequence of the pregnancy itself. In the UK, women attending HIV related clinical 
care who are pregnant have a higher average CD4 count and lower viral load and are 
more likely to be asymptomatic than non-pregnant women [162]. Although they may 
indicate some benefit to the woman’s health in using short-course ART intended for 
PMTCT.   
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2.3 Pregnancy and CD4 count 
There is evidence that pregnancy affects cell-mediated immunity [195] but its impact on 
the immune system is not fully understood. Some studies have found that the CD4 cell 
count declines during pregnancy, returning to baseline afterwards perhaps as a 
consequence of hemodilution [147, 192, 196]. Others have reported an increase in CD4 
count at delivery [147, 185] including a study in the late 1990s in Côte d'Ivoire which found 
that the placebo group (women who did not use ART in pregnancy) had a stable CD4 cell 
count throughout pregnancy and a raised CD4 count at delivery. In this study the average 
CD4 count fell after delivery but remained above the baseline level at six months 
postpartum [197].  
 
2.4 Zidovudine (ZDV) 
ZDV, also called Azidothymidine (AZT), is a nucleoside reverse transcriptase inhibitor 
(NRTI). It was the first antiretroviral therapy licensed for the treatment of AIDS (in 1987) 
and HIV (in 1990) and remains the only ART drug licensed for use in pregnancy (in the 
third trimester). In 1994, the Paediatric AIDS Clinical Trials Group (PACTG) 076 clinical 
trial found that ZDV was safe and effective at reducing HIV mother-to-child transmission 
(MTCT) [148]. This proof of concept study found a 68% reduction in the transmission rate, 
from 23% in the placebo group to 8% in the treatment group who started ZDV between 14 
and 34 weeks gestation, and were given intravenous ZDV at delivery and whose infants 
were given oral ZDV for 6 weeks and formula fed [198]. Further studies in the late 1990s 
found further evidence that ZDV monotherapy (ZDVm) started in late pregnancy was 
effective at reducing MTCT among breastfeeding [199, 200] and non-breastfeeding 
populations [201]. Several studies found that ZDVm used for the prevention of MTCT 
(PMTCT) did not cause toxicity [148, 193, 199-201] or accelerate disease progression 
[193]; prospective reporting to the Antiretroviral Pregnancy Register (APR) indicates that in 
utero exposure to ZDVm does not increase the risk of teratogenicity (congenital 
malformations). [202].  
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With the increased evidence regarding the effectiveness of ZDV at preventing MTCT, it 
became widely used during pregnancy both as a monotherapy then as a dual therapy and 
later as part of combination antiretroviral therapy (cART) [128, 203-205]. Although ZDV is 
commonly chosen as part of the antenatal cART regimen, this choice is primarily related to 
the history of its use in pregnancy.  
British HIV Association (BHIVA) treatment guidelines for the use of ART for PMTCT have 
changed over time with the emphasis moving towards the use of cART and away from 
ZDVm (Table 2.1). Until September 2015, when ART was recommended for everyone 
living with HIV irrespective of their CD4 count [86], the use of short-term ZDVm in 
pregnancy was reserved for women not wishing to use cART who were willing to deliver by 
pre-labour Caesarean section (PLCS) and who had repeatedly low viral load (HIV RNA 
<10,000 copies/mL), and wild-type virus [144]. Its antenatal use in resource rich settings, 
such as the UK, was viewed by some as substandard compared to the use of cART [206]. 
Some studies found that use of cART reduces the risk of MTCT to a greater extent than 
ZDVm [127, 207]. However, when used in women with a high CD4 count and low viral 
load, and in combination with pre-labour caesarean section [149], ZDVm is effective at 
preventing MTCT [153] and had some advantages over cART. Not without its own risks 
[208], the use of ZDVm may have avoided some of the risks associated with antenatal use 
of cART such as the increased risk of pre-term delivery [209-213], hepatotoxicity and the 
development of drug and drug class resistance associated with the use of non-nucleoside 
reverse transcriptase inhibitors (NNRTIs). It also minimised the exposure of the developing 
fetus to potentially harmful drugs. Use of NRTIs, including ZDV, have been associated with 
mitochondrial toxicity in infants exposed in utero [178, 179], the risk being higher in infants 
exposed to NRTI combinations than ZDVm [179]. In a study in Botswana, in utero 
exposure to cART increased the risk of neutropenia in infants up to one month old, 
compared to the use of ZDVm [180].  
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Table 2.1. Summary of the changing BHIVA guidelines on the use of ZDVm during 
pregnancy for PMTCT 
Year of publication  Summary of Recommendations 
1999 [214] 
 
ZDVm is recommended for women:  
 Not requiring treatment for their own health 
 With a high CD4 count (suggested cut off >200 
cells/mm
3
) 
 Low viral load, <30,000 copies/ml 
 Delivery by elective caesarean section 
2001 [172] cART is offered as an alternative to ZDVm 
ZDVm is recommended for women: 
 Not requiring treatment for their own health 
 With a high CD4 count (suggested cut off >200 
cells/mm
3
) 
 Low viral load, <20,000 copies/ml 
 Delivery by elective caesarean section 
2005, 2008 & 2012 
[144, 168, 173] 
ZDVm is offered as a ‘valid option’ for women not wishing to use 
cART 
ZDVm can be used by women: 
 Not requiring treatment for their own health                                        
(i.e. with CD4 count >350 cells/mm
3
) 
 Low viral load, <10,000 copies/ml 
 Delivery by elective caesarean section 
 With the wild-type virus 
2015 [86] Although the pregnancy guidelines have not yet been updated, 
the recommendation for cART use by all adults living with HIV 
means that the use of ZDVm in pregnancy is no longer 
appropriate 
 
In many countries, including the UK, few women used ZDVm for PMTCT in recent years 
[215]. This was a result of an increasing proportion of women conceiving on ART, and an 
increase in the use of short-course cART among women not on ART at conception who 
had not yet reached the CD4 threshold for starting life-long ART [151].  
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In many resource-limited settings single-dose nevirapine (sd-NVP) has been widely used 
for PMTCT due to its effectiveness, low cost and ease of administration [216, 217]. 
However, a combination of sd-NVP with two NRTIs such as ZDV and lamivudine (3TC) is 
more effective at reducing the risk of MTCT and NNRTI-resistance compared to sd-NVP 
alone [218, 219]. Therefore, in 2006 the WHO recommended that, where cART was not 
available, that ZDVm be used from 28 weeks of pregnancy until seven days after delivery, 
with the addition of 3TC plus sd-NVP at delivery (WHO Option A). The availability of ZDV 
in settings where cART was not available means that some women who required 
treatment for their own health or who would have been better suited to using short-course 
cART used ZDV instead [220, 221].  
When undertaking the analysis of outcomes after use of ZDVm, the latest WHO 
guidelines, published in 2010, [152] recommended ZDVm as an alternative to cART for 
women not requiring treatment for their own health (i.e. with CD4 count ≥350 cells/mm3 
and no clinical symptoms, WHO stage 3 or 4). Those guidelines stated that ZDVm should 
be started as early as 14/40 weeks, as there is increasing evidence that starting ART 
earlier in the pregnancy decreases the risk of vertical transmission [148, 149]. As with the 
earlier guidelines, sd-NVP was recommended at delivery and with the addition of 
lamivudine (3TC) to ZDV from the time of delivery and for the next 7 days, although the 
2010 guidelines also state that sd-NVP can be omitted if ZDV is used for at least 4 weeks 
before delivery. At that time, US guidelines also offered ZDVm as an option for women not 
requiring treatment for their own health with low viral load (<1000 copies/mL) [222]. The 
equivalent European treatment guidelines did not mention ZDVm as an alternative to 
cART for PTMCT [223].   
 
2.5 Antenatal ART use  
Due to the ethical and logistical constraints of undertaking clinical trials among pregnant 
women, observational studies and prospective reporting to the Antiretroviral Pregnancy 
Register (APR) [202] are used to assess the safety of antenatal ART use for the infant and 
mother. Prospective reporting (to the APR) of congenital birth defects in babies with first-
trimester exposure to ART is used to identify ART drugs which might be teratogenic. The 
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congenital malformation rate is calculated once 200 first-trimester exposures have been 
reported. Thus it is not possible to quickly assess newer ART drugs used by few women.  
When starting this research, efavirenz was not recommended for use in pregnancy or 
among women likely to conceive as it was associated with birth defects in one animal 
study [224] and a small number of case studies had reported neural tube defects following 
first trimester exposure [225-227]. As such, treatment guidelines recommended that 
women planning a pregnancy avoid using efavirenz [144]. Efavirenz together with a 
nucleoside backbone is now the recommended first-line ART regimen in the UK and is 
therefore widely used by women. There has been little further evidence to indicate that 
efavirenz has any teratogenic effect [228] and as such it is now recommended for use by 
women starting therapeutic ART in pregnancy without additional precautions [169]. At no 
point were women who conceived whilst on efavirenz recommended to switch to an 
alternative regimen for reasons of safety [172].  
There are a number of other ART drugs which are not recommended for use during 
pregnancy due to their adverse side effects on the mother or foetus. Since 2005 the 
BHIVA guidelines have noted that stavudine and didanosine should not be used in 
pregnancy [173, 229]. The US Food and Drug Administration (FDA) issued a warning 
against these drugs in 2001 after a number of deaths from lactic acidosis were reported 
among pregnant women using these drugs in triple therapy [230-233]. These drugs are no 
longer in use [67].   
NVP is not recommended for pregnant women with a CD4 count >250 cells/μl [144, 229] 
due to the risk of hepatotoxicity [234, 235]. Raised liver enzymes have been observed in 
women on NVP-containing regimens, with Grade 3-4 liver enzyme elevation (LEE) 
occurring in 0.5-9% [236-241] with 3-29% requiring a treatment change as a result of 
toxicity [236, 242, 243] (Appendix Ib: Table 5). A number of deaths among pregnant 
women have been reported as a result of Stevens-Johnson syndrome, a hypersensitivity 
reaction to NVP [237]. 
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2.6 Antenatal ART use and disease progression  
Studies in non-pregnant people living with HIV assessing the merits of structured ART 
interruption and re-initiation, based on specific CD4 thresholds, have found that ART 
treatment interruptions significantly increased the risk of morbidity and mortality. As such, 
this strategy is not recommended [244-246]. Postpartum cessation of short-course ART 
used during pregnancy for PMTCT could be seen as a type of treatment interruption, since 
women who stop ART postpartum will subsequently restart ART, either for their own health 
or for PMTCT in a subsequent pregnancy. 
Few studies have assessed the impact of short-course ART use in pregnancy on the 
mother’s health (Appendix Ib: Table 2). However, randomised control trials (RCTs) 
comparing the effectiveness of two short-course regimens used in pregnancy have 
generally observed low rates of disease progression following pregnancy [247, 248]. An 
early study which randomised HIV-positive women (with CD4 >200 cells/mm3 and low viral 
load) to receive either ZDVm or placebo treatment in pregnancy found that CD4 count and 
viral load did not significantly differ between the groups at 6 months post-partum. Neither 
was there a significant difference in the rate of disease progression (from asymptomatic to 
symptomatic disease) or in the time to AIDS/death between the groups [193] indicating 
that the use of short-course ZDVm during pregnancy was neither beneficial nor detrimental 
to the women’s health compared to no ART use. A number of studies have found that 
women who remained on treatment after pregnancy have better outcomes [249-253], 
lower rates of loss to follow-up [254] and better infant survival [253] than women who used 
short-course ART (Appendix Ib: Table 2). However, these were small observational 
studies and some included women in the short-course ART group with CD4 counts below 
350 cells/mm3 [254, 255]. As yet, there are no results from RCTs assessing the benefits 
remaining on ART after pregnancy in women with a high CD4 count.  
 
2.7 Drug resistance among women with a pregnancy  
ART drug resistance in pregnant women could increase the risk of vertical transmission 
[256, 257] as well as compromise the woman’s future treatment options. One study linked 
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data from the NSHPC, the Survey of Prevalent HIV Infections Diagnosed (SOPHID) and 
the UK HDRD to examine the prevalence of transmitted drug resistance (TDR) in ART 
naïve women diagnosed with HIV in pregnancy. They found that in 2000-2013 5.2% had 
TDR increasing to 10.1% in 2012-2013 (when the most recent data were available) (Figure 
2.1). However, only half the women in the NSHPC had a resistance test result in the UK 
HDRD. Factors associated with having a resistance test were having had at least one 
pregnancy, being diagnosed more recently (in 2010-2013 compared to earlier years), 
attending antenatal care in London and being born in the UK/rest of Europe compared to 
elsewhere [258].   
 
Figure 2.1. TDR in women diagnosed with HIV during pregnancy in the UK 
1. TDR by drug 
class 
Woman’s year of HIV diagnosis (n=1032) 
2000-
03 
2004-
05 
2006-
07 
2008-
09 
2010-
2011 
2012-
2013 
Total P 
value 
Any resistance 3.4% 7.3% 2.4% 5.2% 5.4% 10.1% 5.2% <0.01 
Any NRTI 
resistance 
1.1% 2.6% 0.8% 2.1% 2.0% 4.5% 1.9% 0.18 
Any NNRTI 
resistance 
1.1% 3.9% 1.3% 1.7% 4.4% 6.3% 2.8% 0.02 
Any PI resistance 1.1% 1.7% 0.8% 1.7% 0.5% 1.8% 1.2% 0.65 
Number of 
women with a RT 
88 234 375 291 203 111 1302  
This table includes women diagnosed during their index pregnancy, classified as ‘ART naïve’ on the resistance 
test request, with a resistance test performed during pregnancy. RT: resistance test; TDR: transmitted drug 
resistance. Adapted from : Byrne et al. 2015 [258].  
 
ZDV resistance 
Several point mutations in pol, the gene which codes for reverse transcriptase (RT), confer 
resistance to ZDV (Figure 2.2). Shortly after ZDV was first used for the treatment of AIDS 
and HIV infection, resistance to the drug was identified in individuals with AIDS. Four 
amino acid substitutions in the RT protein were initially identified as important for 
conferring ZDV resistance at codons 67, 70, 215 and 219 [103, 259] (Figure 2.2). Other 
important mutations have since been identified at codons 41 and 210 [260-262]. A single 
mutation at codon 70 or 215 confers some resistance, but single mutations at either codon 
67 or 219 do not [263]. Development of a mutation at codon 70 alone does not have a 
great impact on phenotypic resistance, although it may be associated with a rise in viral 
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load. Development of a mutation at codon 215 then at 41 is associated with high level 
resistance and increased viral load. Mutation at codon 215 is the most common mutation 
leading to ZDV resistance and occurs prior to mutations at the other codons (although 
mutation at codon 70 appears first it quickly reverts to wild-type) [264]. 
 
Figure 2.2. Mutations in the RT gene associated with resistance to ZDV  
 
 
 
 
Source: Johnson et al. 2008 [265]. 
Unlike resistance to NVP or 3TC which requires a single mutation, resistance to ZDV 
requires multiple sequential mutations. As such, the development of resistance to ZDV 
following short-term ZDVm for PMTCT is uncommon [193, 197, 266, 267]. However use of 
ZDV does not completely suppress viral replication and so there were initially concerns 
that used as a monotherapy it might result in ZDV resistance. Some early studies found 
that this was the case in 9.6% (6/62) [268], 17% (38/220) [269], 24% (34/142) [256] and 
25% (4/16) [270] of women who used short-course ZDVm in pregnancy. However, in these 
studies many women had advanced disease and would therefore not meet clinical criteria 
for ZDVm use in other settings in more recent years [169, 214]. A postpartum follow-up 
study to an RCT of ZDVm use in pregnancy (among HIV-positive women with CD4>200 
cells/L and with a low viral load), found no significant difference in the proportion of 
women with ZDV resistance between the treatment and placebo groups [193]. Since 1998, 
cART has been recommended for women with advanced disease and current treatment 
guidelines recommend the use of ZDVm only for pregnant asymptomatic women with CD4 
count >350 cells/mm3 and repeated viral RNA <10,000 copies/mL [144]. A comparison of 
women given ZDVm in pregnancy before and after 1998 found that a higher proportion of 
women treated before 1998 developed genotypic resistance than women treated after 
1998 (10.5% [2/19] vs. 0% [0/21] respectively, p=0.22) [267]. In a further analysis of this 
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cohort, no ZDV resistant minority strains were detected [266]. In studies of pregnant 
women with CD4 counts >200 cells/l who used ZDVm, no women developed genotypic 
resistance [197, 266, 271] but a small proportion (2.5%; 1/39) had low-level resistance 
(K70R mutation) after delivery [271].  
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ART drug resistance following short-course ART in pregnancy  
The use of sd-NVP administered at labour results in NVP resistance in 15-65% of women 
[109, 272-274]. The HIVNET 012 study found that among drug naïve women given sd-
NVP for PMTCT, 19% (21/111) developed NVP resistance [109]. Although sd-NVP is not 
used in pregnancy in the UK, a large proportion of HIV-positive pregnant women attending 
antenatal care in the UK were born elsewhere, so could have received sd-NVP as part of 
antenatal care received outside the UK.  
Genotypic resistance to NVP has been also reported following the use of short-course 
NVP-containing cART in pregnancy [275, 276]. A study in Ireland found that 5/39 (13%) 
women given short-course NVP-containing triple ART in pregnancy had drug resistant 
mutations shortly after cessation of ART. Four of the five women had also been tested for 
resistance prior to the pregnancy and had no evidence of resistance at that time [275]. A 
study in the US reported resistance mutations in 4/21 (19%) pregnant women who had 
used NVP-based short-course cART in a previous pregnancy [276]. Although it is possible 
this was TDR since these women were not tested for resistance prior to their first 
pregnancy. 
Contrary to the findings of these studies an Argentinian study of 20 women who used 
short-course ART in pregnancy found that when NVP was used in combination with ZDV 
and 3TC it did not select for resistant mutations (at 1-15 months after ART cessation) 
among NVP naïve women [277]. A study in Brazil of asymptomatic or mildly symptomatic 
women with a CD4 count >250 cells/mm3 who took short-course cART in pregnancy found 
that none of the six women who used a NVP-containing regimen developed NVP 
resistance mutations but 24% (4/17) of the women who had taken a nelfinavir (NFV)-
containing regimen had NFV resistant mutations at 24 weeks after ART cessation [278]. 
 
2.8 Treatment outcomes following short-course ART in pregnancy 
A number of studies have looked at response to ART treatment following exposure to sd-
NVP in pregnancy (Appendix Ib: Table 3). A Thai study found that women who used sd-
NVP in pregnancy were more likely to have detectable viral load after 6 months on 
treatment (subsequently started) than women who used ZDVm in pregnancy [274]. In 
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other studies, the use of sd-NVP at delivery was not associated with CD4 response once 
therapy was subsequently started [274, 279]. A Zambian study published in 2010, found 
that in women on therapeutic ART, those with previous exposure to sd-NVP had better 
survival rates than women with no previous ART use.  
The interval between sd-NVP exposure and treatment initiation is important; there appears 
to be an association between sd-NVP exposure and virological failure if the interval is <12 
months but not if the interval is >12 months [279-283]. These differences are a result of the 
decline in the resistant strains during the 6 to 12 months after NVP exposure [109, 284] 
although resistant strains may persist in minority viral populations [285]. 
Fewer studies have examined response to treatment following antenatal use of short-
course cART. A study from the US, Brazil and Peru looked at the outcomes of women 
starting therapeutic ART (efavirenz plus tenofovir and emtricitabine) at least 24 weeks 
after using cART in pregnancy. None of the factors examined were associated with 
virological response and only poor drug adherence was associated with viral rebound 
[286] (Appendix Ib: Table 4). 
 
2.9 Hepatotoxicity and pregnancy 
Drug-related hepatotoxicity can be defined as ‘injury to the liver that is associated with 
impaired liver function caused by exposure to a drug’ [287]. The severity of hepatotoxicity 
varies. Severe ART induced hepatotoxicity is rare, but it can be fatal [236, 288, 289]. Liver 
related conditions are now one of the most common reasons for non-AIDS related deaths 
among individuals living with HIV in Europe [290]. Unlike some other side-effects of using 
ART there are no medications which can be taken to alleviate toxicity. If it is severe then 
the drug regimen must be switched to an alternative regimen, something which could have 
implications on the woman’s future treatment options and, if the woman is pregnant, on the 
risk of MTCT [291].  
Although all ART drugs have been associated with hepatotoxicity [69, 292] the 
mechanisms by which they cause toxicity are not clear and vary according to drug type. 
NRTIs can cause mitochondrial toxicity, this is particularly the case with zalcitabine, 
didanosine and stavudine, which are no longer used, but less so with abacavir and 
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tenofovir, which are still used [293]. Although mild lactate elevation is common with these 
drugs, occurring in 10-40% of patients, severe liver damage is rare [294]. NNRTIs can 
cause a hypersensitivity reaction, a consequence of the immune system over-reacting to 
the presence of the drug, resulting in LEE. Around 10-15% of patients using NVP develop 
any LEE and 1-5% develop severe LEE [295]. The risk of NVP-induced hepatotoxicity is 
higher in women and at higher CD4 counts, most notably >250 cells/mm3 in women and 
>400 cells/mm3 in men [236]. Efavirenz can also cause liver toxicity, but it occurs less 
frequently than in those receiving NVP [296, 297]. 
Although PIs do not cause liver toxicity to the same extent as NNRTIs they can reduce the 
clearance of other hepatotoxic drugs. Among patients taking Kaletra (ritonavir-boosted 
lopinavir) rates of severe liver toxicity are around 2-10% [298-300]. 
There are a number of factors predictive of ART-induced hepatotoxicity. Studies have 
identified female gender as an independent predictor of hepatotoxicity [301-305]. A study 
in Uganda found that male gender predicted hepatotoxicity, but this could be due to 
confounders such as alcohol consumption [306]. Whereas some studies have seen older 
age associated with an increased risk [305, 307] a study of patients using ritonavir-boosted 
lopinavir found that there was a decreased risk with older age [299]. Other factors 
associated with hepatotoxicity include: ethnicity [308]; concurrent drug treatment, for 
example for TB [309] or hepatitis C (HCV) [310]; certain types of human leucocyte 
antigens (HLA) [311, 312]; higher baseline viral load (>100,000 copies/mL) [300, 313]; a 
higher CD4 count [288, 314, 315]; pregnancy [316, 317]; increased duration of ART 
exposure [295]; and recent ART initiation [302].  
Some studies have found that higher baseline levels of hepatic markers, such as alanine 
transaminase (ALT) and aspartate transaminase (AST), are associated with a higher risk 
of hepatotoxicity [305], including studies which measured hepatotoxicity based on a rise 
from baseline ALT [295, 299]. This is presumably because raised levels of these enzymes 
at baseline indicate some pre-existing hepatopathy. 
The interaction between these risk factors is not fully understood and their impact on ART-
induced hepatotoxicity may differ greatly according to which ART drugs are being used. 
There are many other factors which, in the absence of ART, can affect hepatic function 
(and therefore levels of liver enzymes in the blood) including pregnancy (as discussed in a 
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later section), alcohol consumption [313], body mass index (BMI) [313] and the use of 
other medicinal or recreational drugs. Hepatitis B (HBV) and hepatitis C (HCV) are 
important risk factors for hepatopathy among the HIV-positive population. In many cases 
of ART-induced hepatotoxicity the person also has additional risk factors for liver disease 
as well as ART use [237, 302, 303, 307, 314, 318].  
HIV may itself be harmful to the liver [319], since the replication of virus in Kupffer cells 
and other liver cells could cause inflammation. This may explain why toxicity biomarkers 
can fall after ART initiation [306]. 
The level of ART induced hepatotoxicity varies between settings and appears higher in 
resource rich compared to resource limited settings [239, 241, 243, 275, 306, 320, 321]. 
This probably reflects the different characteristics of HIV-positive individuals in these 
settings including ethnicity, the prevalence of HBV/HCV co-infection, average CD4 count 
as well as the different types of ART drugs being used [321].  
Measuring hepatotoxicity 
There are a number of tests used to assess the health of the liver. The least costly and 
least intrusive method is liver function tests (LFTs) which measure the concentration of 
liver enzymes in the blood serum including bilirubin, albumin, GGT (ɣ-glutamyl transferase) 
and transferases such as ALT and AST. ALT is an enzyme found in liver cells and is an 
important catalyst in the alanine cycle. Injury to the liver as a result of disease, infection or 
toxicity can result in the release of this protein into the blood stream, raising serum levels 
to above the normal range. Abnormal levels of ALT, as well as other liver enzymes are 
therefore used in clinical practice as clinical markers to indicate hepatopathy [305] 
including hepatotoxicity but are not a direct test for toxicity. Fibroscan, ultrasound scans 
and liver biopsy are also used to assess liver disease. These are useful tools for assessing 
more advanced hepatopathy but since biopsy is invasive and scans more expensive, they 
are not used for routine monitoring of liver function. Fibroscan, a type of ultrasound, is 
contraindicated during pregnancy [169].  
At present there is no standard used for assessing hepatotoxicity. Most studies 
investigating ART-induced hepatotoxicity use the AIDS Clinical Trial Group criteria [322] 
which grades adverse events on a scale of 1-4, where 1 is mild and 4 is life-threatening. 
LEE is graded according to ALT or AST levels (Table 2.2). Some hepatotoxicity studies 
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consider ALT levels above a grade 3 as their cut off [288, 316, 318, 323], while others use 
grades 1-4 to indicate ‘any LEE’ and grades 3-4 to indicate ‘severe LEE’ [324, 325]. 
Increasingly, studies adapt these grades and measure an increase in ALT from baseline 
[305, 326]. The upper limit of normal (ULN) also varies between settings and laboratories 
[327], as does how the ULN is derived. Few articles state the ULN, but where the ULN is 
stated it is typically between 30 and 45 International Units (IU) [302, 303, 307, 318, 326]. 
The US National Institute of Diabetes and Digestive and Kidney Diseases suggest that the 
use of a common reference is reasonable, particularly when using data from multiple 
centres; they state 40 U/L as the default ULN for ALT [328]. A rule of thumb used in clinical 
drug safety tests, referred to as Hy’s law, classifies a drug as high risk for fatal drug-
induced liver injury if, in the subjects being tested, it results in a 3-fold increase in ALT or 
AST above the ULN compared to the placebo or control drug and, among people with a 3-
fold increase and no pre-existing liver disease or hepatitis A, B or C infection, some also 
have a 2-fold increase above the ULN in serum total bilirubin [329].  
 
Table 2.2. Grading for severity of liver test abnormalities (ALT levels only) using multiples 
of the  upper limit of normal (ULN), as specified by the AIDS Clinical Trials Group, and 
converted to ALT ranges if 40 IU/L is used for the ULN [322] 
 Grade 1 Grade 2 Grade 3 Grade 4 
Description Mild Moderate Severe 
Life 
threatening 
Criteria  1.25-2.5 x ULN >2.5-5.0 x ULN >5.0-10 x ULN >10 x ULN 
ALT (IU/L) if  
ULN is 40 IU/L 
50-100 >100-200 >200-400 >400 
ULN: upper limit of normal 
It is important to remember that although LEE is often used to assess ART-induced 
hepatotoxicity, it is a surrogate marker and there are many factors unrelated to toxicity 
which can also affect ALT levels including obstetric complications, auto-immune liver 
diseases, viral infections, alcohol induced liver disease and liver steatosis (referred to as 
non-alcoholic fatty liver disease [NAFLD]) [330].  
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Monitoring hepatotoxicity in people living with HIV 
People living with HIV who are on ART have regular LFTs performed as part of their 
clinical care. The level of monitoring depends on their risk factors, how recently they 
started ART and their pregnancy status and can vary somewhat between HIV clinics. 
BHIVA guidelines for the management of HIV-positive pregnant women [169] recommend 
that women commencing cART in pregnancy have LFTs as per routine initiation of cART, 
i.e. two weeks after initiation, and at every antenatal visit. Women have a minimum of 
three LFTs during pregnancy irrespective of the type of ART used. Typically, these are 
performed at booking (i.e. when they first present), at 20 weeks and 36 weeks gestation. 
Women are monitored more closely during pregnancy in part due to their risk of obstetric 
complications, particularly in the final trimester [169]. Women with HIV/HBV or HIV/HCV 
co-infection are also recommended to have a liver function test at 2 weeks after 
commencing cART with subsequent monitoring of ALT throughout pregnancy and 
postpartum [169]. 
Pregnancy and the liver 
Pregnancy can increase the risk of some liver disorders, such as hepatic vein thrombosis, 
and in some cases increase the risk of liver dysfunction, such as hepatitis E [331] whilst 
other liver disorders only occur in pregnancy. Two such life threatening examples are, 
HELLP syndrome (haemolysis, elevated liver enzymes, low platelets) and acute fatty liver 
of pregnancy. Other examples are hyperemesis gravidarum, the liver dysfunction 
associated with pre-eclampsia, and obstetric cholestasis. The mechanisms causing these 
dysfunctions are distinct and not fully understood. They are a result of immunological, 
metabolic and hormonal changes. Pregnancy greatly increases the risk of fulminant 
hepatic failure in women with hepatitis E [331], possibly due to changes in the Th1-Th2 
balance or impaired cellular immunity as a result of hormonal changes [332]. In parts of 
Asia, African and Latin America, there can be large hepatitis E epidemics and hepatitis E 
contributes to a significant number of pregnancy complications [333]. However, in the UK, 
the incidence of hepatitis E is very low. In the last quarter of 2015, there were 218 cases of 
hepatitis E reported in England and Wales, less than 42 of which were in women younger 
than 59 years old [334]. Hyperemesis gravidarum may be an adverse reaction to the 
placental hormone, human chorionic gonadotropin, whilst HELLP syndrome is thought to 
be a result of activation of the coagulation cascade. Acute fatty liver of pregnancy is 
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caused by a deficiency in LCHAD (3-hydroxyacyl-CoA dehydrogenase, an enzyme used to 
breakdown fatty acids) by the fetus resulting in an accumulation of unmetabolised fatty 
acids, in the fetus and then the mother. Hormonal changes affecting bile secretion and 
mutations in the genes coding for bile transporter proteins are thought to cause obstetric 
cholestasis [335].  
A 15 month prospective study of >4000 HIV-negative women in antenatal care in Wales 
found that 3% had some form of LEE; two-thirds of these were due to pre-eclampsia and 
only <2% due to drug toxicity [336].  
Even in the absence of disease, some markers of hepatic function change during 
pregnancy. Although at least one study observed an increase in ALT levels in pregnancy 
[337], the general consensus is that ALT levels fall during normal pregnancy but remain 
within the normal range [338-340]. This fall is due to the effect of plasma volume 
expansion (PVE), also referred to as ‘hemodilution’: an increase in plasma volume during 
pregnancy due to the increased circulatory needs of the maternal organs and placenta. 
The average plasma increase is 45% but the increase varies hugely between individuals 
ranging from a minimal change to a doubling of plasma volume. It is not clear why there is 
such variation but positive predictors of PVE include parity, multiple births and pre-
pregnancy maternal BMI. Plasma volume typically starts to increase at 6-10 weeks 
gestation, increasing rapidly in the second trimester and plateauing at around 32 weeks 
[341, 342]. PVE has a significant effect on biomarker concentrations including ALT, which 
is lower during each trimester than outside pregnancy [343]. As such, the reference range 
for liver enzymes during pregnancy differs from the reference range outside pregnancy 
(Table 2.3).  
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Table 2.3. Typical UK reference ranges for liver enzymes by pregnancy trimester  
Liver enzyme  Not 
pregnant 
Pregnant Pregnancy trimester 
1st 2nd 3rd  
ALT (IU/L) 0-40 - 6-32 6-32 6-32 
AST (IU/L) 7-40 - 10-28 11-29 11-30 
Bilirubin (µmol/L) 0-17 - 4-16 3-13 3-14 
GGT (IU/L) 11-50 - 5-37 5-43 3-41 
Alkaline phosphatase (IU/L) 30-130 - 32-100 43-135 133-418 
Albumin (g/L) 35-46 28-37 - - - 
Bile acids (µmol/L) 0-14 0-14 - - - 
Source: Walker et al. [339], originally adapted from other sources [338, 344, 345]. 
Whilst other published reference ranges are similar [346], one Nigerian study provides a 
range for each trimester (1st trimester 3-30 IU/L; 2nd trimester 2-33 IU/L; 3rd trimester 2-25 
IU/L) [347]. It is not clear how quickly ALT levels return to pre-pregnancy levels after 
pregnancy, and this is likely to vary according to the level of PVE and the amount of blood 
loss at delivery [348]. A temporary post-partum increase in ALT above normal levels has 
been reported [343, 346, 349]. A study of 94 women delivering at a London hospital found 
that ALT peaked at 5 days post-partum by 147% on average compared to pre-pregnancy 
levels. At 5 days post-partum, 8% of ALT results were above the non-pregnant range, and 
by 10 days post-partum, 1% remained above the non-pregnant range [349]. A Swedish 
study, which looked at concentrations of biomarkers during and after normal pregnancy, 
found that ALT levels at 45-202 days post-delivery were higher than at any point during 
pregnancy and higher than the reference range used for healthy non-pregnant women 
[343]. A Danish study of Caucasian women with non-complicated pregnancy measured 
ALT in pregnancy, at labour and at 1 and 2 days post-partum. Although ALT fell during 
pregnancy the average ALT was always within the non-pregnant reference range. 
However, at delivery and in the 2 days post-partum it increased above the ULN for non-
pregnant women. Their non-pregnant ALT reference interval was 10.2-44.9 IU/L. They 
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suggested a reference interval for pregnancy of 8.4-35.9 IU/L, for the labour and 
postpartum day 1, 4.8-41.9 IU/L and for postpartum day 2, 7.8-58.1 IU/L [346].  
ART-related hepatotoxicity in pregnancy 
The physiological and hormonal changes that occur during pregnancy affect the 
distribution, absorption, and metabolism of drugs [350, 351]. These pharmacokinetic 
changes may result in an increased susceptibility to ART-related hepatotoxicity. High rates 
of hepatotoxicity have been observed among pregnant women on ART, mostly women 
using NVP. However, the effect of pregnancy on hepatotoxicity is not clear and is likely to 
vary according to ART drug.  
NVP-induced hepatotoxicity in pregnancy has been well documented [236, 288, 316, 317, 
352, 353] (Appendix Ib: Table 5 and Table 6) with the proportion of women who develop 
NVP-hepatotoxicity in pregnancy ranging from 5-34% depending on the setting and how 
hepatotoxicity is defined [243, 354, 355]. A single or double dose of NVP given at delivery 
for PMTCT does not appear to cause hepatotoxicity [217, 356, 357]. Some studies 
comparing the risk of NVP-induced hepatotoxicity in pregnant and non-pregnant women, 
found that pregnant women were at increased risk [236, 316, 317, 320] (Appendix Ib: 
Table 7). In studies, where analyses are not adjusted [316, 320], this increase in risk may 
reflect the characteristics of pregnant women, for example their ethnicity or higher CD4 
count when starting ART. However, pregnancy was independently associated with an 
increased risk of any LEE (grade 1-4) among women using NVP in multivariable analysis 
[317]. Other studies have either found that pregnancy is not associated with NVP-induced 
hepatotoxicity [358, 359] [220, 318] or have found a comparable rate in pregnant women 
as would be expected in non-pregnant women [237, 239, 321, 360, 361]. A systematic 
review of adverse events in pregnant women on NVP found that overall 3.2% [CI 2.1-
4.3%] of women experienced a severe hepatotoxic event, comparable with the level in the 
general population. Pregnant women with a CD4 count >200 cells/mm3 had a higher risk 
than non-pregnant women (OR 1.5 [0.9-2.3]) but this did not reach statistical significance 
[362]. Therefore the relationship between NVP-induced hepatotoxicity and pregnancy is 
unclear. The relationship between pregnancy and ART-induced hepatotoxicity and factors 
predictive of pregnancy, such as gender, black ethnicity and higher CD4 counts, are likely 
to be complex.  
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Given recent guidelines for ART use in pregnancy [169], women starting ART in the first 
half of pregnancy are likely to have a lower CD4 count and be starting treatment for their 
own health, compared to women starting ART in the second half of pregnancy. After 
accounting for this, the timing of NVP initiation in pregnancy could also have an impact on 
the risk of hepatotoxicity. In many studies which noted hepatotoxicity among pregnant 
women, NVP was started late in the second trimester or in the third trimester [236, 288, 
325]. In one study which found that pregnant women were less likely to experience toxicity 
compared to non-pregnant women (in unadjusted analysis), NVP was started in the first 
trimester or early in the second trimester [359]. A study of patients at HIV clinics in London 
found that 5% of women who started ART in pregnancy experienced LEE compared to 0% 
of women who were already on ART [321] (Appendix Ib: Table 8). 
There are few studies which assess the risk of hepatotoxicity among pregnant women 
using antiretroviral drugs other than NVP (Appendix Ib: Table 6). One such study found a 
similar rate of LEE in pregnant women on NVP-containing regimens and pregnant women 
on non-NVP-containing regimens [324]. Toxicity has also been reported in pregnant 
women using nelfinavir (in combination with zidovudine and lamivudine) [236, 289, 316], 
and efavirenz (also in combination with zidovudine and lamivudine) [289] (Appendix Ib: 
Table 6). However, pregnancy does not appear to increase the risk of nelfinavir-related 
hepatotoxicity [316] or hepatotoxicity associated with the use of other ART drugs [359]. In 
a study of pregnant and non-pregnant women with HIV in the Netherlands, in which half 
the women were on a PI-based regimen, pregnancy was not independently associated 
with risk of hepatotoxicity (grade 3 LEE) [318].   
Some studies investigating hepatotoxicity among patients starting therapy only include 
treatment-naive patients [243]. Temporary exposure to ART in pregnancy for PMTCT may 
affect the risk of hepatotoxicity once ART is subsequently started for the woman’s own 
health. There is limited evidence from studies which include both ART naive and ART-
experienced individuals that previous ART exposure is protective against hepatotoxicity 
when ART is started [302].  
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2.10 Postpartum viral rebound  
The impact of ART on HIV viral load and viral replication 
HIV-1 RNA levels in the blood fall rapidly following ART initiation. It takes around 12 weeks 
for levels to fall below 50 copies/mL [363, 364]. They continue to fall for several months 
reaching a plateau (constant phase) of around 3-10 copies/ml in the majority of individuals 
[363-368], a level which is only detectable using RT-PCR assays. A viral load of <50 
copies/ml can be categorised as ‘undetectable’ since RNA 40/50 copies/ml is typically the 
lower limit of detection for standard viral load assays, although some more sensitive tests 
can test below 20 copies/ml. Viral replication can be suppressed for many years, but even 
the most effective antiretroviral drugs cannot eradicate the virus from the body. The 
mechanisms through which the body maintains this residual viraemia are not fully 
understood, but may be due to the presence of cellular reservoirs and/or residual ongoing 
viral replication [369, 370]. The consequence of this residual viraemia is that when ART is 
stopped, or the patient is unable to maintain high levels of adherence, the viral load swiftly 
returns to detectable levels. Viral rebound is associated with higher viral load at treatment 
initiation, poor drug adherence, the use of certain ART drugs and previous treatment 
interruptions [371-373]. A study using the UK Collaborative HIV Cohort (UK CHIC) data 
found that in people who previously interrupted treatment those who had interrupted with a 
detectable viral load were at greater risk of viral rebound when they subsequently started 
ART than those who interrupted with an undetectable viral load [371].  
 
Viral rebound and viral blip definitions  
Viral rebound is an increase in HIV RNA above a specific threshold, following a period of 
viral suppression. Different studies have used different approaches to measure changes in 
viral load after pregnancy. Whilst some studies have measured the change in median viral 
load from baseline (either before pregnancy or at delivery), others have defined viral 
rebound as either HIV-RNA >400 copies/ml [374], a >0.5 log10 increase in viral RNA from 
baseline [375], or ≥0.7 log10 (5-fold) increase from baseline, or if viral load was 
undetectable in pregnancy, then an increase to >500 copies/mL postpartum [376]. In 
Chapter 6 and Chapter 8, viral rebound is defined as a single measure of HIV-RNA >200 
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copies/ml and in Chapter 8, which examines viral rebound in post-pregnant women and 
controls, it is also defined as a single measure >1000 copies/ml in the sensitivity analysis. 
A viral blip is a transient increase in viral load to around 50-1000 copies/ml. Viral blips are 
thought to occur in 20-60% of people on ART including when people are fully adherent to 
their ART regimen. It is unclear whether they are caused by changes in the immune 
system, for example due to illness, or temporary fluctuations in ART concentrations. The 
BHIVA treatment guidelines suggest that a single viral load of 50-200 copies/ml is not a 
cause for concern but a viral load above 200 copies/ml or repeated blips should be 
investigated further [77].  
Viral rebound following cessation of ART 
Viral rebound is almost inevitable when therapeutic ART is interrupted [377]. Studies 
measuring viral load after ART cessation have observed an overshoot in viral load, which 
peaked within the first 3 weeks after discontinuation [378, 379]. The overshoot may be due 
to a temporary increase in target cells (CD4 cells) as a result of the treatment and could be 
similar to the viraemia observed during initial HIV infection [380].  
As is the case outside the context of pregnancy, viral rebound is generally observed 
following cessation of short-course ART after pregnancy [132, 193, 197, 381, 382] 
(Appendix: Table 9, Page 337) although not always [383]. Where this was observed some 
years after pregnancy [384] it is likely a consequence of disease progression which would 
have occurred irrespective of the pregnancy. Increases in viral load shortly after pregnancy 
have also been observed among women who did not use ART in pregnancy [132, 193, 
197, 385] (in the pre-HAART era) and in women who remained on either ZDVm [132, 382, 
385] or on cART [374, 376, 381, 382, 385] (Appendix Ib: Table 10) including in women 
who achieved viral suppression in pregnancy. Viral rebound (measured at anywhere 
between 6 and 24 weeks after delivery) occurs in around 48%-85% [374, 375, 381] of 
women using short-course cART in pregnancy and around 15%-29% [375, 376, 381] of 
women remaining on cART after delivery. This suggests that changes occurring after 
pregnancy or at delivery can also cause or influence postpartum viral rebound. A 
temporary increase in HIV has also been observed in breast milk following cessation of 
ZDV used for PMTCT [386].  
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A number of immunological changes are known to occur in the postpartum period - there 
are changes in inflammatory and coagulation biomarkers, including D-dimer [387], and an 
increase in CD4 T-cells and β2-microglobulin, irrespective of ART use or HIV-infection 
[385]. Physiological changes also occur such as the disappearance of PVE and raised 
levels of oestrogen and progesterone. Some studies have found that drug adherence 
deteriorates after pregnancy [376, 388, 389]. Treatment interruptions and changes to 
medication are also more likely to occur in the postpartum period than at other times [376]. 
The extent to which each of these factors affects the risk of postpartum viral rebound is not 
clear.  
 
2.11 Role of the researcher 
I came to the PhD from a background in HIV surveillance and epidemiology, having 
previously worked on a number of regional and national surveillance systems at the Health 
Protection Agency and on secondment to the Centre for Epidemiological Studies in 
HIV/AIDS and STIs in Catalonia. During my PhD, I was based at the Royal Free Hospital 
within UCL’s HIV Epidemiology and Biostatistics Group. This group is part of the Research 
Department of Infection and Population Health within the Institute of Epidemiology and 
Health Care. I was linked to the UCL Institute of Child Health, where the NSHPC is 
coordinated and where Dr Claire Thorne, my secondary supervisor, is based.  
The areas of research were loosely defined in an initial funding application for the project, 
made by Professor Caroline Sabin and Dr Claire Thorne. On starting the PhD, I undertook 
a literature search and, following this, developed the research questions responding to the 
gaps in knowledge.  
The collaboration between NSHPC and UK CHIC allowed the study of areas which could 
not be addressed using either dataset independently. From the start of the collaboration, it 
was mutually agreed that the combined dataset would only be used for research which 
could not be undertaken using either dataset independently. For example, there is 
evidence that ART use in pregnancy is associated with an increased risk of pre-term 
delivery. This is a question which could be (and has been) investigated using the NSHPC 
dataset, so was not looked at as part of this PhD. Other clinical complications of 
pregnancy, such as antepartum haemorrhage, intrauterine infections and hypertension 
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disorders of pregnancy, could also be investigated using only the NSHPC dataset and use 
of the combined dataset would not provide any additional benefit. Hepatotoxicity is one 
potential side-effect of ART use for which there were some data available and the analysis 
could only be performed using the linked dataset, since the ALT data came only from UK 
CHIC, and the obstetric data from the NSHPC. 
The initial matching strategy was devised by Professor Caroline Sabin, Dr Claire Thorne 
and Dr Loveleen Bansi-Matharu in 2009. It was my role to improve and develop the 
strategy, as well as document the matching process and assess its completeness. From 
2010 onwards I repeated the matching annually using the most up-to-date datasets 
available. This process involved liaison with colleagues at ICH and the Royal Free 
Hospital, cleaning and preparing the separate datasets in preparation for the linkage and 
running the linkage. Once the combined dataset was complete, I created a number of new 
variables required for the analyses. I also produced a condensed database for researchers 
and clinicians analysing the UK CHIC data who wanted to exclude pregnant women or 
women with a previous pregnancy. I designed and conducted all analyses outlined in this 
thesis with advice from Professor Caroline Sabin. I have presented parts of the work at 
national and international conferences as well as producing peer reviewed papers 
(Appendix IIa-e). 
 
2.12 Research objectives  
Globally the use of ART in pregnancy is vital for minimising the risk of MTCT as well as 
improving the health of women living with HIV. In the UK, ART is used by the vast majority 
of the HIV-positive women who are pregnant. Until recently, there have been a 
considerable number of women who use short-course ART during pregnancy for the 
PMTCT, although increasingly ART was being used throughout pregnancy as many 
women were already on life-long ART when they conceived. The consequences for the 
woman of ART use during and after pregnancy and when she subsequently starts life-long 
ART for her own health are not fully understood. This research focuses on the 
associations between ART use in pregnancy and the health of the women during and after 
pregnancy.  
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The main research objectives were to: 
1. Create a dataset containing detailed clinical data for HIV-positive women which 
included antenatal data for women with a pregnancy. 
2. Describe ART use in pregnancy among HIV-positive women.  
3. Estimate the incidence of pregnancy among HIV diagnosed women attending HIV-
clinical care and identify predictors of pregnancy among this group. 
4. Compare the response to treatment once started for the woman’s health in women 
who previously used short-course ZDVm or short-course combination therapy in 
pregnancy and compare these with the response to treatment in women with no 
previous ART use. 
5. Investigate whether pregnancy is associated with liver enzyme elevation (LEE) in 
women using ART in pregnancy.  
6. Assess whether, in women on ART, the risk of viral rebound is higher during the 
postnatal period that at other times outside pregnancy. 
 
2.13 Ethical and research governance 
All the studies used for the analyses in this thesis have ethics approval from the London 
Multi-Centre Research Ethics Committee. The references are as follows: 
 NSHPC: Data protection registration number Z6364106 Section 19.  
London MREC ref: MREC/04/2/009.  
Reviewed 28 January 2004, and approved. Amendment (1), Perinatal HIV Audit 
2002-2005, reviewed 2 February 2006, and approved. Amendment (2), Perinatal 
HIV Audit Protocol reviewed 8 November 2012, and approved.  
 UK CHIC: MREC/00/7/47.  
 UK HIV drug resistance database (HDRD) (described in the methods section of 
Chapter 6): MREC/01/2/1. 
Where data are collected which support the “treatment or prevention” of sexually 
transmitted disease, individual patient consent for data collection and retention is not 
required under the exemption specified in the Department of Health’s STD Regulations 
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2000 [390]. The Department of Health have confirmed that the NSHPC, and similar 
studies, such as UK CHIC, come under this remit11. 
 
2.14 Data security and integrity 
The NSHPC and UK CHIC do not collect unique identifiers, such as National Insurance 
Number, but they do collect some patient identifiers such as date of birth, sex, ethnicity 
and soundex. To maintain patient confidentiality, it is crucial that all data are stored 
securely. Forms containing patient data which are sent to the NSHPC are stored in locked 
cupboards at the ICH. Access to these cupboards is limited to UCL students and staff 
working on the study. Where possible all electronic data are stored as password protected 
files or databases on secure drives where accessed is limited to UCL students or staff 
working on the study. I was sent only the NSHPC data needed for the linkage and 
analyses. The files were transferred to me via a secure document gateway. Files can only 
be downloaded from the gateway using an encryption key (a password) which was sent to 
me via an encrypted email. To enhance security, the encryption key was only valid for one 
day. 
The NSHPC data are archived quarterly and the UK CHIC data are archived annually. I 
stored only one copy of the linked dataset as a SAS file on a secure network drive. No 
backup was needed as the SAS code used to create the dataset was saved as a separate 
file, so a replica linked dataset could be created if required. Linked datasets from previous 
years were kept in case analyses needed rerunning or something needed to be checked. 
When analysing data in SAS, temporary subsets of the data are created. These are 
deleted when the file is closed but can be recreated using the code file. This means that 
data integrity is preserved sine the data in the original file is not easily altered. 
When visiting King’s and North Middlesex hospitals, I was not given access to patient 
records. The clinician or research nurse working at the clinics looked through patient’s 
electronic notes to try to find out why they had been included in the clinics’ list of people 
                                               
11
 Further information on the NSHPC ethics approval is available on the NSHPC website, 
www.ucl.ac.uk/nshpc/ethics (Accessed May 2015). 
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seen for antenatal care, but not included in the linked dataset or in the UK CHIC dataset. 
The lists provided by the sites for the assessment of the linkage were anonymised and 
were a subset of the data normally sent to UK CHIC. 
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Chapter 3 Developing a strategy for record linkage 
between UK CHIC and the NSHPC  
 
3.1 Introduction  
The UK and Ireland’s National Study of HIV in Pregnancy and Childhood (NSHPC) collects 
data on HIV-positive pregnant women. The data collected refer to the perinatal period only 
and it is therefore not possible, using only this data, to assess women’s health after 
pregnancy or to compare the clinical outcomes of pregnant and non-pregnant women. An 
additional limitation of using the NSHPC data in isolation is that it collects few clinical data 
during pregnancy, namely the first and last CD4 counts and viral loads. No data are 
collected on co-infections, toxicity, or comorbidity and it is therefore of limited use when 
investigating the health of women in pregnancy. In contrast, the UK Collaborative HIV 
Cohort (UK CHIC) study, also referred to simply as ‘UK CHIC’, collates extensive clinical 
and laboratory data collated from patients’ medical records. However, the UK CHIC 
dataset cannot be used in isolation to assess the health of women during or after 
pregnancy because no obstetric data are collected. It is therefore not possible to tell 
whether a woman has previously had a pregnancy, whether she has used short-course 
antiretroviral therapy ART in pregnancy or whether clinical tests such as viral loads and 
CD4 counts were performed during pregnancy.   
Collaboration was established between the NSHPC and UK CHIC in order to assess the 
health of HIV-positive women during and after pregnancy. This required finding and linking 
individual patient records from both datasets for women who attended HIV clinical care at 
a UK CHIC site and who had a pregnancy. There was no unique identifier (such as 
national insurance (NI) number or NHS number) which could be used to find records for 
the same woman reported to both studies since UK CHIC, and until recently, the NSHPC, 
collect only pseudonymised data. Therefore, a strategy was developed to find records for 
the same woman in both datasets using a combination of demographic and clinical 
variables. This strategy (referred to as ‘matching’) was initially developed in 2009 by Dr 
Claire Thorne and Dr Loveleen Bansi-Matharu. As part of this PhD, I developed the 
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matching strategy, assessed its completeness and representativeness and created new 
variables using data from both datasets. This chapter also describes the two studies, 
outlines their data collection methods, and summarises the variables in each dataset. 
From 2010 onwards, I repeated the matching annually using the most up-to-date datasets 
available. The number of records matched at each stage of the matching process is 
presented in Appendix V . The datasets created were used for all analyses in this thesis 
and a condensed version of that dataset was used by researchers and clinicians analysing 
the UK CHIC data.    
A paper summarising the matching strategy was published in 2012 (Appendix IIa) [391].  
3.2 The UK CHIC study 
The UK CHIC study is an ongoing observational study collating HIV-related clinical data on 
adults and adolescents aged 16 years and older accessing HIV clinical care in the UK 
(Table 3.1). The study began in 2001 and includes data from 1996 onwards where 
available [392]. Details of the UK CHIC steering committee and collaborating sites are 
included in Appendix VII. The number of sites providing data has increased over time, to 
19 in the latest dataset used in this research. New sites entering the cohort provide data 
from 2000 or 1996 onwards depending on whether the older data were stored in an 
electronic format. The analyses in this thesis concentrate on data from 2000 onwards 
when combination antiretroviral therapy (cART) and the use of short-course ART in 
pregnancy were well established. 
Extensive clinical data, recorded as part of a patient’s medical record, are collated 
annually. Each November a request is made for all data up to 31st December of that year 
to be submitted by the following January. There is a delay of approximately 9-12 months 
from the end of the calendar year to the completion of that years dataset. This is due to the 
complexity of collating data from all the collaborating sites and the subsequent data 
cleaning and deduplication of records required.   
The data fields collated include demographic and clinical data such as: the Soundex 
code12 (a four digit code which is the first letter of the surname followed by a three number 
                                               
12
 The NSHPC website provides a Soundex calculator for reporting sites to use 
www.ucl.ac.uk/nshpc/reporting/soundex these can also be found elsewhere online.  
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code derived from the surname); first name initial; date of birth (DOB); country of birth 
(COB); gender; ethnicity; probable route of HIV infection; date of first HIV-diagnosis; all 
CD4 cell counts and dates; all CD8 cell counts and dates; all HIV-RNA (viral load) 
assessments and dates; ART drugs prescribed and the dates of starting and stopping 
ART; AIDS events; hepatitis test results and dates; and liver function test (LFT) results and 
dates. UK CHIC does not collect obstetric data or pregnancy status. The UK CHIC data 
collection form contains the full list of fields collated. The form used for data to 31st 
December 2012 is included in Appendix IV . Each year the updated form, specifying the 
required data formats and coding, is circulated to participating centres. Sites then upload 
an electronic version of their data, which has been collected as part of the patient’s clinical 
care record, to a secure website. HIV-positive adults of 16 years and older attending HIV 
clinical care at any time since 1996 are included. The datasets are named chronologically; 
the dataset containing data to 31st December 2010 (i.e. data requested in November 2010) 
is called ‘UK CHIC 2010’. In some cases, clinics provide data up to the date they submit 
and beyond the deadline for submission. These are included in the dataset but not in the 
analysis.  
Data received from each centre are checked for accuracy and discrepancies by the UK 
CHIC data manager (Dr Teresa Hill). The reporting site is asked to correct any errors 
identified before their data are incorporated into the final UK CHIC dataset.  
Each individual reported to UK CHIC has one record in the UK CHIC dataset. When a new 
patient enters the cohort they are added to the dataset. If a patient attends multiple sites 
during the same or different years their data are combined into a single UK CHIC record in 
a process referred to as de-duplication. A computerised algorithm uses clinical and 
demographic data including Soundex and DOB to categorise pairs of records as a definite 
match, definite non-match or indeterminate match. Indeterminate matches are then 
manually checked by two independent investigators. A third investigator then manually 
checks records where consensus was not found. If it is unclear whether the records refer 
to the same individual they are left as separate records in the final dataset (typically ~100 
records). These records often contain very little clinical data, hence why it is difficult to 
determine whether or not they refer to the same individual.  
After de-duplication the clinic ID, patient’s initial and Soundex are removed from the 
dataset but remain on an archived dataset stored at the Medical Research Council (MRC) 
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Clinical Trials Unit (CTU). Each individual in the dataset is assigned a unique UK CHIC 
identifying number, referred to as the Patnum. Each year de-duplication is repeated for all 
records. If individuals were seen at multiple sites they are given a DupPatnum. The same 
method is used each year to de-duplicate records. However, an individual identified as a 
non-duplicate in one year might be identified as a duplicate in another year depending on 
the data reported for them. This means that their Patnum may not be consistent across 
years. 
 
Table 3.1. HIV clinical sites participating in UK CHIC and the number of women attending 
care at each site (n=12,970)                         
Name of hospital, site or NHS trust
1
 UK 
CHIC             
site 
code 
Year        
of entry           
into 
study 
Women in          
UK CHIC          
(% of total 
female sample)           
Brighton and Sussex University Hospitals NHS Trust 101 2001 374 3% 
St. Mary's Hospital, Imperial College Healthcare NHS 
Trust, London 
102 2001 1189 9% 
Chelsea & Westminster Healthcare NHS Trust, London 103 2001 1151 9% 
Mortimer Market Centre, London 104 2001 1159 9% 
Kings College Hospital NHS Foundation Trust, London 105 2001 1478 11% 
Royal Free NHS Trust and Royal Free University 
College Medical School, London 
106 2001 1112 9% 
Barts and The London NHS Trust, London 107 2004 985 8% 
The Lothian University Hospitals NHS Trust, Edinburgh 108 2005 374 3% 
North Middlesex University Hospital NHS Trust 109 2005 847 7% 
Homerton University Hospital NHS Trust, London 110 2005 689 5% 
North Bristol NHS Trust 111 2006 425 3% 
University Hospitals of Leicester NHS Trust 112 2008 707 6% 
South Tees Hospitals NHS Foundation Trust 113 2009 203 2% 
South London Healthcare NHS Trust, Woolwich 114 2010 826 6% 
St. George's Healthcare NHS Trust, London 115 2010 799 6% 
York Teaching Hospitals NHS Foundation Trust 116 2011 77 1% 
Coventry & Warwickshire NHS Trust 117 2012 104 1% 
Ashford & St. Peter's Hospitals NHS Foundation Trust 118 2012 257 2% 
The Royal Wolverhampton NHS Trust 119 2012 214 2% 
1 
This refers to the first UK CHIC site at which the woman attended HIV clinical care according to the UK CHIC 
2012 dataset 
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After the creation of the new dataset, additional fields are derived from the reported data. 
These include the first and last date an individual attended care and the dates when ART 
drugs were either started or stopped with variables indicating how many drugs were 
prescribed on each of the dates. ART data are cleaned, removing errors, for example 
where a new regimen is started and a previous regimen overlaps with this period. Data on 
deaths are updated from data received from Public Health England (PHE) and the Office 
for National Statistics (ONS) and the dataset is linked to the latest UK HIV drug resistance 
database (HDRD)13. Much of this data cleaning is undertaken by Sophie Jose, the UK 
CHIC statistician.  
Each year, for the analyses included in this thesis, an extract of the UK CHIC dataset was 
created containing only records for women. Women typically represent just over one-
quarter (28% in recent years) of the individuals reported to the study.  
Each year the new dataset is archived as a SAS file. All statistical analyses are 
undertaken in SAS (SAS Institute, Cary, North Carolina, USA) with the most up-to-date 
version of the software available being used throughout.  
UK CHIC is part of numerous research collaborations. As well as linkage with the UK HIV 
drug resistance database (HDRD) and with the National Study of HIV in Pregnancy and 
Childhood (NSHPC) described in this thesis, it is also linked to the Collaborative HIV 
Paediatric study (CHIPS)14 a longitudinal study of children in the UK and Ireland, to 
provide longitudinal data in adolescents transitioning from paediatric to adult care. UK 
CHIC provides follow-up data to the UK Register of HIV Seroconverters15, a national 
cohort of patients with a known date of HIV seroconversion, and provides an independent 
dataset used to validate findings from the ART Cohort Collaboration (ARTCC)16. UK CHIC 
has also been part of a large collaborative study of 33 HIV cohorts in Europe, The 
Collaboration of Observational HIV Epidemiological Research Europe (COHERE)17, and 
has collaborated with the Canadian HIV Observational Cohort (CANOC)18. More recently 
UK CHIC has been linked with the Pharmacokinetic and clinical observations in people 
                                               
13
 Further details on the UK CHIC study are available at www.ukchic.org.uk 
14
 www.chipscohort.ac.uk 
15
 The UK Register of HIV Seroconverters is part of the Concerted Action on SeroConversion to AIDS and 
Death in Europe (CASCADE) collaboration www.cascade-collaboration.org 
16
 www.art-cohort-collaboration.org 
17
 www.cphiv.dk/COHERE_org 
18
 www.canoc.ca 
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over fifty (POPPY)19 study, an observational study examining clinical outcomes and co-
morbidities in older adults living with HIV, and to the UK CHIC Bio-resource, a consented 
HIV sub-study of the National NIHR BioResource20. These collaborations allow the 
comparison of outcomes across different settings and provide sufficiently large numbers to 
analyse rare outcomes for which there would be insufficient data from any single cohort.   
 
3.3 The NSHPC 
In the UK, antenatal data on HIV-positive women are collected as part of the NSHPC, 
overseen at the UCL Institute of Child Health. The NSHPC has ongoing obstetric and 
paediatric reporting schemes which run in parallel. The study aims to collate data on all 
HIV-positive women with a pregnancy, all infants born to HIV-positive mothers and all 
children living with HIV in the UK and Ireland. In this thesis only data from the obstetric 
scheme is used and therefore only that part of the study is described in detail.21 Details of 
the NSHPC steering committee and funders are included in Appendix VIII. 
The obstetric scheme was started in 1989 and is administered under the auspices of the 
Royal College of Obstetricians and Gynaecologists. All maternity units in the UK (currently 
228) report pseudonymised data through active quarterly reporting. A named respondent 
at each site, typically a specialist midwife, is asked to return a reporting card every quarter 
indicating the number of cases seen during that quarter, including a null form if no cases 
were seen. Cases include all pregnancies in HIV-positive women irrespective of pregnancy 
outcome (including termination or miscarriage) and irrespective of when HIV was 
diagnosed (before or during the pregnancy). A standardised notification form (now mauve 
in colour) is completed for each reported pregnancy (Appendix IIIa). For pregnancies 
expected to reach full term, an outcome form (now yellow in colour) is sent for completion 
at the time of the expected date of delivery (EDD) (Appendix IIIb). The data collected in 
these forms has changed somewhat over time to reflect changes in the management of 
pregnancies among women living with HIV and to address new research questions 
resulting from these changes. The forms included in the appendix were the current forms 
                                               
19
 https://clinicaltrials.gov/ct2/show/NCT01737047 
20
 https://bioresource.nihr.ac.uk/ 
21
 Further details on the NSHPC are available at www.ucl.ac.uk/nshpc 
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when the matching strategy was developed and the data collected are presented in Table 
3.2 and Table 3.3.    
On receipt of a form, the information is entered into the NSHPC database, managed in 
Microsoft Access (Microsoft Corp., Redmond, Washington, USA). A new pregnancy report 
is linked to any previous reports for the same woman with matching of women based on 
DOB and other information such as COB and date of HIV diagnosis. Paediatric reports 
pertaining to the woman’s children, including the child’s HIV infection status, are also 
linked to the record. Increasingly, women with a pregnancy reported to NSHPC are linked 
to their own paediatric report if they themselves acquired HIV vertically as an infant. The 
site providing antenatal care and the site of delivery, which were often, but not always, the 
same site, were both recorded and may differ from the site at which the woman received 
ongoing HIV clinical care. Non-response from maternity units was followed up to ensure a 
high reporting rate. The NSHPC dataset is archived each calendar quarter using R (R 
Development Core Team). It is then imported into STATA (Stata Corporation, College 
Station, Texas, USA) and routine checks carried out.  
An extract of the NSHPC dataset was provided on request for the purpose of matching 
with the UK CHIC dataset. These were sent as password protected Excel files (Microsoft 
Corp., Redmond, Washington, USA) via a secure document gateway. Only variables used 
for the matching and variables used in the analyses in this thesis were included in the 
extracted dataset.  
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Table 3.2. Data collected on the 2008/2009 NSHPC notification form 
Demographic  
 
DOB 
Hospital number (or other reference) 
Soundex 
Postcode (minus last letter) 
Ethnic origin 
Country of birth (COB) 
Date of arrival if COB is not UK/Ireland 
Pregnancy history Previous live births 
Previous stillbirths 
Miscarriages/terminations 
HIV history Exposure group 
HIV infection probably acquired in the UK/abroad 
Date of HIV diagnosis 
Diagnosis in relation to the pregnancy (before/during) 
Seroconversion during the pregnancy (yes/no/NK) 
Setting of HIV diagnosis (GUM/antenatal/other) 
Pregnancy Booking date and expected date of delivery (EDD) 
Pregnancy outcome (continuing to term/miscarriage/termination) 
Dates of pregnancy outcome  
If continuing to term: planned mode of delivery 
ART use Was ART used when the woman became pregnant? 
Was ART used during the pregnancy? 
ART drugs used in pregnancy (name, start & stop dates, use before 
pregnancy) 
Maternal health  Status during the pregnancy (CDC stage C disease/ asymptomatic/ 
symptomatic not stage C) 
Concurrent infection (none/HBV/HCV/syphilis/other) 
First viral load during pregnancy (and date) 
 First CD4 cell count during pregnancy (and date) 
COB: country of birth; DOB: date of birth; GUM: genitourinary medicine clinic; HBV: hepatitis B virus; HCV: 
hepatitis C virus; NK: not known.  
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Table 3.3. Data collected on the 2008/2009 NSHPC outcome form 
Demographic Postcode at delivery (minus last letter) 
Hospital of delivery and paediatrician 
Pregnancy  
 
Pregnancy outcome (live/stillbirth) 
EDD 
Date of delivery 
Gestation at delivery (weeks) 
Infant Gender  
Twin (yes/no) 
Birth weight (kg) 
Hospital number 
NHS number  
Delivery Mode of delivery (ECS /emergency CS/planned VD/unplanned VD, 
reason) 
Planned mode of delivery (VD/ECS/NK) 
Instrumental delivery (yes/no)  
Rupture of membranes and duration  
Complications in pregnancy (no/yes and details) 
Congenital abnormalities (no/yes and details) 
ART use in 
pregnancy 
Ante-partum treatment (no/yes) 
Reason for ART (PMTCT only/maternal health and PMTCT)  
Details of all ART drugs used in pregnancy (including start/stop dates) 
Details of other drugs used in pregnancy (including start/stop dates) 
Intra-partum treatment (none/IV ZDV/sd NVP/other oral antiretrovirals) 
Maternal health  Status at delivery (CDC stage C/asymptomatic/symptomatic not stage 
C/date of death) 
Viral load (and date) near delivery (just before delivery if possible)  
 CD4 cell count (and date) near delivery (just before delivery if possible) 
Resistance testing done this pregnancy (yes/no/NK/clade of virus) 
CS: caesarean section; ECS: elective caesarean section; EDD: expected date of delivery; IV ZDV: intravenous 
zidovudine; HBV: hepatitis B virus; HCV: hepatitis C virus; PMTCT: prevention of mother-to-child transmission; 
sd NVP: single-dose nevirapine; VD: vaginal delivery. 
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3.4   Finding women reported to UK CHIC and the NSHPC  
 The basic matching strategy 3.4.1
The process of finding records for women reported to both NSHPC and UK CHIC is 
referred to here as ‘matching’. Initial attempts were made to match the datasets using 
demographic variables only (DOB, COB, and ethnicity). Although it is difficult to determine 
the level of false matching, the level was thought unacceptably high as 10% (156/1575) of 
the women that were matched were matched with more than one record from the other 
dataset. In an attempt to maximise the number of true matches and minimise the number 
of false matches, a strategy was devised using deterministic decision criteria based on a 
combination of demographic and clinical fields. The strategy, developed in 2009, is 
described below and outlined in Figure 3.1. 
   
 
1. Initially, records in UK CHIC were paired with records in NSHPC if they had the same 
DOB. This created a temporary dataset, referred to as the ‘linked dataset’, containing 
pairs of records which were potential matches (i.e. the NSHPC and UK CHIC records 
for the same woman). Each woman’s UK CHIC record could appear multiple times in 
the linked dataset if her DOB was the same as multiple women in NSHPC and vice 
versa. A series of criteria, based on demographic and clinical variables (described in 
points 2-5), were then used in turn to assess whether the linked records were a 
genuine match (i.e. referred to the same woman). If a woman was part of multiple 
pairings which met the criteria for being a match, the pairings were manually reviewed 
to assess which appeared genuine. In some cases this appeared to be a result of 
incomplete deduplication which was reported to the appropriate data manager. As 
pairs were confirmed as a genuine match, they were moved from the linked dataset to 
the matched dataset and subsequently removed from the linked dataset so they were 
no longer eligible to be a genuine match with another record. Records remaining in 
the linked dataset, which had not yet been confirmed as a genuine match, were then 
assessed according to the next criteria.  
2. The first criterion used to assess whether paired records were a match was the date 
of CD4 cell counts where the CD4 counts were ≤10 cells/mm3 different (on that date). 
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Further, if the date of the CD4 cell counts in both records were the same but the CD4 
counts were >10 cells/mm3 different, the pair was considered to be a genuine match if 
the NSHPC and UK CHIC records came from the same site (i.e. the woman had 
delivered and had ever received HIV clinical care at the same site) or the date of HIV-
diagnosis was the same in the NSHPC and UK CHIC.  
Remaining records which had an exact CD4 date match but were not matched using 
this criterion were then manually reviewed, to determine if matching was possible 
based on further CD4 dates or viral load dates, COB etc.  
3. The second criterion used to assess records remaining in the linked dataset (without a 
matching CD4 date) was month and year of CD4 count. As with the first criterion, 
records were thought to be a genuine match if the NSHPC and UK CHIC records had 
a CD4 count ≤10 cells/mm3 different (on that date), were reported from the same site 
or had the same HIV-diagnosis date. Records not matched using these criteria but 
which had identical month and year of CD4 count were manually reviewed.  
4. Any records remaining in the linked dataset were matched if they had the same month 
and year of HIV-diagnosis and were seen at a London site in both UK CHIC and 
NSHPC.  
5. Finally, records remaining in the linked dataset with either a matching site or month 
and year of HIV-diagnosis (but not seen at a London site) were manually reviewed 
using other fields to assess whether any were genuine matches.  
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Figure 3.1. Diagram showing matching of UK CHIC with NSHPC  
 
Source: Bansi et al. Abstract P56. BHIVA Conference, Liverpool, 2009 [393], with permission. 
 
 Datasets used for developing the matching strategy 3.4.2
The matching strategy was developed using the UK CHIC 2009 dataset (Figure 3.2). It 
contained records for 8286 women, aged 16-49, who attended HIV-related care at any 
point in the period 1996-2009.  
A restricted NSHPC dataset, containing data until 31st December 2010 was used. This 
contained records for 8932 women with a total of 11,771 pregnancies conceived after 
1995 and reported by 31st December 2010. Women diagnosed with HIV after their only 
reported pregnancy were excluded as were women who only attended care in Ireland 
(since none of the UK CHIC sites were located in Ireland). In this dataset, the highest 
number of pregnancies reported per woman was six (after HIV-diagnosis or where HIV 
was diagnosed during the first reported pregnancy).   
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In order to minimise any reporting delay, the most recent datasets were used. This meant 
that the NSHPC dataset, which is updated as and when reports are received and archived 
quarterly, contained data until up to one year after the UK CHIC data, which is collated 
annually with a 12-18 month delay before the dataset is finalised. Only data to the end of 
the UK CHIC period were analysed.  
 
 Developments to the matching strategy  3.4.3
The following additional variables were considered in the development of the matching 
strategy. 
CD4 count/ HIV viral load: 
In the initial matching strategy, only the earliest viral load and CD4 count in pregnancy 
were considered. This was changed to include the latest CD4 count and viral load date 
and measurement in pregnancy. Although these fields were not reported for all women, 
their inclusion increased the likelihood that women could be matched based on exact CD4 
date and CD4 count ±10 cells/mm3. 
Soundex: 
Soundex was not considered in the basic matching. It is a non-unique code derived from 
the patient’s surname and can change over time, if, for example, the woman marries and 
changes her surname. Soundex is provided for the majority of UK CHIC records. The 
NSHPC has requested Soundex on the reporting forms since 2008 and the reporting of 
Soundex has increased over time. However, in the NSHPC dataset used here, only 3.4% 
(n=306) of women had Soundex reported.  
Clinic/site:  
In the initial matching strategy, only site of delivery was considered. This was changed to 
also consider the site of notification, as in some cases no site of delivery was reported or 
the site of notification and delivery differed.  
Approximate dates:  
In the initial matching strategy, month/year was used for the CD4 count and HIV diagnosis 
date comparisons. This was compared with using ±30 days, since two dates could be one 
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day apart but if one fell on the last day of the month and the other on the first day of the 
next month they would not be matched. It was decided that ±30 days was more 
appropriate. 
Changes to the NSHPC data format: 
Previously, the NSHPC data was provided in a single spreadsheet. With developments in 
the matching process, more NSHPC data fields were used in the matching process and so 
the data format was changed, three spreadsheets were extracted from the NSHPC 
database to be used for the matching;  
1. Pregnancy data – one line per pregnancy 
2. ART drug data - one line per ART drug 
3. CD4 and viral load data - one line per test date (either CD4, viral load or both) 
These datasets were transposed and merged to create an NSHPC dataset containing one 
row (referred to as a ‘record’) per woman which included all data for each of her 
pregnancies.  
Discrepancy checking 
Discrepancy checking was introduced as part of the matching strategy. Where paired 
records, thought to be a genuine match had a discrepancy in another field, they were 
manually reviewed to see if the other fields supported or refuted their matched status.  
The discrepancies are categorised in Table 3.4 and Table 3.5. All pairs that were thought 
to be a genuine match but had a strong discrepancy for COB (category 0) or ethnicity 
(category 3) were manually reviewed.  
Table 3.4. Categorising strength of discrepancy for COB reported by NSHPC and UK 
CHIC 
Category Type of match/discrepancy 
0 Not a match 
1 Exact match  
7 One dataset has ‘UK’ the other has a different country 
8 One dataset has ‘Africa’ the other has a specific African 
country  
9 One or both datasets have missing COB  
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Table 3.5. Categorising strength of match/discrepancy for ethnicity reported by NSHPC 
and UK CHIC 
Category Type of match/discrepancy 
1 Exact match  
2 Weak discrepancy e.g. black-African vs. black-other 
3 Strong discrepancy e.g. black vs. white 
9 One or both datasets has missing ethnicity 
 
 
Other discrepancies which led to records being manually reviewed were: drug naivety after 
pregnancy according to UK CHIC; a date of death reported to UK CHIC which predated a 
delivery date or clinical data in NSHPC; a date of UK arrival reported in NSHPC later than 
a CD4 count or viral load measurement reported in UK CHIC; CD4 counts >100 cells/mm3 
different in NSHPC and UK CHIC (where matching was based on having the same CD4 
dates or CD4 dates <30 days apart in both studies and the same HIV diagnosis date or 
clinic site). If manual review of records revealed that one of the records had an obvious 
mistake in a field, such as ethnicity, this was reported to the relevant data manager for 
checking.  
Viral load: 
Viral load measurements and the dates on which they were performed were used in an 
attempt to identify additional matches. Linked records with the same viral load date and 
HIV-RNA ±10 copies/ml (on that date) were matched. This resulted in 32 additional pairs 
being matched, more than half of these pairings (n=17) then had to be checked because 
they had discrepant COB in NSHPC and UK CHIC. Therefore, this step was not used in 
the final matching strategy. Instead, viral load date was used as a variable to identify 
potential genuine matches in the manual matching stage (described below).  
Fuzzy DOB: 
Not all women have their full DOB recorded in their clinic notes. Where DOB is not known 
a proxy date is normally used. If only the month and year of birth are known, the proxy 
date is either the 1st or the 15th of that month. If only the year of birth is known, the proxy 
date is either the 1st January or 30th June (i.e. the start or middle of the year). In the UK 
 100 
 
CHIC 2009 dataset, 5% (443/8929) of women had a DOB on the first of the month, higher 
than the 3% (12/365) we would anticipate. There were 120 (1.3%) women with their DOB 
on 1st January, almost four-times as many as on the following day (n=31) and higher than 
the 0.3% (1/365) we would anticipate. Dates of significance, such as national 
independence days or Christmas day, and dates that are easy to recall, such as 1st 
January, 2nd February, 3rd March and so on, were also more common than we would 
anticipate, presumably because they are chosen by women who did not know their actual 
DOB.  
If the same proxy date was reported to NSHPC as to UK CHIC (i.e. in antenatal care and 
in HIV clinics), then the use of a proxy date should not introduce any selection bias, as 
matching should not be affected by the number of women with a DOB on a particular date, 
if other variables such as CD4 date and CD4 count are available. If however, the full DOB 
was reported in only one clinic and the proxy date was used in the other, this would mean 
the records would not be paired during the first step of the matching strategy.  
To assess the extent to which this might be a problem, all records with a DOB on the 1st or 
15th of the month in UK CHIC or NSHPC were linked to records with a DOB in the same 
month in the other dataset. The same matching strategy was then used as described for 
records with identical DOB.  
Overall, 25 additional pairs were found to be matches, but when they were manually 
reviewed, all had discrepancies which indicated that they were not genuine matches. This 
step was therefore not incorporated into the matching strategy. 
 
 Manual review and matching 3.4.4
Paired records remaining in the linked dataset, i.e. which had identical DOB in UK CHIC 
and the NSHPC but which were not matched based on any of the matching criteria, were 
reviewed to identify any further matches. In the 2009 dataset, at this stage there were 
more than 5000 pairs remaining in the linked dataset and it was not practical to review 
them all. Instead, records were selected for review. In the initial matching strategy pairs 
were reviewed if they were reported from the same site or if they had a matching month 
and year of HIV diagnosis date. In the final matching strategy the following criteria were 
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used to select pairs (with the same DOB) for manual review: records were from the same 
reporting site, the HIV diagnosis dates were <30 days apart, there were drug start/stop 
dates <7 days apart; they had identical Soundex, or the pattern of ART use indicated that 
ART had been used in pregnancy (described in further detail below). The variables used to 
judge whether paired records were a genuine match included, from UK CHIC: date of 
death; from NSHPC: date of UK arrival; and from both studies: COB, ethnicity, HIV 
diagnosis date, viral load and date, CD4 count and date, ART drug dates and site. No 
discrepancy checks were run on the records matched in this step since the variables used 
in the discrepancy checking had already been reviewed.  
Although many of the variables used in the manual review were the same as the variables 
used in the earlier stages, some further matches were made. In some cases this was 
because whilst reviewing the records I could spot typos or uncommonly occurring 
characteristics which indicated a match. For example, two records with an identical CD4 
date but with discrepant CD4 counts 345 vs. 34 cells/mm3 would not be matched at an 
earlier stage unless the records also had a matching site or HIV diagnosis date. However, 
if there were any other variables which matched, such as COB or ethnicity the reviewer 
would assume that one of the CD4 counts had been recorded incorrectly.  
Soundex: 
At the stage where records with identical Soundex were reviewed, the linked dataset 
contained 152 NSHPC records linked to at least one UK CHIC record where both records 
had Soundex reported. However, only 5% (n=7) of these pairs had matching Soundex in 
NSHPC and UK CHIC. Although few records were matched using the manual review of 
Soundex it was retained in the matching strategy since it was anticipated that the reporting 
of Soundex to the NSHPC would increase over time so it might be more useful in future 
years.   
ART use:   
Pairs of records were reviewed if the pattern of ART use in UK CHIC indicated that ART 
might have been used during pregnancy. Of the 5019 pairs remaining in the linked dataset 
at this stage, 6% (n=309) had an ART start date in UK CHIC which was during a 
pregnancy (indicated in NSHPC), (303 NSHPC records were linked to only one UK CHIC 
record and 6 NSHPC records were linked to multiple UK CHIC records) (Table 3.6).  
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Table 3.6. Criteria used to select pairs for manual review from pairs remaining in the linked 
dataset but not having been matched according to the main matching criteria  
Criteria        n4 M 
Started ART in pregnancy1 x x x x x x  257 - 
Started ART in pregnancy with CD4 >350 cells/µl x   x  x  243 16 
Started zidovudine monotherapy in pregnancy2 x x x     29 19 
‘Pregnancy’ reported as reason for stopping 
ART3 
  x x x  x 70 4 
Number of pairs meeting criteria (indicated by x) 23 5 1 9 8 211 52 309 39 
n: number of pairs; M: number of pairs accepted as a genuine match 
1 
ART start dates from UK CHIC and delivery date from NSHPC  
2 
Second pregnancy trimester onwards  
3 
The reason for ART stop is an under reported field in UK CHIC 
4 
Women could contribute data to multiple rows therefore the total number of linked pairs is less than the sum 
of this column.  
 
 Matching overview 3.4.5
Using the updated matching strategy, the NSHPC and UK CHIC records for 2063 women 
were matched, representing one-quarter (25%) of the women in UK CHIC (Figure 3.2). Of 
the 1996 records which were matched prior to the manual matching stage, 296 (15%) had 
to be reviewed because they had a discrepancy in at least one field. Of these, 253 (85%) 
had sufficient matching data in other fields to indicate that they were a genuine match, 
whilst 43 (15%) did not appear to be a genuine match and were not included in the final 
dataset (Table 3.7).   
The majority of records that were matched met either the first or third matching criteria i.e. 
they either had the same CD4 cell count date (72% of matched records) or a CD4 cell 
count date within 30 days (12% of matched records) plus a CD4 cell count within 10 
cells/mm3. The matching made at other stages of the matching strategy each accounted 
for <5% of the total matches (Table 3.8).  
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Figure 3.2. Criteria used to match records for women reported to NSHPC and UK CHIC  
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Using UK CHIC data to end 2009 and NSHPC data to end 2010 
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Table 3.7. The number and type of discrepancies at each stage of the matching strategy 
and the number of descrepant pairs accepted and rejected as a genuine match (UK CHIC 
2009 dataset) 
Stage of matching Discrepancy reason1 Accepted Rejected2 
Exact CD4 date 
match 
+ 
CD4 count ±10  
Total 139/1494 (9%) 137 2 (1%) 
COB 
Ethnicity 
Drug naïve 
Date of UK arrival 
42 
6 
74 
17 
41 
6 
73 
17 
1 
- 
1 
- 
Exact CD4 date 
match 
+ 
HIV diagnosis 
date/site 
Total 3/40 (8%) 2 1 (50%) 
COB 
Ethnicity 
Drug naïve 
Date of UK arrival 
1 
1 
1 
0 
- 
1 
1 
- 
1 
- 
- 
- 
CD4 date ±30 days 
+ 
CD4 count ±10 
 
Total 51/270 (19%) 32 19 (37%) 
COB 
Ethnicity 
Drug naïve 
Date of UK arrival 
12 
13 
19 
7 
2 
4 
19 
7 
10 
9 
- 
- 
CD4 date ±30 days 
+ 
HIV diagnosis 
date/site  
Total 38/78 (49%) 19 19 (50%) 
COB 
Ethnicity 
Drug naïve 
Date of UK arrival 
35 
1 
2 
0 
16 
1 
2 
- 
19 
- 
- 
- 
Drug start/stop dates 
Exact dates 
Total 21/65 (32%)           20 1 (5%) 
COB 
Ethnicity 
Drug naïve 
Date of UK arrival 
18 
3 
0 
0 
18 
2 
- 
- 
- 
1 
- 
- 
Drug start/stop dates 
±7 days 
Total 44/49 (90%)         43 1 (2%) 
COB 
Ethnicity 
Drug naïve 
Date of UK arrival 
23 
21 
0 
0 
23 
20 
- 
- 
- 
1 
- 
- 
Total  296/1996 253 43 
1
The first row shows the number with a descrepancy/matched during that stage of matching (%). 
2 
percentage of those with a descrepancy who are rejected as a match. 
No women had a date of death earlier than a delivery date or CD4/viral load test date.   
 105 
 
Table 3.8. Number and percentage of women matched at each stage of the matching 
process (UK CHIC 2009 dataset) 
Criteria used to match records 
(All pairs have matching DOB) 
Matched pairs 
(n=2063) 
% % 
Cumulative  
Exact CD4 date + CD4±10 1492 72 72 
Exact CD4 date + diagnosis date/site 39 2 74 
CD4 date ±30 days + CD4±10 251 12 86 
CD4 date ±30 days + diagnosis date/site 59 3 89 
Drug start and stop dates 64 3 92 
Drug start and stop dates ±7 days 48 2 94 
Manual match – site  58 3 97 
Manual match – diagnosis date 4 0.2 98 
Manual match – drug start and stop dates 2 0.1 98 
Manual match – Soundex 7 0.3 98 
Manual match – likely to have had 
pregnancy 
39 2 100 
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3.5   Characterising women found in both studies 
 Women in UK CHIC with a pregnancy 3.5.1
Of the 8286 women in the UK CHIC 2009 dataset, 25% (n=2063) were also found in the 
NSHPC dataset, indicating that they had ever had a pregnancy in the UK during which 
they were known to be HIV-positive. Among women in the combined dataset, 74% were of 
black-African ethnicity, 74% were born in the African WHO region and 87% were infected 
with HIV via heterosexual sex (Table 3.9). There were 3030 pregnancies in total, 87% of 
which resulted in a live birth. Women had between one and six pregnancies, with the 
median number being one. The average age was 30 years at the start of the first reported 
pregnancy and 55% of women were already diagnosed with HIV prior to this pregnancy.  
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Table 3.9. Characteristics of women in the UK CHIC-NSHPC 2009 combined dataset 
(n=2063) 
 n  % 
Ethnicity 
 
Black-African 1535 74.4 
White 243 11.8  
Black-Caribbean 104 5.0 
Other 173 8.4 
Not known 8 0.4 
Region of birth1  
 
African  1527 74.0 
European  347 16.8 
Region of the Americas 87 4.2 
Eastern Mediterranean  53 2.6 
South-East Asia 25 1.2 
Western Pacific 16 0.8 
Not known 8 0.4 
Probable route of infection2 
 
Heterosexual sex 1798 87.2 
Injecting drug use 40 1.9 
Other  135 6.5 
Not known 90 4.4 
Age at start of first pregnancy Median [interquartile 
range (IQR)] (years) 
30               [27-34] 
HIV-diagnosis in relation to first 
reported pregnancy  
 
Before  1131 54.8 
During  911 44.2 
At delivery 21 1.0 
Pregnancy outcome  
(n=3030) 
Live birth 2632 86.9 
Miscarriage 178 5.9 
Termination 113 3.7 
Stillbirth 33 1.1 
Ectopic  4 0.1 
Continuing to term 70 2.3 
1 
WHO World Regions  
2 
Using UK CHIC categories and data 
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 Availability of pre and post-pregnancy clinical data  3.5.2
Half (49.6%, n=1024) the women in the UK CHIC-NSHPC combined dataset had some 
clinical data in UK CHIC prior to their first reported pregnancy, for a median of 2.8 (IQR 
1.2-5.4) years before the pregnancy. The majority of the pregnancies which started prior to 
2009 had some clinical data in UK CHIC following the pregnancy (92.0%, 2471/2685), for 
a median of 3.8 (IQR 1.8-6.4) years. The median time between delivery and the next viral 
load or CD4 assessment was 1.8 (IQR 1.1-3.5) months. The majority of pregnancies with 
no data in UK CHIC after the delivery had resulted in a live-birth (92.5%, 198/214) and 
36% (77/214) had data in UK CHIC before the pregnancy. In some cases this was 
because they had delivered in the last few months before the end of follow-up (i.e. when 
data was reported to). As no data on departure from the UK were available it was not 
possible to determine whether women with no post-delivery data had left the UK, 
transferred care to a non-UK CHIC site or remained in the UK but stopped attending HIV 
clinical care. The percentage with a UK date of arrival was the same for women with and 
without post-delivery data (61% [1523/2496] vs. 61% [115/189], Chi-squared test p=0.96). 
The median time between UK arrival and delivery were also similar (4.1 [IQR 2.0-7.3] vs. 
3.0 [IQR 1.0-5.8] years respectively, Mann-Whitney test p<0.20).  
 
3.6 Representativeness of pregnant women in UK CHIC  
Women in the NSHPC whose record was found in UK CHIC (n=2063), referred to as 
‘matched’, were compared with women in the NSHPC whose record was not found in UK 
CHIC (n=6869), referred to as ‘non-matched’ (i.e. women with a pregnancy who did not 
attend HIV clinical care at a UK CHIC collaborating site). Using logistic regression, 
matched women were more likely to have attended antenatal care in London than non-
matched women (83% [n=1717] vs. 37% [n=2530] respectively, odds ratio [OR] 8.5 [7.5-
9.6], p<0.001) and were slightly older at the start of their first pregnancy (median age: 
matched women 30.4 [IQR 26.5-34.3] years; non-matched women 29.6 [IQR 25.8-33.6] 
years, p<0.001). Using HIV diagnosis date from NSHPC, a greater proportion of matched 
women were diagnosed with HIV before their index pregnancy compared to non-matched 
women; 55% (n=1131) vs. 48% (n=3278) respectively (OR 1.34 [1.21-1.48], p<0.001). 
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A smaller proportion of matched compared to non-matched women had an index 
pregnancy with an outcome not yet reported to NSHPC (i.e. the outcome was reported as 
‘continuing to term’) (2% [n=30] vs 5% [n=342] respectively, OR 0.28 [0.19-0.41], 
p<0.001), most of which were conceived in 2009/10 (73%, 273/372). When first 
pregnancies with an ‘other/missing’ outcome (i.e. women who left the UK or who were lost 
to follow-up, 6 non-matched records and 0 matched) and pregnancies where outcome was 
not yet reported were excluded, the outcomes for first pregnancies were similar for 
matched and non-matched women (Chi-squared test p=0.15), with 90% (1834/2033) vs. 
89% (5782/6521) resulting in a live birth respectively. 
A higher proportion of matched than non-matched women had at least one repeat 
pregnancy; 34% (n=709) vs. 20% (n=1394) (OR 2.00 [1.80-2.23], p<0.001). The likelihood 
of being matched was greater for women with sequential pregnancies than for women with 
a single pregnancy (OR 2.08 [1.86-2.31], p<0.001). 
Ethnicity varied somewhat; a smaller proportion of matched women were black-African 
compared to non-matched women (74% [n=1535] vs. 78% [n=5362], OR 0.82 [0.73-0.92], 
p<0.001). This difference remained significant when ‘ever seen for antenatal care in 
London’ was included in the model (adjusted OR [aOR] 0.67 [0.58-0.76], p<0.001). A 
higher proportion of matched women were black-Caribbean compared to non-matched 
women (5% [n=104] vs. 3% [n=230] respectively, OR 1.53 [1.21-1.94], p<0.001), but this 
difference was attenuated after adjustment for antenatal care in London (aOR 1.00 [0.78-
1.29], p=0.99). The proportion of women who were of white ethnicity was similar among 
matched and non-matched women (12% [n=243] vs. 13% [n=919] respectively, OR 0.86 
[0.74-1.01], p=0.06 and aOR 1.40 [1.18-1.65], p<0.001, adjusted for antenatal care in 
London.)  
A higher proportion of matched than non-matched women were using ART around the 
time of conception (30.4% [n=628] vs. 20.6% [n=1424], respectively, p<0.001). This was 
also the case after excluding women who were not diagnosed with HIV prior to their 
pregnancy.  
In the NSHPC dataset, women of black-African ethnicity were more likely to have a DOB 
where the date matched the month (i.e. 1st January, 2nd February etc.) compared to 
women of white ethnicity (7% [474/6897] vs. 3.9% [45/1162], OR 1.83 (1.34-2.50) 
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p<0.001). Records where DOB date matched the month were less likely to be matched 
(aOR 0.78 (0.64-0.95), p=0.01, adjusted for ethnicity).  
 Geographical representativeness of the UK CHIC dataset  3.6.1
Some of the differences in characteristics between matched and non-matched women 
may be due to differences in women attending care at UK CHIC sites and women 
attending care elsewhere. As a large number of UK CHIC centres are in London (Table 
3.1), in the UK CHIC dataset, 85% (7014/8286) of women ever attended a HIV clinic in 
London and of those attending care in 2009, 82% (3906/4755) attended a London site. 
This is higher than seen in the whole UK HIV-positive population (Table 3.10). In the 
NSHPC dataset, 48%, (4247/8932) of women had ever received antenatal care (whilst HIV 
diagnosed) in London. Women in NSHPC who ever attended antenatal care in London 
differed somewhat from women who only attended for care elsewhere, for example, they 
were older at the start of their first pregnancy (31.1 and 29.6 years respectively, p<0.001), 
they were more likely to be of black-African or black-Caribbean ethnicity and less likely to 
be of white ethnicity compared to women seen outside London (black-African: 79.8% 
[3390/4247] vs. 74.9% [3507/4685], OR 1.33 [1.20-1.47], p<0.001; black-Caribbean: 5.7% 
[n=240] vs 2.0% [n=94], OR 2.93 [2.30-3.73], p<0.001; and white: 8.1% [n=346] vs. 17.4% 
[n=816], OR 0.42 [0.37-0.48], p<0.001 respectively). The proportion of women diagnosed 
with HIV before their first reported pregnancy was similar for women seen in London and 
seen elsewhere, (49% [2061/4247] and 50.5% [2366/4685] respectively, Chi-squared test, 
p=0.06). 
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Table 3.10. The number and percentage of women accessing HIV clinical care in London 
of those accessing care in the UK, according to The Survey of Prevalent HIV Infections 
Diagnosed (SOPHID)22 (2000-2009) [394]. 
Year UK London 
%  
(London/UK total) 
2000 4871 2829 58 
2001 6231 3716 60 
2002 8248 4543 55 
2003 10,413 5189 50 
2004 12,309 5680 46 
2005 14,324 6336 44 
2006 15,921 6798 43 
2007 17,149 7080 41 
2008 18,489 7505 41 
2009 19,312 7696 40 
Total 127,267 57,372 45 
 
3.7  Completeness of the matching   
There was no ‘gold standard’ which could be used to determine whether all women in UK 
CHIC with a pregnancy were found in NSHPC or whether all paired records genuinely 
referred to the same woman.   
After completion of the matching strategy there were 4916 pairs (3014 UK CHIC records 
and 3285 NSHPC records) remaining in the linked dataset i.e. records linked because they 
had the same DOB, which had not been confirmed as genuine matches according to the 
matching criteria. Of these, 137 (2.8%) pairs had records from NSHPC and UK CHIC 
reported from the same site but could not be confirmed as a genuine match due to 
insufficient data in other fields (47% [n=64] had no CD4 count reported to the NSHPC).  
 
                                               
22
 Further details on SOPHID are available at www.gov.uk/hiv-surveillance-systems 
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 Comparing records from sites which record pregnancy 3.7.1
In order to assess the completeness of the matching, two clinics which collaborate in the 
UK CHIC study and which record pregnancy status in women’s clinical records offered to 
generate a list of women (DOB or clinic ID only) attending their clinics who had had a 
pregnancy.  
North Middlesex University Hospital 
North Middlesex University Hospital sent a list of women’s clinic IDs, DOB and their 
delivery date for 288 HIV-positive women known to have had a pregnancy. Although clinic 
ID is reported to UK CHIC by clinics, it is not included in the final UK CHIC dataset. 
Therefore, Dr Teresa Hill, the UK CHIC data manager, provided me with the UK CHIC 
unique IDs (Patnum) for these women. I assessed how many women in the North 
Middlesex list appeared in the combined dataset (Figure 3.3). If women were not found in 
the combined dataset, the NSHPC dataset was searched for any records with the DOB to 
see if the women had ever had a pregnancy reported to the NSHPC. 
   
Figure 3.3. Assessing whether women with a pregnancy at North Middlesex are included 
in the UK CHIC-NSHPC 2009 combined dataset to assess completeness of the matching 
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Of the 288 women in the North Middlesex list, 40 were not found in the UK CHIC dataset 
(12 of whom had a pregnancy before 1996) (Figure 3.3). Of the 248 women in the UK 
CHIC dataset, 171 (69%) were in the UK CHIC-NSHPC 2009 combined dataset (Table 
3.11). Of the 77 women who were not in the combined dataset, 20 had a DOB which did 
not match any DOB in the NSHPC dataset indicating that these women did not have a 
pregnancy reported to NSHPC (12 had a fuzzy DOB match to a record with 1st or 15th of 
the same month and year but no CD4 date match). Of the 57 records not found in the 
combined dataset, but with a DOB matching at least one record in the NSHPC dataset, 7 
had a pregnancy reported to NSHPC by North Middlesex but the paired records had 
insufficient data to confirm that they were a genuine match.  
I visited North Middlesex and spoke with the data manager, midwife and clinician to try to 
understand why some of the women on the list they had produced for me were not found 
in the UK CHIC or NSHPC datasets. The midwife informed me that there was some 
reporting delay of pregnancies to NSHPC, with older records still being reported as and 
when time permitted. However, she could not tell me which pregnancies had or had not 
been reported. When reviewed by the clinician, it was clear that some patients included in 
their list, had not received sufficient HIV clinical care to be included in the UK CHIC 
reporting, for example they had been seen once, but had not received any clinical 
assessments.  
Of the records which were linked to at least one record in NSHPC, but not confirmed as a 
match, it is difficult to know how many were genuine matches. It is probable that the 7 
pairs with data reported from North Middlesex to UK CHIC and the NSHPC were genuine 
matches, but there was no further data to confirm or refute this. This exercise indicated 
that there was likely to be some incomplete matching due to insufficient data, such as CD4 
dates, as well as underreporting or reporting delay. It was not possible to determine the 
level of under-matching. It is further complicated by the fact that women can choose where 
they access antenatal care and where they access HIV clinical care and these might not 
be at the same site.  
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Table 3.11. Comparison of records from North Middlesex University Hospital for women 
living with HIV known to have had a pregnancy and records in matched dataset over time 
 North Middlesex dataset 
 
UK CHIC - NSHPC 
combined dataset1 
% of North Middlesex 
records found in the 
combined dataset 
Year Pregnancies Women Pregnancies Women Pregnancies Women 
1996 4 4 1 1 25 25 
1997 3 3 0 0 0 0 
1998 9 9 4 4 44 44 
1999 11 9 7 6 64 67 
2000 21 20 17 16 81 80 
2001 20 18 17 15 85 83 
2002 16 15 8 7 50 47 
2003 38 29 19 12 50 41 
2004 37 30 22 20 59 67 
2005 27 20 20 14 74 70 
2006 32 23 25 18 78 78 
2007 45 27 40 22 89 81 
2008 37 22 36 21 97 95 
2009 28 14 24 11 86 79 
2010 19 5 14 4 74 80 
Total 347 248 254 171 73 69 
 
1
 Of the women in the North Middlesex dataset 
 
King’s College Hospital 
At King’s College Hospital all appointments with a midwife or doctor regarding pregnancy 
or antenatal care are recorded in the patient’s clinical record. The HIV research nurse 
provided me with a list of the DOB and attendance date of 272 women who had attended 
an antenatal appointment and accessed HIV clinical care at King’s College Hospital. Of 
these, 32 were recent patients who had not yet been reported to UK CHIC, 6 were not 
recent patients and were not in UK CHIC. Of the 234 women in UK CHIC, 80.8% (n=189) 
were in the UK CHIC-NSHPC combined dataset (Figure 3.4).  
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Of the 44 women not in the combined dataset, 7 women did not have a record in NSHPC 
with their DOB (3 from 2005, 3 from 2008 and one from 2009), two did have a record in 
NSHPC with their DOB but the NSHPC record had been matched to a different UK CHIC 
record and was therefore probably not their record. It is therefore probable that these 9 
women did not have a pregnancy reported to NSHPC.  
I visited the research nurse at King’s College Hospital. The research nurse examined the 
records for the women who had been included in the list but who were not in the UK CHIC-
NSHPC combined dataset. In some cases, individuals who had attended an antenatal 
appointment were not pregnant (or were not recorded as being pregnant in their clinic 
record). This included women (and men) who had received fertility advice. In one case a 
woman had received two ultrasound scans despite not being pregnant.   
The number of women receiving antenatal care each year was higher, according to the 
King’s College Hospital records, than the number of women in the combined dataset 
(Table 3.12). This indicates some level of under-matching. However, it is difficult to assess 
the extent of this and it was clear that not all women who received antenatal care at King’s 
had a pregnancy.   
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Figure 3.4. Assessing whether women who attended antenatal care at King’s College 
Hospital were included in the UK CHIC-NSHPC combined dataset   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.12. Comparison of records from King’s College Hospital for HIV-positive women 
known to have had a pregnancy and records in the combined dataset 
Year Women seen for 
antenatal care at 
King’s 
UK CHIC-NSHPC 
combined 
dataset1 
% 
2004 18 17 94.4 
2005 61 52 85.2 
2006 54 47 87.0 
2007 44 39 88.6 
2008 37 24 64.9 
2009 19 10 52.6 
Total 233 189 81.1 
1
 Of the women seen for antenatal care at King’s 
Note that an additional record from 2010 was not included in the table 
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n=38  
Not in UK CHIC 
 
n=32  
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n=44 (19%) 
Not found in 
combined dataset  
n=35  
Linked to ≥1 record in 
NSHPC using DOB 
but insufficient data to 
confirm match  
 
n=9  
Not found in 
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n=1 
Reported as male in 
UK CHIC  
 
n=272 
HIV-positive women receiving 
antenatal care at King’s according 
to centre list 
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 Estimating completeness of the matching using national surveillance data 3.7.2
National HIV surveillance data from the Health Protection Agency (HPA) (now Public 
Health England [PHE]) were used to assess the completeness of the matching between 
the NSHPC and UK CHIC.  
The Survey of Prevalent HIV Diagnosed (SOPHID) collects data on all adults diagnosed 
with HIV who attend clinical care at HIV clinics in the UK and is thought to have near-
complete coverage. The most up-to-date annual report published by the HPA included 
data for adults aged 15-49 years [394], therefore I made a request for data specifically 
relating to adults aged 16-49 years old.  
The number of women (aged 16–49 years) who attended HIV-related care in the 2009 UK 
CHIC dataset increased yearly; from 2036 in 1996 to 4755 in 2009, totalling 45,768 person 
years and representing approximately 29.5% (37,577/127,267 person years) of HIV-
positive women (aged 16–49) attending HIV care in the UK in 2000–2009. 
In 2009, there were 19,312 women (aged 16–49 years) seen for HIV-clinical care in the 
UK (SOPHID data) and 1198 women living with HIV who had a pregnancy (1211 
pregnancies) starting in that year (according to the NSHPC dataset used in this study), 
indicating that approximately 6.2% (1198/19,312) of women living with HIV who attended 
HIV-care in 2009 had a pregnancy starting that year. We would therefore anticipate that 
6.2% of the 4755 women in UK CHIC would have a pregnancy in 2009 equating to 295 
women (95% confidence interval 279–311 women). The UK CHIC-NSHPC combined 
dataset actually contained 275 women with at least one pregnancy in 2009, 4 fewer than 
the lower limit of the anticipated range. 
However, there are a number of limitations to this analysis. Despite good coverage by 
SOPHID and NSHPC, we know from a matching exercise between SOPHID and NSHPC 
and between UK CHIC and SOPHID that there is incomplete matching of records between 
these datasets, so not all women reported to UK CHIC or reported to NSHPC are in fact 
reported to SOPHID. This analysis also assumes that there is no difference in the 
pregnancy rate across the country. Many of the UK CHIC sites are based in London where 
the number of pregnancies among women living with HIV is likely to differ compared to 
elsewhere in England and Wales, as is the case in the general population [395].  
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3.8 Discussion 
A strategy was developed to identify women reported to both NSHPC and UK CHIC, i.e. 
women who attended HIV-related clinical care at a site participating in UK CHIC and who 
had a pregnancy. Since it was not possible to use a single unique identifier to find records 
for the same woman in both studies, a deterministic decision criteria based on 
demographic and clinical data common to both NSHPC and UK CHIC was used. Using 
this strategy we were able to determine that almost one-quarter of HIV-positive women in 
UK CHIC had a pregnancy, as a minimum estimate. This method combined the use of 
automated matching with manual review of selected records, as has been used elsewhere 
[396-400]. It was undertaken within the software used for analysis of data (SAS) allowing it 
to be repeated in subsequent years with the use of minimal resources or programming 
expertise. A number of records were scrutinised as part of the matching process, for 
example where two records from one study were matched to a single record from the other 
study or where two matched records had a discrepancy. This resulted in small 
improvements to both datasets with mistakes being corrected or two records for the same 
woman in the same dataset being merged.   
There was no ‘gold-standard’ available to calculate the completeness of the matching. 
Instead, national HIV surveillance data of individuals attending HIV-related care (SOPHID), 
provided by PHE, were used to estimate the expected number of women with a pregnancy 
in the UK CHIC dataset. The number of women with a pregnancy in the UK CHIC-NSHPC 
combined dataset was lower than the anticipated number for this period, indicating that 
there was incomplete matching. However, this needs to be interpreted with care, as there 
are many limitations to this way of estimating completeness. In reality the level of matching 
may be higher since this estimate assumes that all women in the NSHPC are reported to 
SOPHID, which previous matching studies indicate is not the case [401]. It also assumes 
that the fertility rate is uniform throughout the UK. At the time of the linkage, in the general 
population, the fertility rate of women living in London was lower than in any other region in 
England or Wales (with the exception of the North East of England) [402].  
A large number of records were paired because they had the same DOB but were not 
thought to be a genuine match according to the other criteria used. It is unlikely that many 
of these were genuine matches as we would expect some women to share birth dates 
given the number of women in both datasets, particularly as women who do not know their 
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DOB sometimes use proxy dates, which are therefore more common in the dataset [403]. 
UK CHIC and NSHPC records with identical DOB reported from the same site but no other 
matching variables (137 pairs) may have been genuine matches; however, in this instance 
under-matching was preferable to incorrect matching. The analyses in this thesis focus on 
the period of pregnancy or post-pregnancy, and as such it was preferable to potentially not 
include all pregnancies in the analysis rather than include a period of time which was 
thought to be during pregnancy but was not. Many of these records were not matched 
because they had limited clinical data which could be compared. It is therefore likely that, 
even if they were matched, they would have been excluded from analyses due to lack of 
clinical data such as CD4 counts.  
There are a number of limitations to the methods used, including the use of blocking to 
select records, in this instance DOB. This method is effective at limiting the records in the 
matching process to those likely to be matches and is frequently used in matching large 
datasets [398, 404, 405]. However, it means that incorrect or inconsistent reporting of DOB 
results in a record being excluded; this may be more common among some groups than 
others, potentially introducing selection bias [403, 406]. Use of demographic data for 
record matching, such as age, ethnicity, and COB, within any matching algorithm is likely 
to create some false positive matches. Given our study population of pregnant women, 
multiple women had the same ethnicity, COB, and age, therefore the additional use of 
clinical data was vital for matching. However, this resulted in some selection bias, as 
women with more clinical data (either because they had been diagnosed prior to 
pregnancy, were receiving ART when they conceived or had repeat pregnancies) were 
more likely to be matched than women with less data. This difference also indicates that 
the matching was somewhat incomplete. Since women in the NSHPC had 8.5 times the 
odds of being matched if they attended care in London than if they attended care 
elsewhere (because many of the UK CHIC sites were located in London), other differences 
between the matched and non-matched women could be attributed to differences between 
HIV-positive women living in London and elsewhere. For example, in the general 
population the average age of women giving birth in London is higher than elsewhere in 
England and Wales [407]. This could explain why the matched women were somewhat 
older at the start of their index pregnancy compared to the non-matched women. The 
differences in ethnicity between matched and non-matched women could also be 
explained by differences in ethnicity between women attending care in and outside 
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London. However, when taking location into account, black-African women were still less 
likely to be matched than women of other ethnicities.  
Data discrepancies in fields common to both studies were harmonised where possible, or 
else categorized as ‘not known’ (as described in the following chapter). These 
discrepancies were unlikely to be a result of incorrect matching, as matched records with 
strong discrepancies were manually checked for additional matching variables. A woman’s 
antenatal data, used for completing the NSHPC reporting form, and HIV clinical data 
extracted for inclusion in UK CHIC, are typically stored separately, even within the same 
hospital (although more hospitals are moving to integrated software systems across 
clinics). Reasons why these databases might be discrepant include incorrect or incomplete 
recording of data and inconsistent or inaccurate reporting by patients, for example where 
language is a problem, if they do not know or do not want to disclose their DOB to 
maintain anonymity [403].  
The UK CHIC-NSHPC dataset has a number of applications. As well as helping to improve 
the data quality of both datasets, it and allows analyses which could not be performed 
using either dataset in isolation. Used in combination with all records for women in UK 
CHIC it is possible to compare the health of pregnant women with the health of non-
pregnant women and to assess pregnancy incidence among women accessing HIV clinical 
care. The matching of datasets also allows the exclusion of pregnant women from the UK 
CHIC dataset if required for specific analyses.  
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Chapter 4 Methods  
 
4.1 Introduction  
The matching strategy, described in the previous chapter, resulted in the creation of a 
dataset, referred to as the matched dataset, containing data from the UK Collaborative HIV 
Cohort (UK CHIC) study and the UK and Ireland’s National Study of HIV in Pregnancy and 
Childhood (NSHPC) for women found in both studies. In this chapter I describe the 
creation of new variables using data from one or both studies including the start date for 
life-long ART and the variable which categorises the type of ART used in pregnancy. I also 
describe how I dealt with discrepancies in variables reported to both studies and I define 
commonly used variables. 
 
4.2 Using data from both sources to create variables and dealing 
with discrepancies 
HIV diagnosis date discrepancies 
Of the 2063 women in the matched dataset, 24% (n=503) had identical HIV diagnosis 
dates in their UK CHIC and NSHPC records, 37% (n=756) had diagnosis dates ≤30 days 
apart and 33% (n=652) had dates >30 days apart (Table 4.1). Similar proportions were 
seen for the women with UK CHIC and NSHPC reports from the same site (86% of women 
in the matched dataset). In women for whom UK CHIC and NSHPC reports were from 
different sites, only 10% (29/296) had identical HIV diagnosis dates and 51% (151/296) 
had dates >30 days apart (Table 4.1). It is not clear whether this is a result of incorrect 
matching of UK CHIC and NSHPC records. However, much of the inaccuracy of HIV 
diagnosis dates is likely to be due to non-disclosure or recall bias, i.e. people recall a 
different date when asked at different times, which would result in a higher rate of 
discrepancies when reports come from two different sites.  
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Table 4.1. Summary of discrepancies in HIV diagnosis date between NSHPC and UK 
CHIC records for the same woman 
HIV diagnosis dates 
match/discrepancy 
Overall  
(n=2063) 
No site match  
(n=296) 
Site match1 
(n=1767) 
N % n  % n  % 
Identical dates 503 24 29 10 474 27 
1-30 days apart 756 37 89 30 667 38 
31-365 days apart 429 21 83 28 346 20 
>365 days apart 223 11 68 23 155 9 
One or both had missing dates 152 7 27 9 125 7 
1
At any point they received care from the same site  
Of the 652 women with HIV diagnosis dates >30 days apart, 45% (n=290) had a date in 
NSHPC later than the date in UK CHIC. Of these, 27% (n=79) were diagnosed with HIV 
during their first reported pregnancy according to NSHPC but before their first reported 
pregnancy according to UK CHIC. This discrepancy was not limited to specific sites; at 
least one instance of such a discrepancy occurred in data from each of the UK CHIC sites. 
It is not clear whether this discrepancy was a result of women being retested for HIV whilst 
pregnant (as part of routine antenatal screening), despite already being aware of their HIV-
positive status, or whether their first attendance in antenatal care was reported by NSHPC 
as their HIV diagnosis date despite their diagnosis occurring before the pregnancy. 
Alternatively, women may have been aware of their HIV diagnosis and received HIV-
clinical care at one site whilst attending a different site for antenatal care where they did 
not disclose their HIV status.  
As is the case with DOB, proxy dates are used by some clinics and in the NSHPC 
database if only the month or year of HIV diagnosis is known. In the matched dataset there 
were 303 records with HIV diagnosis date reported as 30th June in one study but not the 
other (NSHPC n=299, UK CHIC n=4). Of these, 58% (n=175) had a diagnosis date 
reported by the other study which was in the same year, either before (n=114) or after 
(n=61) 30th June, suggesting that one clinic reported the actual date of diagnosis whilst the 
other reported only the year or a proxy date.   
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HIV diagnosis date combined variable  
Where the HIV diagnosis dates reported by NSHPC and UK CHIC were not identical, the 
earliest HIV diagnosis date from either study was used (n=1865) unless one date 
appeared to be a proxy date (i.e. either 1st January or 30th June) and the later date 
(believed to be the genuine date) was during the same year, in which case the later date 
was used (n=116). The earliest CD4 cell count, viral load measurement or ART start date 
was used if no HIV diagnosis date was available (n=4), or if that date preceded the earliest 
HIV diagnosis date (n=78).  
Using the HIV diagnosis dates reported, a variable was created which categorised the 
timing of HIV diagnosis in relation to each pregnancy i.e. before or during the pregnancy. 
Although an equivalent variable was reported in NSHPC, it was underreported and in 
some cases was discrepant with the HIV diagnosis date reported. If no HIV diagnosis date 
was reported to the NSHPC but it was reported that the woman was diagnosed prior to the 
pregnancy then diagnosis was categorised as occurring before the pregnancy even if the 
HIV diagnosis date in UK CHIC was after the start of the pregnancy (n=7). If no HIV 
diagnosis date was reported to NSHPC but it was reported that the woman was diagnosed 
during the pregnancy then the woman was categorised as being diagnosed during the 
pregnancy even if the HIV diagnosis date in UK CHIC was after the delivery date (n=2).  
Only if the woman was diagnosed with HIV before or during a pregnancy was the 
pregnancy included in the final dataset, since women who were not diagnosed until 
delivery or later could not have used ART during the pregnancy. Overall, 21 women were 
diagnosed with HIV after their first reported pregnancy, 8 were diagnosed on the day they 
delivered, 8 within a week of delivery and 5, more than a week after delivery. Of these, 9 
women had no further pregnancies and were therefore excluded from the dataset. The 
remaining 12 women had at least one subsequent pregnancy. Their first reported 
pregnancy was excluded, their second pregnancy was re-categorised as their first, their 
third as their second, and so on.  
Country of birth 
Table 4.2 summarises the number of discrepancies in COB for matched records. Overall, 
58% of women had the same COB in their NSHPC and UK CHIC records and 34% had 
COB missing from at least one of the study datasets. The majority of records with 
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discrepant COB had ‘UK’ (or in a handful of cases ‘Scotland’) reported as the COB in one 
study but not in the other (with 37 different countries reported overall as the non-UK 
country).  
Table 4.2. Summary of discrepancies in COB between matched records 
Category of match/discrepancy  n % 
Exact match 1205 58 
UK vs. non-UK  106 
5                                UK in UK CHIC record 89 
                                  UK in NSHPC record 17 
Africa vs. named country in Africa1   6           0.3 
Missing COB  694 34 
 Missing in UK CHIC only 673  
 Missing in NSHPC only 14  
 Missing in both 7  
Other discrepancy 52 3 
1
In all cases it was in the NSHPC record that COB was recorded as ‘Africa’ 
In most of the analyses in this thesis, ethnicity rather than COB is considered, since so 
many COB were represented in the dataset. Where region of birth (ROB) was used, this 
was categorised using the WHO regions [408]. Records with discrepant ROB (n=98) were 
categorised as ‘not known’ (n=2) or as the non-European region if the region was 
European in one dataset and non-European in the other (n=96) (94 had UK as the COB in 
one study but not in the other).  
Ethnicity 
The two studies categorise ethnicity slightly differently. The studies use four common 
categories: White; Black-African; Black-Caribbean; Other Asian/Oriental; and Other/mixed. 
However, the UK CHIC uses a further four categories: Black-unspecified/black-other; 
Indian/Pakistani/Bangladeshi; Other; and Not known, while the NSHPC uses a further two: 
black-other; Asian/Indian/Subcontinental. The NSHPC form also has a text field for 
ethnicity to be entered where ethnicity is ‘other or mixed’.  
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The strength of the match/discrepancy between data in the matched pairs was categorised 
into four categories (Table 4.3). Where ethnicity was not an exact match (n=161), for 
example ‘black-African’ versus ‘black-other’, the ethnicity reported to UK CHIC was used 
since some analyses included women reported to UK CHIC but not to the NSHPC. There 
were 17 pairs with a strong discrepancy, for example, ‘black-African’ vs. ‘white’. These 
records had been checked at the discrepancy checking stage of the matching and had 
sufficient data in common from other fields, including COB, to indicate that they referred to 
the same woman. Where there was a strong discrepancy, this was assumed to be due to 
an error in one dataset and the COB was used to indicate which ethnicity was more likely 
to be correct. For example, a woman reported as being ‘white’ in UK CHIC and ‘black-
Caribbean’ in NSHPC had her COB reported as Trinidad in both datasets and was 
therefore categorised as being of ‘black-Caribbean’ ethnicity in the final dataset. Where the 
COB could not be used, the child’s ethnicity was checked (as this is reported to NSHPC) 
to indicate if there was an obvious mistake in the reporting of the mother’s ethnicity. Where 
ethnicity could not be determined it was coded as ‘not known’ in the combined dataset 
(n=8). 
 
Table 4.3. Summary of discrepancies/matching in ethnicity between matched records 
Category of match/discrepancy n % 
Exact match 1808 88 
One or more have missing ethnicity 
Missing in UK CHIC  
Missing in NSHPC 
77 
(74) 
(3) 
4 
Discrepancy 
Matched using CD4 date  
Matched using CD4±30 days  
Matched using ART start/stop dates  
Manually matched  
17 
(7)  
(5) 
(3)  
(2) 
0.8 
Not exact match - weaker discrepancy 161 8 
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Soundex  
Soundex was not used in the analysis, but discrepancies in soundex were examined. This 
was to identify any false matches and to gauge how many apparently genuine matches 
had different soundex, indicating to what extent soundex might be useful in the matching 
strategy. Of the 2063 women in the matched dataset, only 1% (n=24) had soundex 
recorded in UK CHIC and the NSHPC due to underreporting of this variable to the 
NSHPC. Of these women, 7 had been matched at the manual matching stage because 
they had matching soundex (as well as similarities in other variables). For the remaining 
17 women with records matched using other criteria, 65% (n=11) had the same soundex in 
the NSHPC and UK CHIC and 35% (n=6) did not. These were all reviewed and appeared 
to be genuine matches indicating that although soundex could be used to confirm a match 
(in combination with other variables) we would anticipate that around one-third of genuine 
matches would have discrepant soundex in the NSHPC and UK CHIC. There are 
numerous possible reasons for these discrepancies: chance; women changing their 
surname when they marry or divorce; incorrect spelling of surname; or multiple names 
used by the same individual. The use of Soundex as a variable for record linkage is 
particularly problematic within this population, since many of the women will be married or 
get married whilst under HIV care and may therefore change their surname and because 
of the stigma still associated with HIV, some patients attending HIV clinics may not 
disclose their real name.  
Site 
At many hospitals a pregnant woman with HIV would receive antenatal care in a different 
department to where she receives routine HIV clinical care. Especially in London, women 
may choose to access antenatal care at a different hospital from where they receive HIV 
clinical care since different sites offer different antenatal facilities and there may be other 
practical reasons such as proximity to home or work. Women may also change the site at 
which they receive HIV clinical care, for example if they move, their clinician moves or for 
numerous other reasons. Although the UK CHIC dataset includes a list of all sites which 
have ever reported data for an individual (i.e. sites they have ever attended for HIV clinical 
care), it does not contain all the dates of attendance at each of the sites. It was therefore 
difficult, for women who had attended more than one site, to assess whether they attended 
antenatal care at the same site where they attended HIV clinical care. This is also 
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complicated by differences in the division of care between hospital sites, with some sites 
managing antenatal care within the HIV clinic and others having two separate clinics within 
the same trust. Overall, 92% of women had NSHPC and UK CHIC data reported from the 
same site (Table 4.4). 
Table 4.4. The number and percentage of records in the matched dataset with NSHPC 
and UK CHIC data for the same woman from the same or from different sites  
Sites reporting NSHPC and UK CHIC 
data for the same woman  
Number 
(n=2063) 
% 
Match 1899 92 
Not a match - both London sites 62 3 
Not a match - not both London sites 101 5 
Site data missing  1 0.1 
 
HIV viral load  
It was important for a number of analyses to establish the woman’s viral load at delivery, 
and more specifically whether the viral load was undetectable. Viral load measurements 
are collated by both studies; the UK CHIC study collates all viral load measurements 
performed in HIV clinical care and the NSHPC requests the first and last viral load 
measurements performed during pregnancy. In order to create a dichotomous variable 
categorising viral load at delivery as either detectable (HIV-RNA >50 copies/ml) or 
undetectable (HIV-RNA ≤50 copies/ml) using all the available data, all viral load 
measurements ≤30 days before delivery were assessed.  
Of the 3030 pregnancies in the matched dataset, 69% (n=2090) had a viral load 
measurement ≤30 days before delivery reported by at least one study; 41% (n=1257) had 
data from both studies, 16% (n=480) from NSHPC only and 12% (n=353) from UK CHIC 
only. When viral load was categorised as either detectable or undetectable, there were 94 
pregnancies with a discrepancy in the data from UK CHIC and NSHPC (Table 4.5).  
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Table 4.5. Comparison of viral load at delivery reported by NSHPC and UK CHIC for 
pregnancies in the combined dataset (n=3030) 
Viral load at delivery1 UK CHIC 
Undetectable Detectable No VL1 
NSHPC Undetectable 805 62 2 352 
Detectable 32 3 358 128 
No VL1 219 134 940 
VL: viral load 
1 
≤30 days before delivery 
2 
22 of these were reported on the same day 
3 
2 of these were reported on the same day 
The accuracy of assays used to measure viral load has improved over time. For some of 
the older viral load assays, 400 copies/ml was the cut off for detecting viral load. 
Therefore, UK CHIC collected an additional dichotomous variable ‘undet’ which indicates 
whether a viral load was undetectable/detectable according to the assay used at the time.  
Of the 62 discrepancies where viral load was reported as >50 copies/ml in UK CHIC and 
≤50 copies/ml in NSHPC, 22 were reported on the same date. Of these, 11 were reported 
as undetectable according to the UK CHIC undet variable. 
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Figure 4.1. Discrepancies in viral load at delivery: UK CHIC >50 copies/ml and NSHPC 
≤50 copies/ml 
 
 
 
 
 
 
 
 
 
 
VL: viral load (copies/ml) 
For the 26 women with a viral load date in UK CHIC 3-29 days before the date in NSHPC, 
12 had a viral load ≤400 copies/ml. It is possible that some of these women had not 
achieved undetectable levels when the viral load was reported to UK CHIC but had an 
additional viral load measurement taken closer to the time of delivery, by which point they 
had achieved viral suppression.  
For the 14 women with a viral load date in UK CHIC after the NSHPC date, two were 
categorised as undetectable in the undet field. Viral load varied from 54 to 730 and 
although it is feasible that the viral load increased from <50 copies/ml to >50 copies/ml in 
the period between tests, it is very unlikely, since all these women were on ART at this 
point.  
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Figure 4.2. Discrepancies in viral load at delivery: UK CHIC ≤50 copies/ml and NSHPC 
>50 copies/ml 
 
 
 
 
 
 
 
 
 
 
 
VL: viral load (copies/ml) 
For the 32 records where viral load was ≤50 copies/ml in UK CHIC and >50 copies/ml in 
NSHPC, the dates of viral load were the same for 2 records and in both cases the viral 
loads reported to NSHPC were close to 50 copies/ml (82 and 60 copies/ml). The majority 
of viral loads reported were ≤400 copies/ml. It is possible that in some cases the viral load 
fell from the time of the NSHPC viral load measurement to the UK CHIC viral load 
measurement.  
One option would be to only use data from UK CHIC for analysis of viral load at delivery. 
This would mean not utilising all the available data; there were 353 records with viral load 
data only available in NSHPC. It is difficult to know whether discrepancies between 
datasets are due to changes in viral load in the time between tests, inaccurate reporting of 
dates or viral loads (particularly in the NSHPC data, for which forms are manually 
completed), different assays being used in the different laboratories or incorrect matching 
VL ≤400 
n=2 
VL ≤400 
n=0 
NSHPC: detectable VL 
UK CHIC: undetectable VL 
UK CHIC VL date  
= NSHPC VL date 
n=2 
UK CHIC VL date  
< NSHPC VL date 
n=6 
UK CHIC VL date  
> NSHPC VL date 
n=24 
VL ≤400 
n=22 
VL >400 
n=2 
VL ≤400 
n=5 
VL >400 
n=1 
n=32 
n=30 
n=24 
 131 
 
of records (i.e. the UK CHIC and NSHPC records do not refer to the same woman). UK 
CHIC collects data on which viral load assay is used for each viral load assessment. Not 
all sites used the same viral load assay but this field was not examined in detail. 
It was decided that the most appropriate way to categorise viral load at delivery was to use 
the viral load taken closest to the date of delivery from either dataset. Where viral load 
measurements were on the same date in NSHPC and UK CHIC the viral load was 
categorised as undetectable if both viral loads were reported as <100 copies/ml. They 
were also categorised as undetectable if the viral loads were both <400 copies/ml and UK 
CHIC reported that the viral load was undetectable in the undet field. Otherwise, if one 
study reported viral load >100 copies/ml and the other <100 copies/ml, the viral load was 
categorised as not known (NK). 
Using this criteria, of the 62 women with viral load ≤50 copies/ml in NSHPC and >50 
copies/ml in UK CHIC, 14 were recoded as detectable, 40 as undetectable and 8 as NK. 
For the 32 women with viral load >50 copies/ml in NSHPC and ≤50 copies/ml in UK CHIC, 
6 were categorised as detectable and 26 as undetectable. 
Assessing the latest viral load within the 30 days before delivery meant that no viral load 
data were available for 31% of pregnancies. In order to increase the number of 
pregnancies with data available, the period was extended to 91 days (three months) 
before delivery. It is likely that most of the women with undetectable viral load during this 
three month period also had undetectable viral load at delivery. The Women and Infants 
Transmission Study (WITS), in the US, found that approximately 87% of women who 
achieved viral suppression in pregnancy remained virally suppressed at delivery [409]. 
 
4.3 Defining commonly used variables  
Women: 
The WHO defines an adult as someone older than 19 years and an adolescent as 
someone aged 10-19 years inclusive [410]. Throughout the thesis I refer to people in the 
datasets as ‘women’. 
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Childbearing age: 
Childbearing age was defined as 16-49 years. Although childbearing age could extend to 
women younger than 16, the UK CHIC study only collects data for women aged 16 years 
and older. The oldest age at conception in the NSHPC dataset was 49 years.  
Estimated date of conception:  
The estimated date of conception (EDC) was calculated as 266 days (38 weeks) before 
the expected date of delivery (EDD). The EDD is an estimate of 40 weeks gestation which 
includes approximately 14 days between the first day of the last menstrual period and 
conception and is therefore typically calculated using the date of the woman’s last 
menstrual period or the dating ultrasound scan. The EDC was primarily used to establish 
whether the woman was on ART prior to becoming pregnant. Since very few women 
started ART close to the time of conception it was not felt necessary to account for the 
woman’s ethnicity when calculating this variable, although there is evidence that the length 
of gestation differs by a few days according to ethnicity [411]. 
The EDD was used as the reference point from which to calculate the EDC rather than the 
actual delivery date since not all pregnancies had a delivery date reported (for example, 
where the pregnancy was ongoing when reported), some pregnancies ended early (due to 
miscarriage or termination) and because, for pregnancies resulting in a live birth, the 
duration of gestation varied greatly. Although 40 weeks (280 days) is the average duration 
of pregnancy, this includes approximately two weeks prior to conception [412]; thus, I used 
a duration of 266 days to back calculate the EDC.  
Delivery date:  
The EDD was used to indicate the end of the pregnancy if the delivery date had not been 
reported, for example if the pregnancy was on-going when the NSHPC report was 
completed or the woman had moved abroad before delivery.  
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Pregnancy trimesters: 
The first, second and third trimesters of pregnancy were defined (using the EDC as the 
reference date) as: 0 to <14 weeks gestation; 14 to <28 weeks gestation (or the delivery 
date if this was prior to 28 weeks); and 28 weeks until the delivery date respectively. 
Index pregnancy: 
The index pregnancy was the first pregnancy reported to NSHPC following HIV diagnosis 
or during which HIV diagnosis occurred.  
Postpartum: 
The postpartum period refers to the period after childbirth. It typically refers to a period 
from immediately after delivery to around 6-12 weeks after delivery, however, it can refer 
to a longer period of time, up to a year, for example in reference to illnesses which can 
occur within that longer period, such as postpartum depression. In this thesis, the 
postpartum period being referred to is specified in the relevant methods section. 
Infant HIV infection status: 
Infants born to HIV-positive mothers are tested for HIV infection in the first 48 hours after 
delivery, when they are 6 weeks old and 3 months old (using PCR [polymerase chain 
reaction] test). They also have an HIV antibody test at 18 months old and may be tested 
on other occasions if there are additional risks such as breast feeding. Infants were 
categorised as HIV-positive if they were reported (to NSHPC) as ‘presumed HIV-positive’ 
or ‘confirmed HIV-positive’ since it is rare that the later test does not confirm the first test 
result [149].  
Attendance in HIV clinical care: 
For some analyses it was important to include only women who attended HIV clinical care 
in a given period. A dichotomous variable (yes/no) was created for each year to indicate 
whether each woman had received HIV clinical care at a UK CHIC site. Since no marker of 
attendance was available in the dataset, for most analyses a CD4/CD8 cell count, viral 
load, drug start/stop date, or date of an AIDS event were used as a proxy for attendance. 
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Although a CD4 cell count or viral load measurement are not necessarily performed at 
every clinic attendance it was assumed that patients receiving regular care would have 
them measured at least once every six months. In analyses which used only CD4 cell 
count and viral load to indicate clinical care, this is specified in the relevant methods 
section.  
Earliest and latest date of HIV clinic attendance: 
The earliest date on which HIV clinical care was received was estimated using the earliest 
of: CD4 cell count; CD8 cell count; viral load measurement; ART start date; or AIDS event. 
The latest clinical date was the latest of: CD4 cell count; CD8 cell count; viral load 
measurement; ART start date, ART stop date; or AIDS event.  
Hepatitis B virus (HBV) and Hepatitis C virus (HCV) co-infection: 
Since all women in the UK CHIC-NSHPC dataset are HIV-positive, ‘HBV/HCV co-infection’ 
is used throughout to refer to HIV co-infection with either HBV, HCV or both HBV and 
HCV. As part of the routine data collection, the UK CHIC study collates data on hepatitis 
testing and test results. Few data were available on the timing of hepatitis infection, 
whether an individual received treatment for HCV infection or whether the treatment was 
effective. Women were categorised as having HBV/HCV co-infection if they had ever 
received a positive result for hepatitis C antibody or hepatitis B surface antigen. For 
analyses performed on the UK CHIC 2009 and UK CHIC 2010 datasets (Table 4.16), 
hepatitis status of women was determined using only data from UK CHIC.    
In 2013, data on hepatitis status among patients attending HIV-related care at UK CHIC 
sites since 2004 was obtained from clinic notes at 11 of the 16 UK CHIC centres. The data 
collected included hepatitis test results, biopsy results and any use of hepatitis treatment. 
It was undertaken as part of Alicia Thornton’s PhD project focusing on hepatitis co-
infection within the UK CHIC cohort [413]. The ‘enhanced’ hepatitis data were available 
from the start of 2014. They were used to determine hepatitis status for the analyses 
undertaken on the UK CHIC 2011 and UK CHIC 2012 datasets. The existing UK CHIC 
dataset, provided by the centres as part of their routine annual data reporting, was used to 
determine hepatitis status for women who only attended HIV care prior to 2004 or who 
attended one of the five UK CHIC centres which did not provide enhanced hepatitis data.  
 135 
 
With regard to HBV/HCV co-infection status, there were a small number of women with a 
discrepancy in the data available from their clinic notes (enhanced hepatitis data) and the 
existing data in UK CHIC. In these cases the clinic notes were taken as being correct. The 
UK CHIC data were only used if no data were available from the clinic notes.  
 
 
4.4 Categorising ART use in pregnancy  
The UK CHIC and NSHPC datasets both contain data relating to ART use which could be 
used to categorise previous ART experience, ART use at conception and ART use in 
pregnancy. Combining the data from both studies was problematic, for example where 
there was a discrepancy. However, this was necessary in order to utilise all the available 
data pertaining to ART use.  
All variables (reported and derived) relating to ART use are listed in Table 4.6 and Table 
4.7. The numbers presented throughout this chapter refer to the UK CHIC-NSHPC 2009 
dataset, and only pregnancies conceived in 2000-2009 where HIV was diagnosed before 
or during the pregnancy were included (n=2620). In the dataset, the maximum number of 
pregnancies any woman had was six. For this reason there are six variables for each of 
the variables which refer to a specific pregnancy, such as estimated date of conception or 
delivery date. If, for example, a woman only had one pregnancy then the variables 2-6 
were left null. 
Initially, ART status was assessed using the NSHPC and the UK CHIC data separately. 
Where the ART status was in agreement or where one study had any data, the final ART 
status was categorised accordingly. Where there was a discrepancy: one study indicating 
that the woman was using ART and the other indicating that she was not, data were 
examined and a series of criteria were developed to categorise ART use.  
 136 
 
 
Table 4.6. NSHPC variables used to categorise antenatal ART use 
Variable name         n Variable type/categories 
Reported/ 
Created 
Description 
EDC  6 Date Created Estimated date of conception (266 days before EDD) 
DELIVERY 6 Date Reported Delivery date (or EDD if delivery date was missing) 
QRT 6 Numeric Reported Calendar quarter - allowing cross reference to the ART data  
PRETRT 6 Yes/No/NK Reported On ART at conception? 
TRT 6 Yes/No/NK/Declined/Not yet Reported Received ART during pregnancy? 
ART_REASON  6 Maternal health/PMTCT Reported 
Reason for ART use i.e. PMTCT or maternal health and 
PMTCT 
NSHPC_START_ART 6 Yes/No/NK Created Yes if TRT = ‘Yes’ 
No if TRT = ‘Declined’ or ‘No’  
NK if TRT = ‘NK’ or ‘Not yet’ 
P_DRUGSTART 16 Date Reported Date that ART drug was started (either before or during the 
pregnancy) 
P_DRUGSTOP 16 Date Reported Date that ART drug was stopped 
P_DRUG  16 Text Reported ART drug name  
P_DRUG_CON  16 Yes/No Reported Were they on the ART drug at conception? 
P_QRT 16 Numeric Reported Calendar quarter - allowing cross reference to the pregnancy   
EDD: expected date of delivery; NK: not known; PMTCT: prevention of mother-to-child transmission  
1
3
6
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Table 4.7. UK CHIC variables used to establish ART use 
1
Drug dates are either reported or derived by the UK CHIC statistician Sophie Jose from drug data submitted in a different format  
2
A woman was categorised as having attended HIV care if she had a CD4 cell count, viral load measurement or DSTART 
3
This variable is categorised as NK if the EARLIEST_DATE was null, i.e. no clinical data were reported for the woman in UK CHIC 
4
According to the EARLIEST_DATE 
 
Variable name         n Variable type/code 
Created/ 
Reported 
Description 
DSTART 78 Date Created1 Date started ART drug  
DSTOP 78 Date Created1 Date stopped ART drug  
DRUG 78 Coded Reported ART drug  
EARLIEST_DATE  1 Date Created Earliest date in UK CHIC (i.e. earliest viral load/CD4 count/DSTART) 
SEEN_PREG 6 Yes/No Created Attended care at a UK CHIC site during the pregnancy2  
SEEN_12MB4 6 Yes/No Created Attended care at a UK CHIC site in the year before conception2  
SEEN_6MB4 6 Yes/No Created Attended care at a UK CHIC site in the 6 months before conception2  
FIRST_IN_CHIC 6 Before/During/After/NK3 Created Timing of earliest attendance in UK CHIC in relation to the pregnancy4  
1
3
7
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4.5 Using NSHPC and UK CHIC variables to assess ART use  
A hypothetical example is shown in Figure 4.3 and Table 4.8. In this example, the woman 
had two pregnancies, the first in 2006 and the second in 2009. During her first pregnancy 
she was diagnosed with HIV and at that point received HIV clinical care for the first time. 
This meant that her EARLIEST_DATE was during her first reported pregnancy, so the 
variable FIRST_IN_CHIC_1 was categorised as ‘during’. She used a short-course triple 
ART regimen during her first pregnancy, stopping ART use within a week of delivery. 
Some years later, she started life-long ART and was still on this triple regimen when she 
conceived her second pregnancy. She remained on that regimen throughout the 
pregnancy and after delivery. As such, at the end of follow-up, the variables DSTOP 4-6 
were null as were the variables EDC3-EDC6 and DELIVERY3-DELIVERY6 (as she only 
had two pregnancies). 
 
Table 4.8. UK CHIC and NSHPC variables and dates used to assess the timing of ART 
use in relation to pregnancies (from the hypothetical example in Figure 4.3) 
NSHPC UK CHIC 
Date  
(dd/mm/yy) 
EDC1  01/02/06 
 HIV Diagnosis 01/04/06 
 EARLIEST_DATE 04/04/06 
P_DRUGSTART1-3 DSTART1-3 14/06/06 
DELIVERY1  25/10/06 
P_DRUGSTOP1-3 DSTOP1-3 31/10/06 
P_DRUGSTART4-61 DSTART4-6 20/02/08 
EDC2  01/04/09 
DELIVERY2  25/12/09 
1
These dates are reported when the pregnancy is reported to the NSHPC in 2009  
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Figure 4.3. Diagram showing UK CHIC and NSHPC variables used to assess the timing of 
ART use (orange boxes) in relation to pregnancies (yellow boxes) (where the x axis 
represents time) 
a.) UK CHIC variables 
 
 
 
 
 
 
 
 
 
b.) NSHPC variables 
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 ART use at conception 4.5.1
ART use at conception was categorised using UK CHIC and NSHPC data (the criteria 
used are outlined in Appendix VI : Table 1). There was agreement (between UK CHIC and 
NSHPC data) in the categorisation of ART use at conception for 2188 pregnancies (887 on 
ART, 1296 not on ART, 5 NK), a further 1080 pregnancies had data on ART use at 
conception available in only one study (93 on ART, 989 not on ART) and 185 pregnancies 
had discrepant data (Table 4.9). 
 
Table 4.9. ART use according to UK CHIC and the NSHPC 
    NSHPC  
On ART Not on ART NK 
UK CHIC 6 months before conception 
 On ART 336 7 560 
Not on ART 18 14 453 
NK 35 814 383 
 Conception   
On ART 887 100 9 
Not on ART 85 1296 7 
NK 84 982 5 
 During pregnancy 
On ART 2210 15 23 
Not on ART 144 39 32 
NK 99 32 26 
 
There were 85 pregnancies where the UK CHIC data indicated that ART was not being 
used at the estimated time of conception but the NSHPC data indicated that it was. These 
records were manually reviewed to determine the possible reasons for the discrepancies 
and how best to categorise ART use (Table 4.10). Following review, 60 pregnancies were 
re-categorised as being on ART at conception, 20 pregnancies as not being on ART and 5 
as ART use not known.  
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There were a further 100 pregnancies where the UK CHIC data indicated that ART was 
being used at conception but the NSHPC data indicated that it was not. These were 
reviewed and the reasons for the discrepancies are summarised in Table 4.11. Following 
review, 35 pregnancies were re-categorised as on ART at conception, 61 as not on ART 
and 4 as ART status not known.  
Pregnancies with a discrepancy in ART use at conception were compared to those without 
a discrepancy. The chance of having a discrepancy increased slightly over time (odds ratio 
[OR] 1.06 [95% confidence interval CI 1.0-1.3] p=0.04). Having a discrepancy was not 
associated with ethnicity or with the HIV clinic that was attended.  
Overall, 1049 (40%) pregnancies were categorised as having ART use at the time of 
conception, 1559 (60%) as no ART use, and 12 (0.5%) as ART status not known (3 with 
no data in either dataset and 9 due to an unresolved discrepancy).  
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Table 4.10. Discrepancies between ART status at conception (UK CHIC not on ART vs.  NSHPC on ART) (n=85) 
Reason for discrepancy n  ART status  
No clinical data reported in UK CHIC (CD4, ART or VL) for the woman in the 12 months before pregnancy 20 On ART 
No clinical data in UK CHIC (CD4, ART or VL) for the woman in the 6 months before and during pregnancy 10 On ART 
ART was started (according to UK CHIC) within 7 days of the EDC 1 On ART 
Short treatment interruption (according to UK CHIC) around the time of the EDC 5 On ART 
Viral load at conception     <1000 copies/ml indicating ART was being used but not recorded in UK CHIC 20 On ART 
                                           ≥1000 copies/ml indicating ART was not being used 11 Not on ART 
Viral load at conception and in 12 weeks before pregnancy was null and viral load at 12 weeks gestation 
was ≥1000 copies/ml 
1 Not on ART 
Women started ART (according to UK CHIC) after the pregnancy but had viral load ≤50 copies/ml at that 
time indicating that they were probably already on ART 
2 On ART 
Conflicting data on ART status in the NSHPC data 2 Not on ART 
Limited data in ART status in NSHPC record (ie. no date or drug information provided) 6 Not on ART 
Not known 
2 
0 
5 
On ART 
Not on ART  
Not known 
ART: antiretroviral therapy; EDC: Estimated date of conception; VL: viral load 
 
  
1
4
2
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Table 4.11. Discrepancies between ART status at conception (UK CHIC on ART vs.  NSHPC not on ART) (n=100) 
Reason for discrepancy n ART status  
ART use was ZDVm (in UK CHIC) started in previous pregnancy – indicating that drug stop dates were 
missing 
6 Not on ART 
Previous use of combination ART (in UK CHIC) started in pregnancy with CD4 count >350 cells/mm3  
indicating that drug stop dates were missing 
11 Not on ART 
No drug start or stop dates reported by NSHPC 6 On ART 
Viral load at conception 
<1000 copies/ml indicating ART use at that time 18 On ART 
≥1000 copies/ml indicating no ART use at that time 26 Not on ART 
Viral load 6 months before conception1  
<1000 copies/ml indicating ART use at that time 10 On ART 
≥1000 copies/ml indicating no ART use at that time 5 Not on ART 
Viral load at 12 weeks gestation     ≥1000 copies/ml indicating no ART use1 8 Not on ART 
Not known 
1 
5 
4 
On ART          
Not on ART 
Not known 
1 
No viral load data from the time of conception was reported. ZDVm: Zidovudine monotherapy. 
 
1
4
3
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 ART use at 6 months before conception 4.5.2
As with ART status at conception, ART status at six months before pregnancy was 
established for NSHPC and UK CHIC separately, and then both were used to create a 
combined variable. The criteria used are outlined in Appendix VI : Table 2.  
ART status at 6 months before conception was in agreement for 733 pregnancies (336 
on ART, 14 not on ART, 383 NK), a further 1862 records had ART status available 
from only one study (595 on ART, 1267 not on ART) and 25 pregnancies had a 
discrepant ART status in UK CHIC and NSHPC (Table 4.9). The reasons for these 
discrepancies were investigated and summarised in Table 4.12. In the final dataset, 
906 (35%) pregnancies were categorised as being on ART at 6 months before 
conception, 1557 (59%) as not being on ART and 157 (6%) as ART use not known 
(Table 4.13). 
 
 145 
 
 
 
Table 4.12. Discrepancies between ART status in UK CHIC and NSHPC datasets at 6 months before conception  
Reason for discrepancy  n ART status 
UK CHIC not on ART vs. NSHPC on ART 18  
Viral load at 6 months before conception            <1000 copies/ml indicating ART use at that time 7 On ART 
                                                                             ≥1000 copies/ml indicating no ART use at that time 4 Not on ART 
Short treatment interruption due to treatment switch (according to UK CHIC) around this time  1 On ART 
Started ART 5 months before conception according to UK CHIC and 6-12 months before according to NSHPC 3 On ART 
Other 3 Not known 
UK CHIC on ART vs. NSHPC not on ART 7  
Viral load at 6 months before conception            <1000 copies/ml indicating ART use at that time  4 On ART 
                                                                            ≥1000 copies/ml indicating no ART use at that time 1 Not on ART 
Other 2 Not known 
 
1
4
5
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Table 4.13. Summary of ART use at six months before conception according to UK 
CHIC, NSHPC and in the final dataset (n=2060) 
UK CHIC NSHPC Final dataset n  Drug data used1 
Yes Yes Yes 336 UK CHIC 
Yes NK 
Yes 520 UK CHIC 
NK 402 - 
NK Yes Yes 35 NSHPC 
No No No 14 - 
No NK 
No 439 - 
NK 143 - 
NK No No 814 - 
NK NK 
NK 98 - 
No 2854 - 
No Yes 
Yes 11 NSHPC 
No 4 - 
NK 3 - 
Yes No 
Yes 4 NSHPC 
No 1 - 
NK 2 - 
1
Drug regimen, number of drugs and drug start and stop dates. 
2
NSHPC data indicated that ART was not being used at the time of conception.  
3
NSHPC data indicated that ART was being used at the time of conception. 
4
HIV diagnosis date was after 6 months before conception (n=77). ART was not being used at conception 
(n=208).   
 
 ART use at 6 and 12 months after delivery 4.5.3
As limited data were available from NSHPC on drug use after pregnancy, only UK 
CHIC data were used to categorise ART use at 6 and 12 months after delivery 
(Appendix VI : Table 3).  
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 ART use during pregnancy 4.5.4
As with ART use at conception, ART use during pregnancy was categorised using 
NSHPC and UK CHIC data separately and then a combined variable was created 
(Appendix VI : Table 4).  
UK CHIC and NSHPC were in agreement for the majority of pregnancies (n=2371, 
90.5%) (ART status was: n=2332 on ART; n=39 not on ART), 195 (9.5%) pregnancies 
had ART status only available from one study (ART status was: n=122 on ART; n=64 
not on ART) and a further 26 pregnancies did not have ART status available from 
either. There were 159 pregnancies with discrepant ART status (Table 4.9).  
Where data from the NSHPC indicated that the woman was on ART at some point 
during the pregnancy and UK CHIC indicated that they were not (n=144) they were 
categorised as being on ART in the final dataset. It could be that the ART drugs 
prescribed during pregnancy were not noted in their medical notes at the site where 
they received their ongoing HIV clinical care.  
There were 15 pregnancies in which the UK CHIC data indicated that ART was used 
but the NSHPC data indicated that it was not. This could be because the NSHPC 
reporting form was completed prior to ART initiation. UK CHIC drug start dates indicate 
that some of these women took ART for only a short time during the pregnancy (close 
to the end), indicating that they may have declined treatment initially and accepted 
treatment at a later time during the pregnancy or delayed ART start for some other 
reason. If, according to UK CHIC, they had not conceived on ART, but started ART 
during pregnancy the woman was re-coded as being on ART. This gave a total of 2457 
(94%) that were categorised as being on ART, 103 (4%) as not on ART and a further 
60 (2%) pregnancies where ART status was not known (Table 4.14).  
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Table 4.14. Summary of ART use during pregnancy according to UK CHIC and 
NSHPC and its final categorisation in the combined dataset (n=2060 pregnancies) 
UK CHIC NSHPC Final dataset n  Drug data used1 
Yes Yes Yes 2210 NSHPC 
Yes NK Yes 23 UK CHIC 
NK Yes Yes 99 NSHPC 
No No No 39 - 
No NK No 32 - 
NK No No 32 - 
NK NK NK 26 - 
No Yes Yes 118 NSHPC 
No 0 - 
NK 26 - 
Yes No Yes 7 UK CHIC 
No 0 - 
NK 8 - 
1
Drug regimen, number of drugs and drug start and stop dates. 
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 Categorising ART use during pregnancy 4.5.5
ART status at 6 months before conception, at conception, during pregnancy and at 6 
and 12 months after pregnancy (the variables previously described) were used to 
categorise ART use during pregnancy into broad categories (Appendix VI : Table 5).  
1. ART use limited to pregnancy and post-pregnancy. 
This refers to women who started ART in pregnancy and stopped ART within six 
months of delivery. It includes women with a CD4 count above 350 cells/mm3 
who used short-course ART in pregnancy for PMTCT and stopped ART at 
delivery. It also includes a smaller number of women who, according to treatment 
guidelines, should have started life-long ART but stopped ART within 6 months of 
delivery.  
2. Long term treatment used for the woman’s own health continued after delivery. 
Additional variables were created to indicate whether the woman was also pregnant at 
6 months before or at 6 or 12 months after the pregnancy of interest, and if they were 
pregnant at that time, whether there had been a gap in treatment between 
pregnancies.  
In some cases categorising ART use was straightforward, for example if the woman 
was using ART before, during and after the pregnancy. However, the data were more 
complex for many pregnancies due to treatment interruptions either before, during or 
after pregnancy.  
Overall, ART use was limited to the time of pregnancy and post-pregnancy in 31% 
(n=823) of pregnancies. For 39% (n=1023) of the pregnancies, ART was being used at 
the time of conception (18 of these conceived during a short treatment 
break/interruption), and life-long ART was started during 19% (n=493) of pregnancies. 
ART was not used (or at least no ART use was reported) during 4% (n=103) of the 
pregnancies in the dataset, 35 of these went to full term (30 resulting in a live birth), 45 
resulted in a miscarriage and 23 were terminated. ART category was not available for 
7% (n=178) of pregnancies. 
The way that ART use was categorised was simplified for the analysis of response to 
treatment following short-course ART use in pregnancy (Chapter 6). The simplified 
criteria were outlined in the relevant methods section. 
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4.6 Start date for life-long ART 
A series of criteria were developed to pinpoint the date on which each woman started 
life-long ART. Previously, the first date on which any ART drug was started (the 
DSTART1 variable in the UK CHIC dataset) was used as the ART start date. However, 
it was not appropriate to use this date since women could have used short-course ART 
in one or more pregnancies for PMTCT before subsequently starting ART for 
therapeutic reasons.  
Initially, a dataset was created including all women reported to UK CHIC and antenatal 
data from NSHPC for those with a pregnancy (i.e. the UK CHIC-NSHPC 2009 dataset 
was merged with the UK CHIC 2009 dataset). The dataset contained 9726 women, 
7898 of whom were aged 16-49 years when they attended care, 2063/7898 of whom 
had a pregnancy reported to NSHPC. Since only women with a pregnancy had data in 
both datasets, only ART dates and CD4 cell counts from UK CHIC were considered 
(i.e. the NSHPC data for these variables were ignored). 
Using ART start and stop dates, each period of ART use was measured and variables 
were created characterising the woman at the start of each period. These variables 
included: CD4 cell count, pregnancy status, AIDS diagnosis and HBV diagnosis. Each 
period of non-ART use was also measured. 
The start of the earliest period of ART use which met any of the criteria outlined in 
Table 4.15 was used as the start date for life-long ART. This was typically the first 
period of any ART use but in some cases followed one or multiple short periods of ART 
use (in pregnancy). Some women had a short period of ART use outside pregnancy, 
not meeting the criteria. This was not considered as the start date of life-long ART. 
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Table 4.15. Criteria used to indicate if and when life-long ART was started among 
women who attended HIV clinical care at a UK CHIC site in 2000-2009 aged 16-49 
(n=7898). 
Criteria1 Started 
life-long 
ART2 
n   % 
ART use ≥12 months Yes 4286 54 
ART use ≥12 months with interruptions <3 months  Yes 233 3 
ART started within 3 months of AIDS diagnosis Yes 111 1 
ART started with CD4 count <200 cells/mm3 Yes 475 6 
ART started with CD4 
count <350 cells/mm3 
a. Not during pregnancy Yes 338 4 
b. During pregnancy (year 
≥2008) 
Yes 36 <1 
ART started following diagnosis of HBV3 (year ≥2008) Yes 3 <1 
ART started with CD4 % <14 (year ≥2008) Yes 39 <1 
ART started outside pregnancy <9 months before end of 
follow-up and still on ART at end of follow-up 
Yes 171 2 
No evidence of ART use No 1625 21 
Not on ART at end of follow-up but short period/s of ART 
use (<12 months) were started during pregnancy or with 
CD4 count >350 cells/mm3 
No 496 6 
Inconclusive treatment patterns or limited follow up 
period4 
Yes 18 1 
No 5 <1 
NK 62 <1 
1 
The start of the earliest period meeting any criteria was used as the start date for life-long ART  
2 
By end of follow-up 
3 
Defined as a positive result for hepatitis B surface antigen test in the 3 months before starting ART  
4 
Assigned after manual review  
 
On the last day of follow-up, of the 7898 women (aged 16-49) who accessed HIV 
clinical care at a UK CHIC site at some point during 2000-2009, 5710 (72%) had 
already started life-long ART, 2126 (27%) had not started life-long ART and 62 (1%) 
had not started life-long ART but had previously been on ART. Among the women who 
started life-long ART, 93% (5281/5710) had no previous ART experience when 
starting.  
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4.7 Summary data for UK CHIC-NSHPC combined datasets used 
in 2009-2012 
The linkage between the NSHPC and UK CHIC datasets was repeated annually using 
the most up-to-date datasets available. The number of women included in each dataset 
is summarised in Table 4.16. Over the four years for which the datasets were linked, 
the UK CHIC-NSHPC combined dataset included 21%-26% of the women in UK CHIC 
and 23%-30% of the women in the NSHPC dataset. There was an increase in the 
percentage of women linked in the 2010 compared to in 2009 (from 21% to 25% of UK 
CHIC and from 23% to 30% of NSHPC). After this, the percentage of women included 
was fairly consistent across the 2010, 2011 and 2012 datasets. The increase in 
percentage of women included from the 2009 to the 2010 dataset might, in part, be due 
to improved competence in the linkage process, although this would probably only 
have a small impact, since the same coding was used and updated. It is more likely 
that the improvement was due to improvements in the data quality since this was a 
time when the HIV commissioners started using patient outcomes data and when 
national HIV reporting to Public Health England was altered to collect more detailed 
and data more regularly. 
Each year it took around nine months for the UK CHIC data to be collated, validated, 
de-duplicated and then linked to the NSHPC data. The last two analyses were 
performed in 2014 using the 2012 dataset, since the 2013 dataset was not yet 
finalised. These two analyses were then published in early 2015 [414, 415] and the 
PhD submitted later that year.  
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Table 4.16. Summary of the matching between UK CHIC and NSHPC and the creation of combined datasets: 2009-2012 
UK CHIC-NSHPC combined dataset 2009 2010 2011 2012 
UK CHIC     
Data to end (year) 2009 2010 2011 2012 
Number of HIV clinics contributing data 13 15 16 19 
Number of women in dataset1 9726 11,305 11,971 12,970 
Percentage found in NSHPC 21% 25% 26% 26% 
NSHPC     
Date of archive  Sept 2010  Sept 2011  June 2013  March 2014  
Number of women in dataset2 8929 9501 10,556 11,033 
% found in UK CHIC 23% 30% 30% 30% 
UK CHIC-NSHPC combined dataset     
Total number of women  2063 2823 3150 3317 
Total number of women after exclusions3 2048 2793 3070 3283 
Pregnancies conceived in the period of interest4                2634 3733 4291 4732 
Pregnancies conceived in 2000-20095 2634 3475 3584 3652 
1 
This includes women with CD4 cell count/viral load measurements at any point since 1995. In each dataset <5 women were excluded because they had no DOB 
reported 
2 
This excludes women who only attended antenatal care in Ireland/Isle of Man/Channel Islands and women diagnosed with HIV after delivery of their only/last 
reported pregnancy 
3 
Women were excluded if they only had a pregnancy starting after the period for which UK CHIC data was available 
4 
2000 to end 2009/2010/2011/2012 
5 
In this row each column contains data for to the same period of time thereby allowing comparison between the datasets 
1
5
3
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Chapter 5 Predictors of pregnancy and trends in 
ART use and pregnancy incidence among women 
accessing HIV clinical care  
 
5.1 Introduction  
Diagnosed HIV-positive women accessing HIV clinical care in the UK include women of 
different ethnicities, ages and levels of morbidity [416]. The characteristics of this 
diverse group have continued to change over time such that current clinic populations 
now include an increasing proportion of older women and women on antiretroviral 
therapy (ART) [417]. With advances in ART and developments in prescribing practice 
[78, 418, 419] leading to the improved wellbeing and longevity of HIV-positive women 
[59, 420], coupled with effective prevention of mother-to-child-transmission (PMTCT) 
[131, 149] many women living with HIV choose to have children [163, 170]. In many 
cases, women have consecutive pregnancies [160, 421]. This increased pregnancy 
rate is occurring both in women who are already on life-long ART as well as diagnosed 
women with no current indication to start treatment i.e. those without symptoms who 
have a high CD4 count [171]. 
In the UK and Ireland, almost three-quarters of pregnancies in HIV-positive women are 
now in women already diagnosed [422]. The changing demographic and clinical 
characteristics of pregnant women living with HIV are likely to reflect, to some extent, 
the changing characteristics of all women living with HIV in the UK. However, there 
may also be changes in the pregnancy rate among specific subgroups. For example, 
as the proportion of diagnosed women receiving ART has increased, so we would 
expect the proportion of pregnant women who conceive on ART to also increase. We 
would also expect an increase in the average age of women conceiving due to an 
increase in the number of repeat pregnancies and an increase in the median age of 
women having children seen in the general population [402]. 
A paper summarising the data presented in the latter half of this chapter was published 
in 2013 and is included in Appendix IIb [423].  
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5.2 Methods 
The main objectives of this chapter were, in HIV-positive diagnosed women, to identify 
factors predictive of having a pregnancy and changes in the pregnancy incidence. The 
analysis was split into two sections: 
1) All women in UK CHIC with a pregnancy  
Using the UK CHIC-NSHPC 2009 dataset, the number of pregnancies 
conceived each year and the use of ART at conception and during each 
pregnancy were assessed using generalized estimating equations (SAS 
command PROC GENMOD) accounting for repeat measures. 
2) Women attending HIV clinical care at a UK CHIC site 
 Characteristics of women attending clinical care 
 Characteristics of women with a pregnancy  
 Factors predictive of having a pregnancy  
 Pregnancy incidence over time  
For the second part of the analyses, the UK CHIC 2009 and UK CHIC-NSHPC 2009 
datasets were combined to produce a dataset containing data for all women reported to 
UK CHIC at any point during 2000-2009 plus NSHPC data for women with a pregnancy 
during that period. The dataset was reformatted so that it contained one row per 
woman per year. It only included data for years in which some clinical data were 
available and when the woman was of childbearing age (16-49 years). This meant that 
pregnancies conceived during a calendar year in which the woman did not access care 
at a UK CHIC site were excluded.  
Variables included in the dataset were: ethnicity, probable route of HIV infection, age at 
start of year, ART status at start of year, earliest CD4 count in the year (determined 
using UK CHIC data) and whether the women became pregnant during that year. For 
women with a pregnancy, data were also included on the estimated date of conception 
(EDC), pregnancy outcome and whether the pregnancy was an index or repeat 
pregnancy. Index pregnancy referred to the first pregnancy after HIV-diagnosis in the 
UK or the pregnancy during which HIV-diagnosis occurred, whereas repeat pregnancy 
referred to any subsequent pregnancy (even if it was their first pregnancy during the 
study period). As pregnancies could overlap two calendar years, the year of pregnancy 
referred to the year of the EDC.  
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Pregnancies resulting in a live or stillbirth were categorised as ending at delivery and 
pregnancies resulting in miscarriage or termination, and ectopic pregnancies, were 
categorised as ending early. Where pregnancy outcome was not known (n=23), the 
pregnancy was excluded from the analysis of factors predictive of pregnancy outcome.  
As only women with a pregnancy had any data in the NSHPC dataset, UK CHIC data 
alone were used to determine ethnicity, route of infection, HIV diagnosis date, ART 
status and CD4 count.  
If a woman was diagnosed with HIV during her index pregnancy and attended care for 
the first time during that year (463 pregnancies), the attendance and pregnancy for that 
year were excluded (i.e. removed from the numerator and denominator for that 
calendar year).  However, all future years during which the woman attended care (and 
any subsequent pregnancies) were included. If a woman had more than one pregnancy 
starting in the same calendar year, only the first was considered (only 5 women 
conceived two pregnancies in the same year which both resulted in a live or stillbirth). 
In a separate analysis, in order to assess trends in index pregnancies, women with an 
index pregnancy before 2000 were excluded as were data for all years following an 
index pregnancy (among women who had an index pregnancy in 2000-2009). Data 
were manipulated in this way because once a woman had an index pregnancy she was 
no longer ‘at risk’ of having a further index pregnancy.  
The characteristics of women under follow-up and with a pregnancy in each year were 
first described. The pregnancy rate was described for each calendar year using the 
number of women (aged 16-49 years) with clinical data in UK CHIC as the denominator 
and the number with a pregnancy (all outcomes) starting during that year as the 
numerator.  
Predictors of pregnancy were identified using generalised estimating equations 
(Poisson regression), unadjusted and adjusted for year, age, CD4, ethnicity and ART 
use (Yes/No binary variable), and accounting for repeat measures. I also considered 
the addition of interaction terms between calendar year and each covariate in the 
model in order to investigate whether there was evidence that calendar year trends 
varied in some subgroups of the population. The model parameters were centred so 
that the intercept provided the predicted pregnancy rate in 2005 for a woman aged 30 
years. Trends in index pregnancies were assessed in a similar way, although as 
women could only have one index pregnancy, this assessment did not take account of 
repeat measures. 
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5.3  Results 
5.3.1  Overall number of pregnancies and ART use in pregnancy 
A total of 2620 pregnancies were conceived in the 1888 women attending care in 2000-
2009; 1306 women (69%) had a single pregnancy, 459 (24%) had two pregnancies, 
102 (5%) had three, and 21 (1.1%) had four or five pregnancies. The total number of 
pregnancies conceived each year increased in the period 2000-2006 (from 159 to 321) 
but decreased subsequently to 280 in 2009 (Table 5.1). A small number of women had 
two pregnancies starting in the same calendar year. This meant that the number of 
pregnancies in some years was slightly higher than the number of women with a 
pregnancy in that year. In most cases, the first of the two pregnancies resulted in a 
miscarriage (21/28).  
Information on the use of ART at the time of conception was available for 2339 (89%) 
pregnancies. Where ART status was known, the percentage of women on ART when 
they conceived increased over time (22.6% [124/548] in the period 2000-2003 
compared to 45.0% [399/886] in the period 2007-2009) (Figure 5.1 and Table 5.1). 
These denominators included pregnancies among women who were not diagnosed 
with HIV when they conceived. 
Among women who were on ART when they conceived, non-nucleoside reverse 
transcriptase inhibitor (NNRTI)-based regimens were the most commonly used (53% 
[474/901]). The use of protease inhibitor (PI)-based regimens increased during the 
decade (29% [10/35] in 2000 and 46% [62/136] in 2009), whilst the use of regimens 
which contained only nucleoside reverse transcriptase inhibitors (NRTIs) fell from a 
peak of around 15% in 2002 to 1.5% (2/136) by 2009 (Figure 5.2 and Table 5.1).  
Over the decade, the use of short-course ART (including combination ART [cART] and 
zidovudine monotherapy [ZDVm]) in pregnancy declined among women not on ART 
when they conceived (from 64% in 2000 to 59% in 2009). At the same time, there was 
an increase in women starting life-long ART during pregnancy (Table 5.2 and Figure 
5.3). 
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Table 5.1. ART use among HIV-positive women with a pregnancy starting in 2000-2009 that resulted in a live or stillbirth 
1
ART use during pregnancy was other/not known for 80 pregnancies: this included 29 pregnancies where ART data was incomplete, 35 pregnancies where the woman was on 
ART before and after the pregnancy but not on the EDC and 16 pregnancies where the woman was receiving ART before the pregnancy but was not on treatment at 6 and 12 
months after delivery. OR: Odds ratio – per additional year - calculated using logistic regression for variables which outcomes are percentages. Coefficient – per additional year 
- calculated using linear regression for time since diagnosis.  
Year of conception 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 Total 
OR/Coefficient 
(95% CI) 
p-value 
(trend) 
Number of women with a pregnancy 156 185 202 270 299 288 316 310 290 275 2591 - - 
Number of pregnancies 159 187 202 271 299 295 321 313 293 280 2620 - - 
Number of pregnancies where ART 
status at conception was known
1
 
131 168 184 250 270 272 292 290 253 229 2339 - - 
Pregnancies conceived on ART  35 42 47 84 87 101 106 125 138 136 901   
% (of those with known ART status)  26.7 25.0 25.5 33.6 32.2 37.1 36.3 43.1 54.5 59.4 38.5 
1.21  
(1.17-1.25) 
<0.001 
Median time since HIV-diagnosis (years) 2.7 4.2 4.3 3.3 4.2 4.8 3.7 5.0 4.9 5.9 4.6 
1.07  
(1.04-1.09) 
<0.001 
Type of ART 
regimen used (%)                                          
NNRTI-based 51.4 69.0 42.6 51.2 60.9 56.4 55.7 47.2 48.6 50.7 52.6 
1.10  
(0.41-2.97) 
0.85 
PI-based 28.6 14.3 27.7 31.0 21.8 35.6 34.0 48.0 47.1 45.6 37.0 
1.17  
(1.11-1.24) 
<0.001 
NRTIs-only 0.0 11.9 14.9 11.9 13.8 5.9 3.8 2.4 1.4 1.5 5.7 
0.74  
(0.74-0.90) 
<0.001 
Other/not specified 20.0 4.8 14.9 6.0 3.4 2.0 6.6 2.4 2.9 2.2 4.8 
0.79  
(0.70-0.89) 
<0.001 
1
5
8
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Figure 5.1. ART experience at the time of conception among pregnancies conceived 
from 2000 to 2009 (before or during which HIV was diagnosed) 
 
 
Figure 5.2. The type of regimen used by women on ART at conception 
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Table 5.2. ART use during pregnancy among HIV-positive women not on ART at conception with a pregnancy starting in 2000-2009 which 
resulted in a live or stillbirth 
Year of start of pregnancy 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 Total 
OR/Coefficient 
(95% CI) 
p-
value 
(trend) 
Not on ART at time of conception 96 126 137 166 183 171 186 165 115 93 1438   
% (of those with known ART status) 73.3 75.0 74.5 66.4 67.8 62.9 63.7 56.9 45.5 40.6 61.5   
ART use in pregnancy (%) 
All short-course ART  63.5 62.7 67.9 60.2 59.6 50.3 52.2 47.3 44.3 59.1
1
 56.3 
0.90  
(0.87-0.94) 
<0.001 
ZDVm (of those on short-course ART)  32.8 31.6 26.9 22.0 23.9 10.5 6.2 10.3 9.8 5.5 18.4 
0.79  
(0.73-0.85) 
<0.001 
 Start life-long ART 25.0 31.7 21.9 33.7 33.9 40.4 36.6 47.3 40.9 10.8
1
 33.7 
1.05  
(1.00-1.09) 
0.03 
 No ART used 4.2 2.4 2.2 1.8 2.2 2.3 2.7 1.2 0.9 3.2 2.2 
0.97  
(0.77-1.22) 
0.81 
 Other/not known 7.3 3.2 8.0 4.2 4.4 7.0 8.6 4.2 13.9 26.9
1
 7.9 
1.36  
(1.20-1.54) 
<0.001 
Diagnosed prior to that pregnancy 34 43 56 61 80 80 115 97 66 65 697   
% (of those not on ART) 35.4 34.1 40.9 36.7 43.7 46.8 61.8 58.8 57.4 69.9 48.5 
1.27  
(1.12-1.22) 
<0.001 
Previous ART experience (n) 11 13 27 25 36 46 57 53 41 42 351   
% (of those not on ART at conception) 11.5 10.3 19.7 15.1 19.7 26.9 30.6 32.1 35.7 45.2 24.4 
1.21  
(1.15-1.27) 
<0.001 
% (of those not on ART at conception 
and diagnosed before that pregnancy) 
32.4 30.2 48.2 41.0 45.0 57.5 49.6 54.6 62.1 64.6 50.4 
1.16  
(1.09-1.23) 
<0.001 
Median time since HIV diagnosis (years) 1.9 2.3 2.1 2.0 2.5 2.5 2.9 3.0 3.6 3.2 2.7 
1.06  
(1.03-1.10) 
<0.001 
1
6
0
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Footnote for Table 5.2. 
1
The number of women starting life-long ART is likely to be underestimated and the number using short-
course ART overestimated in 2009 due to limited follow-up time. OR: Odds ratio – per additional year - 
calculated using logistic regression for variables which outcomes are percentages. Coefficient – per 
additional year - calculated using linear regression for time since HIV-diagnosis.  
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Figure 5.3. ART use during pregnancies where the woman was not on ART at conception 
 
NB: The number of women starting life-long ART is likely to be underestimated and the number using short-course ART overestimated in 2009 due to the limited follow-up time. 
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5.3.2 Pregnancies among women already attending HIV clinical care 
Characteristics of women attending clinical care at UK CHIC sites 
In total, 7853 women aged 16-49 years accessed HIV care at a UK CHIC site at some 
point during the period 2000-2009. During this time, the number of women accessing 
care more than doubled from 2074 in 2000 to 4876 in 2009 (Table 5.3). The majority of 
women accessing HIV care were of black-African ethnicity and most were infected via 
heterosexual sex (Table 5.3). The characteristics of women accessing care changed 
somewhat during the period of interest; the proportion of women of black-African, 
black-Caribbean or black-other ethnicity increased whilst the proportion of women of 
white ethnicity decreased. The proportion whose probable route of HIV infection was 
heterosexual sex increased whilst the proportion whose probable route of infection was 
injecting drug use (IDU) or contaminated blood/blood products decreased. The median 
age of women attending care increased from 33 to 37 years and the number of women 
in the oldest age group (36-49 years) almost quadrupled (Table 5.3 and Figure 5.4a). 
Age varied according to ethnicity; compared with black-African women, women of 
black-Caribbean, black-other or ‘other’ ethnicity were more likely to be in the youngest 
age group (16-25 years) whilst women of white ethnicity were less likely to be in this 
age group (p<0.001 in logistic regression) (data not shown). The proportion of women 
born in the UK varied by ethnicity (white, 64.3%, 594/924; black-African, 7.3%, 
231/2284; black-Caribbean, 38.3%, 88/230, where country of birth was reported). 
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Table 5.3. Characteristics of all HIV-positive women of childbearing age receiving HIV clinical care at UK CHIC sites in 2000-2009 
 2000/1 % 2002/3 % 2004/5 % 2006/7 % 2008/9 % 
 
Number of women receiving 
HIV clinical care 
4555 
 
6340 
 
7901  9359  9942 
 
 
          
Median age (years) [IQR] 33 [29-38] 34 [29-39] 35 [30-40] 36 [31-41] 37 [32-42] 
Age group 
(years) 
16-25 450 9.9 621 9.8 782 9.9 855 9.1 778 7.8 
26-35 2401 52.7 3059 48.2 3426 43.4 3631 38.8 3410 34.3 
36-49 1704 37.4 2660 42.0 3693 46.7 4873 52.1 5754 57.9 
           
ART use On ART 2220 48.7 3278 51.7 4371 55.3 5863 62.7 6780 68.2 
 
           
CD4 count 
(cells/mm
3
) 
≤200 1140 25.0 1336 21.1 1326 16.8 1226 13.1 1045 10.5 
201-350 1146 25.2 1602 25.3 2045 25.9 2121 22.7 1927 19.4 
>350 1849 40.6 2979 47.0 4131 52.3 5542 59.2 6654 66.9 
NK 420 9.2 423 6.7 399 5.0 470 5.0 316 3.2 
           
Median CD4 (cells/mm
3
)  [IQR] 338 [220-532] 353 [217-520] 380 [247-543] 420 [280-583] 463 [319-640] 
 
          
Probable 
route of 
infection 
Heterosexual sex 3606 79.2 5238 82.6 6703 84.8 7883 84.2 8297 83.5 
IDU 355 7.8 373 5.9 367 4.6 378 4.0 332 3.3 
Blood products 27 0.6 35 0.6 40 0.5 47 0.5 32 0.3 
Other/NK 567 12.4 694 10.9 791 10.0 1051 11.2 1281 12.9 
           
Ethnicity White 1147 25.2 1275 20.1 1408 17.8 1547 16.5 1616 16.3 
Black-Caribbean 134 2.9 221 3.5 306 3.9 374 4.0 448 4.5 
Black-African 2749 60.4 4113 64.9 5238 66.3 6214 66.4 6523 65.6 
Black-other 100 2.2 143 2.3 189 2.4 268 2.9 304 3.1 
Other 216 4.7 305 4.8 427 5.4 540 5.8 581 5.8 
Not reported 209 4.6 283 4.5 333 4.2 416 4.4 470 4.7 
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Figure 5.4. Women attending for HIV clinical care at UK CHIC sites stratified by age 
group 
a. All women  
b. Women with a pregnancy 
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Pregnancies among diagnosed women accessing HIV clinical care  
Of the 7853 women who accessed HIV care over the period 2000-2009, 1291 women 
had at least one pregnancy: 1000 (77.5%) women had a single pregnancy, 245 
(19.0%) had two pregnancies and 46 (3.6%) women had three or more pregnancies. 
There were 1637 pregnancies in total. The number of pregnancies increased each year 
from 72 in 2000 to 230 in 2009.  
The number of pregnancies and the characteristics of pregnant women under follow-up 
are presented in Table 5.4. The proportion of pregnancies which were repeat 
pregnancies (sequential pregnancy after HIV diagnosis) increased from 30.1% (47/156) 
in 2000/01 to 52.2% (235/450) in 2008/09 (p<0.001 using generalized estimating 
equation accounting for repeat measures), with 735 (44.9%) of the pregnancies being 
repeat pregnancies overall. The majority of women with a pregnancy were aged 26-35 
years and this remained the case over time, the percentage of women in the older age 
group increased from 17.9% in 2000/1 to 24.4% in 2008/9 and there was an increase in 
the median age of pregnant women from 31 to 32 years respectively (Figure 5.4b). The 
proportion of pregnancies which were repeat pregnancies increased among all age 
groups (16-25 years, 25.0% (4/16) in 2000/01 to 46.4% (32/69) in 2008/09, p<0.001; 
26-35 years, 33.0% (37/112) to 51.3% (139/271), p<0.001 and 36-49 years, 21.4% 
(6/28) to 58.2% (64/110), p<0.001). 
The proportion of pregnant women on ART (at the start of the year in which they 
conceived) increased (p<0.001). In line with this, among women with a pregnancy, the 
median CD4 cell count (at the start of the year) gradually increased over time and the 
proportion with CD4 <350 cells/mm3 decreased (p<0.001). The proportion of 
pregnancies among women of black-African or black-Caribbean ethnicity increased 
(p<0.001) and that among white women decreased (p<0.001) (Table 5.4). Most 
pregnancies were in women infected via heterosexual sex (97.0%, 1432/1477, where 
probable route of exposure was reported), with 1.9% (n=28) in women infected via 
injecting drug use, 0.7% (n=11) in women infected via MTCT and six pregnancies in 
women infected via other routes. 
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Table 5.4. Characteristics of HIV-positive pregnant women who were already accessing HIV clinical care at UK CHIC sites in 2000-2009 before 
their pregnancy 
 2000/1 % 2002/3 % 2004/5 % 2006/7 % 2008/9 % 
           
Women with a pregnancy 
accessing HIV clinical care 
[95% CI] 
156 
3.4 
[2.9-4.0] 
250 
3.9 
[3.5-4.4] 
347 
4.4 
[3.9-4.8] 
434 
4.6 
[4.2-5.1] 
450 
4.5 
[4.1-4.9] 
           
Repeat pregnancies 47 30.1 90 36.0 156 45.0 207 47.7 235 52.2 
           
Median age (years) [IQR]  31 [27-34] 31 [27-34] 31 [27-35] 32 [27-35] 32 [28-35] 
Age group (years) 16-25 16 10.3 45 18.0 56 16.1 68 15.7 69 15.3 
26-35 112 71.8 165 66.0 218 62.8 266 61.3 271 60.2 
36-49 28 17.9 40 16.0 73 21.0 100 23.0 110 24.4 
 
          
ART use                      On ART 72 46.2 127 50.8 179 51.6 225 51.8 287 63.8 
 
           
CD4 count 
(cells/mm
3
)           
≤200 31 19.9 35 14.0 36 10.4 44 10.1 37 8.2 
201-350 49 31.4 65 26.0 98 28.2 106 24.4 103 22.9 
>350 74 47.4 137 54.8 204 58.8 264 60.8 302 67.1 
NK 2 1.3 13 5.2 9 2.6 20 4.6 8 1.8 
Median CD4 count  
(cells/mm
3
) (IQR)         
338 [220-532] 389 [257-544] 401 [283-564] 425 [287-597] 458 [321-630] 
           
Ethnicity                           White 35 22.4 30 12.0 48 13.8 42 9.7 48 10.7 
Black-Caribbean  3 1.9 6 2.4 14 4.0 18 4.1 18 4.0 
Black-African 104 66.7 182 72.8 236 68.0 322 74.2 329 73.1 
Black-other 5 3.2 12 4.8 10 2.9 11 2.5 11 2.4 
Other 4 2.6 7 2.8 26 7.5 18 4.1 20 4.4 
Not reported 5 3.2 13 5.2 13 3.7 23 5.3 24 5.3 
           
 
1
6
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Pregnancy incidence and predictors of pregnancy 
Pregnancy incidence among women accessing HIV care was 3.5% (72/2074, 95% 
confidence interval (CI) 2.7-4.3) in 2000 and 4.7% (230/4876, 95% CI 4.1-5.3) in 2009, 
with the highest incidence in 2006 (4.8%, 216/4528, 95% CI 4.1-5.4). The likelihood 
that women had a pregnancy increased over the study period (relative rate [RR] per 
later year: 1.03 [1.01-1.05], p<0.001), even after controlling for other factors (adjusted 
RR (aRR) per later year: 1.05 [1.03-1.07], p<0.001) (Table 5.5).  
There were a number of independent predictors of pregnancy: older women were less 
likely to have a pregnancy than younger women (aRR 0.44 per 10 year increment in 
age [95% CI 0.41-0.46], p<0.001) as were women with CD4 <200 cells/mm3 compared 
with women with CD4 200-350 cells/mm3 (aRR 0.65 [0.55-0.77], p<0.001). Women of 
white ethnicity were less likely to have a pregnancy compared with women of black-
African ethnicity (aRR 0.67 [0.57-0.80], p<0.001) as were women of black-Caribbean 
ethnicity after controlling for differences in age, ART use and CD4 count (aRR 0.75 
[0.58-0.97], p=0.03). Women infected via injecting drug use were less likely to have a 
pregnancy than women infected via heterosexual sex (aRR 0.58 [0.35-0.97], p=0.04). 
In unadjusted analyses, women on ART were less likely to have a pregnancy than 
women not on ART (RR 0.82 [0.74-0.91], p<0.001) but this was not the case after 
adjusting for other factors.  
The pregnancy rate increased for women in all age groups over the study period (16-25 
years, aRR 1.07 per later calendar year [1.02-1.12], p=0.004; 26-35 years, aRR 1.06 
[1.04-1.09], p<0.001; 36-49 years, aRR 1.05 [1.00-1.09], p=0.03) (Figure 5.5). The rate 
of increase in pregnancy incidence was not significantly different for the three age 
groups (p-value for interaction=0.15). Similarly, there was an increase in pregnancy 
rate for all CD4 groups with little evidence that the rate of increase was significantly 
different for any of these groups (p-value for interaction=0.07). Pregnancy incidence 
increased among women of black-African ethnicity (aRR 1.06 [1.03-1.08], p<0.001). 
There was no evidence that the rate of change of pregnancy incidence differed for any 
ethnic group relative to that of women of black-African ethnicity, apart from women 
categorised as ‘black-other’, who experienced a somewhat slower increase in 
pregnancy rate (p=0.02). As only a small proportion of women with a pregnancy 
acquired HIV via routes other than heterosexual sex, it was not possible to assess 
trends over time in pregnancy rate for different routes of infection. The rate of increase 
in pregnancy incidence over this period did not significantly differ between women on 
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ART and women not on ART (p-value for interaction=0.14), with predictors of 
pregnancy being the same regardless of treatment. 
 
Figure 5.5. Pregnancy incidence in 2000-2009 among women accessing HIV clinical 
care – by age group (the shaded areas show the 95% confidence intervals)  
 
 
Pregnancy outcome 
The majority of pregnancies resulted in a delivery (86.8%, 1421/1637; 1401 live births 
and 20 stillbirths) and 193 (11.8%) pregnancies ended early (126 miscarriages, 63 
terminations and 4 ectopic pregnancies). Information on pregnancy outcome was 
unavailable for 8 (0.5%) pregnancies, with a further 15 (0.9%) ongoing at the time of 
data submission. Among women with a pregnancy, older women were less likely than 
younger women to have a pregnancy resulting in delivery (aRR 0.95 [0.92-0.99], 
p=0.02, adjusted for calendar year, CD4 count and ethnicity) and women infected via 
contaminated blood/blood products were more likely to have a pregnancy resulting in a 
delivery than women infected via heterosexual sex (aRR 1.22 [1.10-1.34], p=0.001). 
Ethnicity, ART use and CD4 count were not predictive of whether pregnancies resulted 
in a delivery. The proportion of pregnancies resulting in delivery increased over time 
(aRR 1.01 [1.00-1.02], p=0.05) and there was a fall in the proportion of pregnancies 
resulting in a termination, from 12.8% (20/156) in 2000/01 to 2.9% (13/450) in 2008/09, 
p<0.001. 
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Table 5.5. Characteristics associated with having a pregnancy among HIV-positive women already accessing HIV clinical care at UK CHIC 
sites in 2000-2009 
 
Person-
years 
(PY) 
Pregnancies 
Pregnancy 
rate  
(per 100 PY) 
95% CI 
Relative 
Rate 
95% CI p-value 
Adjusted 
Relative 
Rate
1
 
95% CI p-value 
Year of conception
2
 38,097 1637 4.3 4.1 - 4.5 1.03 1.01-1.05 <0.001 1.05 1.03-1.07 <0.001 
 
     
      
Age 
group 
16-25 years 3486 254 7.3 6.4 - 8.1 1.12 0.98-1.29 0.10 1.12 0.98-1.29 0.11 
26-35 years 15,927 1032 6.5 6.1 - 6.9 1.00 - - 1.00 - - 
 36-49 years 18,684 351 1.9 1.7 - 2.1 0.30 0.26-0.34 <0.001 0.29 0.25-0.33 <0.001 
 
     
      
ART use On ART 22,512 890 4.0 3.7 - 4.2 0.82 0.74-0.91 <0.001 0.95 0.85-1.05 0.32 
CD4 count 
(cells/mm
3
)         
≤200 6073 183 3.0 2.6 - 3.4 0.64 0.54-0.76 <0.001 0.65 0.55-0.77 <0.001 
201-350 8841 421 4.8 4.3 - 5.2 1.00 - - 1.00 - - 
 
>350 21,155 981 4.6 4.4 - 4.9 0.98 0.87-1.10 0.71 0.99 0.88-1.11 0.83 
NK 2028 52 2.6 1.9 - 3.3 0.54 0.41-0.72 <0.001 0.52 0.39-0.68 <0.001 
 
    
      
Ethnicity White 6993 203 2.9 2.5 - 3.3 0.62 0.52-0.73 <0.001 0.67 0.57-0.80 <0.001 
Black-Caribbean  1483 59 4.0 3.0 - 5.0 0.85 0.65-1.11 0.23 0.75 0.58-0.97 0.03 
Black-African 24,837 1173 4.7 4.5 - 5.0 1.00 - - 1.00 - - 
Black-other 1004 49 4.9 3.5 - 6.2 1.04 0.77-1.39 0.81 0.94 0.71-1.25 0.68 
Other 2069 75 3.6 2.8 - 4.4 0.77 0.59-0.99 0.04 0.71 0.56-0.91 0.01 
Not reported 1711 78 4.6 3.6 - 5.5 0.96 0.75-1.23 0.76 0.95 0.75-1.20 0.66 
           
 
1
 Where all variables in the table were included in the model. 
2 
Estimated year of conception is a continuous variable. RRs refer to an increase of one year
1
7
0
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Index pregnancies 
A separate analysis was undertaken looking only at index pregnancies. The number of 
index pregnancies increased each year from 46 in 2000 to 98 in 2009, with 902 in total. 
Overall there were 153 index pregnancies in women aged 16-25 years, 571 in women 
aged 26-35 years and 178 in women aged 36-49 years. Among all women of child 
bearing age accessing care the index pregnancy rate increased (aRR 1.03 [1.01-1.06], 
p=0.007). The rate increased among women aged 26-35 years (aRR 1.06 [1.03-1.10], 
p<0.001) but the increase in rate in women aged 16-25 years and those aged over 35 
years were not statistically significant (aRR 1.05 [0.99-1.11], p=0.12 and aRR 1.02 
[0.96-1.07], p=0.61 respectively). There was no evidence that the rate of increase in 
women aged 16-25 differed from the rate in women aged 26-35 years (p-value for 
interaction=0.58). There was evidence that the rate of increase differed in women aged 
26-35 years compared to women aged 36-49 years (p-value for interaction=0.004). 
There was no statistically significant difference in the rate of increase in index 
pregnancies between women on ART and women not on ART (p-value for 
interaction=0.26), between women with different CD4 counts (p-value for 
interaction=0.15) or between different ethnic groups (interactions: white vs. black-
African p=0.31, black-Caribbean vs. black-African p=0.08). 
As was the case with all pregnancies, younger age was predictive of having an index 
pregnancy (aRR 0.37 per 10 year increment in age [95% CI 0.34-0.41], p<0.001, 
adjusted for CD4, ART use, ethnicity, exposure group and year). Women with CD4 
<200 cells/mm3 were less likely to have a pregnancy compared with women with CD4 
200-350 cells/mm3 (aRR 0.63 [0.51-0.79], p<0.001) and when adjusted for other factors 
the chance of women on ART having an index pregnancy did not significantly differ 
from that of women not on ART (aRR 1.04 [0.90-1.12], p=0.57). With regard to 
ethnicity, only women of white ethnicity had less chance of having an index pregnancy 
compared to women of black-African ethnicity (aRR 0.67 [0.54-0.82], p<0.001). There 
was no statistically significant difference in the chance of having an index pregnancy 
between women of black-Caribbean ethnicity and women of white ethnicity (aRR 0.82 
[0.59-1.15], p=0.26). With regard to exposure group, only women infected via vertical 
transmission had significantly less chance of having an index pregnancy compared to 
women infected via heterosexual sex when other factors were considered (aRR 0.29 
[0.14-0.62], p=0.001). The difference in chance of having an index pregnancy was not 
statistically significant when women infected via injecting drug use were compared with 
women infected via heterosexual sex (aRR 0.67 [0.40-1.08], p=0.10).  
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5.4 Discussion 
Among women attending care at a UK CHIC site with a pregnancy, there was an 
increase in the number (and proportion) of women already on ART at conception, as 
has been reported from the UK and Ireland (using the NSHPC data) [422] and 
elsewhere [131]. This increase is number is due to the cumulative effect of additional 
women starting treatment each year whilst those who previously started remain on 
treatment. In the future, the vast majority of HIV diagnosed women will be on ART 
when they conceive since they will be recommended life-long ART at diagnosis [9][86]. 
In pregnancies conceived on ART, the fetus is exposed to cART for the full duration of 
its development including the early weeks of pregnancy when neural development 
occurs. The short and long-term implications of this in utero exposure, are not clear. 
The Antiretroviral Pregnancy Register (APR)23 collates data on pregnancy outcome in 
women who use ART in pregnancy. Each year it enrolls around 1300 women from the 
US and 200 from elsewhere. The latest estimated prevalence of birth defects in women 
with first trimester use of ART was 2.9 [95% CI 2.5-3.3] per 100 live births [202], not 
significantly higher than the estimated prevalence in the general US population [424]. 
The data collated by the registry is limited for a number of reasons. For some ART 
drugs, particularly newer drugs, the number of women using them in pregnancy is very 
small - making it difficult to identify rare events. Data refer to the duration of pregnancy 
and shortly after and there is no long-term follow up. In addition, there is likely to be 
bias in which pregnancies are reported - with birth defects or adverse events likely to 
be reported than uneventful pregnancies resulting in an overestimation of the 
tetratogenic effect of a drug. 
As well as the possible risks posed by ART use throughout pregnancy, the are also 
some benefits. The risk of toxicity is highest when ART is first started. Therefore, 
toxicity is less likely to occur in women already on ART at conception than in women 
starting ART in pregnancy – an area which I explore in a Chapter 7. Use of ART 
throughout pregnancy also minimises the risk of vertical transmission [129] since 
women who conceive and remain on ART throughout pregnancy are more likely to be 
virally suppressed in pregnancy and at delivery than women who use short-course ART 
during pregnancy [131]. 
The increasing number of repeat pregnancies in combination with an increasing 
number of women on ART at the time of conception also meant that by 2009 only 1 in 5 
                                               
23
 Information on the Antiretroviral Pregnancy Register can be found at www.apregistry.com 
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pregnancies were among women naïve to ART. The majority of women not on ART at 
conception (around 39% overall), used ART during pregnancy with only a small 
proportion not using any ART (2.4% overall, trend p=0.44) either because they 
declined it, were diagnosed close to the time of delivery and/or delivered early i.e. 
before ART could be started. Among women who did not conceive on ART, the 
proportion who started life-long ART increased over the decade, reflecting a move 
towards starting treatment at a higher CD4 count, [78] even before the 2008 BHIVA 
guidelines recommended starting at or before a CD4 count of 350 cells/mm3. For some 
women, pregnancy provided them with an opportunity to start life-long ART because 
they were diagnosed in pregnancy and already had a CD4 count at which life-long ART 
was recommended. For women who are lost-to-follow up or disengaged with clinical 
care, pregnancy can provide an opportunity and the motivation to re-engage with 
clinical care.  
The pregnancy incidence among women attending HIV care was more than double the 
incidence in the general population at the time. In 2000, the pregnancy incidence 
among women aged 15-44 in England and Wales was 1.4% compared to 3.5% among 
women in this study. In 2009, the pregnancy incidence in England and Wales was 
1.7% compared to 4.7% in this study [425]. Whether the differences in pregnancy 
incidence between women attending HIV care and the general population are due only 
to the differences in the age and ethnic breakdown of the two groups is not clear as the 
national data for this period were not available by ethnicity or age group. There was an 
increase in the overall pregnancy rate among HIV-positive women accessing clinical 
care over the period 2000-2009. The increased pregnancy rate in later years remained 
after adjusting for the changing characteristics of women under HIV care in these 
clinics over the decade, such as increased average age - changes which also occurred 
elsewhere in Europe [426]. Of note, there was no evidence that the pregnancy rate 
increased more among women on ART than among women not on ART or among 
women of a particular age, ethnicity or CD4 category.  
The increase in pregnancy rate across this diverse group is likely to reflect 
improvements in HIV treatment and management which have led to reduced morbidity 
[59, 420] and MTCT rates [131, 149]. During this period there was also in increase in 
the pregnancy rate in the general population in England and Wales [425]. An 
increasing number of pregnancies were repeat pregnancies, as has previously been 
reported in the UK and Ireland (using the NSHPC data) [427] and elsewhere [160]. 
However, the increase in pregnancy rate also occurred in index pregnancies and was 
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therefore not only because of an increase in the rate of repeat pregnancies. Changing 
attitudes towards childbearing following improvements in ART treatment and a fall in 
the risk of vertical transmission have been reported [163, 428, 429]. These changes 
include an increased desire to have children and may have contributed to the fall in the 
number of terminations among women living with HIV, also reported elsewhere [428]. 
Whilst in the general population in England and Wales, in women aged 15-44 years, 
the number of pregnancies which were terminated increased from 174,198 to 187,637 
over this period, and the percentage of pregnancies which were terminated remained 
stable at around 22% [425]. The fall in the number of terminations among women living 
with HIV could also be due to a reduction in the number of unplanned pregnancies, 
thought to be high among this population [162, 430, 431]. However, no data were 
available on the use of contraception or pregnancy intention. It should also be noted 
that the number of terminations reported to the NSHPC is an underestimation because 
only HIV-positive women accessing antenatal care are reported to the study. As such, 
diagnosed HIV-positive women who seek a termination would not normally be reported 
to the NSHPC. 
There were a number of characteristics predictive of having a pregnancy among 
women receiving HIV clinical care. Younger women were more likely to have a 
pregnancy than older women as we see in the general population [402] and as has 
been reported from studies of pregnancy rate [428, 432] and pregnancy intention [433-
436] among HIV-positive women. Women infected via injecting drug use were less 
likely to have a pregnancy than women infected via heterosexual sex, after accounting 
for age, CD4 count and ethnicity. This has been found elsewhere [161, 436] and may 
reflect differences in health, lifestyle, desire for children [436] or menstrual changes 
associated with methadone maintenance and illicit drug use [437]. These could not be 
assessed as no data on these variables were collected by either dataset. Women of 
black-African ethnicity were more likely to have a pregnancy than women of white 
ethnicity or women of black-Caribbean ethnicity reflecting cultural differences in 
attitudes to childbearing and family size. African ethnicity was predictive of fertility 
intention among HIV-positive women in Canada [432]. In France, HIV-positive women 
born in Africa were more likely to want children than women born in Europe [436]. 
Differences in the pregnancy rate between women of black-African and black-
Caribbean ethnicity likely reflect cultural differences and differences in the proportion 
that were UK born.  
When other factors were considered, ART use did not remain an independent predictor 
of pregnancy, although it has been found to be in some studies [428, 435]. However, 
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analyses that consider the impact of ART on pregnancy rate may suffer from the 
problems of time-varying confounding, and may be biased as a result.  
Predictors of pregnancy were similar for index pregnancies as they were for all 
pregnancies although some of the associations did not reach statistical significance. 
This may be a result of insufficient statistical power due to small numbers.  
In UK CHIC the number of pregnancies increased from 156 in 2000/01 to 450 in 
2008/09, due to an increase in the number of women accessing and remaining in care 
[417], and an increase in the likelihood that women became pregnant. Among all 
diagnosed HIV-positive women in the UK and Ireland, including those diagnosed during 
pregnancy, the number of pregnancies stabilised in 2006 at around 1500 pregnancies 
per year [145], when pregnancy incidence in our study was highest (4.8%). This 
plateau could be a result of reporting delay, but could also be due to the increasing 
number of older women accessing care, women who, in general, are less likely to have 
a pregnancy. Recently, the number of sequential pregnancies in the UK and Ireland 
has also plateaued as an increasing number of women may have completed their 
family [145].  
As the number of pregnancies has risen, so has the use of specialist antenatal 
services. All HIV-positive women who are pregnant or planning a pregnancy require a 
high level of clinical care from a multidisciplinary team including specialist midwives, 
obstetricians, HIV specialists, GPs, paediatricians and health workers. Many women 
may also require additional support in areas such as ART adherence support, advice 
regarding HIV disclosure and social/immigration issues [439] and assisted 
reproduction. Demand for these services is likely to remain or increase further, 
particularly as an increasing number of older women have pregnancies (as is the case 
in the UK as a whole [440, 441]). Older women may require additional support, 
particularly those aged over 40, as they are at increased risk of experiencing fertility 
problems [442] and pregnancy complications [443-445], some of which are also 
associated with ART use in pregnancy [175, 210, 426, 446]. Infants born to older 
women also have an increased risk of neural tube defects [447] and Down’s Syndrome 
[448]. Older maternal age and HIV have both also been associated with an increased 
risk of stillbirth [449] and miscarriage [450-452]. An updated analysis, using more 
recent data would help inform those planning and commissioning HIV services in 
estimating the number of women attending HIV clinical care likely to have a pregnancy.  
There were a number of limitations to the data available for analysis. Some variables 
which might be predictive of pregnancy, such as parity, were available in NSHPC but 
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not in UK CHIC. Since I examined characteristics predictive of pregnancy among 
women in UK CHIC it was not possible to assess parity – since only women with a 
pregnancy since HIV diagnosis (and were therefore reported to NSHPC) had any data 
on parity.  
The analyses focused on HIV diagnosed women already attending care and 
pregnancies during which HIV was diagnosed were not included in the analysis. 
Factors predictive of pregnancy in women not aware of their HIV status may differ from 
those of diagnosed women.  
Another limitation of the analysis was that instead of considering CD4 count and ART 
use as time-dependent variables, only the first CD4 count and ART status at start of 
each year were considered. This strategy was used to simplify the analysis and 
although CD4 counts are likely to be stable and ART status consistent throughout the 
year they may have changed by the time the woman conceived. ART status did not 
take into account whether the woman was on ART for her own health or for PMTCT 
during an earlier pregnancy. Women whose pregnancies ended in termination or first 
trimester miscarriage may not have accessed antenatal care, and therefore not been 
reported to the NSHPC. As such, the proportion of pregnancies ending early is likely to 
be a minimum estimate and despite there being no significant change in the rate of 
miscarriages among reported pregnancies there may have been changes in the rate 
during this period.    
The incomplete linkage between records in UK CHIC and NSHPC for women reported 
to both could result in an underestimation of pregnancy incidence. However, any such 
underestimation is unlikely to affect our assessment of the predictors of pregnancy or 
the trends over time. A higher proportion of women in the UK CHIC dataset accessed 
care in London than is the case nationally. The characteristics of pregnant women 
accessing care in London may differ from those accessing care outside London. 
However, changes in pregnancy incidence at UK CHIC sites are likely to be similar to 
changes in pregnancy incidence elsewhere.  
In conclusion, an increasing number of pregnancies among women accessing HIV 
clinical care reflect increases in the pregnancy rate among this group as well as 
increases in the total number of women accessing care. HIV-positive women who are 
pregnant or planning a pregnancy require a high level of clinical care. The care needed 
by this population as a whole may increase as more older women have pregnancies.   
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Key points 
 An increasing number of pregnancies were among women already on life-long 
ART (27% in 2000 and 59% in 2009).  
 In women who conceived whilst not already on ART, the percentage with 
previous exposure to ART rose (from 12% in 2000 to 45% in 2009). 
 In women who were not on ART when they conceived, the percentage that 
started life-long ART in pregnancy rose (from 25% in 2000 to 41% in 2008) while 
the percentage that used short-course ART in pregnancy fell (from 64% in 2000 
to 59% in 2009).  
 Independent predictors of pregnancy among women attending HIV clinical care 
included: younger age, having a CD4 count 200-350 cells/mm3 (compared to a 
lower CD4 count) and black-African ethnicity (compared to white ethnicity). After 
adjusting for other factors, women on ART were no more likely to have a 
pregnancy than women not on ART.  
 The overall pregnancy rate increased over time as did the index pregnancy rate. 
This increase was not focused in any one particular group.  
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Chapter 6 Short-course ART use in pregnancy 
and the response to ART once therapy is 
subsequently started  
 
6.1 Introduction  
The results of the previous chapter indicate that in recent years around 20% of 
pregnant women in UK CHIC used short-course combination antiretroviral therapy 
(cART) and 5% used short-course zidovudine monotherapy (ZDVm) for PMTCT. It is 
not clear whether this short-term use of ART in pregnancy has any impact on treatment 
outcomes once women subsequently start life-long ART for their own health.  
In this chapter I assess, in women starting life-long ART, how many had previously 
used short-course ART in pregnancy. Then, in two separate analyses, I examine 
treatment outcomes in women starting life-long ART who have been diagnosed with 
HIV for at least one year. Firstly I compare the outcomes of women who previously 
used short-course ZDVm in pregnancy with women who had never previously used 
ART (ART-naïve) and secondly, I compare the outcomes of women who previously 
used short-course cART in pregnancy with the outcomes of ART-naïve women. Parts 
of this analysis were published in 2014 [453] (Appendix IIc). 
 
6.2 Methods 
Categorising ART use in pregnancy 
The type of ART used in each pregnancy was determined using a combination of ART 
data from NSHPC and UK CHIC. For each pregnancy, ART use was categorised as 
ZDVm if this drug was reported by both studies or by one study if the other had missing 
data. If data were contradictory, i.e. one study reported the use of cART and the other 
reported the use of ZDVm, this was categorised as ART type not known. Short-course 
cART was defined as the use of three or more ART drugs started during pregnancy 
and stopped within six months of delivery. This definition, which extends into the 
postnatal period, was used because although the vast majority of women who used 
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short-course cART stopped at delivery, some stopped ART several months after 
delivery. This postnatal use of ART could have been because they were breastfeeding. 
However, it is more likely to be a result of inaccurate reporting of the ART stop date or 
the delivered date, if for example the expected date of delivery was reported as a proxy 
for the actual date of delivery. 
I examine ZDVm use in pregnancy in the period 1997-2010. This period was selected 
since it includes most of the pregnancies during which ZDVm was used in women 
included in the later analyses. Data from all years prior to 1997 were examined when 
assessing ART experience in women in the later analyses.  
The date on which a woman started life-long ART (considered the baseline date) was 
determined (using UK CHIC data) using the earliest of: cART use for ≥12 months (this 
could include treatment changes or interruptions of <3 months), cART started with a 
CD4 count <200 cells/mm3; cART started with a CD4 count <350 cells/mm3 outside 
pregnancy; cART started with a CD4 count <350 cells/mm3 in pregnancy after 2008; or 
cART started within 6 months of an AIDS event. 
When starting life-long ART (sometimes referred to in this chapter as starting 
‘treatment’), women were categorised as ‘ZDVm-experienced’ if they had used short-
course ZDVm in pregnancy but had never used cART, as ‘cART-experienced’ if they 
had used short-course cART in pregnancy (irrespective of whether they had used 
ZDVm in any other pregnancy) or as ‘ART-naïve’ if they had no evidence of any prior 
ART use. Women with one or more previous pregnancies, but with no evidence of ART 
use were excluded from the ART-naïve group since ART use in pregnancy could not 
be ruled out. Women were excluded from the ART-experienced group if they had used 
ART at times outside pregnancy and the 6 months postpartum. In some cases, the 
pattern of ART use (in UK CHIC) suggested that short-course cART had been used in 
pregnancy but this could not be confirmed because no pregnancy was recorded in 
NSHPC for that period. Alternatively, the pregnancy may have been reported to 
NSHPC but the UK CHIC record was not matched to the NSHPC record in the dataset 
linkage. 
Throughout the analyses I continue to refer to women as either ‘ZDVm-experienced’, 
‘cART-experienced’ or ‘ART-naïve’. This refers to their ART status at the point of 
starting life-long ART (baseline) since no women were ART-naïve and all were cART-
experienced once they had started life-long ART.  
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Baseline CD4 cell count and viral load were established using the latest measurement 
available in UK CHIC within the 3 months before initiation of life-long ART. The CD4 
count and viral load measurements closest to 6, 12 and 24 months after initiation were 
identified as long as they were measured within 3 months of the date of interest (i.e. 
within the 3-9, 9-15 and 21-27 month windows respectively).   
Inclusion and exclusion criteria 
Women were included in the analysis if they were aged ≥16 years and had been 
diagnosed with HIV for at least one year when starting life-long ART, thereby excluding 
late diagnosed women who would likely have worse outcomes. Only women aged 49 
years or younger at diagnosis were included, thereby including only women who could 
have used short-course cART or ZDVm in pregnancy before starting long-term 
treatment.  
Statistical analysis 
The characteristics of women who had previously used ART and women who were 
ART-naïve, including their clinical characteristics at baseline, were compared using t-
test (for comparing mean CD4 counts), the Kruskal-Wallis test for non-Normally 
distributed continuous variables and the Chi-squared test for categorical variables, 
unless expected values in any group were <5, when Fisher’s exact test was used. The 
availability of viral load and CD4 data were compared in the same way.  
In women on ART, the outcomes examined were: time to death/AIDS, change in CD4 
count from baseline at 6 and 24 months; time to viral suppression (viral load ≤50 
copies/ml) within 6 months; time to viral rebound (a single measure of HIV-RNA >200 
copies/ml) 0-6 months after suppression in women with viral suppression by 6 months; 
time to viral rebound >6-24 months after viral suppression among women who had 
suppressed within 6 months and were still under follow-up (i.e. had not experienced a 
rebound within 6 months of suppression), time to any regimen change within 24 
months (not including treatment interruptions) and time to a treatment interruption of at 
least 30 days within 24 months. 
The Kaplan-Meier method was used to produce figures showing the cumulative 
incidence of viral suppression within 6 months and the cumulative incidence of viral 
rebound 0-6 months and >6-24 months after suppression in women who virally 
suppressed within 6 months. Outcomes were compared using Cox proportional 
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hazards regression (time to AIDs/death, viral suppression, viral rebound, regimen 
change and regimen interruption) or linear regression (change in CD4 count).  
For the time to AIDS/death analysis, follow-up was right-censored at the last clinic visit 
or on 31st December 2012, whichever occurred first. For the time to virological 
suppression analysis, only women with a viral load measurement in the first six months 
on ART were included and follow-up was right-censored at six months after starting 
treatment or when ART was interrupted for any period of time. Then in sensitivity 
analysis, any treatment interruption was ignored. For the analysis of time to viral 
rebound, follow-up started at the point of viral suppression and was right-censored if 
the woman died or interrupted treatment, six months after the last viral load 
measurement within 2 years of starting treatment, or on 31st December 2012, 
whichever occurred first. For the time to treatment switch and treatment interruption 
analyses, follow-up was right-censored after two years, if the woman died or at her last 
clinic visit, whichever occurred first.  
For both analyses (1: ZDVm-experienced vs. ART-naïve; 2: cART-experienced vs. 
ART-naïve) the UK CHIC dataset containing data to end 2012 was used. Due to the 
small number of women in the ZDVm-experienced group, variables were categorised 
slightly differently in the two analyses and slightly different inclusion criteria were used 
(described below). 
Analysis 1: ZDVm-experienced vs. ART-naïve women 
Women were included in the analysis if they started long-term cART in the period 
2003-2010, allowing at least two years of follow-up. Women not attending care at a UK 
CHIC site (i.e. those with no viral load or CD4 measurements reported) in the first two 
years on ART were excluded. 
In adjusted analyses the variables included in the model were: age at baseline; 
pregnancy status at baseline (pregnant/not pregnant); ethnicity (black-African/other); 
HIV risk/exposure group (heterosexual sex v other); years since HIV diagnosis; year 
starting treatment; type of ART regiment started (non-nucleoside reverse transcriptase 
inhibitor [NNRTI]-based/protease inhibitor [PI]-based [including ritonavir boosted and 
non-boosted]/nucleoside/nucleotide reverse transcriptase inhibitor [NRTI] only and 
other regimens); baseline viral load (categorised as either ≤10,000/>10,000 
copies/ml/not known or as a continuous variable [log10 copies/ml]); baseline CD4 
(categorised as either ≤200/201-350/>350 cells/mm3/not known or as a continuous 
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variable); hepatitis B or hepatitis C (HBV/HCV) co-infection and previous AIDS event at 
baseline (yes/no).  
Women with no baseline viral load were categorised as having viral load ≤10,000 
copies/ml (n=241) but were excluded in sensitivity analysis and in the analysis of time 
to viral suppression/rebound. Due to the immunological and physiological changes that 
occur during pregnancy, and potential differences in drug adherence rates, women 
starting life-long ART whilst pregnant may experience different treatment outcomes 
from women starting whilst not pregnant. A sensitivity analysis was therefore also 
performed excluding women who were pregnant when starting life-long ART. 
Analysis 2: cART-experienced vs. ART-naïve women 
Women were included in the analysis if they started life-long cART in the period 2006-
2010, allowing at least two years of follow-up. Women not attending care at a UK CHIC 
site (i.e. those with no viral load or CD4 measurements reported) in the first two years 
on ART were excluded.  
In addition to the outcomes already listed, time to severe liver enzyme elevation (LEE) 
of ALT (alanine transaminase) (≥ grade 3 according to the Division of AIDS toxicity 
guidelines [322]) was also examined using Cox proportional hazards regression. 
Follow-up was right censored at the last clinic visit, on 31st December 2012 or if the 
woman died. 
In adjusted analyses the variables included in the model were the same as in the 
ZDVm analysis however, since the number of women included in analyses was larger, 
ethnicity was categorised into more categories (black-African/black-
Caribbean/white/other or not known) as was exposure group (heterosexual 
sex/injecting drug use [IDU]/other or not known), CD4 count (≤200/201-350/351-
500/>500 cells/mm3/not known) and ART regimen type (NNRTI-based/PI-based/NRTI 
only/other and not known).  
A sensitivity analysis was performed excluding women with no baseline viral load 
and/or no CD4 cell count. An additional viral rebound sensitivity analysis was 
performed in which follow-up was censored at the start of any subsequent pregnancy.  
Viral suppression and viral rebound could be associated with whether or not viral 
suppression was achieved during the pregnancy in which ART was previously used. 
Therefore an additional analysis was undertaken including only women with previous 
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cART experience and including in the model a variable categorising viral suppression 
(HIV-RNA ≤50 copies/ml) in the final trimester of the previous pregnancy (categorised 
as yes/no/not known).  
Drug resistance was assessed using data from the UK HIV Drug Resistance Database 
(UK HDRD). This dataset, established in 2011, aims to collate the results of all 
genotypic resistance tests performed in routine HIV clinical care in the UK [454]24. Data 
from the UK CHIC study are linked annually to the UK HDRD using common 
pseudonymised identifiers. The dataset used in this analysis was the most up-to-date 
dataset available at the time and contained resistance data to the end of 2010. It 
included approximately 85% of all HIV drug-resistance tests performed in the UK until 
that point.  
Women were defined as having resistance to a class of ART drug if they had least one 
major resistance-associated mutation which gave reduced susceptibility to that class 
(Appendix X) [102]. The four main drug classes were examined: non-nucleoside 
reverse-transcriptase inhibitors (NNRTIs), nucleoside reverse-transcriptase inhibitors 
(NRTIs), protease inhibitors (PIs) and integrase inhibitors (INI). 
In ART-naïve and cART experienced women drug resistance data were examined from 
before initiation of life-long ART and in the month following viral rebound. In cART-
experienced women, drug resistance data prior to any short-course cART use was also 
assessed. The prevalence of genotypic resistance to ≥1 drug class when starting 
treatment was compared in ART-naïve and cART-experienced women using logistic 
regression. Further statistical analysis of the resistance data was not undertaken 
because few of the women had any data available. 
  
                                               
24
 Being initially funded by the Department of Health, the UK HDRD is now funded by the UK Medical 
Research Council (MRC) (grant G0900274) and is coordinated at UCL’s MRC Clinical Trials Unit (CTU). 
Further information is available from the website 
www.ctu.mrc.ac.uk/hivrdb/public/drug_resistance.asp (Accessed June 2016). 
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6.3 Results 
Antenatal ART experience among women starting life-long ART  
In the period 2003-2012, 6207 women (aged 16 years and older and HIV-diagnosed at 
age 49 years or younger) in UK CHIC started life-long ART, representing 55.8% of the 
11,114 women in UK CHIC during this period. Among women starting life-long ART, 
the percentage who had previously had a pregnancy (after or during which HIV was 
diagnosed) rose from 6.2% (39/627) in women starting life-long ART in 2003 to 13.9% 
(35/251) in women starting life-long ART in 2012 (Table 6.1). The median time between 
being diagnosed with HIV and starting life-long ART was shorter in the earlier years of 
this period than in the later years (3.6 [inter-quartile range (IQR) 1.4-26.1] months 
compared to 15.6 [IQR 1.3-72.6] months for women starting ART in 2003 and 2012 
respectively) (Table 6.1). The percentage of women who had been diagnosed for at 
least one year when starting life-long ART rose from 35.4% (222/627) to 52.2% 
(131/251) for women starting treatment in 2003 and 2012 respectively (Table 6.1).  
The majority of women who started life-long ART during the period 2003-2012 had 
never previously used ART (90.3%, 5579/6175) (Table 6.2). However, the proportion 
that had previously used ART increased over time from 4.0% (25/627) in 2003 to 
12.0% (30/251) in 2012. Among all the 596 women with previous ART experience 
when starting life-long ART, 75.2% (n=448) had used short-course cART, whilst 19.3% 
(n=115) had used only ZDVm only and 5.5% (n=33) had used both ZDVm and cART 
during different pregnancies (Table 6.2). 
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Table 6.1.Time since HIV diagnosis and previous pregnancies in women starting life-long ART in 2003-2012 
Year 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
Women attending HIV care at a UK CHIC 
site  
4315 4823 5453 5924 6171 6586 6927 7399 7574 6207 
Already started life-long ART  2771 3232 3728 4411 4766 5285 5828 6464 6867 5947 
(% of those attending care) (64.1) (66.9) (68.2) (74.3) (77.1) (80.1) (84.0) (87.3) (90.6) (95.7) 
            
Started life-long ART  627 584 800 659 664 701 658 641 590 251 
(% of those attending care) (14.5) (12.1) (14.7) (11.1) (10.8) (10.6) (9.5) (8.6) (7.8) (4.0) 
(% of those attending care yet to start ART) (40.6) (36.7) (46.4) (43.6) (47.3) (53.9) (59.9) (68.6) (83.5) (96.5) 
            
Women starting life-long ART           
Any previous pregnancy reported to NSHPC 39 61 98 73 75 99 97 92 76 35 
n (% of those starting ART) (6.2) (10.4) (12.3) (11.3) (11.3) (14.1) (14.7) (14.4) (12.9) (13.9) 
Median time since HIV-diagnosis [IQR] 
(months) 
3.6 8.5 10.7 9.4 18.6 18.3 13.6 16.5 16.3 15.6 
 [1.4-26.1] [1.6-37.5] [1.6-40.9] [1.7-45.6] [2.0-54.9] [2.0-56.0] [1.4-59.7] [1.2-67.9] [1.2-74.5] [1.3-72.6] 
            
Diagnosed ≥1 year before starting ART 222 268 390 312 373 390 338 341 309 131 
n (% of those starting ART)  (35.4) (45.9) (48.8) (47.3) (56.2) (55.6) (51.4) (53.2) (52.4) (52.2) 
This table includes data for women aged ≥16 years when attending care who were aged ≤49 years at HIV diagnosis 
  
1
8
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Table 6.2. Previous use of cART and ZDVm in pregnancy among women in UK CHIC starting life-long ART in 2003-2012 
Year 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Total 
Women starting life-long ART  627 584 800 659 664 701 658 641 590 251 6175 
ART-naïve when starting ART           602 540 736 597 603 618 578 563 521 221 5579 
(% of women starting ART) (96.0) (92.5) (92.0) (90.6) (90.8) (88.2) (87.8) (87.8) (88.3) (88.0) (90.3) 
            
ART-experienced when starting ART 
(% of women starting ART) 
25 
(4.0) 
44 
(7.5) 
64 
(8.0) 
62 
(9.4) 
61 
(9.2) 
83 
(11.8) 
80 
(12.2) 
78 
(12.2) 
69 
(11.7) 
30 
(12.0) 
596 
(9.7) 
            
    short-term ZDVm only 9 13 12 8 14 16 13 14 15 1 115 
(% of ART-experienced women) (36.0) (29.5) (18.8) (12.9) (23.0) (19.3) (16.3) (17.9) (21.7) (3.3) (19.3) 
            
    short-term cART only 16 30 49 50 45 65 62 59 46 26 448 
(% of ART-experienced women) (64.0) (68.2) (76.6) (80.6) (73.8) (78.3) (77.5) (75.6) (66.7) (86.7) (75.2) 
            
    short-term cART and ZDVm used 0 1 3 4 2 2 5 5 8 3 33 
(% of ART-experienced women) (0.0) (2.3) (4.7) (6.5) (3.3) (2.4) (6.3) (6.4) (11.6) (10.0) (5.5) 
            
            
This table includes data for women aged ≥16 years when attending care who were aged ≤49 years at HIV diagnosis 
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ZDVm use in pregnancy among women in UK CHIC 
During the period 1997-2010 there were a total of 234 pregnancies during which ZDVm 
was used (and ART data were available); one pregnancy resulted in a stillbirth and 233 
in a live birth. The median time between conceiving and starting ZDVm was 26 (IQR 
23-29) weeks. The median duration of pregnancy was 36 (IQR 35-37) weeks, and the 
median duration of ZDVm use in pregnancy was 10 (IQR 8-13) weeks or 13 (IQR 10-
21) weeks including postnatal use. In most cases, ZDVm was stopped at/after delivery 
(n=160) or during the final trimester (n=28). This latter group appeared to stop ZDVm 
whilst still being pregnant but may have stopped at delivery as there may be some 
inaccuracy in the reporting of drug stop dates or the delivery date, if for example the 
expected date of delivery was used as a proxy for the actual date of delivery. A small 
number of women switched from ZDVm to cART either during their final trimester (n=3) 
or after delivery (n=39). All these women had had a CD4 count >350 cells/mm3 when 
they started ZDVm. In some pregnancies it was not clear from the data when ZDVm 
was started or stopped (n=4). 
Most pregnancies during which ZDVm was used were index pregnancies (91.0%, 
n=213), with a smaller number being second (n=19) or third (n=2) pregnancies since 
HIV-diagnosis. For the non-index pregnancies, ART use in any previous pregnancy 
had been either cART (n=18), ZDVm (n=1) or not known (n=4).  
Among the 213 women using ZDVm in their index pregnancy, 97 women had at least 
one subsequent pregnancy during which they used short-course cART (n=43), started 
life-long ART (n=19), no ART data were available (n=22) or they had already started 
life-long ART in the interval between pregnancies (n=13).   
  
6.4 Analysis 1: Treatment outcomes in ZDVm-experienced and 
ART-naïve women  
Overall, 93 ZDVm-experienced and 1667 ART-naïve women who started life-long 
cART in 2003–2010 were included in the analysis. Five of the ZDVm-experienced 
women included in Table 6.2 were excluded from the analysis as there was evidence 
from the NSHPC data that they had started therapy at an earlier date than indicated in 
the UK CHIC data. One additional woman was excluded as she had no viral load or 
CD4 count data in the first two years on treatment. ZDVm-experienced women had 
used ZDVm in either one (n=86) or two pregnancies (n=7). None of the infants 
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acquired HIV. In pregnancy, ZDVm was used for a median of 12 (IQR 8–16) weeks and 
was typically started at 26 (IQR 23–28) weeks gestation. The median duration between 
delivery (of the latest pregnancy) and starting life-long ART was 61 (IQR 41–77) 
months; three women started within 12 months of delivery.  
The baseline demographic and clinical characteristics of ZDVm-experienced and ART-
naïve women at the time of starting life-long ART are summarised in Table 6.3. ZDVm-
experienced women had been diagnosed for longer than ART-naïve women (ZDVm-
experienced: median 6 [4-9] years since HIV diagnosis; ART-naïve: 4 [2-7] years, 
p<0.001). ZDVm-experienced women were on average younger than ART-naïve 
women (ZDVm-experienced: median age 33 [30–38] vs. ART-naïve: 35 [30–41] years, 
p=0.04), more likely to have been infected via heterosexual sex (ZDVm-experienced: 
96.8% vs. ART-naïve: 89.8%, p=0.03) and more likely to be pregnant when starting 
life-long ART (ZDVm-experienced: 20.4% vs. ART-naïve: 8.0%, p<0.001). A similar 
proportion of women were of black-African ethnicity (ZDVm-experienced: 63.4%; ART-
naïve: 64.5%, p=0.84). Overall, 31.5% (n=555) used a PI-based regimen (ritonavir-
boosted or non-boosted), 62.8% (n=1106) an NNRTI-based regimen and 5.6% (n=99) 
an NRTI-only or other regimen. The regimens used were similar regardless of prior 
ZDVm experience (p=0.32).  
ZDVm-experienced women were more likely to have at least one viral load 
measurement recorded in the first 6 months on treatment (ZDVm-experienced: 98.9% 
[92/93]; ART-naïve: 91.4% [1523/1667], p=0.01). In women with at least one viral load 
measurement in this period, the median number of measurements was the same for 
ZDVm-experienced and ART-naïve women (median 3 [IQR 2–4], p=0.10). There was 
weak evidence that ZDVm-experienced women were more likely to have at least one 
CD4 count in the first 6 months on treatment (any CD4 measurement: ZDVm-
experienced: 95.7% [89/93]; ART-naïve: 90.0% [1501/1667], p=0.07). 
ZDVm-experienced and ART-naïve women started therapeutic ART at similar mean 
CD4 counts (ZDVm-experienced: 290 [standard deviation (SD) 190] cells/mm3; ART-
naïve: 271 [167] cells/mm3, p=0.65) and viral load (ZDVm-experienced: 4.1 [3.4-4.5] 
log10 copies/ml; ART-naïve: 4.2 [2.8-4.9] log10 copies/ml, p=0.81). Few women in either 
group were known to have HBV and/or HCV (ZDVm-experienced: 5.4%; ART-naïve: 
9.3%, p=0.20) and few had previously had an AIDS event (ZDVm-experienced: 7.5%; 
ART-naïve: 13.6%, p=0.09).  
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Table 6.3. Characteristics of ZDVm-experienced and ART-naïve women starting life-
long ART in 2003-2010 at least one year after HIV-diagnosis 
Characteristics at start of treatment 
ZDVm-experienced 
(n=93) 
ART-naïve 
(n=1667)  
p-
value 
Year, n (%) 
 
2003-2005 28 (30.1) 571 (34.3) 0.59 
2006-2008 38 (40.9) 681 (40.9)  
2009-2010 27 (29.0) 415 (24.9)  
Median age (years) [IQR]                           33 [30-38] 35 [30-41] 0.04 
Ethnicity, n (%)   Black-African 59 (63.4) 1075 (64.5) 0.84 
Non-black-African/not known  34 (36.6) 592 (35.5)  
Exposure group, n (%)  Heterosexual sex 90 (96.8) 1497 (89.8) 0.03 
Other 3 (3.2) 170 (10.2)  
HBV/HCV, n (%) 5 (5.4) 155 (9.3) 0.20 
CD4 count (cells/mm
3
), n (%)                                           
(n=91 and n=1461) 
≤200 60 (25.9) 203 (27.7) 0.81 
201-350 129 (55.6) 408 (55.7)  
>350 43 (18.5) 121 (16.5)  
 Mean [SD] 290 [190] 271 [167] 0.34 
Viral load >10,000 copies/ml, n (%)      
(n=86, n=1433) 
39 (45.4) 652 (45.5) 0.97 
Median viral load [IQR] (log10 copies/ml) 4.1 [3.4-4.5] 4.2 [2.8-4.9] 0.81 
Years since HIV diagnosis, median [IQR]                     6 [4-9] 4 [2-7]  <0.001 
Previous AIDS event, n (%) 7 (7.5) 226 (13.6) 0.09 
Pregnant, n (%) 19 (20.4) 134 (8.0) <0.001 
Type of ART regimen, n (%)         
PI-based (boosted and non-boosted) 25 (26.9) 530 (31.8) 0.32 
NNRTI-based  60 (64.5) 1046 (62.8)  
NRTI/Other  8 (8.6) 91 (5.5)  
Number of drugs in regimen
1
, n (%) 3 62 (72.1) 1119 (68.7) 0.50 
≥4 24 (27.9) 511 (31.4)  
      
1 
A ritonavir boosted PI in combination with two nucleosides was counted at 3 drugs in total. 
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AIDS/death 
Whilst on treatment, 1.1% (n=1) of ZDVm-experienced and 5.1% (n=85) of ART-naïve 
women developed an AIDS defining illness. None of the ZDVm-experienced women 
died but 32 (1.9%) ART-naïve women died. The specific cause of death was not 
reported for 23 of these women. Where the cause of death was reported, it was 
reported as: sepsis (n=2), ‘brain’ (n=1), heart failure and acute myocarditis (n=1), 
malnutrition (n=1), cervical cancer (n=1), obesity (n=1), thrombocytopenia 2 
gastroenteritis (n=1) and toxic shock (n=1). 
The risk of AIDS/death was low in both groups and the AIDS/death event rate was 2.9 
[0-8.7] per 100 person-years of follow-up (PY) in ZDVm-experienced women and 13.7 
[10.7-16.6]/100 PY in ART-naïve women. In crude analysis there was weak evidence 
that the risk of AIDS/death was lower in ZDVm-experienced women than in ART-naïve 
women (hazard ratio [HR] 0.16 [95% confidence interval (CI) 0.02-1.14], p=0.07). 
However, the difference in risk was not statistically significant in adjusted analysis 
(adjusted hazard ratio [aHR] 0.21 [0.03-1.51], p=0.12). In the adjusted model the other 
factors with a statistically significant association with AIDS/death were: having 
previously had an AIDS event (aHR 1.82 [1.19-2.79], p=0.006), having a baseline CD4 
count ≤200 cells/mm3 compared to 201-350 cells/mm3 (aHR 2.30 [1.41-3.75], p<0.001), 
and starting a PI-based regimen compared to starting an NNRTI-based regimen (aHR 
1.75 [1.17-2.61], p=0.006) (Table 6.4).  
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Table 6.4. Cox proportional hazards model for time to AIDS/death among ART-naive 
and ZDVm-experienced women on life-long ART 
Variable aHR 95% confidence   
interval 
p-value 
ZDVm-experience 0.21 0.03 - 1.51 0.12 
Age (per 10 additional years) 1.17 0.92 - 1.49 0.20 
Pregnant when starting ART 0.48 0.17 - 1.33 0.16 
Ethnicity Black-African Reference    
 
Other/not known 1.02 0.68 - 1.54 0.91 
Exposure Heterosexual sex Reference    
 
Other/not known 0.95 0.48 - 1.85 0.87 
Year of HIV diagnosis 1.01 0.97 - 1.06 0.56 
Year of starting treatment 0.99 0.90 - 1.10 0.90 
ART regimen NNRTI-based Reference   0.01 
 
PI-based 1.75 1.17 - 2.61  
 
NRTI/other 1.90 0.98 - 3.65  
Baseline viral load >10,000 copies/ml 1.11 0.74 - 1.69 0.61 
Baseline CD4 count 
(cells/mm
3
)  
≤200 2.30 1.41 - 3.75 <0.001 
201-350 Reference    
>350 1.14 0.57 - 2.25  
 Not known 3.19 1.76 - 5.80  
HBV/HCV  1.31 0.73 - 2.37 0.37 
Previous AIDS event 1.82 1.19 - 2.79 0.01 
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CD4 count increase 
Figure 6.1 and Table 6.5 present the mean CD4 count and mean CD4 increase from 
baseline at each 2 month interval throughout the first 24 months on treatment. These 
appear similar in ART-naïve and ZDVm-experienced women although the line of the 
ZDVm-experienced women has more ‘noise’ due to the smaller number of women in 
this group.  
 
Figure 6.1. Mean CD4 count and CD4 change from baseline within 2 month periods 
since starting long-term ART in ART-naive and ZDVm-experienced women 
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Table 6.5. Mean CD4 count and CD4 change from baseline within 2 month periods since starting long-term ART in ART-naive and ZDVm-
experienced women 
 
 
 
Months since ART start 0-2 >2-4 >4-6 >6-8 >8-10 >10-12 >12-14 >14-16 >16-18 >18-20 >20-22 >22-24 
ZDVm-experienced             
Mean CD4 count 339 347 393 396 425 373 464 408 491 441 503 530 
n 66 59 49 46 40 40 40 32 34 41 25 34 
Mean change in CD4 72 96 105 138 171 138 156 156 218 165 240 266 
n (also with baseline CD4) 65 58 48 44 39 38 39 31 33 41 24 33 
             
ART-naïve             
Mean CD4 count 327 355 366 384 407 419 440 441 447 476 467 483 
n 1056 1028 895 806 831 806 746 725 718 697 623 671 
Mean change in CD4 77 98 114 125 143 155 173 179 189 217 204 223 
n (also with baseline CD4) 997 954 820 739 744 723 671 646 630 621 554 587 
             
1
9
3
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After 6 months on treatment the mean CD4 count was 393 cells/mm3 in ZDVm-
experienced women and 388 cells/mm3 in ART-naïve women. At that time there was no 
statistically significant association between ZDVm experience and mean change in 
CD4 count from baseline in crude or adjusted analysis (difference in mean: -7.2 [95% 
CI -40.1, 25.7] cells/mm3, p=0.67; adjusted difference in mean -10.2 [95% CI -42.4, 
21.9] cells/mm3, p=0.53) (Table 6.6). There were, however, a number of other variables 
associated with CD4 count change (Table 6.6). After 6 months on ART, women who 
had been pregnant when starting treatment had on average a greater increase in CD4 
count than women who were not pregnant when starting treatment (adjusted difference 
in mean 45.2 [95% CI 18.2, 72.2] cells/mm3, p=0.001).  
After 24 months on treatment the mean CD4 count was 526 cells/mm3 in ZDVm-
experienced women and 490 cells/mm3 in ART-naïve women. Again there was no 
statistically significant association between ZDVm experience and change in CD4 
count from baseline in crude or adjusted analysis (difference in mean: 23.1 [95% CI      
-25.2, 71.4] cells/mm3, p=0.35; adjusted difference in mean 16.4 [95% CI -30.9, 63.6] 
cells/mm3, p=0.50). At 24 months, having a higher baseline CD4 count was associated 
with a smaller increase in CD4 count (adjusted difference in mean -13.8 [95% CI -20.9, 
-6.7] cells/mm3 per additional 100 cells/mm3 at baseline, p<0.001). Other variables 
associated with change in CD4 count were: black-African ethnicity compared to 
ethnicity ‘other/not known’ (adjusted difference in mean -31.0 [95% CI -53.8, -8.1] 
cells/mm3, p=0.008), year of starting treatment (adjusted difference in mean per 
additional year 7.0 [95% CI 1.6, 12.3] cells/mm3, p=0.01), and starting an NRTI/other 
type  regimen  compared  to  an  NNRTI-based  regimen  (adjusted  difference in  mean 
-51.9 [95% CI -99.2, -4.6] cells/mm3, p=0.03). Women with a baseline viral load 
>10,000 copies/ml had a greater increase in CD4 count (adjusted difference in mean 
74.1 [95% CI 51.6, 96.8] cells/mm3, p<0.001). Viral load remained associated with CD4 
count change when log10 viral load was included in the model instead of the binary 
variable (≤/>10,000 copies/ml) which resulted in the exclusion of an additional 204 
women with no baseline viral load (adjusted difference in mean 38.6 [95% CI 28.9, 
48.4] cells/mm3, p<0.001). 
After 24 months on ART, women with HBV/HCV had on average a smaller increase in 
CD4 count than women without HBV/HCV (adjusted difference in mean -55.9 [95% CI  
-96.8, -14.9] cells/mm3, p=0.01). This difference was much smaller and did not reach 
statistical significance after only 6 months on ART (adjusted difference in mean -5.0 
[95% CI -31.5, -21.4] cells/mm3, p=0.71). 
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After 24 months on ART the association between pregnancy status when starting life-
long ART and CD4 count was not statistically significant (adjusted difference in mean 
24.7 [95% CI -16.2, 65.6] cells/mm3, p=0.24). 
Viral suppression 
More than three-quarters of women in both groups achieved viral suppression within 6 
months on ART (ZDVm-experienced: 88.4% [76/86]; ART-naïve: 77.2% [1059/1371] 
among women with baseline viral load and a viral load measurement during the first 6 
months on ART). The median time to viral suppression (Kaplan Meier estimate) was 
2.8 (95% CI 2.3-3.2, IQR 1.4-4.4) months for ZDVm-experienced women and 3.2 (95% 
CI 3.0-3.3, IQR 1.8-5.3) months for ART-naïve women.  
In Cox proportional hazards analysis, women with no baseline viral load measurement 
were excluded (ZDVm-experienced n=7 and ART-naïve n=234) as were women with 
no viral load measurement in the first six months of ART use (n=0 ZDVm-experienced 
and n=62 ART-naïve). ZDVm-experienced women were more likely to achieve viral 
suppression within the first 6 months on treatment compared to women who were ART-
naïve (HR 1.32 [1.04-1.66], p=0.02) (Figure 6.2 and Table 6.7). This was also true in 
the adjusted model (aHR 1.31 [1.03-1.66], p=0.03). Women who were pregnant when 
starting life-long ART were more likely to achieve viral suppression (aHR 1.47 [1.19-
1.81], p<0.001). Women starting a PI-based regimen or an NTRI/other regimen were 
less likely to achieve viral suppression compared to women starting an NNRTI-based 
regimen (PI-based: aHR 0.77 [0.67-0.88], p<0.001; NRTI/other: aHR 0.67 [0.51-0.88], 
p=0.004) and women starting ART with a CD4 count >350 cells/mm3 were less likely to 
achieve viral suppression compared to women starting with CD4 201-350 cells/mm3 
(aHR 0.83 [0.70-0.98], p=0.03). Compared to women with a low baseline viral load, 
women with a higher baseline viral load were less likely to achieve viral suppression 
(baseline viral load [log10 copies/ml] aHR 0.78 [0.75-0.82], p<0.001) (Table 6.7).  
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Table 6.6. Mean change in CD4 count after 6 and 24 months on ART in women who were ZDVm-experienced or ART-naïve when starting life-
long ART 
 6 months on ART 24 months on ART 
Variable Adjusted 
difference in 
means 
    95% 
confidence   
interval 
p-value Adjusted 
difference in 
means 
95% confidence 
interval 
p-value 
ZDVm-experience -10.2 -42.4, 21.9 0.53 16.4 -30.9, 63.6 0.50 
Age (per 10 additional years) 1.5 -7.9, 11.0 0.75 6.3 -7.6, 20.3 0.37 
Pregnant when starting ART 45.2 18.2, 72.2 0.001 24.7 -16.2, 65.6 0.24 
Ethnicity  Black-African Reference    Reference    
 Other/not known -16.8 -32.2, -1.4 0.03 -31.0 -53.8, -8.1 0.01 
Exposure  Heterosexual sex Reference    Reference    
 Other/not known 9.2 -17.9, 36.4 0.50 5.5 -36.8, 47.8 0.80 
Year of HIV diagnosis -2.0 -3.9, -0.1 0.04 -2.2 -5.0, 0.6 0.12 
Year of starting treatment 5.7 2.2, 9.2 0.001 7.0 1.6, 12.3 0.01 
ART regimen NNRTI-based  Reference    Reference    
 PI-based 8.3 -8.3, 24.8 0.33 -11.2 -36.0, 13.7 0.38 
 NRTI/other  -33.8 -65.3, -2.3 0.04 -51.9 -99.2, -4.6 0.03 
Baseline viral load >10,000 copies/ml 44.0 28.6, 59.4 <0.001 74.2 51.6, 96.8 <0.001 
Baseline CD4 count (per additional 100 
cells/mm
3
) 
-14.0 -18.8, -9.3 <0.001 -13.8 -20.9, -6.7 <0.001 
HBV/HCV  -5.0 -31.5, 21.4 0.71 -55.9 -96.8, -14.9 0.01 
Previous AIDS event -5.2 -27.0, 16.6 0.64 19.0 -12.8, 50.8 0.24 
Denominators: 6 months: ZDVm-experienced: n=78; ART-naïve: n=1445; 24 months: ZDVm-experienced: n=65; ART-naïve: n=1236.  19
6
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Table 6.7. Cox proportional hazards model for time to viral suppression within 6 months 
on treatment in ZDVm-experienced (n=86) and ART-naive women (n=1371) 
Variable aHR 95% confidence   
interval 
p-value 
ZDVm-experience 1.31 1.03 - 1.66 0.03 
Age (per additional 10 years) 1.06 0.98 - 1.14 0.16 
Pregnant when starting ART 1.47 1.19 - 1.81 <0.001 
Ethnicity Black-African Reference    
 
Other/not known 1.05 0.92 - 1.19 0.48 
Exposure  Heterosexual sex Reference    
 Other/not known 0.92 0.73 - 1.15 0.45 
Year of HIV diagnosis 1.01 0.99 - 1.02 0.28 
Year of starting treatment 1.07 1.04 - 1.10 <0.001 
ART regimen NNRTI-based Reference   <0.001 
 
PI-based 0.77 0.67 - 0.88  
 
NRTI/other 0.67 0.51 - 0.88  
Baseline viral load (log10 copies/ml) 0.78 0.75 - 0.82 <0.001 
Baseline CD4 count 
(cells/mm
3
)  
≤200 0.93 0.81 - 1.08 0.18 
201-350 Reference   
 >350 0.83 0.70 - 0.98 
 Not known 0.97 0.68 - 1.39  
HBV/HCV  0.96 0.77 - 1.21 0.75 
Previous AIDS event 1.03 0.86 - 1.23 0.78 
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Figure 6.2. Cumulative incidence of virological suppression within 6 months on 
treatment: ZDVm-experienced women (red line with 95% CIs in light red) compared to 
ART-naïve women (blue line with 95% CIs in light blue) – where women with no 
baseline viral load or viral load measurement within the 6 months on ART were 
excluded 
  
ART-naïve  1371 1162 948 675 460 348  251 
ZDVm-
experienced  
86 70 54 38 21 16  9 
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Viral rebound 
Among women who achieved viral suppression within 6 months on ART (n=1135) the 
risk of viral rebound was examined within the periods 0-6 and 6-24 months after 
suppression. Few women experienced viral rebound in the first 6 months after 
suppression (ZDVm-experienced 6.6% [5/76]; ART-naïve 2.8% [30/1059] (Figure 6.3a). 
In crude analysis there was weak evidence that ZDVm-experienced women were more 
likely to experience viral rebound (aHR 2.37 [0.92-6.07], p=0.07) but in the adjusted 
analysis there was no statistically significant association between ZDVm experience 
and the risk of viral rebound (aHR 1.65 [0.60-4.56], p=0.33) (Table 6.8). During this 
period, women who had started treatment whilst pregnant were more likely to 
experience viral rebound compared to women who were not pregnant when starting 
treatment (aHR 6.34 [2.86-14.07], p<0.001). The risk of viral rebound was lower in 
older women than in younger women (aHR per additional 10 years 0.47 [0.27-0.80], 
p=0.01). Women who started an NRTI/other regimen were more likely to experience 
viral rebound compared to women who started an NNRTI-based regimen (aHR 4.84 
[1.47-15.88], p=value 0.01). 
In the period 6-24 months after suppression, among women who were yet to 
experience viral rebound, few women experienced viral rebound (ZDVm-experienced 
3.0% [2/66]; ART-naïve 3.6% [35/969] (Figure 6.3b). None of the variables included in 
the adjusted model had a statistically significant association with the risk of viral 
rebound in the 6-24 months after viral suppression including previous use of ZDVm 
(HR 0.91 [0.22-3.79], p=0.90; aHR 0.88 [0.21-3.72], p=0.86).  
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Figure 6.3. Cumulative incidence of viral rebound among women achieving viral suppression within six months of starting ART: women with 
ZDVm experience (red line with 95% CIs in light red) compared to ART-naïve women (blue line with 95% CIs in light blue) 
a.) 0-6 months after viral suppression      b.) 6-24 months after viral suppression  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
At risk   
ART-naïve  1059 1041 1025 1008 993 977 969  969 836 739 628 
ZDVm-
experienced  
76 73 73 73 70 67 66  66 52 48 43 
Both figures include only women with viral suppression within 6 months on ART and b) includes only women still at risk of viral rebound 
 20
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Table 6.8. Time to viral rebound 0-6 months and 6-24 months after viral suppression (within 6 months) in ZDVm-experienced and ART-naive 
women on life-long ART 
 0-6 months after suppression  6-24 months after suppression 
Variable aHR 95% confidence   
interval 
p-value aHR 95% confidence   
interval 
p-value 
ZDVm-experience 1.65 0.60 - 4.56 0.33 0.88 0.21 - 3.72 0.86 
Age (per additional 10 years) 0.47 0.27 - 0.80 0.01 0.94 0.61 - 1.46 0.79 
Pregnant when starting ART 6.34 2.86 - 14.07 <0.001 2.21 0.82 - 5.91 0.12 
Ethnicity Black-African Reference    Reference     
 Other/not known 1.13 0.51 - 2.51 0.77 1.40 0.66 - 2.95 0.38 
Exposure  Heterosexual sex Reference    Reference     
 Other/not known 1.01 0.25 - 4.11 0.99 1.20 0.34 - 4.20 0.78 
Year of HIV diagnosis 0.98 0.88 - 1.09 0.73 1.06 0.99 - 1.15 0.11 
Year of starting treatment 0.97 0.81 - 1.15 0.71 0.91 0.78 - 1.07 0.25 
ART regimen NNRTI-based Reference   0.02 Reference    0.57 
 
PI-based 2.03 0.91 - 4.54  1.46 0.72 - 2.96  
 
NRTI/other 4.84 1.47 - 15.88  -     
Baseline viral load (log10 copies/ml) 1.23 0.88 - 1.71 0.22 1.22 0.90 - 1.64 0.20 
Baseline CD4 count 
(cells/mm
3
)  
≤200 1.41 0.57 - 3.50 0.56 1.23 0.57 - 2.65 0.90 
201-350 Reference    Reference     
>350 1.85 0.76 - 4.47  1.04 0.38 - 2.87  
 Not known 1.78 0.38 - 8.27  1.64 0.37 - 7.30  
HBV/HCV  1.00 0.28 - 3.48 0.99 2.32 0.95 - 5.71 0.07 
Previous AIDS event 1.15 0.33 - 4.07 0.82 0.91 0.36 - 2.26 0.83 2
0
1
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Regimen change or interruption whilst on treatment 
Within the first 24 months on treatment, 41.5% (730/1760) of women changed their 
regimen (ZDVm-experienced: 37.6% (35/93); ART-naïve 41.7% [695/1667]) either by 
increasing the number of drugs by one (29.9%, n=218 overall) or more (11.1%, n=81), 
replacing drugs in the regimen whilst maintaining the overall number (36.3%, n=265) or 
reducing the number of drugs by one (13.0%, n=95) or more (4.8%, n=35). There was 
no statistically significant association between ZDVm experience and changing 
regimen (aHR 0.91 [0.65-1.29], p=0.60) (Table 6.9). However, women who were 
pregnant when starting treatment were more likely to change their regimen compared 
to women who were not pregnant when starting treatment (aHR 1.39 [1.08-1.79], 
p=0.01). Changing regimen was also associated with having HBV/HCV co-infection 
(aHR 1.38 [1.08-1.77], p=0.01), starting treatment with a CD4 count >350 cells/mm3 
compared to 201-350 cells/mm3 (aHR 0.78 [0.62-0.98], p=0.03), starting an NRTI/other 
regimen compared to starting an NNRTI-based regimen (aHR 1.69 [1.27-2.24], 
p<0.001) and the year in which treatment was started (aHR 0.93 [0.90-0.96] per 
additional year, p<0.001) (Table 6.9).  
An interruption of ART for at least 30 days occurred in 14.0% (13/93) of ZDVm-
experienced women and 18.3% (305/1667) of ART-naïve women. In women who 
interrupted treatment, the interruption occurred after a median of 7.9 (IQR 3.0-15.0) 
months on ART and the median time to restarting treatment was 3.7 (IQR 1.9-13.2) 
months from the date of interruption. There was no statistically significant association 
between ZDVm experience and interrupting treatment (aHR 0.73 [0.41-1.28], p=0.26) 
(Table 6.9). As with treatment changes, women who were pregnant when starting 
treatment were more likely to interrupt their regimen (aHR 1.47 [1.03-2.10], p=0.03) 
(Table 6.9). Interrupting ART was also associated with younger age (aHR 0.86 [0.75-
1.00], p=0.05 per 10 additional years), and the year in which treatment was started 
(aHR 0.91 [0.86-0.96] per additional year, p=0.001).  
 203 
 
Table 6.9. Time to switching or interrupting ART regimen in ZDVm-experienced and ART-naive women starting life-long ART 
 Time to any change in regimen  Time to ART interruption 
Variable aHR 95% confidence   
interval 
p-value aHR 95% confidence   
interval 
p-value 
ZDVm-experience 0.91 0.65 - 1.29 0.60 0.73 0.41 - 1.28 0.26 
Age (per 10 additional years) 0.96 0.87 - 1.06 0.37 0.86 0.75 - 1.00 0.05 
Pregnant when starting ART 1.39 1.08 - 1.79 0.01 1.47 1.03 - 2.10 0.03 
Ethnicity Black-African Reference    Reference     
 
Other/not known 1.18 1.00 - 1.38 0.05 1.01 0.79 - 1.29 0.92 
Exposure Heterosexual sex Reference    Reference     
  1.18 0.88 - 1.57 0.27 0.82 0.55 - 1.22 0.32 
Year of HIV diagnosis 1.01 0.99 - 1.03 0.36 1.00 0.97 - 1.03 0.96 
Year of starting treatment 0.93 0.90 - 0.96 <0.001 0.91 0.86 - 0.96 0.001 
ART regimen NNRTI-based Reference   <0.001 Reference    <0.001 
 
PI-based 1.16 0.99 - 1.37  1.60 1.26 - 2.04  
 
NRTI/other 1.69 1.27 - 2.24  1.02 0.62 - 1.70  
Baseline viral load (log10 copies/ml) 1.00 0.85 - 1.17 0.99 1.22 0.96 - 1.54 0.10 
Baseline CD4 count 
(cells/mm
3
)  
≤200 1.07 0.89 - 1.29 0.005 1.29 0.99 - 1.68 <0.001 
201-350 Reference    Reference     
>350 0.78 0.62 - 0.98  0.84 0.60 - 1.16  
 Not known 1.26 1.00 - 1.59  0.50 0.31 - 0.80  
HBV/HCV  1.38 1.08 - 1.77 0.01 1.45 1.02 - 2.05 0.04 
Previous AIDS event 1.11 0.89 - 1.39 0.35 0.78 0.58 - 1.05 0.11 
2
0
3
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Sensitivity analyses  
In sensitivity analyses, when the 153 women who were pregnant when starting life-long 
ART were excluded, the main findings were unaltered. There was no statistically 
significant association between ZDVm experience and AIDS/death (aHR 0.23 [0.03-
1.66], p=0.14), mean change in CD4 count after 6 months (adjusted difference in 
means 6.1 [-29.4, 41.5], p=0.74) or 24 months on ART (adjusted difference in means 
39.3 [-11.4, 90.0], p=0.13), switching treatment (aHR 0.81 [0.53-1.24], p=0.33) or 
interrupting treatment (aHR 0.71 [0.36-1.39], p=0.32). As with the main analysis, 
ZDVm-experienced women were more likely to achieve viral suppression within 6 
months (aHR 1.45 [1.12-1.88], p=0.005) but there was no statistically significant 
association between ZDVm experience and viral rebound at 0-6 months (aHR 1.51 
[0.19-12.0], p=0.70) or at >6-24 months (aHR 0.95 [0.22-4.05], p=0.94) after viral 
suppression.  
 
6.5 Analysis 2: Treatment outcomes in cART-experienced and 
ART-naïve women  
ART use in pregnancy 
There were 248 women who started life-long ART and who had previously used short-
course cART in one (n=208), two (n=20) or three (n=3) pregnancies or who had used 
cART in at least one pregnancy and ZDVm in at least one pregnancy (n=17) (Figure 
6.4).  
In cART-experienced women starting treatment, where the duration of ART use was 
known (281/297 pregnancies), the median duration of use in a pregnancy (including 
any postpartum use) was 15 (10-20) weeks. The median cumulative duration of 
previous ART use was 16 (IQR 11-23) weeks. Where the regimen used in pregnancy 
was reported (290 pregnancies) the regimen was: PI-based (60.7%, n=176); NNRTI-
based (26.9%, n=78), (77 of which contained nevirapine (NVP); or another type of 
regimen (8.9%, n=26). The median interval between the end of their last pregnancy in 
which short-course ART was used and the date on which they started treatment was 
31 (IQR 21-52) months; 10.9% (n=27) of women had an interval of less than one year. 
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Figure 6.4. Diagram showing inclusion in and exclusion from Analysis 2 
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Duration of follow-up and availability of CD4 count and viral load measurements 
The 1042 women included in the analysis were followed for a total of 3877 PY from the 
date they started life-long ART (ART-experienced women: 897 PY and ART-naïve 
women: 2980 PY).  
The percentage of women with at least one viral load measurement within the first six 
months on ART was similar in both groups (cART-experienced: 91.9% [228/248]; ART-
naïve 93.0% [738/794], p=0.59). The median number of viral load measurements in 
this period was the same for both groups (3 [IQR 2-4], p=0.41), this was also the case 
in the first 24 months of treatment (cART-experienced women: 7 [IQR 5-10]; ART-naïve 
women: 7 [IQR 6-10], p=0.23).   
The percentage of women with at least one CD4 cell count within the first six months 
on ART was similar in cART-experienced and ART-naïve women (88.3% [219/248] vs. 
90.7% [720/794] respectively, p=0.27). However, cART-experienced women had, on 
average, fewer CD4 counts in the first 6 months on treatment (cART-experienced: 2 
[IQR 1-3]; ART-naïve: 2 [IQR 1-3]), p-value for distribution <0.001) and in the first 24 
months on treatment (cART-experienced: 5 [IQR 4-7]; ART-naïve: 6 [IQR 4-8], 
p<0.001).  
Availability of drug resistance data 
Prior to starting treatment, 57.3% (n=142) of cART-experienced women had at least 
one resistance test performed (Figure 6.5). The percentage of cART-experienced 
women with a resistance test prior to starting treatment increased over time from 
36.6% (15/41) of women starting therapy in 2006 to 63.0% (34/54) of women starting 
life-long ART in 2010 (Chi-square p-value 0.02). Of women with a resistance test, 69 
women had the test prior to any ART use and 69 women had a test following ART use 
and in the year before starting treatment (22 women had a test at both these times). A 
further 26 women had a resistance test prior to starting treatment but not when ART-
naïve or in the year before starting treatment. 
Prior to starting treatment, 57.1% (453/794) of ART-naïve women had at least one 
resistance test performed (Figure 6.5), with the percentage increasing over time from 
44.7% (67/150) of women starting treatment in 2006 to 61.3% (84/137) of women 
starting treatment in 2010 (Chi-square p<0.001). Of these, 155 (34.2%) women had a 
test within 6 months of their HIV diagnosis, 171 (37.7%) women in the 6 months before 
starting treatment (36 women had a test within 6 months of diagnosis and another test 
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6 months prior to starting treatment) and 91 (20.1%) women had a test at another time 
prior to starting treatment.  
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Figure 6.5. Resistance test data for ART-naïve and cART-experienced women included 
in the analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median number of tests is shown with IQR in square brackets 
Baseline characteristics when starting treatment 
The characteristics of cART-experienced and ART-naïve women starting treatment are 
presented in Table 6.10. Compared to ART-naïve women, cART-experienced women 
were more likely to be of black-African ethnicity (75.4% vs. 61.5% respectively), 
infected with HIV via heterosexual sex (98.0% vs. 90.8%) and be pregnant when 
starting life-long ART (17.3% vs. 10.8%). cART-experienced women were less likely to 
have had an AIDS event (cART-experienced: 6.9%; ART-naïve: 13.7%). When starting 
treatment there was no statistically significant difference in mean CD4 count (cART-
experienced CD4 283 cells/mm3 vs. ART-naïve 269 cells/mm3, p=0.18). A larger 
percentage of cART-experienced women had viral load >10,000 copies/ml than ART-
naïve women (69.0% vs. 59.6%). In both groups, most women started an NNRTI-
based regimen (ART-naïve 54.0%; cART-experienced 61.3%) and most women started 
on a combination of three drugs (57.3% and 64.0% respectively). Baseline ALT data 
were available for only 31.1% (n=77) of cART-experienced and 37.0% (n=294) of ART-
naïve women. 
ART status 
when starting 
life-long ART 
Any resistance 
test data 
Resistance test 
before starting 
life-long ART 
Resistance test 
after starting 
life-long ART 
(at treatment 
failure) 
Yes  
n=37  
1 [1-2] 
Yes  
n=453  
1 [1-1] 
Yes  
n=86  
1 [1-2] 
ART-naïve  
n=794 
Yes  
n=490 
1 [1-2] 
No  
n=304  
No  
n=37  
No  
n=367  
cART-
experienced 
n=248 
Yes  
n=142  
1 [1-2] 
Yes  
n=34  
1 [1-2] 
Yes  
n=157  
1 [1-2] 
No 
n=91 
No  
n=108  
No  
n=15 
Yes  
n=15  
1 [1-2] 
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Table 6.10. Characteristics of women starting treatment in 2006-2010 (n=1042) 
Baseline characteristics cART-experienced 
n=248 
ART-naïve  
n=794 
p= 
       
Year,               
n (%) 
2006-2007 
2008-2009 
2010 
79 
115 
54 
(31.9) 
(46.4) 
(21.8) 
318 
339 
137 
(40.1) 
(42.7) 
(17.3) 
0.05 
       
       
Age,              
n (%) 
16-29 years 
30-39 years 
40-49 years 
Median [IQR] years 
75 
138 
35 
33  
(30.2) 
(55.7) 
(14.1) 
[28-37] 
194 
356 
244 
35  
(24.4) 
(44.8) 
(30.7) 
[30-41] 
<0.001 
       
       
Ethnicity,         
n (%) 
Black African  
White 
Black Caribbean 
Other/NK 
187 
25 
19 
17 
(75.4) 
(10.1) 
(7.7) 
(6.9) 
488 
166 
45 
95 
(61.5) 
(20.9) 
(5.7) 
(12.0) 
<0.001 
       
       
Exposure 
category,         
n (%) 
Heterosexual sex 
IDU 
Other/NK 
243 
3 
2 
(98.0) 
(1.2) 
(0.8) 
721 
39 
34 
(90.8) 
(4.3) 
(4.9) 
0.001 
       
      
HBV/HCV, n (%) 17 (6.9) 78 (9.8) 0.16 
      
       
1
CD4 count 
(cells/mm
3
),   
n (%)
 
n=232,n=732                        
≤200  
201-350 
351-500 
>500 
Mean [SD] 
60 
129 
30 
13 
283 
(25.9) 
(55.6) 
(12.9) 
(5.6) 
[139] 
203 
408 
79 
42 
269 
(27.7) 
(55.7) 
(10.8) 
(5.7) 
[145] 
0.81 
 
 
 
0.18 
       
 
     
1
Viral load >10,000 (copies/ml),               
n (%)
 
n=229,n=726 
Median [IQR] (log10 copies/ml) 
158
 
4.5  
(69.0) 
 
[3.8-4.9] 
433 
 
4.3 
(59.6) 
 
[3.5-4.9] 
0.01 
 
0.02 
 
     
      
Years since diagnosis,                
median [IQR] 
4.4 [2.6-6.9] 3.7 [2.1-6.2] <0.001 
      
      
Previous AIDS event, n (%) 17 (6.9) 109 (13.7) 0.004 
      
      
Pregnant, n (%) 43 (17.3) 86 (10.8) 0.007 
      
       
Type of 
ART 
regimen,        
n (%) 
PI-based 
NNRTI-based 
NRTI-based 
Other 
108 
134 
2 
4 
(43.6) 
(54.0) 
(0.8) 
(1.6) 
302 
522 
12 
15 
(35.8) 
(61.3) 
(1.1) 
(1.8) 
0.18 
       
       
Drugs in 
regimen,             
n (%) 
3 
≥4 
142 
106 
(57.3) 
(42.7) 
508 
286 
(64.0) 
(36.0) 
0.07 
       
1
Latest measurement within the 6 months before starting treatment 
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Drug resistance before starting life-long ART 
In cART-experienced women with a resistance test at any point before starting life-long 
ART, 11.3% (16/142) had resistance to ≥1 drug class (to either one [n=15] or two [n=1] 
drug classes). In women tested prior to using short-course ART in pregnancy, 7.3% 
(5/69) had resistance to a single drug class (Table 6.11). Of the 453 ART-naïve women 
with a resistance test at any point before starting treatment, 12.6% (n=57) had 
resistance to at least one drug class; 46 women had resistance to a single drug class 
and 11 women had resistance to two drug classes.  
When starting treatment, cART-experienced women were no more likely to have 
resistance to ≥1 drug class than ART-naïve women (odds ratio [OR] 0.88 [CI 0.49-
1.59], p=0.68).  
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Table 6.11. Drug resistance prior to starting treatment in ART-naïve and cART-
experienced women with ≥1 resistance test prior to starting treatment 
1 
These women did not have a resistance test when they were ART-naïve   
2 
There were 22 women tested when they were ART-naïve and also tested during the 12 months prior to 
starting life-long ART. The three cART-experienced women with ≥1 drug class resistance prior to starting 
treatment did not have a resistance test when they were ART-naïve 
The major drug resistance mutations identified in these women are shown in Appendix IX 
    
  
Women with ≥1 resistance test 
prior to starting treatment 
Resistance to ≥1 
drug class  
Type of drug class resistance 
[total] 
ART-naïve 
(n=453) 
No  396 (87.4%) 
Yes 57 (12.6%) Single drug class n=46 
      PI 3 
    NRTI 1 
    NNRTI 42 
   Two drug classes n=11 
    PI+NRTI 2 
    PI+NNRTI 3 
    NRTI+NNRTI 6 
cART-
experienced  
When ART-naïve  
(n=69) 
No 64 (92.8%)   
Yes 5 (7.3%) Single drug class n=5 
   PI 1 
   NRTI 1 
   NNRTI 3 
In 12 months 
before starting 
life-long ART  
(n=69) 
No  66 (95.7%)   
Yes 3 (4.3%)
1
 Single drug class  n=2 
    NNRTI 2 
   Two drug classes n=1 
     NRTI+NNRTI 1 
 Any time prior to 
starting life-long 
ART
2
 (n=142) 
No 126 (88.7%) 
 Yes 16 (11.3%) Single drug class  n=15 
   PI 2 
   NRTI 3 
   NNRTI 10 
  Two drug classes n=1 
     NRTI+NNRT 1 
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AIDS/death 
Whilst on treatment, 4.4% (n=11) of cART-experienced women and 5.9% (n=47) of 
ART-naïve women developed AIDS or died. The AIDS/death event rate was 14.7 (95% 
CI 6.0 – 23.4)/100 PY in cART-experienced women and 18.9 (13.5 – 24.3)/100 PY in 
ART-naïve women. The cause of death was reported for only 7 of the 20 women who 
died (18 ART-naïve women and 2 cART-experienced women died). The cause of 
deaths were reported as: ‘brain’; ‘HIV disease’; ‘malnutrition due to bowel obstruction’; 
‘thrombocytopenia 2 gastroenteritis’; ‘murder’; ‘cerebral toxoplasmosis’ and ‘metastatic 
cervical cancer HIV diabetes mellitus’. Only two of the deaths were preceded by an 
AIDS event. One woman was diagnosed with cerebral toxoplasmosis having started 
ART two months before and died within two months of the AIDS event. Another woman 
was diagnosed with ‘Lymphoma, Burkitt’s, immunoblastic or equivalent‘. She died 6 
months after the AIDS diagnosis but the cause of death was not reported. 
There was no statistically significant association between cART experience and 
AIDS/death in crude or adjusted analysis (HR 0.76 [95% CI 0.39-1.46], p=0.41; aHR 
0.82 [0.41-1.65], p=0.58). In the adjusted model, factors with a statistically significant 
association with AIDS/death were: older age (aHR 1.45 [1.01-2.09] per 10 additional 
years, p=0.04); baseline CD4 count ≤200 cells/mm3 compared to 201-350 cells/mm3 
(aHR 2.77 [1.50-5.13], global p<0.001); a baseline viral load >10,000 copies/ml (aHR 
1.92 [1.00-3.71], p=0.05); and starting a PI-based regimen compared to starting an 
NNRTI-based regimen (aHR 1.90 [1.10-3.28], p=0.02) (Table 6.12). 
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Table 6.12. Cox proportional hazards model for time to AIDS/death among ART-naive 
and cART-experienced women on life-long ART 
Variable aHR 95% confidence   
interval 
p-value 
cART-experienced 0.82 0.41 - 1.65 0.58 
Age (per 10 additional years) 1.45 1.01 - 2.09 0.04 
Pregnant when starting ART 0.82 0.30 - 2.21 0.69 
Ethnicity  Black-African Reference   0.48 
 White 0.78 0.36 - 1.70  
 Black-Caribbean 0.93 0.33 - 2.63  
 Other/not known 0.33 0.08 - 1.39  
Exposure group  Heterosexual sex Reference   0.81 
 PWID  1.08 0.28 - 4.09  
 Other/not known 0.52 0.07 - 3.84  
Year of HIV diagnosis 0.97 0.90 - 1.05 0.51 
Year of starting treatment 1.06 0.86 - 1.30 0.60 
ART regimen PI-based 1.90 1.10 - 3.28 0.05 
 
NNRTI-based Reference    
 
NRTI only -     
 Other 4.07 0.94 - 17.63  
Baseline viral load >10,000 copies/ml 1.92 1.00 - 3.71 0.05 
Baseline CD4 count 
(cells/mm
3
)  
≤200 2.77 1.50 - 5.13 <0.001 
201-350 Reference    
351-500 0.30 0.04 - 2.22  
 >500 1.43 0.32 - 6.42  
 Not known 4.50 1.81 - 11.24  
HBV/HCV  1.61 0.69 - 3.77 0.27 
Previous AIDS event 1.44 0.75 - 2.79 0.28 
PWID: People who inject drugs 
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Liver enzyme elevation 
Whilst on treatment, few women in either group experienced severe LEE (cART-
experienced: 2.8% [7/248]; ART-naïve: 2.1% [17/794]). There was no statistically 
significant association between ART experience and severe LEE in crude or adjusted 
analysis (HR 1.24 [0.48-3.17], p=0.65; aHR 0.93 [0.34-2.53], p=0.88). None of the 
variables included in the adjusted model had a statistically significant association with 
LEE (data not presented).  
CD4 count increase at 6 and 24 months 
The mean CD4 cell count and mean increase from baseline CD4 count at each 2 
month interval following initiation of treatment are presented in Figure 6.6 and Table 
6.13. Throughout the first 24 months on treatment the mean CD4 count and the mean 
increase in CD4 count from baseline appear slightly higher in cART-experienced 
women than in ART-naïve women. However, there was no statistically significant 
difference between the two groups with regard to their increase in CD4 count after 6 
months or after 24 months on treatment (Table 6.14). After 6 months, the difference in 
mean was 19.8 [95% CI -3.6, 43.2], p=0.10, and the adjusted difference in mean was 
15.0 [-9.2, 39.1] cells/mm3, p=0.22. After 24 months, the difference in mean was -1.7 [-
35.5, 32.1], p=0.92, and the adjusted difference in mean was 4.2 [-31.0, 39.4] 
cells/mm3, p=0.82. At this time the mean CD4 count was 525 cells/mm3 and 516 
cells/mm3 in cART-experienced and ART-naïve women respectively. 
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Figure 6.6. Mean CD4 count and CD4 change from baseline within 2 month periods 
since starting long-term ART in ART-naive and cART-experienced women 
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Table 6.13. Mean CD4 count and CD4 change from baseline within 2 month periods since starting long-term ART in ART-naive and cART-
experienced women 
 
  
Months since ART start 0-2 >2-4 >4-6 >6-8 >8-10 >10-12 >12-14 >14-16 >16-18 >18-20 >20-22 >22-24 
ART-naïve 
            
Mean CD4 count 339 357 370 390 411 420 445 437 475 485 490 470 
n 526 494 416 376 386 364 317 327 315 310 277 289 
Mean change in CD4 74 97 120 120 150 174 180 184 220 228 217 230 
n (also with baseline CD4) 507 473 400 359 360 348 292 301 290 292 257 268 
             
ZDVm-experienced 
            
Mean CD4 count 359 388 410 422 433 486 475 513 505 530 490 504 
n 155 128 122 104 116 89 96 89 98 97 79 82 
Mean change in CD4 94 121 140 129 160 219 187 206 210 250 226 230 
n (also with baseline CD4) 150 123 119 102 109 84 92 86 89 91 71 78 
2
1
6
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Table 6.14. Adjusted difference in mean CD4 cell count after 6 and 24 months on treatment in cART-experienced and ART-naïve women 
 6 months on ART 24 months on ART 
Variable Adjusted 
difference 
in mean 
    95% CI p-value Adjusted 
difference 
in mean 
95% CI p-value 
cART-experienced  15.0 -9.2, 39.1 0.22 4.2 -31.0, 39.4 0.82 
Age (per 10 additional years) 2.0 -11.4,  15.3 0.77 8.9 -10.7, 28.5 0.37 
Pregnant when starting treatment 37.2 4.3,  70.1 0.03 29.4 -19.0, 77.8 0.23 
Ethnicity Black-African Reference    Reference    
 White 9.5 -18.1. 37.1 0.50 68.8 28.3, 109.4 <0.001 
 Black Caribbean -17.0 -56.8,  22.8 0.40 11.6 -47.4, 70.6 0.70 
 Other/not known 8.1 -24.0,  40.3 0.62 36.2 -11.6, 84.1 0.14 
Exposure group Heterosexual sex Reference    Reference    
 IDU -69.0 -129.1, -8.9 0.02 -45.8 -134.5, 42.9 0.31 
 Other/not known -17.8 -71.0,  35.4 0.51 -10.7 -84.2, 62.7 0.77 
Year of HIV diagnosis -1.3 -4.4,  1.7 0.39 1.4 -3.1, 5.8 0.54 
Year starting ART 4.2 -3.1,  11.4 0.26 -5.1 -16.3, 6.1 0.37 
Regimen NNRTI-based Reference    Reference    
 PI-based 0.1 -21.3, 21.5 0.99 -13.4 -45.4, 18.6 0.41 
 NRTI only -21.8 -117.5,  73.8 0.65 -74.8 -222.1, 72.5 0.32 
 Other 20.3 -54.1,  94.7 0.59 18.0 -93.7, 129.6 0.75 
Baseline viral load >10,000 copies/ml 50.5 29.5,  71.5 <0.001 59.6 28.6, 90.7 <0.001 
CD4 count (per additional 100 cells/mm
3
)  -17.4 -24.5,  10.2 <0.001 -16.0 -27.4, -4.7 0.01 
HBV/HCV  26.1 -12.6,  64.9 0.19 -69.8 -128.1, -11.5 0.02 
Previous AIDS event -2.4 -34.0,  29.1   0.88 -3.0 -50.1, 44.0 0.90 
 
2
1
7
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The adjusted model included only women with a baseline CD4 count (cART-
experienced n=232; ART-naïve n=732). Women who were pregnant when starting 
treatment had a higher mean CD4 cell count at baseline and a greater increase in CD4 
cell count compared to women who were not pregnant when starting treatment (mean 
CD4 cell count at baseline 343 cells/mm3 and 263 cells/mm3 respectively, adjusted 
difference in mean at 6 months: 37.2 [95% CI -4.3, 39.1] cells/mm3, p=0.22) (Table 
6.14).  
Other variables associated with CD4 cell count increase at 6 months were exposure 
group, baseline viral load and baseline CD4 count. On average, women thought to 
have acquired HIV through sharing injecting drug equipment had a smaller increase in 
CD4 cell count compared to women who acquired HIV via heterosexual sex (adjusted 
difference in mean: -69.0 [95% CI -129.1, -8.9] cells/mm3, p=0.02). Women with a 
baseline viral load >10,000 copies/ml had a greater increase in CD4 cell count (at 6 
months and at 24 months) than women with a lower baseline viral load (adjusted 
difference in mean 6 months: 50.5 [95% CI 29.5, 71.5] cells/mm3, p<0.001). This was 
also the case after excluding the 87 women with no baseline viral load measurement, 
who were assumed to have a viral load ≤10,000 copies/ml in the main analysis 
(adjusted difference in mean 52.5 [95% CI 30.8, 74.1] cells/mm3, p<0.001). When the 
binary variable (viral load ≤/>10,000 copies/ml) was replaced by a continuous variable 
(log10 viral load) there was a statistically significant association between log10 viral load 
and CD4 count change (adjusted difference in mean: 27.5. [95% CI 17.9, 37.1] 
cells/mm3, p<0.001) despite no obvious correlation when these data were presented as 
a scatter plot (Figure 6.7).  
Women starting ART with a higher CD4 count had a slightly smaller increase in CD4 
count compared to women starting ART with a lower CD4 count (adjusted difference in 
mean per additional 100 cells/mm3: -17.4 [95% CI -24.5, -10.2], p<0.001) (Figure 6.8). 
Women starting ART with a CD4 count within the categories: ≤200, 201-350, 351-500 
and >500 cells/mm3 had a mean CD4 increase after 6 months of: 142, 153, 120 and 39 
cells/mm3 respectively. 
After 24 months on ART, baseline CD4 count was associated with CD4 cell count 
increase (adjusted difference in mean per additional 100 cells/mm3: -16.0 [95% CI        
-27.4, -4.7], p=0.01). Baseline viral load was also associated with CD4 cell count 
increase (adjusted difference in mean viral load >10,000 copies/ml vs. ≤10,000 
copies/ml: 59.6 [95% CI 28.6, 90.7], p<0.001). In addition, white ethnicity was 
associated with a greater increase in CD4 count compared to black-African ethnicity 
 219 
 
(adjusted difference in mean: 68.8 [95% 28.3, 109.4], p<0.001) and HBV/HCV co-
infection was associated with a smaller increase in CD4 cell count (adjusted difference 
in mean: -69.8 [95% -128.1, -11.5], p=0.02) (Table 6.14).  
Figure 6.7. Scatter plot showing baseline viral load and CD4 cell count change from 
baseline after 6 months on ART 
 
Figure 6.8. Scatter plot showing baseline CD4 count and CD4 cell count change from 
baseline after 6 months on ART 
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Viral suppression within six months 
Overall, 79.9% of women achieved viral suppression within six months of being on ART 
(cART-experienced: 76.8%; ART-naïve: 80.9%) and 92.9% within 2 years (cART-
experienced: 90.7%; ART-naïve: 93.6%). The median time to viral suppression (Kaplan 
Meier estimate) was 3.44 (95% CI 3.02-3.70) months for cART-experienced women 
and 2.98 (2.79-3.18) months for ART-naïve women. In Cox proportional hazards 
analysis, 76 women were excluded because they had no viral load measurement in the 
first six months on ART. In unadjusted analysis there was weak evidence of an 
association between cART experience and viral suppression (HR 0.85 [95% CI 0.72-
1.01], p=0.06) (Figure 6.9). However, the association was not statistically significant 
when only baseline viral load was taken into account (p=0.24) and there was no 
statistically significant association between cART experience and viral suppression in 
the final adjusted model (aHR 0.86 [95% CI 0.72-1.03], p=0.10 (Table 6.15). In 
sensitivity analysis, when ART interruptions were ignored, there was weak evidence 
that women with ART experience were less likely to achieve viral suppression (aHR 
0.84 [0.71-1.01], p=0.058).  
Baseline viral load was negatively associated with viral suppression within 6 months on 
ART; women with a viral load >10,000 copies/ml were less likely to achieve viral 
suppression compared to women with a lower viral load (aHR 0.54 [0.46-0.63], 
p<0.001 or aHR 0.70 [0.65-0.75], p<0.001 when log10 viral load was included in the 
model as a continuous variable resulting in the exclusion of a further 52 women with no 
baseline viral load measurement). In the main model, baseline CD4 count, drug 
regimen and pregnancy status when starting ART were also associated with viral 
suppression (Table 6.15). Women who were pregnant when starting treatment were 
more likely to achieve viral suppression compared to women who were not pregnant 
(aHR 1.77 [1.41-2.21], p<0.001). Women with a higher baseline CD4 count were more 
likely to achieve viral suppression (CD4 count 351-500 cells/mm3 vs. 201-350 
cells/mm3 aHR 1.29 [1.03-1.63], p=0.03) and women starting a PI-based regimen were 
less likely to achieve viral suppression than women starting an NNRTI-based regimen 
(aHR 0.64 [0.55-0.75], p<0.001).  
In cART-experienced women, the interval between ART use in pregnancy and starting 
treatment was not associated with time to viral suppression (aHR 0.99 [0.99-1.01], 
p=0.67 when the interval was a continuous variable and aHR 0.98 [0.59-1.61], p=0.93 
when the interval was categorised as </≥1 year).  
 221 
 
Table 6.15. Adjusted hazard ratio for achieving viral suppression within 6 months on 
treatment in cART-experienced and ART-naïve women 
Variable aHR 95% CI p-value 
cART-experienced   0.86 0.72 - 1.03 0.10 
Age (per 10 additional years) 1.04 0.95 - 1.15 0.38 
Pregnant when starting treatment 1.77   1.41 - 2.21 <0.001 
Ethnicity                                       Black-African Reference   0.33 
 White 0.92 0.75 - 1.13  
 Black-Caribbean 1.04 0.77 - 1.39  
 Other/not known 0.81 0.64 - 1.03  
Exposure group                                             Heterosexual Reference   0.83 
 IDU 0.86 0.53 - 1.40  
 Other/not known 1.00 0.67 - 1.51  
Year of HIV diagnosis 1.01 0.99 - 1.04 0.21 
Year starting ART 0.97 0.92 - 1.02 0.20 
Regimen NNRTI-based Reference   <0.001 
                                             PI-based  0.64 0.55 - 0.75  
 NRTI only 0.59 0.30 - 1.16  
 Other/not known 0.85 0.49 - 1.49  
Baseline viral load >10,000 copies/ml 0.54 0.46 - 0.63 <0.001 
CD4 count category 
(cells/mm
3
)                  
≤200  0.85 0.71 - 1.02 0.006 
201-350  Reference    
 351-500  1.29 1.03 - 1.63  
 >500  0.89 0.64 - 1.22  
 Not known 0.70 0.49 - 0.99  
HBV/HCV  0.94 0.70 - 1.27 0.69 
Previous AIDS event 0.94 0.74 - 1.18 0.57 
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Figure 6.9. Kaplan-Meier plot showing cumulative probability of viral suppression 
during the first six months on ART among ART-naïve women (blue line with 95% CIs in 
light blue) and women with cART-experience (red line with 95% CIs in light blue) at 
baseline 
  
At risk 
ART-naïve  738 615 487 345 224 171 113 
cART-
experienced  
228 197 163 125 86 59 43 
  
 
Few of the women who did not achieve viral suppression within 6 months had a 
resistance test in this period (cART-experienced: 11.3% [6/53] and ART-naïve: 12.8% 
[18/141] had a test). Of those tested, one cART-experienced woman had resistance to 
≥1 drug class (representing 16.7% of the 6 women tested). She had resistance to 
NNRTI and NRTI drug classes (Appendix IX). She had also been tested prior to 
starting treatment and had no evidence of resistance at that time. In the ART-naïve 
group, 5 women (representing 27.8% of the 18 women tested) had resistance to either 
one (NNRTI n=1; NRTI n=1), two (NNRTI and NRTI n=2) or three (NNRTI and NRTI 
and PI n=1) drug classes. Two of these women had evidence of the same type of drug 
resistance prior to starting treatment whilst two did not and one was not tested for 
resistance prior to starting treatment. 
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Viral rebound 
Among women who achieved viral suppression within 6 months on ART (n=772) the 
risk of viral rebound was examined within the periods 0-6 and 6-24 months after 
suppression. In both periods and for both cART-experienced and ART-naïve women, 
less than 10% of women experienced viral rebound, among those who remained on 
ART.  
Within the 0-6 months after suppression there was no statistically significant 
association between ART experience and viral rebound (HR 1.73 [95% CI 0.78-3.86], 
p=0.18; aHR 1.03 [0.42-2.50], p=0.96) (Figure 6.10a). The risk of viral rebound 
decreased with increasing age (aHR 0.54 [0.30-1.00], p=0.05 per 10 additional years) 
and women who were pregnant when starting treatment were six times more likely to 
experience viral rebound than women who were not pregnant when starting treatment 
(aHR 6.24 [2.24-17.34], p<0.001) (Table 6.16).  
There was weak evidence that in women who did not experience a rebound within 6 
months of suppression, the risk of rebound in the 6-24 months after suppression was 
higher in cART-experienced women than in ART-naïve women (HR 2.19 [1.04-4.60], 
p=0.03; aHR 2.14 [0.96-4.77], p=0.06) (Figure 6.10b). The risk of viral rebound was 
associated with year of HIV diagnosis (aHR 1.11 [1.01-1.22], p=0.03) and women who 
started a PI-based regimen were more likely to experience viral rebound than women 
who started an NNRTI-based regimen (aHR 2.98 [1.32-6.73], p=0.01) (Table 6.16). 
The findings were not altered when, in sensitivity analysis, follow-up was censored if a 
woman became pregnant. In a sub-analysis including only women with previous use of 
ART, viral suppression in the final trimester of the previous pregnancy was not 
associated with viral suppression in the first six months on life-long ART (not achieving 
viral suppression vs. achieving viral suppression: aHR 0.78 [0.56-1.23], p=0.20) or with 
viral rebound 0-6 months after suppression (aHR 2.16 [0.31-14.96], p=0.44) or 6-24 
months after suppression (aHR 0.87 [0.14-5.65], p=0.88). The interval between ART 
use in pregnancy and starting life-long ART was not associated with the risk of viral 
rebound (either as a continuous or binary variable).  
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Table 6.16. Time to viral rebound 0-6 months and 6-24 months after viral suppression (within 6 months) in cART-experienced and ART-naive 
women on life-long ART 
Variable 0-6 months after suppression 6-24 months after suppression 
 aHR 95% CI p-value aHR 95% CI p-value 
cART-experienced 1.03 0.42 - 2.50 0.96 2.14 0.96 - 4.77 0.06 
Age (per 10 additional years) 0.54 0.30 - 1.00 0.05 0.82 0.48 - 1.42 0.49 
Pregnant when starting treatment 6.24 2.24 - 17.34 <0.001 1.88 0.71 - 4.98 0.20 
Ethnicity Black-African Reference   0.57 Reference   0.79 
 White 1.24 0.41 - 3.77  1.19 0.39 - 3.64  
 Black Caribbean  1.37 0.36 - 5.24  1.81 0.52 - 6.37  
 Other/not known 2.50 0.68 - 9.24  1.39 0.38 - 5.07  
Exposure group Heterosexual Reference   0.87 Reference   0.39 
  IDU -    2.10 0.36 - 12.43  
 Other/not known 1.63 0.26 - 10.33  2.57 0.52 - 12.74  
Year of HIV diagnosis 0.93 0.80 - 1.09 0.37 1.11 1.01 - 1.22 0.03 
Year starting ART 1.06 0.78 - 1.44 0.69 0.96 0.72 - 1.26 0.75 
Regimen NNRTI-based Reference   0.07 Reference   0.08 
 PI-based 2.73 0.98 - 7.63  2.98 1.32 - 6.73  
 NRTI-based 8.83 0.95 - 81.72  -    
 Other 6.52 0.73 - 58.47  -    
Baseline viral load >10,000 copies/ml 2.52 0.96 - 6.61 0.06 1.32 0.59 - 2.93 0.50 
CD4 count  
(cells/mm
3
) 
≤200  2.26 0.83 - 6.20 0.16 1.61 0.64 - 4.05 0.77 
201-350  Reference    Reference    
351-500  1.06 0.27 - 4.12  1.67 0.55 - 5.12  
 >500  3.81 1.04 - 14.02  -    
 Not known 0.72 0.08 - 6.11  2.01 0.51 - 7.91  
  
2
2
4
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Table 6.16 continued. 
 
  
 0-6 months after suppression 6-24 months after suppression 
 aHR 95% CI p-value aHR 95% CI p-value 
HBV/HCV  1.24 0.28 - 5.54 0.78 1.41 0.40 - 4.96 0.59 
Previous AIDS event 1.70 0.35 - 8.28 0.51 2.22 0.79 - 6.23 0.13 
       
 
  
2
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Figure 6.10. Kaplan-Meier plots showing cumulative probability of viral rebound within 6 months of viral suppression among ART-naïve (blue 
line with 95% CIs in light blue) and cART-experienced women (red line with 95% CIs in light red) with viral suppression within 6 months on ART 
a.) 0-6 months after viral suppression      b.) 6-24 months after viral suppression  
 
At risk  
ART-naïve  597 590 583 574  562  556 553 553  499  452 391 
cART-
experienced  
175 175 173 167  160  155 153 153  130  116 101 
Both figures include only women with viral suppression within 6 months on ART and b) includes only women still at risk of viral rebound 
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The association between having genotypic resistance to ≥1 drug class prior to starting 
life-long ART and the risk of viral rebound was not statistically significant in the 0-6 
months period after suppression (aHR 2.31 [0.75-7.14], p=0.15) but was statistically 
significant in the >6-24 month period (aHR 5.87 [1.30-26.4], p=0.02). These adjusted 
models included resistance prior to ART as a dichotomous variable (yes/no) and were 
restricted to women with a resistance test prior to starting life-long ART and who had 
achieved viral suppression within 6 months. There was no statistically significant 
association between cART experience and viral rebound at 0-6 months after 
suppression (aHR 0.84 [0.27-2.66], p=0.77) but there was at 6-24 months after 
suppression (aHR 11.03 [2.75-46.27], p<0.001).   
Of the 57 women who experienced viral rebound within 24 months of viral suppression, 
only a third had a resistance test within one month of the rebound (cART-experienced: 
30.0% [6/20]; ART-naïve: 35.1% [13/37]). In the cART-experienced group, 2/6 women 
tested had resistance to one (NNRTI, Y181C mutation n=1) or two drug classes 
(NNRTI and NRTI, mutations Y181C, G190A, K103N, L74V and M184V n=1). Both 
women were tested prior to starting ART and had no evidence of drug resistance at 
that time. In the ART-naïve group, 4/13 women tested had resistance to either one (PI 
n=1; NRTI, n=2) or two drug classes (NNRTI and NRTI n=1). One of the women with 
NRTI resistance had no test prior to starting treatment, the other two women with NRTI 
resistance (including one women who also had NNRTI resistance) had evidence of 
NRTI resistance prior to starting treatment. The woman with PI resistance had 
evidence of PI resistance prior to starting treatment. The mutations identified in each 
group are listed in Appendix IX. There were no mutations identified which are 
associated with resistance to integrase inhibitors. 
Regimen change or interruption having started life-long ART 
Within the first 24 months of starting treatment, 39.0% (406/1042) of women changed 
their regimen either by increasing the number of drugs in the regimen by one (31.5%, 
n=128 overall) or more (16.5%, n=67) drugs, replacing drugs in the regimen whilst 
maintaining the overall number of drugs (30.5%, n=124) or reducing the number of 
drugs by one (17.2%, n=70) or more (4.2%, n=17). The percentage of women who 
changed regimen was 42.3% (105/248) in cART-experienced women and 37.9% 
(301/794) in ART-naïve women. There was no statistically significant association 
between ART experience and changing regimen (aHR 1.02 [0.81-1.29], p=0.85) (Table 
6.17). In the adjusted model, women who were pregnant when starting treatment were 
more likely to change their regimen than women who were not pregnant (aHR 1.75 
 228 
 
[1.31-2.33], p>0.001). Changing regimen was also associated with the year in which 
life-long ART was started and with age, with the risk decreasing over time (aHR 0.90 
[0.84-0.97] per additional year, p=0.01) and decreasing with older age (aHR 0.82 [0.71-
0.95], p=0.01). Women starting an NRTI only regimen were more likely to change their 
regimen than women starting an NNRTI-based regimen (aHR 2.62 [1.20-5.69], global 
p=0.007). 
The percentage of women who interrupted treatment for any period of time was 25.0% 
(n=62) in cART-experienced women and 17.4% (n=138) in ART-naïve women. In those 
who interrupted treatment, the interruption occurred after a median of 8.9 (IQR 3.4-
16.1) months on ART and the median time to restarting treatment was 3.3 (IQR 1.7-
10.7) months from the date of interruption. CART-experienced women were more likely 
to interrupt treatment compared to ART-naïve women (HR 1.48 [1.10-2.00], p=0.01; 
aHR 1.48 [1.07-2.04], p=0.02) (Table 6.17). Women starting a PI-based regimen were 
more likely to interrupt their regimen than women starting an NNRTI-based regimen 
(aHR 1.77 [1.32-2.39], global p=0.002), this remained the case after excluding 129 
women who started treatment whilst pregnant (aHR 1.97 [1.45-2.67], p<0.001). 
There was no statistically significant association between baseline pregnancy status 
and interrupting ART (aHR 0.81 [0.51-1.27], p=0.35). The association between ART 
experience and interrupting treatment remained when women who started treatment 
whilst pregnant were excluded (aHR 1.46 [1.02-2.08], p=0.04). 
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 Table 6.17. Time to switching or interrupting ART regimen in cART-experienced and ART-naive women starting life-long ART 
 Time to any change in regimen Time to treatment interruption  
 aHR 95% confidence   
interval 
p-value aHR 95% confidence   
interval 
p-value 
cART-experienced  1.02 0.81 - 1.29 0.85 1.48 1.07 - 2.04 0.02 
Age (per 10 additional years) 0.82 0.71 - 0.95 0.01 0.90 0.74 - 1.10 0.31 
Pregnant when starting treatment 1.75 1.31 - 2.33 >0.001 0.81 0.51 - 1.27 0.35 
Ethnicity Black-African Reference   0.21 Reference   0.19 
 White 1.03 0.78 - 1.36  0.61 0.39 - 0.97  
 Black-Caribbean 0.92 0.60 - 1.42  1.00 0.57 - 1.73  
 Other/not known 0.68 0.47 - 0.99  0.79 0.48 - 1.31  
Exposure group Heterosexual sex Reference   0.19    0.45 
 People who inject drugs  1.25 0.72 - 2.16  1.63 0.76 - 3.51  
 Other/not known 0.60 0.31 - 1.14  0.98 0.43 - 2.25  
Year of HIV diagnosis 1.03 1.00 - 1.06 0.08 0.98 0.94 - 1.03 0.26 
Year starting ART 0.90 0.84 - 0.97 0.01 0.96 0.86 - 1.06 0.39 
Regimen NNRTI-based  Reference   0.007    <0.001 
 PI-based 1.23 0.99 - 1.52  1.77 1.32 - 2.39  
 NRTI only 2.62 1.20 - 5.69  1.84 0.57 - 5.90  
 Other 2.11 1.11 - 4.00  -    
Baseline viral load >10,000 copies/ml 1.04 0.84 - 1.30 0.70 0.79 0.59 - 1.07 0.13 
CD4 count (cells/mm
3
)  ≤200  1.13 0.89 - 1.44 0.10 1.18 0.84 - 1.66 0.12 
201-350  Reference        
 351-500  0.69 0.48 - 1.00  0.71 0.42 - 1.20  
 >500  0.83 0.51 - 1.33  0.79 0.40 - 1.57  
 Not known 1.23 0.85 - 1.79  0.51 0.26 - 1.00  
HBV/HCV  1.14 0.79 - 1.66 0.49 1.43 0.86 - 2.37 0.17 
Previous AIDS event 0.86 0.63 - 1.19 0.37 1.30 0.86 - 1.97 0.22 
2
2
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6.6 Discussion 
Of the women in UK CHIC who started life-long ART in 2003-2012, almost one in ten 
had previously used ART, a smaller proportion than in many settings [220]. The 
majority (81%) of these women had used a combination of ART drugs, whilst 19% had 
used only ZDVm (Table 6.2). The observed decline in the use of ZDVm in pregnancy 
has previously been reported in the UK [170] and elsewhere [127], including in 
resource limited settings [455]. It reflected the increasing number of women who 
conceived whilst already on cART and the shift towards the use of cART in women who 
used short-term ART for PMTCT, reflecting the growing evidence that antenatal use of 
cART was both safe and effective [127, 131, 149, 361, 456-458].  
The recent changes to the UK treatment guidelines [86]. mean that in the UK, as well 
as elsewhere, women will no longer use short-course ART in pregnancy. This means 
that the vast majority of women living with HIV who become pregnant will either already 
be on ART, if they are already diagnosed, or will start life-long ART, if they are 
diagnosed whilst pregnant. In each of the final five years of data presented in this 
chapter (2008-2012), 12% of women starting life-long ART had some previous ART 
experience (Table 6.2). Assuming this was also true in more recent years, we can 
estimate that approximately 12% of women who have recently started life-long ART, 
since the changes to the guidance, will have some previous exposure to ART from 
short-course antenatal use. It is important for clinicians to be able to anticipate the 
treatment outcomes of these women.  
In this chapter I compared the response to ART in women starting treatment for their 
own health who had used either short-course ZDVm (Analysis 1) or cART (Analysis 2) 
in pregnancy for PMTCT with the response in women who had never previously used 
ART. As we would anticipate, the treatment outcomes of women in this study were 
similar or better than the outcomes for women starting ART in 1998-2006, observed in 
a previous UK CHIC study [459] which included recently diagnosed women. The risk of 
AIDS/death was low in all the groups assessed in this study. Since the outcome 
assessed was AIDS or death it did not allow for direct comparison with the risk of death 
in the general population. There was limited information on the cause of death for the 
small number of women who died. The data that were available indicate that few 
women died of HIV related causes, although in some cases it was not clear, since the 
reported cause of death was non-specific. Women starting treatment who had 
previously used cART were at no greater risk of AIDS/death compared to ART-naïve 
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women (Table 6.12). There was weak evidence that ZDVm-experienced women 
starting treatment had a lower risk of AIDS/death compared to ART-naïve women 
starting treatment (Table 6.3). The association was not statistically significant when 
other factors were considered in adjusted analysis. The other variables associated with 
the risk of AIDS/death - a previous AIDS event, having a lower CD4 count when 
starting treatment, older age, and higher baseline viral load - have also been reported 
elsewhere [460-462]. 
All the groups assessed showed a good immunological response to treatment with an 
increase of >200 cells/mm3 from the pre-treatment CD4 count at 24 months. The 
average CD4 counts after 6, 12 and 24 months on ART were similar to those 
previously reported from men and women starting treatment at the Royal Free Hospital 
which included people who were recently diagnosed (Figure 6.1 and Figure 6.6) [463]. 
The previous use of cART or ZDVm did not predict CD4 count increase after 6 or 24 
months on ART (Table 6.5 and Table 6.13). The only previous study which compared 
response to treatment in ART-naïve and cART-experienced women did not examine 
CD4 response [286]. In studies which compared response to treatment in ART-naïve 
and single dose NVP exposed women, immunological response was not associated 
with previous ART use in women starting therapy [220, 274, 279]. Larger increases in 
CD4 cell counts were seen among women who started treatment when pregnant. The 
reasons for this are unclear as no data were collected on possible confounders such as 
drug adherence, diet, exercise and weight. 
HBV or HCV co-infection was negatively associated with CD4 cell count increase. 
Previous studies have found such an association between HCV and CD4 cell changes 
once ART is initiated [464], whereas studies assessing the association between HBV 
infection and CD4 cell count provide conflicting results [465, 466]. Few of the women in 
this study had HBV or HCV; only 5% of ZDVm-experienced women and 7% of cART-
experienced had either HBV, HCV or both HBV and HCV coinfection. It was therefore 
not possible to separate these into smaller categories as this would create very small 
groups and therefore reduce statistical power.   
Women with a higher baseline CD4 count had a slightly smaller increase in CD4 count 
compared to women with a lower baseline CD4 count; the average increase in CD4 at 
24 months was 14-16 cells/mm3 less with each additional 100 cells/mm3 at baseline 
(Table 6.6 and Table 6.14). This is probably because women with a lower CD4 count at 
baseline had a greater scope for improvement. Although these differences were 
statistically significant they were small and may not have clinical importance particularly 
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as the average CD4 count after 24 months on ART was around 500 cells/mm3 in all the 
groups.  
An undetectable viral load, the main aim of treatment, was achieved by the majority of 
women within 6 months on ART and by around half within 3 months. In women with a 
viral load measurement within the first six months on ART, ZDVm-experienced women 
were 31% more likely to achieve viral suppression than ART-naïve women. It is 
possible that women who had used ZDVm in pregnancy had better engagement with 
clinical services, particularly as more of them were pregnant when starting life-long 
ART or would have become pregnant during follow-up. However, if this were the case 
then we would also anticipate an association between cART experience and viral 
suppression, but there was no such association in Analysis 2. Therefore, it is unclear 
why ZDVm-experienced women were more likely to achieve viral suppression. 
Women starting a PI-based regimen were less likely to achieve viral suppression within 
6 months compared to women starting an NNRTI-based regimen (aHR 0.77 in analysis 
1 and aHR 0.64 in analysis 2) and the use of PI-based regimen was associated with a 
two-fold increased risk of AIDS/death in both analyses. These differences are probably 
due to unmeasured confounders since, at the time, the recommended first line 
treatment was efavirenz with PI-based regimens only recommended for people with 
NNRTI or NRTI resistance, women planning to become pregnant and patients with 
psychiatric problems [78].  
As we might anticipate, baseline viral load was negatively associated with viral 
suppression, since women with a higher baseline viral load had a larger gap between 
their starting point and viral load ≤50 copies/ml. In this group of women who had been 
diagnosed for at least one year, having very high viremia at baseline could indicate a 
greater length of infection and therefore we would anticipate a slower immune 
response as has previously been observed in a large European HIV cohort [467]. 
In both analyses, women who started treatment whist pregnant were more likely to 
achieve viral suppression (Table 6.7) and (Table 6.15). Women starting ART during 
pregnancy have increased contact with health care professionals regarding antenatal 
care as well as ongoing HIV clinical care. They will therefore be more regularly 
monitored and receive adherence support as well as being highly motivated to achieve 
viral suppression in order to minimise the risk of MTCT.  
Although only women with a viral load measurement within the period of interest were 
included in the time to viral suppression analysis, differences in the frequency and 
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timing of viral load measurements will impact on the outcome and it is important to bear 
in mind that the Kaplan-Meier plots (Figure 6.2 and Figure 6.9) do not depict viral 
response but rather the first viral load assay performed where the viral load is 
undetectable. 
Viral rebound was more likely to occur in cART-experienced women than in ART-naïve 
women (Table 6.16). This association was only seen in the 6-24 months period after 
viral suppression, not in the first six months after suppression, when very few of the 
women developed viral rebound. There was no statistically significant association 
between ZDVm experience and viral rebound.  
Viral rebound can be the result of drug resistance. Drug resistance is however unlikely 
to be the reason that cART-experienced women were more likely to develop viral 
rebound. A smaller proportion of cART-experienced women had drug resistance prior 
to starting life-long ART compared to the ART-naïve women (11% vs. 13% 
respectively) and the association between cART experience and viral rebound 
remained and was statistically significant when baseline drug resistance was taken into 
account. Although drug resistant HIV strains have been identified in women following 
the use of short-course ART in pregnancy [278, 468] there is little evidence to suggest 
that the use of short-course cART or ZDVm (among those meeting the strict clinical 
criteria for its use) in pregnancy increases the prevalence of drug resistance [193, 469]. 
The prevalence of drug resistance was considerably higher than the prevalence of 
transmitted drug resistance (TDR) in HIV-positive women in the UK for this period (4-
7%) [470] and higher than the prevalence in women diagnosed in pregnancy in 2000-
2013 (5.2%) [258]. Although this latter analysis of NSHPC data found an increasing 
prevalence over time with 10.1% prevalence in 2012-2013. The high prevalence 
observed here could be because women with a ‘positive’ result for drug resistance 
were more likely to have data reported, because women with more complete data were 
more likely to have their UK CHIC and NSHPC records linked and therefore be 
included in the dataset or because of selective testing in areas of higher TDR 
prevalence.  
Resistance data were not available for all women. In ART-naïve and cART-
experienced women, 57% had at least one resistance test before starting ART. Over 
the period of the study there have been technical improvements in resistance testing. 
The percentage of women who had a resistance test performed increased over the 
study period to >60% in the latest year. In a direct linkage between the NSHPC and the 
UK HDRD (undertaken by Dr Laura Byrne at ICH), 50% of the women in the NSHPC 
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had at least one resistance test in the UK HDRD [258]. Resistance tests are normally 
performed prior to starting ART [84]. It is not clear whether lack of resistance data for 
some women was the result of reporting delay, incomplete linkage between the UK 
HDRD and UK CHIC or no test being performed.  
Viral rebound can also be the result of poor drug adherence [389, 471, 472]. Previous 
studies have found that pregnancy impacts drug adherence and retention in care – and 
these can also be altered in the postnatal period [473]. A study from the US, Brazil and 
Peru which examined the outcomes of women starting therapeutic ART at least 24 
weeks after using cART in pregnancy found that poor drug adherence was associated 
with viral rebound [286]. Although some of the differences between ART-naïve and 
ART-experienced women were accounted for in adjusted analysis, there are likely to be 
other important confounders which were not measured including parental 
responsibilities, family size, and socioeconomic status [474].  
Having ZDVm or cART experience was not predictive of changing drug regimen within 
24 months of starting life-long ART (Table 6.9 and Table 6.17). Observational studies 
show that regimen changes are more often due to toxicity than to immunological or 
virological failure [475, 476]. In both analyses, regimen switching decreased over time 
but was more common in women who were pregnant when starting treatment than in 
women who were not pregnant. In earlier years, this could be due to women switching 
away from regimens not recommended for use in pregnancy such as didanosine (no 
longer prescribed) or efavirenz (no longer contraindicated in pregnancy) [477]. In this 
analysis, pregnancy was not associated with severe LEE, however, the results of the 
next chapter indicate that there is an association between pregnancy status and toxicity 
which could explain the association between pregnancy and switching observed here.  
Compared to ART-naïve women, women with previous cART experience were 1.5 
times more likely to interrupt ART (Table 6.9 and Table 6.17). It is possible that some 
of the women were misclassified as starting life-long ART and were actually starting 
short-course cART in pregnancy which they later stopped. This might also explain why 
starting a PI-based regimen, the typical regimen prescribed for short-course ART in 
pregnancy, was associated with treatment interruption. However, there was no 
statistically significant association between pregnancy status when starting ART and 
interrupting ART and when women who were pregnant at baseline were excluded in 
sensitivity analysis, the association between ART experience and treatment 
interruption remained. The association between cART experience and treatment 
interruption might be due to difficulties in maintaining ART adherence among women 
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with a previous pregnancy i.e. mothers with parental responsibilities. In analysis 1 there 
was no statistical association between ZDVm experience and interrupting ART.  
The women included in these analyses are not representative of all women starting life-
long ART in the UK. The analyses did not include women diagnosed within the past 
year or women older than 49 years. Women with no clinical data who might have 
transferred to a clinic not part of UK CHIC or who may have been lost to follow-up were 
excluded, as they had no clinical data to analyse. 
The use of ART data from both UK CHIC and NSHPC for the same women meant that 
analysing the timing of ART use and whether it was used in pregnancy or not was at 
times problematic. This was a result of contradictory data in the two datasets or 
differences in the dates of ART use reported to the two studies. In women starting life-
long ART with some evidence of previous ART use it was not clear for about 30% 
whether this had been cART or ZDVm used in pregnancy or some other type of ART 
use such as starting long-term ART but then interrupting for an extended period. This 
was a result of underreporting of ART stop dates, inconsistencies in NSHPC and UK 
CHIC data and the reporting to NSHPC of antenatal ART use but no drug use dates. It 
is not clear whether the women reported as being on a drug regimen containing 4 
drugs were genuinely on a non-standard regimen or whether this was a result of under-
reporting of drug stop dates.  
The need to use drug data from UK CHIC to assess drugs started before pregnancy 
and stopped afterwards meant that some women who used ZDVm (according to their 
NSHPC record) were not included in the analysis of ZDVm use, as there were no drug 
data in UK CHIC at that time i.e. they did not attend care at a UK CHIC site at the time 
of their pregnancy. Analysis 1 suffered from lack of statistical power since only 93 
women had only ZDVm experience. Although 213 women used ZDVm in their index 
pregnancy 43 then went on to use short-course cART in a subsequent pregnancy and 
other women were excluded from the analysis for other reasons. Using a larger 
dataset, for example a European HIV cohort, would increase the number of women in a 
similar analysis.  
At baseline, more than one-quarter of women had no baseline viral load measurement 
and more than one-quarter had no baseline CD4 cell count. All women should all have 
had their viral load and CD4 counts monitored at the time of starting ART as part of 
their clinical care [78]. Missing data may be due to incomplete reporting to the UK 
CHIC study and/or transfer of care around the time of starting treatment to clinic not 
participating in the UK CHIC study. Exclusion of these women in sensitivity analysis did 
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not change the main findings. However, in future analyses baseline CD4 count and 
viral load could be imputed for women with missing data by assessing measurements 
of similar women or by using earlier CD4 counts/viral load data. Some women could 
have used sd-NVP during a pregnancy abroad, which, if used in the past 12 months, 
could impact their response to life-long ART. This could not be assessed as there were 
no data on ART regimens used prior to arrival in the UK. 
Conclusion 
The findings of these analyses add support to the limited number of studies which 
indicate that short-term use of ART for PMTCT is not detrimental to women’s long-term 
outcomes [193, 382, 478, 479]. Whilst we may expect slightly higher rates of viral 
rebound and treatment interruption in women who have previously used ART in 
pregnancy for PMTCT, the differences are small and are likely to be a consequence of 
unmeasured confounders or differences in adherence. It is therefore important that 
these women are supported in their drug adherence. This might be most effective if 
given by peers with similar experiences of ART use. If the differences between women 
with and without prior use of ART in pregnancy are due to differences in adherence this 
warrants further studies to identify interventions which promote adherence in women 
with children.  
Key points from this chapter 
 Among women in UK CHIC who started life-long ART in 2003-2012, 9.7% had 
previously used ART.  
 Once life-long ART was started, compared to ART-naïve women, women who 
had previously used ART in pregnancy: 
 had similar increases in CD4 count   
 had a similar low risk of AIDS/death  
 had a higher (ZDVm-experienced) or similar (cART-experienced) 
chance of achieving viral suppression 
 were more likely to develop viral rebound during the 6-24 months after 
viral suppression (cART-experienced women)  
 were more likely to interrupt ART (cART-experienced) 
 In the analysis of cART-experienced vs ART naïve women starting life-long 
ART, 57% of women had a resistance test prior to starting life-long ART; at this 
time 11% of cART-experienced and 13% of ART-naïve women had resistance 
to at least one drug class. 
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Chapter 7 The impact of pregnancy and ART use 
in pregnancy on hepatotoxicity in women living with 
HIV 
 
7.1 Introduction  
High rates of hepatotoxicity (chemical-driven liver damage) have been observed 
among pregnant women on antiretroviral therapy (ART), mostly women on nevirapine 
(NVP). Whether pregnancy increases the risk of hepatotoxicity among women on ART 
is not clear. Cross-sectional studies that compare the rate of liver enzyme elevation 
(LEE) in pregnant and non-pregnant women on ART have produced conflicting results, 
with some finding that pregnancy increases the risk of LEE and others finding no such 
association. 
In the UK, the vast majority of women living with HIV use ART in pregnancy. The 
characteristics of women starting ART in pregnancy may mean that they are more 
susceptible to LEE than non-pregnant women, since they are more likely to start with a 
higher CD4 count, a factor which, at least in the case of NVP, is associated with an 
increased risk of hepatotoxicity [480]. As was observed in Chapter 5, women are 
increasingly conceiving on life-long ART and therefore use ART for the full duration of 
pregnancy. Few studies have examined hepatotoxicity rates in women already on ART 
at conception. The linkage of the NSHPC and UK CHIC datasets allows the analysis of 
ALT levels before, during and after pregnancy as well as comparison with non-
pregnant women, something not possible using either dataset independently.  
In this chapter I aim to examine the impact of pregnancy on average alanine 
transaminase (ALT), identify characteristics predictive of LEE and examine whether 
pregnancy increases the risk of LEE in pregnancies during which ART is started and in 
pregnancies conceived on ART. Findings from this chapter were published in 2015 
(Appendix IId) [414].  
  
 238 
 
7.2 Methods 
The analysis is divided into three sections:  
1. Preliminary descriptive analyses 
 Assessing the availability of ALT data in the UK CHIC dataset and identifying 
characteristics predictive of having ≥1 ALT measurement  
 Descriptive analysis taking each ALT measurement as a separate observation 
2. The impact of pregnancy on median ALT levels  
 Comparing median ALT before, during and after pregnancy with median ALT in 
non-pregnant controls 
 Identifying factors predictive of ALT  
 Comparing median ALT before, during and after pregnancy in women already 
on ART and in women starting ART in pregnancy 
3. The impact of pregnancy on the risk of LEE 
 Identifying factors independently associated with LEE and severe LEE including 
pregnancy status 
 Examining changes/interruptions of ART following LEE/severe LEE 
 
 Methods Section 1: preliminary descriptive analyses  7.2.1
Liver function tests (LFTs), including the test for alanine transaminase (ALT), are 
performed in all HIV clinics in the UK. However, LFTs are not performed routinely in all 
women. Testing occurs more regularly in some groups of women and at particular 
periods of time. Also, some clinics participating in the UK CHIC study do not store LFT 
data in an electronic format which can easily be reported to UK CHIC and therefore do 
not report ALT data to the study. Therefore, as a first step, I assessed the availability of 
ALT data in the dataset and the demographic and clinical characteristics associated 
with having any ALT data.  
Dataset  
For the first two analyses of this chapter, the UK CHIC 2011 dataset was used (women 
only). In order to obtain pregnancy information for women with a pregnancy during this 
period, the UK CHIC dataset was linked to NSHPC dataset (archived in June 2013). 
Only data to 31st December 2011 were analysed. For this analysis, therefore the 
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dataset contained all women in UK CHIC irrespective of whether or not they had a 
pregnancy. The use of short-course ART in pregnancy or life-long treatment was 
determined using a combination of data from UK CHIC and NSHPC, as described in 
Chapter 4.  
Descriptive analysis taking each ALT measurement as a separate observation 
Each ALT measurement in the UK CHIC dataset within the period 2000-2011 was 
taken as a separate observation. Repeat measures from the same woman were 
included in the analyses and as this was a preliminary analysis, no adjustment was 
made to take this into account. Time updated variables were created at the time of 
each ALT measurement. These included: current pregnancy status, whether the 
woman had a previous pregnancy whilst HIV-positive, ART use, duration of ART use 
and latest CD4 count within the previous 3 months.  
 
 Methods Section 2: the impact of pregnancy on median ALT 7.2.2
In the second section, which examines the impact of pregnancy on median ALT, non-
pregnant women in UK CHIC with similar characteristics to pregnant women were used 
as controls in order to minimise the confounding effect of differences between pregnant 
and non-pregnant women. The median ALT before, during and after pregnancy was 
calculated for women who conceived on ART. These three values were compared to 
the median ALT in non-pregnant women on ART for equivalent periods of time. In the 
same way, median CD4 count was compared in pregnant and non-pregnant women.  
In order to assess the impact of the timing of ART initiation on ALT levels in pregnancy, 
ALT measurements before, during and after pregnancy were compared in three 
groups: women on ART at conception; women starting ART in the first half of 
pregnancy (women likely to require ART for their own health); and women starting ART 
in the second half of pregnancy (women likely to require ART for PMTCT only).  
Developing a selection process to find non-pregnant controls in the dataset 
I devised a simple selection strategy to identify and match pregnant women with 
controls i.e. non-pregnant women with characteristics similar to those of the pregnant 
women.  
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Selecting pregnancies 
For each pregnancy in the dataset conceived in 2000-2011, the woman was 
characterised on the estimated date of conception (EDC) for example, her age, ART 
status, latest CD4 count and so on. A single variable was then created summarising 
the woman’s characteristics. This variable was then used to find a suitable control. 
Table 7.1 shows an example. The summary variable (a concatenated variable) was 
formed by combining the code for the following variables: calendar year; ART status; 
age group; previous pregnancy (whilst HIV positive); CD4 count; and previous ART 
experience. If, for example, a woman conceived in the year 2009 (code: 2009), was not 
on ART (code: 0), was 20-24 years old (code: 2), had previously been pregnant (code: 
1), had a CD4 count >500 cells/mm3 (code: 4) and had ART experience (code: 1) the 
summary variable would be ‘200902141’ – created by combining the codes 2009, 0, 2, 
1, 4 and 1.  
Finding controls 
In order to find suitable controls, time updated variables were created to characterise 
each woman in the dataset on 48 different reference dates (four dates per year at three 
month intervals) throughout the period 2000-2011. This included characteristics which 
were to be used to create the summary variable and characteristics which were used to 
assess whether the woman was eligible to be a control at that particular time, such as 
pregnancy status. A summary variable, with the same format as the variable used to 
characterise women at the start of each pregnancy, was then created for each woman 
at each of the 48 references dates.  
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Table 7.1. Example variables used to find non-pregnant controls for pregnant women in 
UK CHIC 
Variable Category Code 
Calendar year 2000 
2001 
etc. 
2000 
2001 
etc. 
ART status
1 
On ART  
Not on ART 
1 
0 
Age group (years) 16-19  
20-24  
25-29  
35-39  
40-44  
45-49 
1 
2 
3 
4 
5 
6 
Previous pregnancy Yes 
No 
1 
0 
CD4 count (cells/mm
3
) 0-200  
201-350  
351-500 
>500 
1 
2 
3 
4 
Previous ART use
2
  Experienced 
Naive 
1 
0 
A summary variable was created for each woman for each time point by combining the codes for each 
variable listed in the table. 
1
NSHPC data were used to assess ART use at the time of conception, unless no data were provided, in 
which case UK CHIC data were used.  
2
NSHPC and UK CHIC data were used to assess previous ART use. 
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Selecting controls  
Two separate tables were then created. 
1. Table of pregnant women  
This table contained the variables: woman’s unique ID, summary variable, EDC. 
A woman was only included when the pregnancy resulted in a live birth, there 
was ≥1 ALT measurement in the 9 months following the EDC and a recent CD4 
count (within the 6 months before the EDC). Each woman’s first pregnancy 
during the period 2000-2011 that met the criteria was included.  
2. Table of controls  
This contained the variables: woman’s unique ID, summary variable, reference 
date, random number (generated in SAS – used to select the control if there 
was more than one appropriate control available). A woman could only be 
included in this table when she was not pregnant, did not have a pregnancy in 
the subsequent 18 months, had at least 3 ALT measurements in the following 
year, and had a recent CD4 count (within the previous 6 months). If a woman’s 
summary variable was the same on multiple reference dates in the same year, 
only the earliest was included. Each woman could be used as a control multiple 
times but for non-overlapping periods of time. 
Multiple pregnant women had the same summary variable which complicated the 
merging of tables. In this example, the same summary variable occurred up to nine 
times i.e. there were a maximum of nine pregnant women seen in the same year with 
the same characteristics. To get round this problem, separate tables containing only 
one woman with each summary variable were created. The first table contained the 
first instance of each summary variable, the second table contained the second 
instance of each summary variable, and so on, with the ninth table containing data for 
only one woman. In this example, nine separate tables were created. The first table 
was then merged with the list of all potential controls (merged using the summary 
variable), thereby matching pregnancies and controls with the same status. Since the 
list of controls was ordered using the random number, if there were multiple controls 
with the same status, it was random as to which was selected. As controls were 
matched to pregnant women, that period of follow-up was removed from the list of 
potential controls. This process was then repeated for each of the remaining 8 tables. 
For these analyses, two controls were sought for each pregnant woman. Therefore, the 
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whole process was repeated using the original 9 tables of pregnant women and the list 
of remaining controls.  
The reference date was used as a pseudo date of conception for the controls. The 
duration from the EDC to delivery was measured for each pregnancy. This duration 
was used to create a pseudo delivery date for each of the controls. Dates 3, 6, and 9 
months before and after pregnancy, and equivalent time points for the controls were 
then calculated.  
Statistical analyses 
The characteristics of pregnant women were compared to those of the controls using 
Chi-squared test for categorical variables and Kruskal-Wallis test for continuous 
variables (not Normally distributed). If a woman had more than one ALT measurement 
within any three month period, the mean of her ALT values was used for that woman 
for that period. The median value for each group for each 3 month period was then 
calculated (not Normally distributed data). The median values for the two groups were 
then compared using Kruskal-Wallis test. The proportion of women with at least one 
ALT measurement above the upper limit of normal (ULN) (40 IU/L) were calculated for 
each period of interest. Median CD4 counts for pregnant and non-pregnant women 
were calculated and summarised in the same way. 
Random effects mixed regression model  
A random effects mixed regression model with unstructured covariance matrix was 
constructed to confirm whether pregnancy was independently associated with ALT. 
This approach takes into account the within-individual correlations between repeated 
measures within each woman’s data (SAS function: proc mixed). The unstructured 
covariance matrix was chosen (instead of autoregressive, compound symmetry or 
toepliz structures) because it gave the smallest values for AICC and BIC (fit statistics). 
Age (more specifically, (age-35)/10, i.e. a unit of 10 years where age 35 was 
considered as the reference value) was used as the ‘time’ covariate. Each ART drug 
was initially assessed as a dichotomous variable (used/not used) in unadjusted 
analysis and included in the final model if it had p value <0.10 in unadjusted analysis 
and was statistically significant in the adjusted model.  
Women were included in the analysis if they attended care at any point during 2000-
2011 and had ≥1 ALT measurement from that period. Data were included from the start 
of 2000 to the end of 2011, unless a woman entered or left UK CHIC during that period, 
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in which case data from her earliest to her latest attendance were used. The period 
2000-2011 was split into 3 month intervals, creating 48 reference dates. Time-
dependent covariates were created for each woman for each reference date including: 
age; pregnancy status (pregnant/not pregnant); previous pregnancy whilst HIV-positive 
(yes/no); pregnancy trimester (1st, 2nd, 3rd); ART use (yes/no); current ART regimen; 
previous ART status (yes/no); and most recent CD4 count, ALT and viral load (within 
the previous 6 months). For each woman, data at each time point were only included if 
≥1 ALT measurement was reported in the past 6 months, if the woman was aged 16-49 
and had some clinical data in UK CHIC during that calendar year.  
Assessing median ALT before, during and after pregnancy among women 
starting ART before or during pregnancy 
Index pregnancies in 2000-2011 resulting in a live or still birth and where ≥1 ALT 
measurement was available were included. For each group, a median ALT value was 
calculated for each pregnancy trimester and each 3 month period from 9 months before 
to 18 months after pregnancy. The three groups were: women already on ART before 
the pregnancy; women who started ART in the first 20 weeks of pregnancy (women 
likely to be starting long-term therapeutic ART); and women who started ART at or after 
20 weeks of pregnancy (women likely to be starting short-course ART for PMTCT). 
ART status at the start of pregnancy and, in women not yet on ART, the timing of ART 
initiation during pregnancy were assessed using the NSHPC data unless no data were 
available, when UK CHIC data were used (if available). If data were not available from 
either study regarding ART use in pregnancy, the pregnancy was excluded from the 
analysis (n=20). When categorising the women into the three groups, ART use 
following pregnancy was not considered.   
The analysis was undertaken among women without hepatitis B or hepatitis C 
(HBV/HCV) co-infection. A separate analysis was undertaken including only women 
with HBV/HCV co-infection.  
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 Methods Section 3: the impact of pregnancy on the risk of LEE 7.2.3
Dataset  
In the third section, which examines the impact of pregnancy on LEE risk, the dataset 
used was created by linking the UK CHIC dataset containing data until 31st December 
2012 to the NSHPC dataset archived in March 2014.  
Inclusion criteria 
The analyses were limited to women not on any ART on 31st December 1999 and who 
started ART at any point during 2000-2012 whilst aged 16-49 years. The date of ART 
initiation was considered the baseline date. Women with >1 ALT measurement while 
on ART and CD4 count and viral load data available were included. When assessing 
incident LEE, only the first initiation of ART over the study period was considered for 
each woman, i.e. if she temporarily stopped ART and restarted at a later point, only the 
first period of use was considered. Women with severe LEE (i.e. >5 times the ULN) at 
baseline, indicating liver dysfunction, were excluded (n=10). Women were included 
irrespective of pregnancy status or previous ART experience at baseline as these 
characteristics were taken into account in adjusted analyses. All pregnancy outcomes 
were included. 
Outcomes 
The UK CHIC dataset was previously used to assess ALT levels among HIV-positive 
men and women not on ART in order to establish a robust definition of an ‘ALT flare’. 
The recommendation from this previous publication was that an ALT flare should be 
defined on the basis of two consecutive measurements >200 IU/L >14 days apart, 
since many patients not on ART had a single increase in ALT [481]. However, this is 
not an appropriate measure to use in the context of pregnancy since the follow-up time 
is short and many of the women in UK CHIC only had one ALT measurement during 
pregnancy. Therefore, ALT levels were graded according to the Division of AIDS 
toxicity guidelines [322]. The primary outcomes were incidence of any LEE (grade 1-4) 
and incidence of severe LEE (grade 3-4). LEE was defined as ≥1.25 times the ULN 
among women with no evidence of LEE at baseline or ≥1.25 times the baseline ALT 
among women with ALT >ULN at baseline. Severe LEE was defined in the same way, 
but using >5 times the ULN. The secondary outcomes were regimen changes (any 
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addition or discontinuation of at least one drug in the regimen) and interruptions within 
three months of incident LEE.  
It was assumed that women with no ALT data before starting ART (n=1856) did not 
have ALT above the ULN. A sensitivity analysis was undertaken excluding women with 
no baseline ALT. An additional sensitivity analysis was undertaken to account for the 
fall in median ALT during pregnancy. This was done by adding 8 IU/L to all ALT 
measurements taken during pregnancy since the upper limit of the typical ALT ranges 
in pregnancy is 8 IU/L lower than at other times, summarised in Table 2.3 [339]). 
As the risk of LEE may be higher in the first few months of ART use, an increase in the 
risk of LEE in pregnant women may be a consequence of women starting ART 
antenatally. A sensitivity analysis was therefore undertaken excluding women who 
were pregnant when starting ART. 
Although women could act as their own controls, contributing data when pregnant and 
when not pregnant, some women did not have a pregnancy during follow-up. Analyses 
were adjusted in order to account for any differences between women who had a 
pregnancy and those who did not. However, since there could be residual confounding 
and no data were collected on possible confounders such as alcohol consumption, diet 
and weight, a sensitivity analysis was undertaken including only women who had a 
pregnancy at some point during follow-up. 
Analysis 
Initially the baseline characteristics of women with and without a pregnancy at any 
point during follow-up were compared using Chi-squared and Kruskal-Wallis tests. 
Follow-up was started on the date of first ART use and was censored at ART 
discontinuation, at last clinic visit or at 31st December 2012, whichever occurred first. 
Kaplan-Meier analyses were used to describe the probability of LEE and severe LEE. 
Cox proportional hazards models were used to calculate crude and adjusted hazard 
ratios for the associations between factors and incident LEE/severe LEE (SAS 
command PROC PHREG). The counting process style of input was used and 
covariates were either considered as fixed or time-dependent [482]. Fixed 
characteristics at baseline considered for inclusion were: calendar year; previous 
antenatal use of short-course ART; pre-ART CD4 count (not known (NK)/≤250/251-
350/351-500/>500 cells/mm3); pre-ART viral load (≤/>100,000 copies/ml); pre-ART 
ALT; route of exposure; ethnicity and HBV/HCV co-infection. For pre-ART CD4 count, 
viral load and ALT, the latest measurement in the six months prior to baseline was 
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used. Time-dependent covariates considered, assessed at one month intervals, were 
age, pregnancy status, cumulative use of ART, latest CD4 count category, latest viral 
load category and current drug regimen (dichotomised as used/not used for each 
drug). Any covariates that were associated with the outcome (p<0.10) in the univariate 
models were considered for inclusion in the multivariable models; covariates with a p-
value ≤0.05 were retained in the final model, as were age, route of exposure, ethnicity 
and HBV/HCV co-infection, as these were of interest for our research question. 
Finally, I examined changes in ART regimen and interruption of ART in women who 
experienced LEE. 
 
7.3 Results 
 Results Section 1: preliminary descriptive analyses  7.3.1
ALT data among women in UK CHIC 
The UK CHIC dataset contained clinical data for 11,439 women who attended HIV-
related clinical care (i.e. had a CD4 count or viral load reported in UK CHIC) at any 
point during the period 2000-2011. The dataset contained 100,105 ALT measurements 
in total; more than half the women had at least one ALT measurement (54.1%, 
n=6188) and just under half had multiple ALT measurements (49.6%, n=5677). The 
number of ALT measurements per woman ranged from 0 to 238. Among women with 
≥1 ALT measurement, the median number of measurements was 11 (interquartile 
range [IQR] 5-22).  
Of the 8658 women who started life-long ART, i.e. not including short-course ART use 
in pregnancy, 22.0% (n=1908) had ≥1 ALT measurement prior to starting ART and 
51.9% (n=4497) had ≥1 ALT measurement after starting, although they were not 
necessarily still on ART when these measurements were taken. In women with ≥1 ALT 
measurement, the median number of measurements was 3 [IQR 1-6] prior to starting 
ART, 10 [IQR 5-23] after starting ART and 5 (IQR 3-7) within one year of starting ART. 
Overall, 19.9% (n=1725) of women had ≥1 ALT measurement before and ≥1 ALT 
measurement after starting ART.  
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ALT data during pregnancy in UK CHIC  
Of the 11,439 women of any age who attended HIV-related clinical care in 2000-2011, 
one-quarter (25.1%, n=2872) had at least one pregnancy starting in that period; 1817 
women had a single pregnancy, 770 women had two pregnancies, 221 women had 
three pregnancies and 62 women had four or five pregnancies. Just over half the 
women with a pregnancy had ≥1 ALT measurement (51.3%, n=1473) and just under 
half had multiple ALT measurements (48.0%, n=1378) at any point during 2000-2011. 
At least one ALT measurement was taken during 27.4% (1175/4288) of pregnancies 
conceived in 2000-2011; 26.7% (724/2711) of index pregnancies and 28.6% 
(451/1557) of subsequent pregnancies. There were a total of 4582 ALT measurements 
taken during the pregnancies conceived in 2000-2011. The median number of ALT 
measurements during pregnancies with ≥1 ALT measurement, was 4 (IQR 2-5) during 
index pregnancies and 3 (IQR 2-5) during subsequent pregnancies.  
Hepatitis co-infection among women in UK CHIC 
Overall, 83.7% (9574/11,439) of women had evidence that they had received a test for 
HBV and 86.8% (9934/11,439) for HCV. There were 870 women with HBV, HCV or 
HBV and HCV co-infection, representing 7.6% of women who received HIV care in 
2000-2011. This makes the assumption that women with no evidence of having been 
tested for hepatitis were not infected. There were 363 women who were HBV co-
infected and 528 women who were HCV co-infected, representing 3.2% and 4.6% of 
women in UK CHIC in 2000-2011 respectively. Of these, 21 were co-infected with HIV, 
HBV and HCV. 
Of the 870 women with HIV-HBV/HCV co-infection, more than two-thirds (68.9%, 
n=599) had ≥1 ALT measurement in the dataset and 62.2% (n=541) had multiple ALT 
measurements. Within this group, among women with ≥1 ALT measurement, the 
median number of ALT measurements was 14 (IQR 5-32).     
Characteristics predictive of having ≥1 ALT measurement in the UK CHIC 
database 
There were a number of characteristics predictive of having ≥1 ALT measurement in 
the UK CHIC dataset (Table 7.2). Women with HBV/HCV co-infection were more likely 
to have ≥1 ALT measurement (69% vs. 53%, aOR 1.46, 95% confidence intervals (CI) 
[1.23-1.74]), as were women of white ethnicity compared to women of black-African 
ethnicity (73% vs. 50%, aOR 2.55 [2.24-2.90]). Women whose probable route of HIV 
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infection was injecting drug use (IDU) were more likely to have ≥1 ALT measurement 
than women infected via heterosexual sex in unadjusted analysis (71% vs. 53%, OR 
2.12 [1.70-2.64]) but were less likely to have ≥1 ALT measurement when HBV/HCV co-
infection and ethnicity were taken into account (aOR 0.78 [0.60-1.01], p-value 0.06 in a 
model including only those three variables, and aOR 0.75 [0.58-0.98], p-value 0.03 in 
the overall model). More than two-thirds of women who had been infected with HIV 
through sharing injecting drug equipment had HBV/HCV co-infection (69.4%, 281/405, 
compared to 7.6%, n=870 overall), and 85.4% (346/405) were of white ethnicity, 
(compared to 15.6%, n=1785 overall). The longer a woman had been attending HIV-
care the more likely she was to have ≥1 ALT measurement and the more 
measurements she had (Table 7.3). Women who had ever used ART were more likely 
to have ≥1 ALT measurement than women who had not (57% vs. 42%, OR 1.81) but to 
a lesser extent when duration of HIV-care was taken into account (aOR 1.14 in the 
overall model). 
Women who had a pregnancy (conceived in 2000-2011) were less likely to have ≥1 
ALT measurement than women who did not have a pregnancy in this period (51% vs. 
55%, aOR 0.73 [0.66-0.80]). The median number of ALT measurements was 1 [IQR 0-
12] in women who had a pregnancy and 2 [IQR 0-12] in women who had not (p-value 
0.09). In women with ≥1 ALT measurement, the median number of ALT measurements 
was 12 [IQR 6-23] in women who had a pregnancy and 11 [IQR 4-22] in women who 
had not (p<0.001) (Table 7.3). In unadjusted analysis, the likelihood of having ≥1 ALT 
measurement increased with age (OR 1.09 per additional 10 years), but the opposite 
was true when other factors were taken into account (aOR 0.91 per additional 10 
years). Women aged ≤49 at the start of 2000 were more likely to have ≥1 ALT 
measurement than women aged >49 years (aOR 1.52 [1.21-1.91], p-value <0.001).  
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Table 7.2. Characteristics predictive of having ≥1 ALT measurement in the UK CHIC database 
  
Total n  %   OR p-value aOR p-value 
         
All women 
 
11,439 6188 54.1 - - - - 
         
Ever pregnant  No 8567 4715 55.0 Baseline 
 
Baseline 
 
 
Yes 2872 1473 51.3 0.86 (0.79-0.94)  <0.001 0.73 (0.66-0.80) <0.001 
         
HBV/HCV co-infection No/not tested  10,569 5589 52.9 Baseline 
   
 
Yes 870 599 68.9 1.97 (1.70-2.28) <0.001 1.46 (1.23-1.74) <0.001 
         
Route of infection Heterosexual sex 10,099 5396 53.4 Baseline 
 
Baseline 
 
 
IDU 405 287 70.9 2.12 (1.70-2.64) <0.001 0.75 (0.58-0.98) 0.03 
 
Other/NK 935 505 54.0 1.02 (0.90-1.17) 0.73 1.24 (1.07-1.48) 0.004 
         
Ethnicity Black-African 7582 3802 50.2 Baseline 
 
Baseline 
 
 
White 1785 1305 73.1 2.70 (2.41-3.03) <0.001 2.55 (2.24-2.90) <0.001 
 
Black-Caribbean  505 239 47.3 0.89 (0.75-1.07) 0.22 0.94 (0.78-1.12) 0.48 
 
Other/NK 1567 842 53.7 1.16 (1.04-1.29) 0.01 1.27 (1.13-1.43) <0.001 
         
Duration in UK CHIC  
(years) 
0-1 1639 500 30.5 Baseline 
 
Baseline 
 2-5 4258 2101 49.3 2.22 (1.97-2.51) <0.001 2.24 (1.97-2.56) <0.001 
 
6-10 3453 2087 60.4 3.48 (3.07-3.95) <0.001 3.81 (3.30-4.39) <0.001 
 
>10 2089 1500 71.8 5.80 (5.03-6.69) <0.001 5.96 (5.07-7.01) <0.001 
         
Any ART use No 2076 874 42.1 Baseline 
 
Baseline 
 
 
Yes 9363 5314 56.8 1.81 (1.64-2.00) <0.001 1.14 (1.02-1.28) 0.03 
        
Median age at start 2000 (years) [IQR]                  29  [23-35] 1.09 (1.04-1.13) <0.001 0.91 (0.87-0.95) <0.001 
         
 
  2
5
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Footnote for Table 7.2. 
This table includes data for women who attended care at any point in 2000-2011. aOR: adjusted odds ratio - multivariable logistic regression includes all variables listed in the 
model. The odds ratio for age refers to an increase of 10 years.  
2
5
1
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Table 7.3. Median number of ALT measurements in UK CHIC among all women and 
among women with ≥1 ALT measurement in 2000-2011 
Characteristic 
All women 
Women with ≥1 ALT 
measurement 
Median  IQR p-value Median  IQR p-value 
     
   
All women 
 
1 0-12 
 
11 5-22  
   
   
Ever 
pregnant  
No  2 0-12 0.09 11 4-22 <0.001 
Yes 1 0-12 
 
12 6-23  
    
   
HBV/HCV      
co-infection 
No/not tested  1 0-11 <0.001 11 5-22 0.002 
Yes 6 0-20  14 5-32  
     
   
Exposure 
group 
Heterosexual sex 1 0-12 <0.001 11 5-23 <0.001 
IDU 6 0-27 
 
15 5-40  
Other/NK 1 0-8   7 3-15   
     
   
Ethnicity Black-African 1 0-11 <0.001 11 4-21 <0.001 
 
White 7 0-21 
 
13 6-30  
 
Black-Caribbean  0 0-9 
 
10 4-17  
 
Other/NK 1 0-11 
 
11 4-21  
     
   
Duration in 
UK CHIC  
(years) 
0-1 0 0-1 <0.001 2 1-4 <0.001 
2-5 0 0-7 
 
7 4-12  
6-10 5 0-17 
 
14 8-24  
>10 13 0-38 
 
29 11-42  
     
   
Any ART 
use 
No 0 0-2 <0.001 3 1-6 <0.001 
Yes 3 0-14 
 
12 6-25  
  
      
IQR: inter quartile range. Overall p-values were calculated using Kruskal-Wallis Test 
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Upper limit of normal (ULN) among ART naïve women in UK CHIC  
All ALT measurements among women who were not known to have HBV/HCV co-
infection and who were ART naïve at the time of the measurement were included (2717 
women, 13,096 ALT measurements). The median ALT was 20 (IQR 15-29) IU/L, the 
95th percentile was 73 IU/L and the 97.5th percentile was 115 IU/L. ALT data were 
highly skewed (Figure 7.1). 
 
Figure 7.1. Distribution of ALT results (within the range 0-150 IU/L) among ART naïve 
women not diagnosed with HBV/HCV co-infection attending HIV care in at a UK CHIC 
site in 2000-2011 (n=2717) 
 
Preliminary descriptive analysis of ALT data 
Among the 5589 women with ≥1 ALT measurement, there were a total of 100,105 ALT 
measurements in the period 2000-2011 (Table 7.4).  
The median ALT overall was 22 (IQR 16-32) IU/L and among women without 
HBV/HCV co-infection it was 21 (IQR 15-30) IU/L. Among all women on ART, the 
median ALT was 21 (IQR 15-29) IU/L, there was some evidence that this was higher 
than the level among women not on ART (median ALT 20 [IQR 15-30] IU/L, p=0.06). 
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P
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Table 7.4. Preliminary descriptive analysis of ALT data among 5589 women in UK 
CHIC with ≥1 ALT measurement: each ALT measurement was taken as a separate 
observation and pregnancy status and ART use was determined at each ALT 
measurement 
Status at time of ALT measurement Number of ALT 
measurements 
Median ALT              
(IU/L) [IQR] 
p-value 
Total 100,105 22 [16-32] - 
     
HBV/HCV co-infected
1
 13,701 34 [22-56] <0.001 
Non-HBV/HCV co-infected  86,404 21 [15-30]  
     
On ART 69,357 21 [15-29] 0.06 
Not on ART 17,047 20 [15-30] 
      
Women on ART     
0-3 months since ART start  7719 22 [15-33] <0.001 
3-6 months since ART start  3835 21 [15-31] 
 6-12 months since ART start  5595 20 [15-29] 
      
Pregnant  4372 15 [11-22] <0.001 
Not pregnant 82,032 21 [15-30] 
      
All pregnant women 
    1st trimester 1133 17 [12-24] <0.001 
2nd trimester 1790 14 [10-20] 
 3rd trimester 1449 15 [11-24]  
  
    
Women on ART at conception 3525 
   1st trimester 767 17 [13-25] <0.001 
2nd trimester 1395 14 [10-19] 
 3rd trimester 1363 15 [11-24]  
  
    
Women on ART post-partum 2724    
0-3 months post-partum  738 19 [13-28] <0.001 
3-6 months post-partum  659 21 [15-30] 
 6-12 months post-partum  1327 19 [14-28] 
       
1
Women with HBV/HCV co-infection are excluded from all subsequent rows.  
 
The median ALT during pregnancy was 15 (IQR 11-22) IU/L, this was lower than in 
non-pregnant women (21 [IQR 15-30] IU/L, p<0.001). In pregnant women, the median 
ALT was 17, 14 and 15 IU/L during the 1st, 2nd and 3rd trimesters respectively. Median 
ALT measurements among post-partum women remaining on ART were 19, 21 and 19 
IU/L respectively at 0-3 months, 3-6 months and 6-12 months after pregnancy.  
This preliminary analysis indicates that median ALT levels may be lower during 
pregnancy than outside pregnancy, quickly returning to pre-pregnancy levels following 
delivery.  
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 Results Section 2: the impact of pregnancy on median ALT  7.3.2
Comparing pregnant women with controls to assess the impact of pregnancy on 
ALT  
There were 760 pregnancies meeting the inclusion criteria for the first part of this 
section, i.e. a woman’s first pregnancy with ≥1 ALT measurement conceived on ART in 
2000-2011. Of these, 643 were matched with at least one control; two controls were 
found for 435, with only one control found for the remaining 208. This gave a total of 
1078 controls. There were 894 women used as a control: 739 women were used as a 
control once; 129 women were used twice, and 26 women were used three or four 
times. The median pregnancy duration was 37 weeks (IQR 37-38 weeks) and 
pregnancy duration ranged from 26-42 weeks. 
The characteristics of women who were pregnant were compared to the characteristics 
of those who were not (controls) (Table 7.5).  
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Table 7.5. Comparison of pregnant women and controls – characteristics at the start of 
pregnancy (pregnancy group) or reference date (controls) 
Characteristic  Pregnancy group 
(n=643) 
Controls  
(n=1078) 
p-value 
Year*, n (%) 2000-2002 
2003-2005 
2006-2008 
2009-2011 
96   
143  
174 
230   
(14.9) 
(22.2)  
(27.1) 
(35.8) 
158 
235 
308 
377 
(14.7) 
(21.8) 
(28.6) 
(35.0) 
- 
Age*, n (%) 16-24 years 
25-29 years 
30-34 years 
35-49 years 
Median (IQR) years 
81 
135 
229 
198 
32  
(12.6) 
(21.0) 
(35.6) 
(30.8) 
(28-36) 
117 
213 
381 
367 
32 
(10.9) 
(19.8) 
(35.3) 
(34.0)  
(29-36) 
- 
Ethnicity,         
n (%) 
Black African  
White 
Black Caribbean 
Other/NK 
448 
92 
26 
77 
(69.7) 
(14.3) 
(4.0) 
(12.0) 
691 
210 
30 
147 
(64.1) 
(19.5) 
(2.8) 
(13.6) 
0.01 
Exposure 
category,         
n (%) 
Heterosexual sex 
Injecting drug use 
Other/NK 
617 
4 
22 
(96.0) 
(0.6) 
(3.4) 
1007 
7 
64 
(93.4) 
(0.7) 
(5.9) 
0.07 
Previous pregnancy*                 
(whilst HIV-positive) 
135 (21.0) 225 (20.9) - 
CD4 count* 
(cells/mm
3
),   
n (%) 
≤200  
201-350 
351-500 
>500 
Median (IQR) 
89 
158 
173 
223 
420 
(13.8) 
(24.6) 
(26.9) 
(34.7) 
(280-580) 
161 
274 
270 
373 
405 
(14.9) 
(25.4) 
(25.1) 
(34.6) 
(257-571) 
- 
Viral load 
(copies/ml),       
n (%)             
≤50 
51-1000 
1001-10,000 
>10,000 
No VL reported  
245 
40 
43 
49 
266 
(38.1) 
(6.2) 
(6.7) 
(7.6) 
(41.4) 
473 
98 
81 
109 
317 
(43.9) 
(9.1) 
(7.5) 
(10.1) 
(29.4) 
<0.001 
Years since 
diagnosis,       
n (%) 
<2  
2 to <5  
5 to <10 
10+ 
Median [IQR] 
255 
133 
184 
71 
3.6 
(39.7) 
(20.7) 
(28.6) 
(11.0) 
[0.4-7.2] 
356 
284 
263 
175 
3.8 
(33.0) 
(26.4) 
(24.4) 
(16.2) 
[1.2-7.8] 
 
 
 
 
0.01 
* Variables used to select suitable controls.  
All women were on ART and therefore had previous ART exposure. 
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The time since HIV diagnosis was slightly shorter for the pregnant women than for the 
controls (3.6 vs. 3.8 years, p-value 0.01). A larger percentage of pregnant women were 
of black-African ethnicity than of the controls (69.7% vs. 64.1%, global p-value 0.01). In 
both groups, more than one-third of women were virally suppressed (HIV RNA ≤50 
copies/ml), however, the percentage with viral suppression was lower in pregnant 
women than in the controls (58.6% vs. 70.6%, global p-value <0.001 where viral load 
was known).  
The availability of ALT data was compared during the pre-pregnancy, pregnancy and 
postpartum periods (Table 7.6). The controls were more likely to have ALT data 
compared to the pregnancy group.  
Table 7.6. Availability of ALT data among pregnant women and controls 
1
Equivalent periods for controls where the reference date is used as the pseudo-date of conception  
2
0-6 months before pregnancy  
3
0-6 months after pregnancy 
 
Median ALT levels for pregnant women and controls are presented in Table 7.7 and 
Figure 7.2. Prior to pregnancy, the median ALT was similar in both groups. Whilst all 
median ALT values remained within the normal range, ALT levels fell during the first 
and second pregnancy trimester, plateauing during the third. In the third trimester the 
median ALT was 15 IU/L, 5 IU/L less than the median ALT among the control group at 
the equivalent time. During all three pregnancy trimesters the median ALT was lower 
than in the controls. Shortly after pregnancy, ALT returned to pre-pregnancy levels and 
the median ALT at 3-6 months postpartum was similar for both groups (p-value 0.60). 
  
Period in relation to pregnancy 1 
Pregnancy 
group 
n=643 
Controls 
n=1078 p-value 
Before2 ≥1 ALT measurement, n (%) 
median count [IQR] 
346 
1 
(53.8) 
[0-2] 
734 
1 
(68.1) 
[0-2] 
<0.001 
       
During  ≥1 ALT measurement, n (%) 
median count [IQR] 
636 
4 
(99.0) 
[3-5] 
1076 
3 
(99.8) 
[3-4] 
0.01 
       
After3 ≥1 ALT measurement, n (%) 
median count [IQR] 
501 
1 
(77.9) 
[1-2] 
972 
2 
(90.2) 
[1-2] 
0.001 
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Table 7.7. Median ALT levels during defined periods before, during and after 
pregnancy – and in equivalent periods for controls   
Period of interest1 
Pregnancy group            
Median (IQR) 
Controls         
Median (IQR) 
p-value 
Before 
pregnancy 
3-6 months 
(n=265, n=579) 
20 (15-26) 20 (14-29) 0.68 
0-3 months 
(n=269, n=602) 
19 (14-27) 21 (15-29) 0.10 
During 
pregnancy 
1st trimester 
(n=426, n=809) 
16 (13-24) 21 (15-30) <0.001 
2nd trimester 
(n=552, 
n=1002) 
14 (11-20) 21 (16-30) <0.001 
3rd trimester 
(n=496, n=717) 
15 (11-22) 20 (15-28) <0.001 
After pregnancy 0-3 months 
(n=395, n=827) 
19 (14-28) 20 (15-29) 0.04 
3-6 months 
(n=371, n=747) 
21 (14-30) 20 (15-29) 0.60 
1
Equivalent periods for controls where the reference date is used as the pseudo-date of conception 
 
Figure 7.2. Median ALT levels among women on ART: pregnant women and controls 
(the shaded areas indicate the three pregnancy trimesters) 
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The proportion of women with ALT above ULN during each perinatal period is 
presented in Table 7.8 and Figure 7.3. Prior to pregnancy, the percentage of women 
with ALT above ULN was higher in the control group than in the pregnancy group, but 
this difference was not statistically significant. Among the pregnant women, the 
percentage with ALT above ULN fell during the first trimester, but increased during the 
second and third trimesters, increasing to above pre-pregnancy levels after delivery. A 
smaller percentage of pregnant women had ALT above ULN in the first and second 
trimester than in the controls.  
Table 7.8. Proportion of women with mean ALT above ULN during each perinatal 
period  
Period of interest1 Pregnancy group 
 %        (n/N) 
Control group 
  %         (n/N) 
p-value 
(Chi-
squared) 
Before 
pregnancy 
3-6 months 8.3 (22/265) 12.1 (70/579) 0.10 
0-3 months 8.2 (22/269) 12.3 (74/602) 0.07 
During 
pregnancy 
1st trimester 5.2 (22/426) 12.1 (98/809) <0.001 
2nd trimester 6.0 (33/552) 13.6 (136/1002) <0.001 
3rd trimester 9.5 (47/496) 11.7 (84/717) 0.22 
After pregnancy 
0-3 months 8.9 (35/395) 11.4 (94/827) 0.18 
3-6 months 14.0 (52/371) 10.3 (77/747) 0.07 
1
Equivalent periods for controls where the reference date is used as the pseudo-date of conception 
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Figure 7.3. Proportion of women with mean ALT above ULN during each perinatal 
period or equivalent periods for controls (shaded areas indicate the three pregnancy 
trimesters) 
 
The analysis was repeated using a stricter matching criterion; this included the addition 
of ethnicity, exposure group and type of ART regimen, categorised as PI-based, 
NNRTI-based, NRTI-based or other drug regimen. The outcome was unchanged and 
the results are not included.  
Median CD4 count before, during and after pregnancy 
Median CD4 count was assessed for the periods before, during and after pregnancy 
(Table 7.9 and Figure 7.4). Although the median CD4 count appeared to dip during 
pregnancy, there was only a significant difference in the second trimester (395 vs. 420 
cells/mm3 respectively in the pregnancy and control groups) with median CD4 counts 
being similar for pregnant women and controls in the first and third trimesters. Before 
and after pregnancy, the median CD4 count was higher in the pregnancy group than in 
the controls.  
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Table 7.9. Median CD4 count during defined perinatal periods among the pregnancy 
group and controls 
Period of interest1 
Pregnancy group             Controls                           
p-value 
Median CD4 count (cell/mm3) [IQR]  
Before 
pregnancy 
3-6 months 
(n=298, n=600) 
458 [310-600] 425 [297-609] 0.31 
 0-3 months 
(n=291, n=610) 
460 [330-615] 420 [280-581] 0.04 
During 
pregnancy 
1st trimester 
(n=442, n=765) 
422 [270-584] 425 [297-600] 0.18 
 2nd trimester 
(n=569, n=677) 
395 [274-548] 420 [280-604] 0.05 
 3rd trimester 
(n=488, n=456) 
436 [309-576] 431  [287-597] 0.85 
After pregnancy 0-3 months 
(n=424, n=803) 
504 [360-668] 452 [320-630] 0.01 
 3-6 months 
(n=381, n=733) 
500 [360-640] 453 [322-635] 0.04 
1
Equivalent periods for controls where the reference date is used as the pseudo-date of conception.               
IQR: interquartile range. 
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Figure 7.4. Median CD4 counts among women on ART: pregnant and matched non-
pregnant women (the shaded areas indicate the three pregnancy trimesters)  
 
Variables independently associated with ALT 
A mixed effect regression model was developed to identify variables independently 
associated with ALT, whilst taking into account repeated measures (i.e. multiple ALT 
measurements for the same woman). In total, 5394 women contributed 19,397 person-
years (PY) of follow-up to the analysis. The characteristics of women at the start of 
follow-up are summarised in Table 7.10.   
At the start of follow-up, 14.5% (n=783) of women had previously had a pregnancy. In 
total, 598 PY of follow-up were contributed by women when pregnant and 18,799 PY 
when not pregnant. Overall, 16.5% (n=888) of women were pregnant at some point 
during follow-up, including 6.5% (n=353) who were pregnant at the start of follow-up. 
During follow-up there were a total of 1390 pregnancies with 510 women having one 
pregnancy; 276 having two pregnancies and 102 having three or more pregnancies. 
The majority of pregnancies resulted in a live birth (88.1%, n=1225), with 6.4% (n=89) 
resulting in a miscarriage, 3.0% (n=42) being terminated, and the remaining 34 having 
other outcomes (including unknown outcome because the woman was lost to follow-
up). The majority of women with a pregnancy had been infected with HIV via 
heterosexual sex (94.8%, n=842) and two-thirds of women were of black-African 
ethnicity (67.7%, n=601).  
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Table 7.10. Demographic and clinical characteristics of women in the longitudinal 
analysis 
Baseline characteristics 
All women                      
(n=5394) 
Pregnancy during follow-up 
Yes (n=888) No (n=4506) 
Age, n (%) 16-24 years 
25-29 years 
30-34 years 
35-39 years 
40-49 years 
Median [IQR] years 
530 
837 
1228 
1290 
1509 
35 
(9.8) 
(15.5) 
(22.8) 
(23.9) 
(28.0) 
[29-40] 
149 
260 
303 
153 
18 
30 
(16.8) 
(29.3) 
(34.7) 
(17.2) 
(2.0) 
[26-34] 
381 
577 
925 
1137 
1491 
36 
(8.5) 
(12.8) 
(20.5) 
(25.2) 
(33.1) 
[31-41] 
        
Ethnicity,         
n (%) 
Black African  
White 
Black Caribbean 
Other/NK 
3373 
1120 
186 
715 
(62.5) 
(20.8) 
(3.5) 
(13.3) 
601 
140 
45 
102 
(67.7) 
(15.8) 
(5.1) 
(11.5) 
2772 
980 
141 
613 
(61.5) 
(21.7) 
(3.1) 
(13.6) 
Exposure 
category,         
n (%) 
Heterosexual sex 
IDU 
Other/NK 
4717 
260 
417 
(87.5) 
(4.8) 
(7.7) 
842 
15 
31 
(94.8) 
(1.7) 
(3.5) 
3875 
245 
386 
(86.0) 
(5.4) 
(8.6) 
HBV/HCV infection 538 (10.0) 58 (6.5) 480 (10.7) 
CD4 count 
(cells/mm
3
),   
n (%) 
≤200  
201-350 
351-500 
>500 
NK 
Median [IQR] 
1101 
1217 
1139 
1554 
383 
373 
 (20.4) 
 (22.6) 
 (21.1) 
 (28.8) 
 (7.1) 
[221-554] 
158 
225 
208 
249 
48 
376 
 (17.8) 
 (25.3) 
 (23.4) 
 (28.0) 
 (5.4) 
[245-540] 
943 
992 
931 
1305 
335 
371 
 (20.9) 
 (22.0) 
 (20.7) 
 (29.0) 
 (7.4) 
[220-557] 
Viral load      
(copies/ml),       
n (%)              
≤50 
51-1000 
1001-10,000 
>10,000 
NK  
2131 
806 
809 
1313 
335 
(39.5) 
(14.9) 
(15.0) 
(24.3) 
(6.2) 
270 
166 
170 
224 
58 
(30.4) 
(18.7) 
(19.1) 
(25.2) 
(6.5) 
1861 
640 
639 
1089 
277 
(41.3) 
(14.2) 
(14.2) 
(24.2) 
(6.1) 
ALT (IU/L),          
n (%) 
<40 
40 - ≤100 
>100 
Median [IQR] 
4592 
673 
129 
20 
(85.1) 
(12.5) 
(2.4) 
[15-30] 
795 
82 
11 
18 
(89.5) 
(9.2) 
(1.2) 
[13-25] 
3797 
591 
118 
21 
(84.3) 
(13.1) 
(2.6) 
[15-31] 
ART use ART experienced 
On ART 
3572
3204 
(66.2) 
(59.4) 
553 
487 
(62.3) 
(54.8) 
3019 
2717 
(67.0) 
(60.3) 
Current type 
of ART 
regimen  
 
 
ART drug in 
regimen 
PI-based 
NNRTI-based 
NRTI-based 
Other 
 
Zidovudine 
Tenofovir 
Ritonavir  
Darunavir 
Saquinavir 
1199 
1517 
86 
402 
 
972 
1393 
1192 
150 
148 
 (37.4) 
(47.4) 
(2.7) 
(12.6) 
 
(18.0) 
(25.8) 
(22.1) 
(2.8) 
(2.8) 
 
221 
199 
12 
55 
 
235 
237 
275 
23 
37 
(45.4) 
(40.9) 
(2.5) 
(11.3) 
 
(26.5) 
(26.7) 
(31.0) 
(2.6) 
(4.2) 
 
978 
1318 
74 
347 
 
742 
1246 
995 
141 
114 
(21.7) 
(29.2) 
(1.6) 
(7.7) 
 
(16.5) 
(27.7) 
(22.1) 
(3.1) 
(2.5) 
IQR: interquartile range; NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; 
NRTI: nucleoside/nucleotide reverse transcriptase inhibitor. 
  
 264 
 
Table 7.11. Results from mixed effects regression model to describe associations 
between each factor and the ALT value 
Predictor 
  
Univariate Multivariable 
Estimate p-value Estimate p-value 
      
Constant    22.7 <0.001 
      
Pregnant  -4.5 <0.001 -3.3 <0.001 
Previous pregnancy                        
(whilst HIV-positive) 
-2.2 <0.001 -1.0 <0.001 
      
Hepatitis co-infected 20.3 <0.001 17.1 <0.001  
      
Ethnicity  
  
  
Black-African Reference  <0.001 Reference  <0.001 
White 9.0  4.2  
Black-Caribbean 0.2  -0.03  
Other/NK 3.0  1.7  
      
Exposure group 
  
  
Heterosexual sex Reference  <0.001 Reference  <0.001 
IDU 20.5  4.7  
Other/NK 1.0  -0.4  
      
CD4 count 
(cells/mm
3
) 
  
  
  
≤200 4.0 <0.001 2.6 <0.001 
201-350 0.6  -0.06  
351-500 -0.1  -0.3  
>500 Reference   Reference  
NK 0.1  0.2  
      
Viral load 
(copies/ml) 
  
  
 
≤50 Reference  <0.001 Reference 0.01 
51-1000 0.7  0.6  
1001-10,000 0.3   0.4  
>10,000 1.9  1.0  
NK  1.5  1.4  
      
Drug regimen 
  
  
  
  
No ART Reference <0.001  Reference  <0.001 
PI-based -2.3  0.7  
NRTI-based 1.2  0.9  
NNRTI-based -0.2  3.0  
Other 0.2  2.6  
     
Duration on ART (per additional year) -0.2 <0.001 -0.05 0.27 
     
ART drug Zidovudine -2.1 <0.001 -2.2 <0.001 
 Tenofovir 0.7 0.002 1.2 <0.001 
 Ritonavir  -3.2 <0.001 -2.7 <0.001 
 Darunavir -3.0 <0.001 -2.2 <0.001 
 Saquinavir 0.6 0.27 1.4 0.01 
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The model identifies a number of factors which are independently associated with ALT 
(Table 7.11). The mean ALT for a person who, at any time over the study, is 35 years 
old, is not pregnant, has not previously been pregnant, is of black-African ethnicity, 
acquired HIV via heterosexual sex, has a CD4 count >500 cells/mm3, has an 
undetectable viral load and is not on ART is 25.6 IU/L. ALT increases by, on average, 
22.7 IU/L per 10 year increase in age. Pregnancy decreased ALT by, on average, 3.3 
IU/L. Women who had previously been pregnant (when HIV-positive) had ALT, on 
average, 1.0 IU/L lower than women with no previous pregnancy (since HIV diagnosis).  
Factors predictive of higher ALT were: HBV/HCV co-infection; white or ‘other/NK’ 
ethnicity (compared to black-African ethnicity); probable route of infection through 
sharing injecting drug equipment (compared to heterosexual sex); CD4 count ≤200 
cells/mm3 (compared to CD4 count >500 cells/mm3); having detectable viral load or 
having no viral load reported in the previous 6 months (compared to having 
undetectable viral load); the use of an NNRTI-based regimen (compared to not using 
any ART); and the use of the ART drugs tenofovir or saquinavir. Use of zidovudine, 
ritonavir and darunavir were associated with lower ALT.  
The association between cumulative time on ART and ALT was not statistically 
significant (p-value 0.27). Having had a pregnancy in the past 6 months was not 
associated with ALT in univariate analysis (estimate -0.6, p-value 0.30). 
Median ALT before, during and after pregnancy according to ART use 
Median ALT during pregnancy and in the 9 months before and 18 months after 
pregnancy was examined in three groups: women who were already on ART when 
they conceived; women who started ART in the first half of pregnancy; and women who 
started ART in the second half of pregnancy. The data are presented in Table 7.12 and 
Figure 7.5. Data were available for 793 women in total; 646 had ≥1 ALT measurement 
during pregnancy and 275 had ≥1 ALT measurement in the periods before, during and 
after pregnancy. Among women already on ART when they conceived, ALT levels fell 
during pregnancy, plateauing in the final trimester and returning to pre-pregnancy 
levels by 0-3 months post-partum (Table 7.12 and Figure 7.5). A similar pattern was 
seen in women who started ART during the first 20 weeks of pregnancy; the median 
ALT fell during the first half of pregnancy, increasing during the 6 months following 
pregnancy, returning to pre-pregnancy levels by 6-9 months postpartum with a 
temporary peak above pre-pregnancy levels at 3-6 months post-partum, (79.5% 
[89/112] of these women were still on ART at 3 months post-partum). Women starting 
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ART after 20 gestational weeks had a somewhat lower median ALT prior to pregnancy 
(17 IU/L), the fall in ALT was not as marked during pregnancy which meant that all 
groups had similar median ALT at the end of pregnancy. Median ALT peaked at 3-6 
months post-partum and returned to pre-pregnancy levels by 9-12 months postpartum. 
In this group, 58.1% (126/217) were on ART at 3 months post-partum. 
 
Figure 7.5. Trends in median ALT (IU/L) before, during and after pregnancy according 
to ART status among HIV-positive women with an index pregnancy in 2000-2011 (the 
shaded areas indicate the three pregnancy trimesters) 
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Table 7.12. Median ALT measurements before, during and after index pregnancies resulting in a live or still birth where ALT data was available 
in 2000-2011 
Perinatal Period1  Initiation of ART 
   
Before conception <20 weeks ≥20 weeks 
    
n 
(n=318) 
Median [IQR] 
(IU/L) 
n 
(n=142) 
Median [IQR]   
(IU/L) 
n 
(n=288) 
Median [IQR] 
(IU/L) 
Before 
pregnancy 
6-9 months 160 20 [15-28] 17 21 [17-29] 32 17 [13-21] 
3-6 months 167 21 [16-29] 25 20 [15-23] 39 16 [14-26] 
0-3 months  170 21 [15-28] 24 21 [15-32] 37 15 [13-24] 
During 
pregnancy 
1st trimester 212 18 [14-25] 72 17 [13-24] 88 15 [12-19] 
2nd trimester 221 14 [11-20] 99 15 [11-27] 200 14 [11-20] 
  3
rd trimester 194 15 [12-22] 84 15 [11-27] 198 14 [10-23] 
After 
pregnancy 
  
0-3 months 174 21 [15-30] 85 18 [13-26] 151 17 [13-23] 
3-6 months 182 20 [15-29] 57 24 [17-34] 123 21 [14-32] 
6-9 months 160 21 [15-30] 65 21 [14-36] 116 19 [14-27] 
9-12 months 163 20 [15-27] 64 21 [14-32] 103 17 [13-22] 
12-15 months 164 18 [14-26] 54 20 [15-28] 110 16 [13-23] 
15-18 months 156 19 [14-28] 64 18 [15-24] 121 16 [14-22] 
1
Equivalent periods for controls where the reference date is used as the pseudo-date of conception  
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For all groups, the median ALT remained within the normal range throughout. The 
percentage of women with a mean ALT above the ULN was assessed in each three 
month period of interest (Table 7.13 and Figure 7.6). The overall pattern showed a fall 
in the percentage of women with ALT above ULN during pregnancy with an increase 
following pregnancy. However, due to the small number of ALT measurements 
available for each group there was a lot of fluctuation in the proportion of women with 
ALT above ULN and comparison between groups was not possible. 
 
Table 7.13. The proportion of women with mean ALT above ULN (40 IU/L) during each 
period before, during and after index pregnancy in 2000-2011 
Perinatal Period    On ART at 
conception (n=318) 
Start ART at <20 
weeks (n=142) 
 Start ART at ≥20 
weeks (n=288) 
    % n/N % n/N % n/N 
Pre-pregnancy 6-9m 11.3 18/160 11.8 2/17 3.1 1/32 
  3-6m 10.2 17/167 0.0 0/25 10.3 4/39 
  0-3m 10.0 17/170 8.3 2/24 5.4 2/37 
Trimester 1
st
 6.6 14/212 6.9 5/72 4.6 4/88 
 
2
nd
 5.0 11/221 8.1 8/99 6.5 13/200 
  3
rd
 5.7 11/194 13.1 11/84 11.6 23/198 
Post-partum 0-3m 12.1 21/174 3.5 3/85 5.3 8/151 
  3-6m 13.2 24/182 17.5 10/57 18.7 23/123 
 6-9m 14.4 23/160 16.9 11/65 6.9 8/116 
 9-12m 6.8 11/163 10.9 7/64 4.9 5/103 
 2-15m 6.7 11/164 13.0 7/54 6.4 7/110 
 5-18m 9.0 14/156 9.4 6/64 6.6 8/121 
m: months 
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Figure 7.6. The proportion of women with mean ALT above ULN (40 IU/L) during each 
period before, during and after their index pregnancy in 2000-2011 (the shaded areas 
indicate the pregnancy trimesters) 
 
 
 
The analysis was repeated for women with HBV/HCV co-infection, of whom 57 had 
perinatal ALT data from their index pregnancy. Due to small numbers comparison 
between groups was not possible but the overall pattern of ALT in women with 
HBV/HCV co-infection was similar to that in non-co-infected women although with, on 
average, higher pre-pregnancy ALT. The results are not presented here. 
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The 3815 women included in the analysis contributed 17,753 PY of follow-up. The 
median duration of follow-up was 4.1 (IQR 1.6-7.2) years. When starting ART, the 
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ART and 46.5% had a CD4 count ≤250 cells/mm3. Over half the women were on a non-
nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen; 19.2% (n=732) 
used an NVP-containing drug regimen. At baseline, 304 women had an ALT above 
ULN, representing 8.0% of the total or 15.5% of the 1959 women with baseline ALT 
data. 
When starting ART, 14.2% (n=541) of women were pregnant; 25.7% (n=982) were 
pregnant at some time during follow-up (including the 541 pregnant at baseline): 742 
women had one pregnancy and 240 women had more than one pregnancy. Women 
with a pregnancy during follow-up differed from women without: they were less likely to 
be of white ethnicity (12.7% (n=125) vs. 18.6% (n=526), p-value <0.001), to have 
acquired HIV through sharing injecting drug equipment (0.9% (n=9) vs. 4.0% (n=113), 
p-value <0.001) and be HBV/HCV co-infected (5.7% (n=56) vs. 9.2% (n=261), p-value 
<0.001). Women with a pregnancy were less likely to start ART with CD4 ≤250 
cells/mm3 and more likely to start with CD4 >500 cells/mm3 (49.6% (391/789) vs. 
65.7% (1383/2105), and 12.3% (97/789) vs. 6.7% (140/2105) respectively, p-value 
<0.001) and more likely to use an NVP-containing drug regimen (25.3% (n=248) vs. 
17.1% (n=484), p-value <0.001). Women with a pregnancy were less likely to have ALT 
>40 IU/L at baseline (4.2% (n=41) vs. 9.3% (n=263), p-value <0.001). 
In the first 6 months on ART, the proportion of women with at least one ALT 
measurement was similar in both groups (63.4% (n=623) vs. 65.4% (n=1852), p-value 
0.27) and the median number of ALT measurements during this period was the same 
(2 [IQR 0-4], p-value 0.72). The median number of ALT measurements undertaken in 
the first 6 months on ART remained stable over time (three or four for each year). ALT 
monitoring, in general, did not increase over time. 
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Table 7.14. Baseline characteristics of 3815 HIV-positive women starting ART in 2000-
2012 
Characteristic n  (%) 
Age, median [IQR] 34  [29-39] 
Exposure group Heterosexual sex 3456  (90.6) 
 IDU 122 (3.2) 
 Other/Not known 237 (6.2) 
Ethnicity Black-African 2517 (66.0) 
 White 651 (17.1) 
 Black-Caribbean  133 (3.5) 
 Other/Not known 514 (13.5) 
HIV-HBV/HCV co-infection 317 (8.3) 
Year of starting ART 2000-2002 793 (20.8) 
 2003-2005 1020 (26.7) 
 2006-2008 1062 (27.8) 
 2009-2014 940 (24.6) 
Time since                        
HIV-diagnosis 
<3 months 1460 (38.3) 
3-<12 months  651 (17.1) 
 1-<5 years 928 (24.3) 
 ≥5 years 776 (20.3) 
 Median months [IQR] 7.5 [1.5-46] 
CD4 count 
(cells/mm
3
) 
≤250  1774 (46.5) 
251-350 564 (14.8) 
351-500 319 (8.4) 
 >500 237 (6.2) 
 Not known 921 (24.1) 
Viral load  
(copies/ml) 
≤400  463 (12.1) 
400-≤10,000 605 (15.9) 
10,000-≤100,000 1074 (28.2) 
 ≥100,000 779 (20.4) 
 Not known 894 (23.4) 
ALT >ULN at baseline 304 (8.0) 
Previous ART use 218 (5.7) 
Pregnancy status  Non-pregnant 3274 (85.8) 
Pregnant <20 weeks gestation 208 (5.5) 
Pregnant ≥20 weeks gestation 333 (8.7) 
Type of ART 
regimen 
NNRTI 2134 (55.9) 
PI
a
 1176 (30.8) 
NRTI
b
 130 (3.4) 
Other 375 (9.8) 
ALT: alanine transaminase; HBV: hepatitis B; HCV: hepatitis C; IDU: injecting drug use; IQR: interquartile 
range; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside/nucleotide reverse 
transcriptase inhibitor; PI: protease inhibitor; ULN: upper limit of normal.  
a 
1036 women were on a ritonavir-boosted PI and 140 were on a non-boosted PI.  
b
 This includes
 
68 women on zidovudine monotherapy. 
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Incidence of LEE  
Overall, 1080 (28.3%) women developed LEE. After one year on treatment the 
cumulative incidence of LEE was 15% (95% CI 14%-17%), increasing to 30% (95% CI 
28%-31%) by five years. The overall estimated rate of LEE was 6.3 (95% CI 5.9-
6.7)/100 PY. The rate of LEE was 14.5 (11.4-17.5)/100 PY in pregnancy and 6.0 (5.6-
6.4)/100 PY outside pregnancy. In women with HBV/HCV co-infection, 149 (47%) 
developed LEE, with LEE rates being 14.4 (12.1-16.7)/100 PY in women with 
HBV/HCV co-infection and 5.8 (5.4-6.1)/100 PY in women without co-infection.  
In the first six months on ART, the rate of LEE was 21.8 (19.7-23.8)/100 PY. For this 
period, the rate was higher in women who were pregnant than in women who were not 
pregnant (32.2 [23.9-40.5]/100 PY vs. 20.8 [18.7-22.8]/100 PY, respectively). In women 
who had been on ART for more than six months, the rate of LEE was 4.2 (3.9-4.6)/100 
PY. The rate was higher in women who were pregnant than in women who were not 
pregnant (7.0 [4.5-9.5]/100 PY vs. 4.2 [3.8-4.5]/100 PY, respectively) (Table 7.15). 
 
Table 7.15. Rates of LEE and severe LEE per 100 person-years, with 95% confidence 
intervals (CIs), according to pregnancy status and duration on ART 
 
All women,  
CI 
Pregnant,  
CI 
Not pregnant, 
CI 
LEE       
Overall  6.3 5.9-6.7 14.5 11.4-17.5 6.0 5.6-6.4 
≤6 months on ART 21.8 19.7-23.8 32.2 23.9-40.5 20.8 18.7-22.8 
>6 months on ART 4.2 3.9-4.6 7.0 4.5-9.5 4.2 3.8-4.5 
 
Severe LEE 
Overall 0.7 0.6-0.8 3.9  2.4-5.3 0.6 0.5-0.7 
≤6 months on ART 2.9 2.2-3.7 9.0  4.7-13.3 2.4 1.7-3.0 
>6 months on ART 0.5 0.4-0.6 2.0 0.7-3.2 0.4 0.3-0.5 
 
LEE occurred during 11.6% (63/541) of pregnancies in which ART was started. In 
women who developed LEE during such a pregnancy, it occurred at a median of 30 
(IQR 25-33) weeks gestation and 8 (IQR 4-12) weeks after ART initiation. In 
pregnancies conceived on ART during which LEE occurred, it occurred at median of 16 
(IQR 9-28) weeks gestation. 
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Incidence of severe LEE  
Overall, 151 (4.0%) women developed severe LEE. The cumulative incidence of 
severe LEE at one and 5 years after treatment initiation was 2.2% (1.7%-2.7%) and 
4.3% (3.5%-5.0%), respectively. The overall estimated rate of severe LEE was 0.7 
(0.6-0.8)/100 PY. The rate of severe LEE was 3.9 (2.4-5.3)/100 PY in pregnancy and 
0.6 (0.5-0.7)/100 PY outside pregnancy. In women with HBV/HCV co-infection (both 
pregnant and non-pregnant), 18 (5.7%) developed severe LEE; the rates were 1.2 (0.6-
1.8) in women with HBV/HCV co-infection and 0.7 (0.6-0.8)/100 PY in women without 
co-infection. 
In the first six months on ART the rate of severe LEE was 2.9 (2.2-3.7)/100 PY. For this 
period, the rate was higher in women who were pregnant than in women who were not 
pregnant (9.0 [4.7-13.3]/100 PY vs. 2.4 [1.7-3.0]/100 PY, respectively). In women who 
had been on ART for more than 6 months, the rate of severe LEE was 0.5 (0.4-
0.6)/100 PY. The rate was higher in women who were pregnant than in women who 
were not pregnant (2.0 [0.7-3.2]/100 PY vs. 0.4 [0.3-0.5]/100 PY, respectively) (Table 
7.15). 
Severe LEE occurred during 3.3% (18/541) of pregnancies during which ART was 
started. In women who developed severe LEE during such a pregnancy, it occurred at 
a median of 30 (IQR 27-31) weeks gestation and 9 (IQR 3-12) weeks after ART 
initiation. In pregnancies conceived on ART with severe LEE, this occurred at a median 
of 24 (IQR 11-29) weeks gestation. 
Factors associated with LEE  
Being pregnant was independently associated with an increased risk of LEE (Table 
7.16). This remained the case in further analyses limited to women conceiving on ART 
(aHR 1.91 [1.28-2.84], p=0.001). The recent CD4 count, but not the CD4 count at ART 
initiation, was associated with LEE with women who attained a CD4 count >500 
cells/mm3 having a decreased risk of LEE. Women receiving zidovudine (ZDV)-
containing regimens had a lower risk of LEE than women on ZDV-sparing regimens.  
Whilst women receiving NVP or efavirenz were at increased risk of LEE (Table 7.16), 
this risk dropped with longer exposure to the NNRTI drug class. Other factors 
independently associated with LEE were HBV/HCV co-infection and having acquired 
HIV via IDU. There was a small, but significant, increase in the risk of developing LEE 
in later calendar years. 
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Factors associated with severe LEE  
Factors associated with developing severe LEE were similar to those associated with 
developing any LEE (Table 7.17). Being pregnant was associated with an increased 
risk; this was also the case when women who started ART whilst pregnant were 
excluded (aHR 4.99 [2.55-9.80], p<0.001). Calendar year, age, and CD4 count were all 
associated with the risk of severe LEE, but there were no specific antiretroviral drugs 
which were significantly associated with severe LEE in univariate analyses. There were 
no deaths related to severe LEE. 
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Table 7.16. Results from unadjusted and adjusted Cox proportional hazards regression analyses to identify factors associated with the 
incidence of any LEE 
 Unadjusted Adjusted 
 HR (95% CI) p-value HR (95% CI) p-value 
Pregnant 1.38 (1.11-1.73) 0.004 1.66 (1.31-2.09) <0.001 
Age (per 10 year increase) 1.00 (0.92-1.08) 0.98 1.05 (0.96-1.14) 0.31 
Route of exposure Heterosexual sex Reference <0.001 Reference 0.02 
IDU 2.60 (2.00-3.37)  1.55 (1.12-2.15)  
Other/Not known 1.02 (0.78-1.33)  0.93 (0.71-1.22)  
Ethnicity Black-African Reference 0.001 Reference 0.35 
 White 1.37 (1.18-1.60)  1.17 (0.98-1.38)  
 Black-Caribbean 1.08 (0.76-1.52)  1.03 (0.73-1.46)  
 Other/Not known 1.09 (0.91-1.31)  1.08 (0.90-1.30)  
Calendar year 1.06 (1.03-1.08) <0.001 1.05 (1.03-1.08) <0.001 
HBV/HCV co-infection 2.22 (1.87-2.64) <0.001 1.85 (1.52-2.27) <0.001 
LEE at baseline 1.56 (1.21-2.01) <0.001 -  
Latest CD4 count 
(cells/mm
3
) 
≤250  
251-350 
351-500 
>500 
Not known 
Reference 
0.85 (0.70-1.04) 
0.88 (0.73-1.06) 
0.77 (0.63-0.93) 
0.62 (0.52-0.76) 
<0.001 Reference 
0.82 (0.67-0.99) 
0.83 (0.68-1.00) 
0.72 (0.59-0.87) 
0.62 (0.51-0.75) 
 
0.05 
0.05 
0.001 
<0.001 
Table 7.16 is continued on the next page 
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Table 7.16 continued. Results from unadjusted and adjusted Cox proportional hazards regression analyses to identify factors associated with 
the incidence of any LEE 
 Unadjusted Adjusted 
 HR (95% CI) p-value HR (95% CI) p-value 
CD4 count at ART start 
(cells/mm
3
) 
≤250  
251-350 
351-500 
>500 
Not known 
Reference 
0.74 (0.57-0.96) 
0.73 (0.58-0.92) 
0.66 (0.53-0.82) 
0.81 (0.65-1.01) 
0.004 -  
Latest viral load 
(copies/ml) 
≤50  
>50  
Reference 
0.88 (0.74-1.04) 
 
0.13 
-  
Viral load at ART start 
(copies/ml) 
≤100,000  Reference  -  
>100,000 0.88 (0.70-1.10) 0.25   
ART drug in regimen 
 
 
Zidovudine 0.68 (0.59-0.79) <0.001 0.73 (0.62-0.85) <0.001 
Efavirenz 1.00 (0.88-1.14) 0.52 1.26 (1.07-1.48) 0.005 
Nevirapine 1.02 (0.88-1.18) 0.77 1.54 (1.27-1.87) <0.001 
Raltegravir 1.88 (1.14-3.08) 0.01 -  
Duration on ART (per additional year) 1.03 (0.95-1.12) 0.43 -  
Duration on PI regimen 1.07 (1.03-1.11) 0.001 -  
Duration on NNRTI regimen 0.94 (0.91-0.98) 0.004 0.90 (0.86-0.95) <0.001 
Duration on NRTI regimen 1.10 (0.98-1.24) 0.11 -  
ALT: alanine transaminase; HBV: hepatitis B; HCV: hepatitis C; HR: hazard ratio; IDU: injecting drug use; IQR: interquartile range; LEE: liver enzyme elevation; NNRTI: non-
nucleoside reverse transcriptase inhibitor; NRTI: nucleoside/nucleotide reverse transcriptase inhibitor; PI: protease inhibitor; ULN: upper limit of normal. Adjusted by covariates 
in the table with aHR presented.   
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Table 7.17. Results from unadjusted and adjusted Cox proportional hazards regression analyses to identify factors associated with the 
incidence of severe LEE 
 Unadjusted Adjusted 
 HR (95% CI) p-value HR (95% CI) p-value 
Pregnant 3.68 (2.40-5.64) <0.001 3.57 (2.30-5.54) <0.001 
Age (per 10 year increase) 0.74 (0.60-0.91) 0.005 0.77 (0.61-0.98) 0.04 
Route of exposure Heterosexual sex Reference 0.09 Reference 0.16 
IDU 1.70 (0.79-3.63)  1.16 (0.46-2.93)  
Other/Not known 0.37 (0.12-1.16)  0.33 (0.10-1.06)  
Ethnicity Black-African Reference 0.60 Reference 0.58 
 White 1.26 (0.84-1.90)  1.31 (0.84-2.04)  
 Black-Caribbean 0.86 (0.32-2.34)  0.84 (0.31-2.28)  
 Other/Not known 0.89 (0.53-1.48)  0.91 (0.54-1.53)  
Calendar year at baseline 1.04 (0.99-1.10) 0.13 1.06 (1.00-1.12) 0.05 
HBV/HCV co-infection  1.64 (1.00-2.68) 0.05 1.55 (0.88-2.73) 0.13 
LEE at baseline 1.19 (0.59-2.43) 0.63 -  
Latest CD4 
count 
(cells/mm
3
) 
≤250  
251-350 
351-500 
>500 
Not known 
Reference 
0.61 (0.34-1.09) 
1.01 (0.63-1.62) 
0.66 (0.39-1.12) 
0.65 (0.39-1.08) 
0.14 Reference 
0.51 (0.29-0.91) 
0.77 (0.48-1.24) 
0.30 (0.30-0.84) 
0.57 (0.35-0.95) 
 
0.02 
0.28  
0.01 
0.03 
Table 7.17 is continued on the next page. 
 2
7
7
 
 278 
 
 
Table 7.17 continued. Results from unadjusted and adjusted Cox proportional hazards regression analyses to identify factors associated with 
the incidence of severe LEE 
 Unadjusted Adjusted 
 HR (95% CI) p-value HR (95% CI) p-value 
CD4 count at 
ART start 
(cells/mm
3
) 
≤250  
251-350 
351-500 
>500 
Not known 
Reference 
1.11 (0.69-1.78) 
1.19 (0.63-2.25) 
0.91 (0.40-2.10) 
1.02 (0.69-1.51) 
0.97 -  
Latest viral load 
(copies/ml) 
≤50  
>50  
Reference 
0.94 (0.60-1.47) 
 
0.79 
-  
Viral load at ART 
start (copies/ml) 
≤100,000  Reference  -  
>100,000 1.01 (0.67-1.51) 0.96   
ART drug in 
regimen 
 
 
Zidovudine 0.84 (0.59-1.20) 0.33 -  
Efavirenz 0.75 (0.53-1.07) 0.12 -  
Nevirapine 0.91 (0.61-1.36) 0.63 -  
Raltegravir 2.42 (0.78-7.60) 0.13 -  
Duration on ART (per 1 year increase) 0.92 (0.76-1.11) 0.38 -  
Duration on PI regimen 1.10 (0.98-1.24) 0.10 -  
Duration on NNRTI regimen 0.89 (0.80-1.00) 0.05 -  
Duration on NRTI regimen 0.95 (0.69-1.31) 0.75 -  
ALT: alanine transaminase; HBV: hepatitis B; HCV: hepatitis C; HR: hazard ratio; IDU: injecting drug use; IQR: interquartile range; LEE: liver enzyme elevation; NNRTI: non-
nucleoside reverse transcriptase inhibitor; NK: not known; NRTI: nucleoside/nucleotide reverse transcriptase inhibitor; PI: protease inhibitor; ULN: upper limit of normal. 
Adjusted by covariates in the table with adjusted HR presented.   
2
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Sensitivity analyses 
Pregnancy remained associated with an increased risk of LEE and severe LEE when 
the analyses included only the 982 women who had a pregnancy during follow-up. 
Pregnancy was independently associated with an increased risk of LEE (aHR 2.03 
[1.52-2.72], p-value <0.001) and with an increased risk of severe LEE (aHR 5.97 [3.12-
11.42], p-value <0.001). Overall, 271 (27.6%) women developed LEE and 49 (5.0%) 
women developed severe LEE. 
The main findings were not changed when only the 3274 women who were not 
pregnant when they started ART were included. Pregnancy (as a time-updated 
variable) was independently associated with an increased risk of LEE (aHR 1.91 [1.28-
2.84], p-value 0.001) and with an increased risk of severe LEE (aHR 4.37 [2.15-8.88], 
p-value <0.001).  
Taking into account the fall in ALT which occurs during pregnancy did not change the 
main findings of the analysis. Pregnancy (as a time-dependent variable) was 
independently associated with an increased risk of LEE (aHR 2.01 [1.62-2.50], p-value 
<0.001) and with an increased risk of severe LEE (aHR 3.86 [2.44-6.12], p-value 
<0.001). Overall, 1095 (28.7%) women developed LEE and 152 (4.0%) women 
developed severe LEE.  
The main findings were unaltered when women with no baseline ALT measurement 
were excluded. In the main analyses these women (n=1856) were categorised as 
having no evidence of LEE at baseline. 
I undertook an additional analysis comparing the risk of LEE in pregnant women who 
conceived on ART (n=280) with the risk in non-pregnant controls on ART (n=474). For 
this I used a Cox proportional hazards model to calculate crude hazard ratios (aHRs). 
The pregnant women were similar to controls with regard to: calendar year; age; 
ethnicity; exposure group; previous pregnancy (dichotomised as yes/no); CD4 count 
category and type of ART regimen used. The full results of the analysis are not 
presented. In brief, where LEE was defined as ALT ≥50 IU/L (40 IU/L x1.25) outside 
pregnancy and ALT ≥40 IU/L (32 IU/L x1.25) in pregnancy, the risk of LEE was similar 
in both groups (hazard ratio (HR) 0.82 [0.54-1.25], p-value 0.36). The risk of severe 
LEE (defined as ALT >200 IU/L (40 IU/L x5) outside pregnancy and ALT >160 IU/L (32 
IU/L x5) in pregnancy), was higher in the pregnant women than in the controls (HR 
3.09 [1.03-9.21], p-value 0.04). The analysis was limited to the duration of pregnancy, 
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to women who conceived on ART and, despite using controls similar to the pregnant 
women, not all differences between the groups could be accounted for. 
 
Treatment switches and interruptions among women with LEE 
Among women who developed LEE, 5.9% (64/1080) stopped/interrupted ART and 
12.0% (n=130) switched regimen at a median of 44 (15-69) and 24 (9-50) days after 
LEE diagnosis respectively. The percentage who altered their regimen was 14.8% 
(122/826) among women with ALT 50-100 IU/L, 21.0% (34/162) among women with 
ALT 101-200 IU/L and 41.3% (38/92) among women with ALT >200 IU/L (global 
p<0.001). 
Women who developed LEE in pregnancy were more likely to stop/interrupt their 
regimen or switch their regimen than women who were not pregnant when they 
developed LEE (stop/interrupt regimen: 23.9% [21/88] vs. 4.3% [43/992] respectively, 
odds ratio [OR] 6.92 [3.88-12.33], p<0.001; switch regimen: 21.6% [19/88] vs. 11.2% 
[111/992], respectively, OR 2.19 [1.27-3.78], p=0.005).  
Among the 21 women who developed LEE in pregnancy and then stopped/interrupted 
ART, 20 stopped at delivery or postpartum and one interrupted ART during pregnancy. 
This woman conceived on an efavirenz-containing regimen, interrupted ART in the first 
trimester and started a ZDV-containing regimen in the second trimester. Among the 19 
women who developed LEE in pregnancy and then switched regimen, 17 switched 
during pregnancy, in the first (n=4), second (n=7) or third trimester (n=6), and 2 
switched postpartum. 
Among women who developed severe LEE, 13.3% (20/151) stopped/interrupted ART 
and 25.2% (n=38) switched regimen within 90 days at a median of 41 (17-50) days and 
23 (6-51) days, respectively, after the elevated ALT measurement. The difference in 
the percentage of women who altered their regimen among women who developed 
severe LEE in pregnancy and women who developed severe LEE whilst not pregnant 
was not statistically significant (stop/interrupt regimen: 22.2% [6/27] vs. 11.3% [14/124] 
respectively, OR 2.25 [0.78-5.41]; switch regimen: 25.9% [7/27] vs. 25.0% [31/124], 
respectively, OR 1.05 [0.41-2.72]). 
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7.4 Discussion 
The availability of ALT data in UK CHIC  
The number of women included in each ALT analysis was limited by the fact that 
almost half the women in UK CHIC had no ALT data in the dataset. This was also true 
for one-quarter of women with a pregnancy. This meant that, for some analyses, there 
was insufficient statistical power to measure differences between groups due to small 
numbers.  
White ethnicity, having hepatitis B or C, and acquiring HIV through sharing injecting 
drug equipment were all characteristics predictive of having any ALT data in the 
dataset and therefore predictive of inclusion in ALT analyses. These characteristics 
were also associated with having a higher ALT in the mixed effects regression model. 
This is a consequence of the UK CHIC study being an observational study; LFTs are 
performed as part of routine monitoring but they are also performed where indicated. 
Therefore, women at greater risk of, or with clinical indication for, hepatic dysfunction 
have more regular monitoring of ALT. An increase in the frequency of ALT monitoring 
is likely to increase the detection rate of raised ALT. Closer monitoring of higher risk 
groups is likely to result in an overestimation of the median ALT and in the incidence of 
LEE and severe LEE (in the final analysis) in groups which are monitored more closely. 
Increased monitoring in higher risk groups is the likely explanation for why women with 
a pregnancy during follow-up were less likely to have any ALT data compared to 
women without a pregnancy, since the characteristics associated with having a higher 
ALT (HBV/HCV co-infection, white ethnicity and HIV infection via IDU) are 
characteristics negatively associated with having a pregnancy among women living 
with HIV (Chapter 5).  
During antenatal care, liver enzymes are closely monitored, even among women with a 
low risk of liver dysfunction, because a rise in some liver enzymes can indicate 
obstetric complications such as pre-eclampsia and obstetric cholestasis. In pregnancy, 
women typically have a minimum of three LFTs (at first antenatal visit, 20 weeks and 
36 weeks gestation) compared to one every 6 months outside pregnancy (in women 
stable on treatment) [169]. This is probably why, among women with any ALT data, 
women who were pregnant had, on average, more ALT measurements than their non-
pregnant counterparts (Table 7.6, Page 257). 
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Median ALT during pregnancy  
In preliminary analysis, where each ALT measurement was taken as an independent 
observation, the median ALT was 6 IU/L lower in pregnancy than at other times (15 vs. 
21 IU/L). In the mixed effect regression model, pregnancy decreased ALT by 3.3 IU/L 
in the adjusted analysis, or 4.5 IU/L in crude analysis (Table 7.11, Page 264). These 
values are lower than the 8 IU/L difference between the upper limit of the reference 
ranges used in clinical practice inside and outside of pregnancy (ALT 32 IU/L vs. 40 
IU/L, respectively) [339]. This would suggest that the creation of a reference range 
inside and outside of pregnancy specific to individuals living with HIV in the UK would 
be beneficial to clinicians and their patients.  
The comparison of ALT levels in pregnant and non-pregnant women was achieved by 
developing a repeatable method which allowed non-pregnant controls to be found and 
selected at random from the dataset using SAS. The variables used to find controls 
could be specified according to the requirements of the analysis, and as such the 
strategy was later adapted for use in the analysis of postpartum viral rebound (Chapter 
8).  
Whilst small variations in median ALT were observed over time in the non-pregnant 
controls, there was an obvious drop in ALT during the first two trimesters of pregnancy, 
with ALT plateauing in the third trimester and returning to pre-pregnancy levels by 3-6 
months after delivery (Figure 7.2, Page 258). A similar pattern was observed in 
pregnancy among women with HBV/HCV co-infection, who had, on average, higher 
ALT levels. This drop in ALT during pregnancy is thought to be a consequence of 
plasma volume expansion (PVE) rather than liver pathology [342, 348] and has 
previously been documented among HIV-negative pregnant women [339, 343, 346]. A 
change in CD4 count was also observed among women during pregnancy (Figure 7.4, 
Page 262), although to a lesser extent. This too has previously been reported [483]. 
Since the fall in ALT in pregnancy is thought to be a consequence of physiological 
rather than pathological changes it is unlikely to have any implications for the woman’s 
health. However, ignoring changes in ALT which occur during normal pregnancy could 
mean that LEE and severe LEE are underestimated or overlooked in pregnancy. 
Clinicians should be mindful that a lower ALT threshold is more appropriate during 
pregnancy and further work is needed to examine normal changes in ALT during 
pregnancy among HIV-positive women. 
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Characteristics associated with ALT  
Women with a prior pregnancy had ALT levels, on average 1 IU/L lower than women 
who had not previously had a pregnancy. This small difference in ALT was statistically 
significant (p-value <0.001) but not clinically relevant. Women infected with HIV 
through sharing injecting drug equipment had a higher mean ALT than women infected 
via heterosexual sex, (whilst adjusting for HBV/HCV co-infection) perhaps due to 
undiagnosed HBV/HCV infection among women who had injected drugs. 
ALT after delivery  
There was some evidence of a temporary peak in ALT, above pre-pregnancy levels, 
following delivery (Figure 7.5, Page 266). This post-partum overshoot in ALT, may be 
due to a temporary increase in serum ALT immediately after delivery, has been 
observed in other studies [343, 346, 349] and was also seen, to a lesser extent, in the 
postpartum CD4 count (Figure 7.4, Page 262). However, in women who conceived on 
ART (and remained on ART after delivery), ALT swiftly returned to pre-pregnancy 
levels with little or no peak in ALT after delivery (Figure 7.2, Page 258 and Figure 7.5, 
Page 266). This indicates that the temporary peak in ALT is not only a result of 
physiological changes occurring after delivery, since these would affect all postpartum 
women. The number of women with postpartum ALT data was small (only 174 women 
who conceived their index pregnancy whilst on ART had ALT data for 0-3 months 
postpartum). Further analysis with a larger sample size and where LFTs are performed 
according to a schedule is required to gain a clearer understanding of postpartum ALT 
changes and the clinical implications of such changes.  
LEE in pregnancy  
When the proportion of women with ALT above the ULN, i.e. raised liver enzymes, was 
compared in pregnant women and non-pregnant controls, a smaller proportion of 
pregnant women had raised liver enzymes than non-pregnant women (Figure 7.3 Page 
260 and Table 7.8, Page 259). This reflects the small drop in ALT during pregnancy 
previously discussed. When the Cox proportional hazards models were used, 
pregnancy was found to be independently associated with an increased risk of LEE 
and severe LEE. The overall rates of LEE and severe LEE in HIV-positive women on 
ART were 6.3/100 and 0.7/100 PY respectively. The rate of severe LEE was lower than 
in a study of pregnant and non-pregnant women in Côte d'Ivoire who started NVP-
containing regimens (2.2 [1.1-4.0]/100 PY) [220], but Côte d'Ivoire is a very different 
setting from the UK. No other studies have reported LEE rates. In our study, LEE and 
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severe LEE developed during 11.6% and 3.3% of pregnancies during which ART had 
been initiated, lower than percentages reported among pregnant women starting NVP-
containing regimens [316, 321] but similar to pregnant women starting nelfinavir-
containing regimens [316] or when only a small proportion of women start NVP-
containing regimens [318]. 
The initial period on ART is a time of increased toxicity risk. This was supported by the 
results here, where half of the 30% of women who developed LEE within 5 years did so 
within the first year. Therefore, it is to be expected that some of the women who were 
pregnant when starting ART would develop LEE. However, the results suggest that 
pregnancy itself confers an additional risk of 70% for LEE (a 1.7-fold increase in risk) 
and 260% (a 3.6-fold increase in risk) for severe LEE. The increase in risk was 
apparent both in women who had recently started ART and women who had been on 
treatment for more than six months (Table 7.15, Page 272). 
Some previous cross-sectional studies also adjusting for factors associated with LEE, 
failed to observe an association between LEE and pregnancy [318, 320, 358]. These 
only assessed pregnancies during which ART was started and had a short follow-up. In 
my study and in a US study [317], which also observed an association between 
pregnancy and LEE, pregnancies conceived on ART were included. In my study 
women acted as their own controls by contributing data when pregnant and when not 
pregnant. Pregnancy remained associated with LEE and severe LEE in sensitivity 
analysis when women with no pregnancy during follow-up were excluded supporting 
the idea that it is being pregnant which increases the risk of LEE rather than any 
differences between women who had a pregnancy and women who did not. 
In sensitivity analysis, when the fall in ALT due to PVE in pregnancy was taken into 
account, pregnancy remained associated with LEE and severe LEE. No previous 
studies assessing the association between pregnancy and LEE accounted for the fall in 
median ALT during pregnancy. Previous studies which did not observe an association 
between pregnancy and LEE may have had a different outcome if the ALT threshold for 
defining LEE differed according to pregnancy status [220, 318, 320, 358]. In studies 
which found an increased risk of LEE in pregnancy, but which ignored pregnancy 
status when defining LEE, the risk of LEE in pregnancy may have been underestimated 
[317]. 
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Reasons for the increased risk of LEE in pregnancy  
The mechanism by which pregnancy could increase susceptibility to ART-induced 
hepatotoxicity is not clear and may differ by ART drug [326]. The biological 
mechanisms which increase susceptibility to liver dysfunction during pregnancy in other 
diseases, such as hepatitis E or hepatic vein thrombosis, including those unique to 
pregnancy, such as obstetric cholestasis, are diverse and poorly understood.  
As ALT is a biomarker used to indicate hepatocellular injury, LEE does not equate to 
ART-induced hepatotoxicity. In pregnancy, LEE could be a result of obstetric 
complications. However, obstetric complications, such as pre-eclampsia, typically occur 
in late pregnancy, whereas in this study, LEE occurred in the first half of pregnancy 
among women already on ART. Also, the rate of LEE was higher than would be 
anticipated due to obstetric complications; a study of non-HIV-positive pregnant women 
observed liver dysfunction in 3% of pregnancies [336] which is thought to be similar in 
HIV-positive pregnant women [355]. 
Other factors associated with LEE  
HBV/HCV infection can lead to LEE and is associated with an increased risk of ART-
induced hepatotoxicity [326]. In our setting, HBV/HCV co-infection increased the risk of 
LEE 1.9-fold and severe LEE 1.6 fold. The latter association was not statistically 
significant; probably due to insufficient statistical power, since only 18 women with 
HBV/HCV co-infection developed severe LEE.  
There was a small but statistically significant increase in risk of LEE and severe LEE 
with increasing calendar year. This is unlikely to be due to changes in ALT monitoring 
since monitoring did not increase overall or in women starting treatment. It could be 
due to changes in variables not measured by UK CHIC but known to affect ALT such 
as BMI, alcohol consumption, co-medication or use of illicit drugs [313].  
To minimize hepatotoxicity risk, NVP-containing regimens are not recommended for 
individuals starting ART with CD4 >250 cells/mm3 [84]. In our study, where one-fifth of 
women were receiving an NVP-containing regimen, higher CD4 count category, as a 
time-dependent variable, was associated with a lower risk of LEE and severe LEE, 
which counters the evidence that starting ART with CD4 count >250 cells/mm3 
increases the risk of NVP-induced hepatotoxicity [240, 320], although other studies 
have not found such an association [239, 358].  
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Treatment switches and interruptions after LEE 
As anticipated, the proportion of women who altered their ART regimen following LEE 
was higher the more severe the elevation was. It is not surprising that women who 
experienced LEE in pregnancy were more likely to stop/interrupt treatment than women 
who experienced LEE outside pregnancy, since many of the pregnant women would 
have planned to stop ART at delivery irrespective of LEE. The woman who interrupted 
ART during pregnancy probably did so to avoid using efavirenz [477]. Switching 
regimens can cause disruption and increased the risk of viral rebound and therefore 
vertical transmission. It is concerning that pregnant women with LEE had twice the 
odds of switching regimen compared to women with LEE outside pregnancy.  
Limitations 
No data were collected by either study on body mass index (BMI) or body fat 
distribution, variables which are strongly predictive of ALT levels [484]. This was also 
true for alcohol consumption, the use of hormonal contraceptives, other medications 
(other than ART) or illicit/recreational drug use. These variables are important 
confounders when studying toxicity and should be included in any future studies 
assessing ALT levels in pregnancy. 
The characteristics of women more closely monitored were negatively associated with 
having a pregnancy, so if anything, this would increase the detection rate of LEE in 
non-pregnant women. On the other hand, there may be an increased detection rate of 
LEE in pregnancy due to more regular monitoring of liver enzymes. This was not the 
case for women who recently started ART - the median number of ALT measurements 
was the same in and outside pregnancy. This is because all women starting ART are 
recommended to have LFTs performed at 2-4 weeks and 3 months after starting ART, 
irrespective of pregnancy status (women starting an NVP-containing regimen are 
recommended more regular LFTs; every fortnight during the first 2 months and then at 
3 months after starting ART) [84].  
For the analysis of median ALT in women who conceived on ART and in women who 
started ART in pregnancy (Table 7.12, Page 267 and Figure 7.5, Page 266) it was 
important to categorise the reason for ART use in pregnancy (i.e. PMTCT or mother’s 
health). This categorisation is not straightforward and in an attempt to simplify the 
method described in Chapter 4 a 20 week cut-off was used reflecting treatment 
guidelines at the time [169]. ART use was categorised as starting life-long ART for the 
woman’s health if it was started at <20 weeks gestation or as short-course ART for 
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PMTCT if it was started at ≥20 weeks gestation. However, examining ART use among 
the women who were categorised into each group showed that using this cut-off was 
somewhat flawed. One-fifth of women categorised as starting life-long ART, actually 
stopped ART in the first three months after delivery and more than half the women 
thought to have used short-course ART remained on ART for at least 3 months after 
delivery. In some cases there was also a discrepancy in the timing of ART use in the 
NSHPC and UK CHIC data. 
The clinical consequences of LEE in pregnancy 
The clinical consequences of LEE are not clear; few women developed severe LEE 
(2% of pregnancies and 0.7% of women) and none experienced liver failure. Women 
experiencing LEE may have symptoms including rash, nausea, vomiting, pain or 
diarrhoea or have no symptoms. Due to the risk of viral rebound, treatment changes 
are not recommended where toxicity is mild but there is currently no agreement on how 
to manage pregnant women who develop LEE whilst on ART. Close monitoring of liver 
biomarkers and any symptoms of toxicity, including rashes is important during 
antenatal care [168]. Particularly with severe LEE, further tests are required since LEE 
could indicate obstetric complications. Clearer guidance is required for clinicians caring 
for pregnant women on ART as to the best course of action when LEE occurs.   
Key points from this chapter 
 Approximately half the women in the UK CHIC study had some ALT data 
reported for the period 2000-2011.  
 Factors predicative of women having ALT data in UK CHIC were dissimilar to 
those predictive of having a pregnancy. Even after accounting for these 
differences, women who had a pregnancy were less likely to have any ALT data 
in UK CHIC compared to women who did not have a pregnancy.  
 Within the study population, the median ALT fell by 3-5 IU/L during pregnancy, 
returning to the pre-pregnancy level within a few months of delivery. This fall 
occurred in the first two trimesters.  
 The risk of LEE and severe LEE was raised in pregnancies conceived on ART 
and in pregnancies during which ART was started even when the temporary 
drop in ALT during pregnancy was taken into account.   
 Pregnant women who experienced LEE had two times the odds of switching 
regimen than women who experienced LEE outside pregnancy. 
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Chapter 8 Post-pregnancy viral rebound in women 
on suppressive antiretroviral therapy at delivery 
 
8.1 Introduction  
Viral rebound generally occurs rapidly following cessation of antiretroviral therapy 
(ART) including discontinuation of short-course ART after delivery [132, 197, 381, 382]. 
Postpartum increases in viral load have also been observed in women who remain on 
ART, even when viral suppression was achieved in pregnancy [374, 376, 382].  
In this chapter I assess the risk of viral rebound following pregnancy in women who are 
virally suppressed at delivery by comparing the risk of viral rebound in post-pregnant 
women with the risk in non-pregnant women who have not recently had a pregnancy 
(controls). One of my initial intentions was to assess viral rebound immediately after 
delivery. However, if women did experience a short-term peak in viral load immediately 
after pregnancy it was unlikely to be captured in the data, since the median time to first 
viral load assessment was 49 days after delivery. Therefore, since the availability of 
viral load data in the first 3 months postpartum was insufficient for such an analysis, the 
analysis was revised to consider the risk of viral rebound in the 12 months after 
pregnancy. The findings from this chapter were published in 2015 (Appendix IIe) [415].  
 
8.2 Methods  
The aims of this chapter were:  
1) To assess the availability of HIV-RNA data during pregnancy and post-pregnancy in 
women in UK CHIC and in the UK CHIC-NSHPC combined dataset.  
2) To identify factors associated with viral rebound in the post-pregnancy year in 
women virally suppressed at delivery.  
3) To compare the risk of viral rebound during the post-pregnancy year with the risk at 
other times outside pregnancy, stratified by when ART was started.  
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 Assessing the availability of viral load data 8.2.1
The dataset contained UK CHIC data for all women reported to UK CHIC and NSHPC 
data for those with a pregnancy. Data to 31st December 2012 were analysed.  
Both studies collect viral load data. The NSHPC aims to collect two viral load 
measurements per pregnancy, the first measurement taken during pregnancy and the 
second measurement ‘near delivery – just before delivery if possible’ (Appendix IIIa 
and Appendix IIIb). UK CHIC collects date and outcome of all viral load measurements 
performed as part of HIV clinical care (Appendix IV). Viral load data from both studies 
were examined. When assessing the number of viral load measurements for a given 
period, if a viral load measurement was reported to both studies on the same day it 
was only counted once. 
  
 Identifying factors associated with viral rebound in the post-pregnancy 8.2.2
year 
Inclusion criteria 
Pregnancies in women aged 16 and older, resulting in a live birth in 2006-2011 were 
included in the analysis, allowing at least one year of post-pregnancy follow-up. 
Women with repeat pregnancies during this period were included in the analysis 
multiple times. If, during the 12 months following delivery, a woman became pregnant 
again, the data were censored on the estimated date of conception (EDC) of the 
second pregnancy. Pregnancies were only included in the analysis if at least one viral 
load measurement was available in the UK CHIC data in the post-pregnancy year, 
indicating that the woman had received HIV-clinical care at a UK CHIC site during that 
period.  
Since the outcomes might differ according to the type of pregnancy (i.e. index or non-
index), in sensitivity analysis, only a woman’s first pregnancy meeting the criteria was 
included. In a second sensitivity analysis, only a woman’s last pregnancy meeting the 
criteria was included.  
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Categorising the type of ART used in pregnancy 
The NSHPC and UK CHIC data were used to assess whether each woman was on 
ART at conception, during pregnancy, at delivery and in the six months following 
pregnancy. Data relating to ART use in UK CHIC were compared with data in the 
NSHPC. This comparison is included in the results section. There were some 
discrepancies between whether women were on ART or not according to UK CHIC and 
the NSHPC (82 pregnancies had a discrepancy at conception and 53 at delivery). 
Where there was a discrepancy, a woman was categorised as being on ART if data 
from only one study indicated that she was on ART but the other did not.  
The type of ART use was categorised according to ART use at conception, delivery 
and 6 months post-pregnancy and was categorised as follows: 
 Continuing use of life-long ART – the woman conceived on ART and was still 
on ART 6 months after delivery.  
 Short-course ART for the prevention of mother-to-child-transmission (PMTCT) – 
the woman started ART during her pregnancy and stopped (for at least 30 
days) within 6 months of delivery.  
 Starting life-long ART in pregnancy – the woman did not conceive on ART, but 
started ART during pregnancy and was still on ART 6 months after delivery.   
This strategy was used rather than the more complex strategy described in Chapter 4 
or the simplified strategy of using 20 weeks gestation as a cut-off to indicate life-long or 
short-course ART use, as was used in Chapter 7. The method used in Chapter 7 was 
not used here because although women starting ART in the second half of pregnancy 
could be assumed to be starting short-course ART, closer examination of the data 
showed that this was not always the case. The NSHPC also captures data on the 
reason for ART use in pregnancy (i.e. for PMTCT only or for the mother’s health), a 
variable which is underreported. Where it was reported, the results were compared with 
the ART categorisation using the ART data in UK CHIC and the NSHPC. 
Statistical analysis 
Kaplan-Meier analyses were used to assess the cumulative probability of viral rebound 
within 12 months of delivery. Due to the limited number of viral load measurements in 
this period, viral rebound was defined as a single measure of HIV-RNA >200 copies/ml. 
The analysis started on the first day after delivery. Follow-up was censored if the 
woman died, became pregnant again or at 12 months after delivery, whichever 
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occurred first. Cox proportional hazards models were used to calculate the crude and 
adjusted hazard ratios viral rebound (aHRs) of viral rebound (SAS command PROC 
PHREG). In unadjusted analysis the baseline characteristics assessed included: CD4 
at conception and delivery, type of ART regimen and type of ART use (as described 
above). Other variables assessed included age, hepatitis B virus (HBV)/hepatitis C 
virus (HCV) infection, ethnicity and exposure group. All variables were included in the 
adjusted model.  
In a secondary analysis, Kaplan-Meier analysis was used to assess the cumulative 
probability of viral rebound only when ART was being used. For this analysis, follow-up 
was also censored at the point that ART was interrupted. 
 
 Comparing the risk of viral rebound in post-pregnant women and 8.2.3
controls 
The risk of viral rebound in the post-pregnancy year was compared with the risk at 
other times outside pregnancy among women on ART. This was done by comparing 
the risk of viral rebound in post-pregnant women (women with a pregnancy in the 
previous year) with the risk in controls (women who had not been pregnant in the 
previous year). Post-pregnant women were stratified by when they had started life-long 
ART (before or during the pregnancy) and controls were selected who had been on 
ART for a similar duration.  
Selecting cases 
Women were included in the analysis if they had a pregnancy resulting in a live birth in 
2006-2011, an HIV-RNA ≤50 copies/ml at latest viral load ≤3 months before delivery 
and they remained on cART (use of ≥3 ART drugs) for ≥6 months after delivery. 
Women with at least one viral load measurement in the year after delivery were 
included and only a woman’s earliest pregnancy meeting the criteria was included.  
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Analysis-specific criteria for selecting controls 
The criteria used to select suitable controls were: 
Analysis1:  Women continuing on life-long ART throughout pregnancy and after 
delivery: 
Pregnant women and controls were matched using age (year), calendar 
year and the number of years since starting their most recent period of ART 
use.  
Analysis 2: Women starting life-long ART in pregnancy:  
Pregnant women and controls were matched using age (grouped as: 16-19; 
20-24; 25-29; 30-34; 35-39; 40-44; 45-49 years), two year calendar period 
(grouped as: 2006-2007; 2008-2009; 2010-2011), number of months since 
starting treatment (grouped as: 0 -<3; 3-<6; 6-<9 months) and CD4 count 
when starting treatment (grouped as: ≤200; 201-350; 351-500; >500 
cells/µl).  
For Analysis 2, age and year intervals were used rather than the exact age or year. 
This was to maximise the number of controls available for this analysis, where controls 
must recently have started life-long ART.  
Differences in other characteristics were accounted for in adjusted analyses.  
Selecting controls 
Two controls were sought for each post-pregnant woman using a strategy adapted 
from that described in Chapter 7.  
Analysis 1:  In order to find controls for women who were already on life-long ART 
when they conceived, the period 2006-2011 was spilt into 3 month 
intervals creating 24 reference dates. The same woman could be used 
as a control multiple times, but only for non-overlapping periods of time.  
Analysis 2:  In order to find controls for women who started life-long ART during their 
pregnancy, the period 2006-2011 was split into 1 month intervals 
creating 72 reference dates. Women could only be used as a control 
once, since women could only be used as a control when they had 
recently started treatment.  
On each of the reference dates the characteristics of each woman in UK CHIC were 
assessed. The characteristics that were considered were: previous and current 
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pregnancy status; latest CD4 count (in the previous 6 months); latest viral load (in the 
previous 6 months); as well as the variables used for selecting controls. Women were 
only eligible to act as a control when they were not pregnant and had not been 
pregnant in the previous year. The pregnancy status in the subsequent year was not 
considered. Women acting as a control also had to have undetectable viral load (HIV-
RNA ≤50 copies/ml) at their latest viral load measurement, remain on ART for at least 6 
months, and have at least one viral load measurement in the year following the 
reference date, indicating that they attended HIV-clinical care. For controls, the 
reference date was used as the pseudo delivery date. 
Statistical analysis 
Initially, the number of viral load measurements in the 12 month follow-up was 
assessed. Characteristics of post-pregnancy women and controls were compared 
using the Chi-squared test for categorical variables and Kruskal-Wallis test for 
continuous (non-Normally distributed) variables. 
The primary outcome was viral rebound (defined as a single measure of HIV-RNA 
>200 copies/ml) within 12 months of the delivery (post-pregnant women) or pseudo-
delivery (controls). In sensitivity analysis, viral rebound was defined as a single 
measure of HIV-RNA >1000 copies/ml. Kaplan-Meier analysis was used to assess the 
cumulative probability of viral rebound and Cox proportional hazards models to 
calculate crude and adjusted hazard ratios (HRs). As the Kaplan-Meier analyses 
suggested that hazards were likely to diverge after 3 months, separate models are 
presented for the periods <3 months and 3-12 months post-delivery/pseudo-delivery, 
with the latter model including only women who had not experienced viral rebound and 
whose follow-up had not been censored during the first three month period. In 
unadjusted analyses, the baseline characteristics assessed were: post-pregnancy 
status (post-pregnancy/control), CD4 count category, type, duration and number of 
drugs in the ART regimen (where ritonavir was not counted as an additional drug when 
it was used to boost a protease inhibitor (PI) regimen), parity (the number of live births 
since HIV diagnosis), HBV/HCV co-infection, ethnicity and exposure group. Follow-up 
was censored at 12 months post-delivery/pseudo-delivery, if a woman died, interrupted 
ART, or became pregnant again, whichever occurred first. 
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8.3 Results  
 Availability of viral load data  8.3.1
Availability of viral load data among women in UK CHIC 
There were a total of 247,496 viral load measurements in the UK CHIC 2012 dataset 
for the period 2000-2012 (women only). Of the women who attended HIV care during 
that period, 96% (12,001/12,458) had ≥1 viral load measurement during that time. For 
women with ≥1 viral load measurement, the median number of measurements per 
woman was 15 (interquartile range [IQR] 5-30, range 1-118) and the median interval 
between measurements was 3.0 (IQR 1.8-4.1) months.  
Availability of viral load data in pregnancy 
In the UK CHIC-NSHPC 2012 combined dataset, there were 4100 pregnancies 
resulting in a live birth in 2000-2012 among 2889 women; 1910 women had a single 
pregnancy and 979 had two or more (up to five) pregnancies. The majority of these 
pregnancies (98%, n=4028) had ≥1 viral load measurement during the pregnancy in 
either the NSHPC or UK CHIC; 95% (n=3911) had ≥1 measurement reported to the 
NSHPC and 86% (n=3534) had ≥1 measurement in the UK CHIC dataset. The median 
number of viral load measurements in pregnancy was 4 (IQR 3-6) among women with 
≥1 viral load measurement (Table 8.1). The percentage of pregnancies with a viral load 
measurement from the third trimester was high (89%, n=3638 overall). This is of 
interest because the latest viral load measurement from the third trimester was used in 
later analyses to assess whether women had undetectable viral load at delivery. 
The period of time prior to pregnancy of the same duration as the pregnancy was 
examined (the median duration of pregnancy being 37 (IQR 36-38) weeks). For 
pregnancies in which at least one viral load measurement was performed (and 
reported), just over half (55% 1953/3534) had at least one viral load measurement 
performed in the period before the pregnancy. In other words, these women attended 
HIV clinical care before and during pregnancy. When only women who were already 
diagnosed with HIV prior to their pregnancy were included, 80% [1935/2428] had at 
least one viral load measurement performed in the (roughly) nine months prior to the 
pregnancy. In pregnancies during which at least one viral load measurement was 
performed, 83% (n=3534) had at least one viral load measurement during the same 
duration of time after the pregnancy. Among pregnancies in which at least one viral 
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load measurement was available, the median number of viral load measurements was 
2 (IQR 2-3), 4 (3-6) and 2 (1-3), in the periods (of the same duration) before, during 
and after pregnancy.  
Availability of post-pregnancy viral load data 
Viral load measurements reported to UK CHIC and the NSHPC were examined in the 
12 months post-pregnancy. Although many of the viral load measurements reported to 
the NSHPC were also found in the UK CHIC dataset, the percentage of women with ≥1 
viral load measurement in the 12 months post-pregnancy was slightly higher when data 
from both datasets were considered than when only UK CHIC data was considered 
(UK CHIC-NSHPC dataset: 80% vs. UK CHIC: 78%) (Table 8.1).  
Overall, 15% (n=625) of women had a viral load measurement in the first month post-
pregnancy. The percentage of women with ≥1 viral load measurement by 3, 6, 9 and 
12 months post-pregnancy was 58%, 72%, 77% and 80% respectively, with most of 
this data coming from UK CHIC (Table 8.1).  
Among women with ≥1 viral load measurement within 6 months of delivery, the median 
time between delivery and the first viral load measurement was 50 (IQR 35-81) days in 
UK CHIC, 18 (2-54) days in the NSHPC and 49 (33-79) days if data from both studies 
were considered. 
For this preliminary analysis, the pregnancy status of women was not considered when 
assessing post-pregnancy viral load data. However, it is likely that a small number of 
viral load measurements performed in the 12 months post-pregnancy were obtained 
during a subsequent pregnancy. 
 
 296 
 
Table 8.1. Availability of viral load data during and after pregnancy in the NSHPC, UK CHIC and the combined dataset (n=4100 pregnancies) 
Period of interest UK CHIC NSHPC Combined dataset 
≥1 VL 
measurement 
(%) 
Median VL [IQR] ≥1 VL 
measurement 
(%) 
Median VL [IQR] ≥1 VL 
measurement 
(%) 
Median VL [IQR] 
All ≥1 VL1 All ≥1 VL1 All ≥1 VL1 
In pregnancy 
Pregnancy 3534 (86.2) 4 [2-5] 4 [3-6] 3911 (95.4) 2 [1-2] 2 [1-2] 4028 (98.2) 4 [3-6] 4 [3-6] 
1
st
 trimester 2201 (53.7) 1 [0-1] 1 [1-2] 1706 (41.6) 0 [0-1] 1 [1-1] 2481 (60.5) 1 [0-1] 1 [1-2] 
2
nd
 trimester 3064 (74.7) 1 [0-2] 2 [1-3] 1634 (39.9) 0 [0-1] 1 [1-1] 3369 (82.2) 2 [1-3] 2 [1-3] 
3
rd
 trimester 2984 (72.8) 1 [0-2] 2 [1-3] 3205 (78.2) 1 [1-1] 1 [1-1] 3638 (88.7) 2 [1-2] 2 [1-3] 
After pregnancy 
0-1 month post-pregnancy 546 (13.3) 0 [0-0] 1 [1-1] 193 (4.7) 0 [0-0] 1 [1-1] 625 (15.2) 0 [0-0] 1 [1-1] 
0-3 months post-pregnancy 2290 (55.8) 1 [0-1] 1 [1-1] 266 (6.5) 0 [0-0] 1 [1-1] 2364 (57.7) 1 [0-1] 1 [1-1] 
0-6 months post-pregnancy 2892 (70.5) 1 [0-2] 2 [1-2] 324 (7.9) 0 [0-0] 1 [1-1] 2963 (72.3) 1 [0-2] 2 [1-2] 
0-9 months post-pregnancy 3086 (75.3) 2 [1-3] 2 [2-3] 420 (10.2) 0 [0-0] 1 [1-1] 3161 (77.1) 2 [1-3] 3 [2-4] 
0-12 months post-pregnancy 3189 (77.8) 2 [1-4] 3 [2-4] 534 (13.0) 0 [0-0] 1 [1-1] 3275 (79.9) 2 [1-3] 3 [2-4] 
1 
Refers to the median number of viral load (VL) measurements among women with at least one VL measurement during the period of interest. 
If a VL measurement is reported to UK CHIC and the NSHPC (with the same date) it is only counted as 1 VL measurement in the combined dataset. 
 
2
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 Identifying factors associated with viral rebound in the 12 months post-8.3.2
pregnancy 
Overall number of pregnancies 
In the period 2006-2011, there were 1512 deliveries among 1301 women that resulted 
in a live birth; 1108 women had one delivery, 176 women had two and 17 women had 
three or four such deliveries during this period. An additional 756 pregnancies were not 
included in the analysis for the following reasons: the woman did not attend a UK CHIC 
site in the year following delivery (n=431); the latest viral load measurement in 
pregnancy was detectable (n=309); no viral load data were available in the third 
trimester (n=9); it was not clear whether viral load was detectable or undetectable at 
delivery due to discrepant data in the NSHPC and UK CHIC (n=7). 
Categorising ART use 
At conception more than half of the women were already on ART (57%) (Table 8.2). Of 
the 645 women not on ART, 40% started ART during the first 20 weeks of pregnancy 
and 59% during or after 20 weeks gestation. Three women had no evidence of ART 
use during pregnancy and one woman was reported as using ART but with no further 
information available. The ART data indicated that 15 women were not on ART at 
delivery, although this could be a consequence of inaccurate reporting/estimation of the 
delivery date.  
For the pregnancies included in the analysis, 802 women were categorised as being on 
life-long ART, 179 as using short-course ART in pregnancy and 424 as starting life-
long ART during the pregnancy. There were a further 107 pregnancies which did not fit 
within these three categories of ART use and were therefore categorised as ‘other’; 15 
were not on ART at delivery; 52 interrupted treatment after delivery despite conceiving 
on ART; and 40 had no post-pregnancy ART data (Table 8.2).  
Overall, for the women included in the analysis, the NSHPC reported variable ‘reason 
for ART use in pregnancy’ categorised 51% (n=768) as using ART in pregnancy for 
maternal health, 24% (n=356) as using ART for PMTCT and 26% (n=388) had no 
reason reported. There were some discrepancies between the categorisation of ART 
use according to the reported variable in NSHPC and according to the ART data from 
both studies. Among the 802 women categorised as already on life-long ART according 
to the ART data, 5% (n=40) were reported to the NSHPC as using ART for PMTCT. 
 298 
 
Among women categorised as using short-course ART according to the ART data, 
15% (n=27) were reported to the NSHPC as using ART for maternal health. Among 
women categorised as starting life-long therapy according to the ART data, 43% 
(n=183) were reported as using ART for PMTCT, 31% (130) were reported as using 
ART for maternal health, and no reason was reported for the remaining 26% (n=111) 
(26%).  
 
 
Table 8.2. Summary of ART use at conception, during pregnancy, at delivery and 
during the first 6 months after delivery (n=1512 pregnancies) 
On ART at 
conception 
n (%) 
Start ART during 
pregnancy 
n (%) 
ART use at 
delivery 
n 
Post-pregnancy ART use
1
    
 
n (%)               
Yes  867 (57.3%) - No 7 -  
Yes 
 
 
860 Stop 0-3 m 29  (3.4) 
Stop 3-6 m 23  (2.7) 
Continue >6 m 802  (93.3) 
NK 6  (0.7) 
No  645 (42.7%) At <20 
weeks 
259 
(40.2%)               
No 1 -  
Yes  258 Stop 0-3 m 40  (15.5) 
Stop 3-6 m 6  (2.3) 
Continue >6 m 202  (78.3) 
NK 10  (3.9) 
At ≥20 
weeks 
 
382 
(59.2%) 
No  3 -  
Yes 379 Stop 0-3 m 119  (31.4) 
Stop 3-6 m 14  (3.7) 
Continue >6 m 222  (58.6) 
NK 24  (6.3) 
No/NK 4 (0.6%) No  4 -  
1 
m refers to months after delivery. NK: not known. 
Baseline characteristics  
The characteristics of women included in the analysis at delivery are presented in 
Table 8.3. In brief, median age at delivery was 33 years, 76% of women were of black-
African ethnicity and 97% had acquired HIV via heterosexual sex. This was the first 
pregnancy since HIV-diagnosis for 59% of the women and 21% of women were 
diagnosed during the pregnancy. At delivery, median CD4 count was 450 cells/µl and 
61% of women were on a PI-based regimen. The deliveries were evenly distributed 
across the study period (2006-2011). 
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Table 8.3. Characteristics of women at the time of delivery in 2006-2011 stratified by ART use in pregnancy 
 All   On life-long ART Short-course ART Start life-long ART 
 n  % n % n % n % 
Total number  1512  802  179  424  
Year of delivery 2006-2007 
2008-2009 
2010-2011 
497   
499  
516 
32.9 
33.0  
34.1  
222 
268 
312 
27.7 
33.4 
38.9 
101 
54 
24 
56.4 
30.2 
13.4 
139 
138 
147 
32.8 
32.6 
34.7 
          
Age  16-29 years 
30-34 years 
35-39 years 
40-49 years 
Median [IQR] years 
461 
527 
398 
126 
33  
30.5 
34.9 
26.3 
8.3 
[28-36] 
160 
272 
280 
90 
34 
20.0 
33.9 
34.9 
11.2 
[31-37] 
83 
65 
23 
8 
30 
46.4 
36.3 
12.9 
4.5 
[25-33] 
174 
154 
76 
20 
31 
41.0 
36.3 
17.9 
4.7 
[27-34] 
          
Ethnicity Black African  
White 
Black Caribbean 
Other/NK 
1152 
154 
55 
151 
76.2 
10.2 
3.6 
10.0 
624 
78 
17 
83 
77.8 
9.7 
2.1 
10.4 
129 
20 
11 
19 
72.1 
11.2 
6.2 
10.6 
318 
46 
20 
40 
75.0 
10.9 
4.7 
9.4 
          
Exposure category Heterosexual sex 
Injecting drug use 
Other/NK 
1472 
12 
28 
97.4 
0.8 
1.9 
781 
8 
13 
97.4 
1.0 
1.6 
179 
0 
0 
100 
- 
- 
408 
4 
12 
96.2 
0.9 
2.8 
          
Previous deliveries 0 
1 
≥2 
884 
442 
186 
58.5 
29.2 
12.3 
377 
281 
144 
47.0 
35.0 
18.0 
131 
38 
10 
73.2 
21.2 
5.6 
320 
90 
14 
75.5 
21.2 
3.3 
         
HBV/HCV co-infection 77  5.1 43 5.4 12 6.7 15 3.5 
          
CD4 count (cells/µl)         
(n=1494, n=789, n=178) 
≤200  
201-350 
351-500 
>500 
Median [IQR] 
186 
264 
460 
584 
450 
12.3 
17.5 
30.4 
38.6 
[330-590] 
93 
142 
255 
299 
450 
11.8 
18.0 
32.3 
37.9 
[330-580] 
13 
32 
60 
73 
472 
7.3 
18.0 
33.7 
41.0 
[350-590] 
76 
75 
109 
162 
430 
18.0 
17.8 
25.8 
38.4 
[290-610] 
         
2
9
9
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Table 8.3 continued 
 All   On life-long ART Short-course ART Start life-long ART 
 n  % n % n % n % 
HIV diagnosed during this pregnancy  322 21.3 0 - 92 51.4 207 48.8 
          
Pregnancy duration  Median [IQR] (weeks) 37 [36-38] 37 [36-38] 37 [36-38] 37 [36-38] 
          
Type of ART regimen               No ART  
PI 
NRTI 
NNRTI 
Other 
15 
916 
63 
483 
35 
1.0  
60.5 
4.2 
31.9 
2.3 
- 
391 
18 
378 
15 
- 
48.8 
2.2 
47.1 
1.9 
- 
155 
11 
9 
4 
- 
86.6 
6.2 
5.0 
2.2 
- 
315 
64 
29 
16 
- 
74.3 
15.1 
6.8 
3.8 
          
Number of drugs in 
regimen           
0 
1-2 
3 
≥4 
15 
48 
1356 
93 
1.0 
3.2 
89.7 
6.2 
- 
15 
718 
69 
- 
1.9 
89.5 
8.6 
- 
8 
164 
7 
- 
4.5 
91.6 
3.9 
- 
18 
392 
14 
- 
4.3 
92.5 
3.3 
          
NNRTI: non-nucleoside reverse-transcriptase inhibitor; NRTI: nucleoside reverse-transcriptase inhibitor; PI: protease inhibitor. There were an additional 107 pregnancies with             
ART use categorised as ‘other’. These are included in the total column (All) but not as a separate column. 
 
3
0
0
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The median follow-up time was 12 (IQR 12-12) months, with a median number of viral 
load measurements of 3 (IQR 2-4). There were 131 (9%) women who became 
pregnant again within a year of delivery.  
Two women died, both within 3 months of delivery. The causes of the death were not 
reported. Three infants (0.2%) were known to have become infected with HIV. 
Number of women experiencing viral rebound 
Overall, one-third (33%, n=497) of women experienced viral rebound in the year 
following pregnancy. The cumulative incidence of viral rebound at 3 months post-
pregnancy was 19% (95% CI 17%-21%); by 6 months post-pregnancy this had 
increased to 27% (25%-29%). The median time to viral rebound was 2.6 (IQR 1.5-4.8) 
months after delivery. The cumulative incidence of viral rebound at 3 and 6 months 
post-pregnancy was: for women already on life-long ART, 4.3% (2.9%-5.7%) and 6.6% 
(4.8%-8.3%); for women who started life-long ART, 32% (27%-36%) and 42% (37%-
47%); and for women who used short-course ART in pregnancy, 50% (43%-58%) and 
76% (73%-83%) (Figure 8.1a). 
A similar pattern was observed when follow-up was censored if/when ART was 
stopped or interrupted (Figure 8.1b). Censoring data in this way meant that follow-up 
on all women who used short-course ART was censored by 5 months post-pregnancy 
(the red line). Women who started life-long ART during pregnancy had a lower 
cumulative probability of viral rebound when follow-up was censored at any ART 
interruption than when follow-up was not censored in this way.  
The availability of post-pregnancy viral load data  
The availability of viral load data and the percentage of women with detectable viral 
load were assessed for each post-pregnancy month (Table 8.4). For each group, the 
first month after pregnancy had the fewest women with any HIV-RNA measurement 
and the second month had the highest.  
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Figure 8.1a. Kaplan-Meier plot showing cumulative probability of viral rebound in the 
year after pregnancy stratified by type of ART used in pregnancy 
 
Figure 8.1b. Where follow-up was censored if ART was stopped 
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Table 8.4. Percentage of women with detectable viral load among women with ≥1 viral load measurement during each month in the year 
following delivery according to type of ART use 
  
Months since delivery 
              
Type of ART use in pregnancy 1 2 3 4 5 6 7 8 9 10 11 12 
              
              Already on           
life-long ART  
% with VL data 10.1 40.4 26.4 22.8 25.6 25.8 23.8 25.6 22.2 27.3 23.7 21.4 
% with detectable VL
1
 4.9 9.9 11.8 8.7 9.3 10.6 7.3 11.7 10.7 11.4 16.3 12.2 
 
             
Short-course 
ART 
% with VL data 10.6 43.6 21.2 22.3 22.9 21.2 22.9 16.2 26.8 25.1 22.3 25.7 
% with detectable VL
1
 47.4 80.8 89.5 87.5 95.1 81.6 82.9 82.8 77.1 82.2 77.5 78.3 
 
             
Start life-long 
ART  
% with VL data 12.7 50.5 28.8 22.9 22.9 21.0 19.6 19.6 23.3 18.4 18.9 21.9 
% with detectable VL
1
 18.5 45.8 38.5 39.2 45.4 37.1 48.2 36.1 44.4 39.7 45.0 39.8 
 
             
Other % with VL data 14.0 36.4 25.2 22.4 25.2 17.8 23.4 21.5 21.5 29.9 16.8 29.0 
 
% with detectable VL
1
 33.3 51.3 44.4 45.8 48.1 42.1 44.0 52.2 34.8 37.5 44.4 48.4 
VL: viral load;
 1
 % with detectable VL (HIV RNA >50 copies/ml) of women with VL data i.e. women with ≥1 viral load measurement during that month. 
3
0
3
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Factors associated with viral rebound 
In adjusted analysis including all the variables in Table 8.5, women who had used 
short-course ART in pregnancy had 16 times the risk of viral rebound in the year 
following pregnancy compared to women who were on life-long ART when they 
conceived. Women who did not conceive on ART but who started life-long ART during 
pregnancy had 7 times the risk of experiencing viral rebound in the year following 
pregnancy compared to women who had conceived on ART. Women in the group 
categorised as ‘other’ (aHR 6.2) also had a higher risk of viral rebound in the year 
following pregnancy than women who conceived and remained on ART.   
In the year after pregnancy, age and calendar year were both associated with risk of 
viral rebound. The risk decreased with increasing age (aHR 0.75 per 10 year increase 
in age) and over time (aHR 0.95 per additional year). Women with at least one 
pregnancy (since HIV-diagnosis) prior to the pregnancy being considered had a higher 
risk of viral rebound (aHR 1.2) than women with no pregnancy prior to the one being 
considered in this analysis. Women with a higher CD4 count also had a higher risk of 
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Figure 8.2. Percentage of women with detectable viral load among women with at least 
one viral load measurement during each month in the year following delivery according 
to ART use category 
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viral rebound compared to women with a CD4 count ≤250 cells/µl (aHR 2.17 for women 
with a CD4 count > 500 cells/µl) (Table 8.5). 
Women with HBV/HCV co-infection had less risk of viral rebound (aHR 0.61) compared 
to women without hepatitis (26% [20/77] of women with HBV/HCV co-infection 
experienced viral rebound compared to 33% [477/1435] of women without co-
infection).  
Sensitivity analysis 
In sensitivity analysis, only a woman’s first pregnancy meeting the inclusion criteria 
during the period of interest was included in the analysis (1301 pregnancies). The 
results were similar to the results of the primary analysis. Women who used short-
course ART were at increased risk of viral rebound (aHR 16.2 [11.8-22.4], p<0.001) 
compared to women on life-long ART when they conceived, as were women who 
started life-long ART in pregnancy (aHR 7.0 [5.2-9.4], p<0.001). As in the main 
analysis, risk of viral rebound was higher in women with a previous pregnancy, 
although this lost statistical significance probably due to lack of power (aHR 1.18 [0.95-
1.47], p-value 0.14). In the sensitivity analysis fewer women had a prior pregnancy than 
in the primary analysis (32% [417/1301] vs. 42%).  
In an additional sensitivity analysis, only a woman’s last pregnancy meeting the 
inclusion criteria during the period of interest was included (1301 pregnancies). Again, 
the results were similar to primary analysis results. Use of short-course ART was 
associated with an increased risk of viral rebound (aHR 15.8 [11.5-21.8], p<0.001) as 
was starting life-long ART (aHR 7.3 [5.5-9.6], p<0.001) compared to the group already 
on life-long ART. More than three-fifths of the women (42%, [546/1301]) had previously 
had a pregnancy; as in the main analysis, these women had an increased risk of viral 
rebound compared to women without a prior pregnancy (aHR 1.28 [1.04-1.57], p-value 
0.02).   
In adjusted analysis, ethnicity and route of exposure were not associated with the risk 
of viral rebound.  
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Table 8.5. Unadjusted and adjusted Cox proportional hazards regression analyses to identify factors associated with the incidence of post-
pregnancy viral rebound 
 Unadjusted Adjusted 
 HR (95% CI) p-value HR (95% CI) p-value 
Type of ART use Already on life-long ART Reference <0.001 Reference <0.001 
Short-course ART 18.3 (13.9-24.1)  16.0 (11.9-21.6)  
Start life-long ART 6.9   (5.3-8.9)  7.23 (5.52-9.47)  
Other 6.7   (4.7-9.5)  6.18 (4.33-8.81)  
Previous pregnancy  0.73 (0.61-0.88) <0.001 1.21 (1.00-1.47) 0.05 
Age (per 10 year increase) 0.47 (0.40-0.55) <0.001 0.75 (0.63-0.89) 0.001 
Calendar year (per 1 year increase) 0.87 (0.82-0.91) <0.001 0.95 (0.89-1.00) 0.05 
Route of exposure Heterosexual sex Reference 0.53 Reference 0.77 
IDU 0.66 (0.21-2.06)  1.03 (0.31-3.40)  
Other/NK 0.72 (0.34-1.51)  0.76 (0.36-1.61)  
Ethnicity Black-African Reference 0.06 Reference 0.61 
 White 1.17 (0.88-1.56)  0.97 (0.72-1.32)  
 Black-Caribbean 1.67 (1.12-2.49)  0.92 (0.61-1.38)  
 Other/NK 1.15 (0.86-1.53)  1.20 (0.61-1.38)  
HBV/HCV co-infection 0.71 (0.46-1.14) 0.14 0.61 (0.38-0.96) 0.03 
CD4 count (cells/µl) ≤250  
251-350 
351-500 
>500 
NK 
Reference 
1.34 (0.92-1.95) 
1.61 (1.14-2.27) 
1.93 (1.39-2.69) 
0.75 (0.23-2.42) 
<0.001 Reference 
1.47 (1.01-2.16) 
2.00 (1.41-2.85) 
2.17 (1.54-3.06) 
1.40 (0.43-4.53) 
<0.001 
3
0
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Separate models were created after stratifying by type of ART (Table 8.6). The results 
were similar for each group, although many associations were not statistically 
significant in the short-course ART and starting life-long ART groups, which contained 
small numbers. The notable difference between groups was the association between 
CD4 count and viral rebound. Among women already on life-long ART, women with a 
CD4 count ≤250 cells/µl had the highest risk of viral rebound. This was not the case for 
women who started life-long ART during their pregnancy. In this group, women with 
CD4 ≤250 cells/µl had a lower risk of viral rebound than women with CD4 251-350 
cells/µl, CD4 351-500 cells/µl, or CD4 >500 cells/µl (Table 8.6). 
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Table 8.6. Adjusted Cox proportional hazards regression analyses to identify factors associated with the incidence of post-pregnancy viral 
rebound stratified by type of ART use 
 Already on life-long ART 
(n=802) 
Short-course ART 
(n=179) 
Start life-long ART 
(n=424) 
 aHR (95% CI) p-value aHR (95% CI) p-value aHR (95% CI) p-value 
Previous pregnancy  1.94 (1.2-3.1) 0.006 1.01 (0.7-1.5) 0.9 1.19 (0.9-1.6) 0.26 
Age (per 10 year increase) 0.65 (0.4-1.0) 0.05 1.06 (0.8-1.4) 0.7 0.80 (0.6-1.0) 0.10 
Calendar year (per 1 year increase) 0.93 (0.8-1.1) 0.26 1.00 (0.9-1.1) 0.9 0.95 (0.9-1.0) 0.26 
Route of 
exposure 
Heterosexual sex - - - - Reference 0.79 
IDU     1.41 (0.4-5.2)  
Other/NK     0.83 (0.4-2.0)  
Ethnicity Black-African Reference 0.44 Reference 0.2 Reference 0.61 
 White 0.38 (0.1-1.2)  1.73 (1.0-3.0)  0.81 (0.5-1.3)  
 Black-Caribbean -  0.83 (0.4-1.6)  0.98 (0.5-1.8)  
 Other/NK 1.05 (0.5-2.1)  1.10 (0.7-1.9)  1.23 (0.8-2.0)  
HBV/HCV co-infection 1.31 (0.5-3.3) 0.56 0.52 (0.3-1.1) 0.1 0.49 (0.2-1.2) 0.11 
CD4 count 
(cells/µl) 
≤250  
251-350 
351-500 
>500 
NK 
Reference  
0.40 (0.2-0.8) 
0.51 (0.3-1.0) 
0.47 (0.3-0.9) 
0.40 (0.1-3.0) 
0.11 Reference 
1.35 (0.6-2.8) 
1.62 (0.8-3.2) 
0.81 (0.4-1.6) 
- 
0.01 Reference 
2.25 (1.2-4.2) 
3.05 (1.7-5.5) 
5.90 (3.4-10.3) 
9.38 (2.1-41.4) 
<0.001 
No model was created for the ART use group categorised as ‘other’.  
3
0
8
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 Comparing the risk of viral rebound in post-pregnant women and 8.3.3
controls  
Analysis 1: Post-pregnant women conceiving on cART and controls   
There were 623 post-pregnant women who conceived on cART, with two controls 
identified for 607, only one for 11 and none for five women, giving a total of 1225 
controls, this included 174 who were controls for multiple women.  
The post-pregnant women and controls were similar with regard to age, year and 
duration on cART (the matching characteristics) (Table 8.7). They were also similar 
with regard to time since HIV-diagnosis (median 5.9 years), type of regimen used 
(overall, 55% used an NNRTI-based regimen), the proportion with HBV/HCV co-
infection (7% overall), and ethnic group (73% black-African overall). The two groups 
differed with regard to HIV exposure category, latest CD4 count and parity (Table 8.7).   
In the month following delivery/pseudo-delivery, 10% (64/618) of post-pregnant women 
had a viral load measurement and 26% (320/1225) of controls (p<0.001). After 3 
months, 70% (435/618) of post-pregnant women and 70% (862/1225) of controls had 
had at least one viral load measurement (p-value 0.99). The median number of viral 
load measurements overall was 3 (2-4) for both the groups (p-value 0.11).   
Viral rebound in post-pregnant women conceiving on cART and controls 
A larger percentage of post-pregnant than control women experienced viral rebound 
(post-pregnant: 10.7% [66/618]; controls: 7.4% [91/1225]). The cumulative probability 
of viral rebound at one, three and six months post-delivery/pseudo-delivery was 1.1% 
(95% CI 0.3%-2.0%), 5.9% (4.0%-7.7%) and 8.6% (6.3%-10.8%), respectively in post-
pregnant women, and 0.9% (0.0%-1.4%), 2.2% (1.4%-3.0%) and 4.5% (3.3%-5.6%) in 
controls (Figure 8.3a).  
In adjusted analysis, risk of viral rebound in the first three months after 
delivery/pseudo-delivery was significantly associated with post-pregnant status, 
calendar year and CD4 count (Table 8.8). Post-pregnant women were more likely to 
experience viral rebound over this period than controls (aHR 2.63) although the risk of 
viral rebound itself decreased in later calendar years (aHR 0.81 per later year). A CD4 
count ≤200 cells/µl at delivery/pseudo-delivery was also significantly associated with 
viral rebound (aHR 2.89). 
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The risk of viral rebound in the 3-12 month period after delivery/pseudo-delivery was 
associated with years since HIV diagnosis, type of drug regimen and number of drugs. 
There was no statistically significant association between viral rebound and post-
pregnant status after restricting to this subgroup who had maintained viral suppression 
for at least 3 months. Women who were diagnosed with HIV more than 10 years ago 
were more likely to experience viral rebound than women diagnosed 2-10 years ago 
(aHR 1.83).  Women on a ≥4 drug regimen were more likely to experience viral 
rebound than women on a triple drug regimen (aHR 2.41) as were women on a PI-
based regimen compared to women on an NNRTI-based regimen (aHR 1.89). 
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Table 8.7. Baseline characteristics of post-pregnant women and controls 
 
 
 
Baseline characteristic
3
 
On ART at conception
1
  Started ART during the pregnancy
2
  
Post-pregnant  
n=618 
Controls 
n=1225 
p-value Post-pregnant  
n=321 
Controls  
n=568 
p-value 
N % n (%) n % n (%) 
Year
4
 2006 – 2007 
2008 – 2009 
2010 – 2011 
206 
207 
205 
(33.4) 
(33.6) 
(33.2) 
407 
413 
405 
(33.3) 
(33.7) 
(33.1) 
- 114 
99 
108 
(35.5) 
(30.8) 
(33.6) 
207 
176 
185 
(36.4) 
(31.0) 
(32.6) 
- 
Age
4
 Median [IQR] years 34 [31-37] 34  [31-37] - 31 [28-35] 32 [28-35] - 
Ethnicity Black African  
White 
Black Caribbean 
Other/NK 
479 
61 
14 
64 
(77.5) 
(9.9) 
(2.3) 
(10.4) 
882 
163 
36 
139 
(72.0) 
(13.3) 
(2.9) 
(11.8) 
0.07 251 
25 
14 
31 
(78.2) 
(7.8) 
(4.4) 
(9.7) 
375 
78 
30 
85 
(66.0) 
(13.7) 
(5.3) 
(15.0) 
0.002 
Exposure 
category 
Heterosexual sex 
Injecting drug use 
Other/NK 
604 
6 
8 
(97.7) 
(1.0) 
(1.3) 
1140 
31 
54 
(93.1) 
(2.5) 
(4.4) 
0.001 309 
0 
12 
(96.3) 
- 
(3.7) 
520 
10 
38 
(91.6) 
(1.8) 
(6.7) 
0.01 
Parity
5
  0 
1 
≥2 
353 
196 
69 
(57.1) 
(31.7) 
(11.2) 
855 
252 
118 
(69.8) 
(20.6) 
(9.6) 
<0.001 280 
37 
4 
(87.2) 
(11.5) 
(1.3) 
470 
68 
30 
(82.8) 
(12.0) 
(5.3) 
<0.01 
Latest CD4 
count (cells/µl) 
≤200  
201 – 350 
351 – 500 
>500 
39 
153 
191 
234 
(6.3) 
(24.8) 
(31.0) 
(37.9) 
58 
201 
315 
651 
(4.7) 
(16.4) 
(25.7) 
(53.1) 
<0.001 51 
93 
81 
96 
(15.9) 
(29.0) 
(25.2) 
(29.9) 
113 
172 
159 
124 
(19.9) 
(30.3) 
(28.0) 
(21.8) 
0.05 
3
1
1
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Table 8.7 continued 
 
 
Baseline characteristic
3
 
On ART at conception
1
  Started ART during the pregnancy
2
  
Post-pregnant  
n=618 
Controls 
n=1225 
p-value Post-pregnant  
n=321 
Controls  
n=568 
p-value 
n % n (%) n % n (%) 
HBV/HCV co-infection 37 (6.0) 93 (7.6) 0.20 8 (2.5) 46 (8.1) 0.001 
Median time since HIV diagnosis [IQR] 
(years)                      
5.9 [3.7-8.3] 5.9  [3.6-8.7] 0.33 0.6 [0.5-3.8] 2.8  [0.7-6.5] <0.001 
Duration of 
current period 
of ART use
4
  
0 – 2 months 
3 – 5 months 
6 – 8 months 
8 – 12 months 
1 – 4 years 
≥5 years 
- 
- 
- 
39 
394 
185 
- 
- 
- 
(6.3) 
(63.8) 
(29.9) 
- 
- 
- 
78 
785 
362 
- 
- 
- 
(6.4) 
(64.1) 
(29.6) 
 
 
 
- 
65 
233 
22 
- 
- 
- 
(20.3) 
(72.8) 
(6.9) 
- 
- 
- 
106 
416 
46 
- 
- 
- 
(18.7) 
(73.2) 
(8.1) 
- 
- 
- 
- 
 
 
 
 
 
Type of ART 
regimen 
PI 
NRTI 
NNRTI 
Other 
221 
7 
332 
58 
(35.8) 
(1.1) 
(53.7) 
(9.4) 
404 
22 
676 
123 
(33.0) 
(1.8) 
(55.2) 
(10.0) 
0.49 84 
3 
221 
13 
(26.2) 
(0.9) 
(68.9) 
(4.1) 
160 
3 
388 
17 
(28.2) 
(0.5) 
(68.3) 
(3.0) 
0.68 
Number of 
drugs in 
regimen 
2 
3 
≥4 
12 
552 
54 
(1.9) 
(89.3) 
(8.7) 
43  
1064 
118 
(3.5) 
(86.9) 
(9.6) 
0.26 - 
308 
13 
- 
(96.0) 
(4.1) 
- 
557 
11 
- 
(98.1) 
(1.9) 
0.06 
1 
Or 9 months prior to pseudo-delivery for controls; 
2 
Or in the 8 months prior to pseudo-delivery for controls; 
3 
At delivery (post-pregnant women) or pseudo-delivery (controls); 
4
 Characteristics used to identify suitable controls for post-pregnant women. In addition, post-pregnant women who started ART during pregnancy were also matched to 
controls using CD4 count at ART start. 
5
 Previous live births reported to NSHPC not including live births delivered prior to HIV diagnosis. 
3
1
2
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Figure 8.3. Kaplan-Meier plot showing cumulative probability of viral rebound among women on ART: post-partum women (black line) and 
controls (grey line) 
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Table 8.8. Adjusted hazard ratios for viral rebound in post-pregnant women who 
conceived on ART and controls stratified by time since delivery 
Baseline characteristic                         
at delivery/pseudo-delivery 
<3 months since 
delivery/pseudo-delivery 
3-12 months since 
delivery/pseudo-delivery 
aHR (95% CI) p-
value 
aHR (95% CI) p-
value 
Group Control   
Post-pregnant 
Reference  
2.63 (1.58-4.39)           
<0.001 Reference  
0.93 (0.59-1.47)           
0.76 
Calendar year (per additional year) 0.81 (0.70-0.95) 0.01 0.96 (0.84-1.09) 0.50 
Age (per 10 additional years)  0.93 (0.55-1.55) 0.77 0.84 (0.55-1.28) 0.42 
Ethnicity                   Black African  
White 
Black Caribbean 
Other/NK 
Reference 
1.79 (0.87-3.71) 
1.52 (0.36-6.35) 
1.34 (0.62-2.91) 
0.41 Reference 
0.75 (0.36-1.57) 
0.45 (0.06-3.28) 
0.69 (0.33-1.45) 
0.59 
Exposure 
category                 
Heterosexual sex 
Injecting drug use 
Other/NK 
Reference 
0.41 (0.05-3.72) 
0.56 (0.08-4.17) 
0.63 Reference 
0.73 (0.14-3.84) 
1.21 (0.45-3.25) 
0.87 
Previous live birth 1.31 (0.79-2.20) 0.10 1.37 (0.89-2.11) 0.16 
HBV/HCV co-infected 1.43 (0.58-3.55) 0.44 1.25 (0.59-2.65) 0.57 
Latest CD4 
count 
(cells/µl)          
≤200  
201-350 
351-500 
>500 
2.89 (1.14-7.31) 
1.74 (0.88-3.46) 
1.79 (0.96-3.36) 
Reference 
0.10 2.05 (0.96-4.34) 
1.12 (0.65-1.95) 
0.64 (0.36-1.13) 
Reference 
0.05 
Duration of 
ART use 
8-12 months  
1-4 years 
≥5 years 
1.34 (0.56-3.25) 
Reference  
0.57 (0.29-1.13) 
0.19 0.98 (0.41-2.34) 
Reference  
0.83 (0.50-1.37) 
0.77 
Time since 
HIV diagnosis                         
8-23 months 
2-9 years 
≥10 years 
0.66 (0.25-1.74) 
Reference 
1.04 (0.49-2.21) 
0.69 1.66 (0.82-3.37) 
Reference 
1.83 (1.08-3.09) 
0.04 
Type of ART 
regimen                 
PI 
NRTI 
NNRTI 
Other 
1.13 (0.66-1.93) 
- 
Reference 
0.95 (0.38-2.34) 
0.96 1.89 (1.19-3.00) 
0.92 (0.12-6.87) 
Reference 
1.39 (0.66-2.95) 
0.06 
Number            
of drugs in 
regimen                  
2 
3 
≥4 
2.36 (0.51-11.0) 
Reference 
1.86 (0.91-3.81) 
0.17 2.17 (0.73-6.50) 
Reference 
2.41 (1.36-4.25) 
0.01 
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Analysis 2: Post-pregnant women starting cART in pregnancy and controls  
There were 363 post-pregnant women who started cART during pregnancy, with two 
controls identified for 247, only one for 74 and none for 42 women, giving a total of 568 
controls. 
Post-pregnant women and controls were similar with regard to age, year, duration on 
cART and CD4 count when starting cART (the matching characteristics) (Table 8.7). 
They were also similar regarding type of drug regimen (overall, 69% used an NNRTI-
based regimen) but differed with regard to ethnicity, exposure category, parity, 
HBV/HCV co-infection, duration since HIV diagnosis and latest CD4 count. On 
average, post-pregnant women had been diagnosed more recently, had a higher 
median CD4 count (391 vs. 350 cells/µl), and were less likely to have had a previous 
live birth (since HIV diagnosis).  
More than half (53% [171/321]) of post-pregnant women were diagnosed with HIV 
during the recent pregnancy, of whom 65% (111/171) had a CD4 count <350 cells/µl 
when starting cART, with 47% (81/171) having a CD4 count <200 cells/µl. In women 
already diagnosed when they became pregnant, 59% (89/150) had a CD4 count <350 
cells/µl when starting cART, with 32% (48/150) having a CD4 count <200 cells/µl; of 
these almost two-thirds (65% [98/150]) attended care at a UK CHIC site in the year 
prior to the pregnancy, of whom 53% (52/98) started cART with a CD4 count <350 
cells/µl. Of the remaining 46 women not attending a UK CHIC site in the year prior to 
pregnancy, 22 had no evidence that they had ever attended care at a UK CHIC site 
prior to their pregnancy and 24 had attended care at a UK CHIC site more than one 
year before the pregnancy. In this latter group, the median time between their latest 
attendance before the pregnancy and their first attendance in pregnancy was 22 (IQR 
18-32) months and two-thirds (67% [16/24]) started cART with a CD4 count <350 
cells/µl.   
In the month following delivery/pseudo-delivery, 14% (44/321) of post-pregnant and 
27% (152/568) of controls (p<0.001) had a viral load measurement. At 3 months post-
delivery/pseudo-delivery, 80% (256/321) of post-pregnant women and 79% (450/568) 
of controls had had at least one viral load measurement (p-value 0.85). The median 
number of viral load measurements in the first year after delivery/pseudo-delivery was 
3 (2-4) for the post-pregnant women and 3 (3-4) for the controls (p-value <0.001).   
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Viral rebound in post-pregnant women starting cART in pregnancy and controls  
A larger percentage of post-pregnant women experienced viral rebound than controls 
(post-pregnant: 37.1% [119/321]; controls: 9.2% [52/568]). The cumulative probability 
of viral rebound at one, three and six months after delivery/pseudo-delivery was 1.9% 
(95% CI 0.4%-3.5%), 27% (22%-32%) and 35% (30%-41%) respectively in post-
pregnant women, and 1.1% (0%-1.9%), 3.0% (1.6%-4.4%) and 4.8% (3.0%-6.6%) 
respectively in controls (Figure 8.3b).  
In the adjusted analysis, the risk of viral rebound in the first three months post-
delivery/pseudo-delivery was associated with post-pregnant status (aHR 11.7 for post-
pregnant women) and CD4 count (aHR 0.18 CD4 count <200 vs. >500 cells/µl) (Table 
8.9). 
The risk of viral rebound in the 3-12 months post-delivery/pseudo-delivery was 
associated with post-pregnant status (aHR 3.94 for post-pregnant women), calendar 
year (aHR 0.82 per later year), ethnicity (aHR 2.44 for women of black-Caribbean 
ethnicity) and parity (aHR 2.92 for women with a previous live birth) (Table 8.9).  
In sensitivity analysis, when viral rebound was defined as HIV RNA >1000 copies/ml, 
similar associations were observed although some lost statistical significance. The 
association between age and viral rebound became statistically significant for women 
who had started cART in pregnancy and controls (0-3 months post-delivery/pseudo-
delivery: aHR 0.63 [0.40-0.98]; 3-12 months post-delivery/pseudo-delivery aHR 0.55 
[0.32-0.93] per 10 additional years). Post-pregnant status remained associated with 
viral rebound when 143 women (46 post-pregnant and 97 controls) with previous cART 
experience were excluded. 
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Table 8.9. Adjusted hazard ratios for viral rebound in post-pregnant women starting 
ART during pregnancy and controls stratified by time since delivery 
Baseline characteristic 
at delivery/pseudo-delivery 
<3 months since 
delivery/pseudo-delivery 
3-12 months since 
delivery/pseudo-delivery 
aHR (95% CI) p-value aHR (95% CI) p-value 
Group Control   
Post-pregnant 
Reference  
11.7 (6.69-20.5)           
<0.001 Reference  
3.94 (2.43-6.40)           
<0.001 
Calendar year (per additional 
year) 
0.99 (0.87-1.12) 0.88 0.82 (0.70-0.95) 0.01 
Age (per 10 additional years)  0.75 (0.50-1.11) 0.14 0.69 (0.44-1.08) 0.10 
Ethnicity                   Black African  
White 
Black Caribbean 
Other/NK 
Reference 
0.68 (0.29-1.62) 
1.12 (0.48-2.64) 
0.95 (0.48-1.87) 
0.83 Reference 
0.72 (0.31-1.71) 
2.44 (1.10-5.45) 
0.86 (0.38-1.92) 
0.10 
Exposure 
category                 
Heterosexual sex 
Injecting drug use 
Other/NK 
Reference 
5.63 (0.59-53.4) 
1.03 (0.36-2.95) 
0.32 Reference 
3.59 (0.38-33.9) 
1.50 (0.53-4.26) 
0.42 
Previous live birth 1.51 (0.82-2.77) 0.19 2.92 (1.53-5.57) 0.001 
HBV/HCV co-infected 0.70 (0.21-2.34) 0.56 0.67 (0.19-2.32) 0.53 
Latest CD4 
count 
(cells/µl)          
≤200  
201-350 
351-500 
>500 
0.18 (0.07-0.46) 
0.40 (0.22-0.71) 
0.88 (0.54-1.43) 
Reference 
<0.001 0.79 (0.39-1.59) 
0.61 (0.33-1.13) 
0.50 (0.24-1.03) 
Reference 
0.21 
Duration of 
ART use 
0-2 months 
3-5 months 
6-8 months 
0.77 (0.46-1.30) 
Reference  
- 
0.63 0.73 (0.39-1.38) 
Reference  
0.54 (0.19-1.52) 
0.35 
Time since 
HIV 
diagnosis                         
8-23 months 
2-9 years 
≥10 years 
0.85 (0.52-1.38) 
Reference 
1.04 (0.36-2.99) 
0.78 0.98 (0.54-1.78) 
Reference 
0.84 (0.30-2.35) 
0.95 
Type of 
ART 
regimen                 
PI 
NRTI 
NNRTI 
Other 
1.02 (0.64-1.65) 
- 
Reference 
1.11 (0.40-3.12) 
0.99 1.52 (0.93-2.49) 
1.99 (0.38-10.45) 
Reference 
0.68 (0.09-5.05) 
0.34 
Number            
of drugs in 
regimen                  
3 
≥4 
Reference 
1.07 (0.33-3.50) 
0.91 Reference 
1.18 (0.36-3.95) 
0.78 
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8.4 Discussion 
Initially, I examined the availability of viral load data in the dataset. The large majority of 
women had at least one viral load measurement reported, but it was surprising that not 
all women had one. In pregnancy too, most, but not all, women had at least one viral 
load measurement in UK CHIC and/or NSHPC. Viral load is routinely tested in clinical 
HIV care. Lack of any viral load data in the dataset is probably not a result of non-
attendance - since only women with some clinical data in the dataset, such as CD4 
count, had their data examined. Although there may be some circumstances under 
which women attending care do not have a blood sample taken/tested, absence of viral 
load data is more likely to be a consequence of non-reporting of data or a technical 
failure in the laboratory to obtain a viral load measurement from the sample. Among 
women with viral load data, the median interval between viral load measurements was 
3 months. This interval will probably increase as clinics move toward less frequent 
monitoring of patients who are stable on treatment [485] and may be affected by the 
short interval between viral load measurements during pregnancy. There was a median 
of 4 viral load measurements reported in pregnancy, double the number reported in the 
period of the same duration before or after pregnancy. This reflects the increase in viral 
load monitoring during pregnancy [169] due to the importance of achieving or 
maintaining viral suppression to minimize vertical transmission. 
The availability of viral load data following pregnancy was also examined. There was 
some evidence of loss-to-follow-up (LTFU) for one in five pregnancies; 20% of 
pregnancies in the combined dataset had no viral load measurement reported in the 
post-pregnancy year, higher than in a UK study of post-pregnancy LTFU which 
estimated that 12% of women did not access care in the post-pregnancy year [486, 
487]. It is likely that some of the women with no viral load data stopped attending HIV 
clinical care for that period of time. However, there are other reasons why women 
might not have any viral load (and CD4) measurement reported from that period. Some 
may have moved abroad or returned to their country of origin and continued to access 
HIV care abroad. Some women may have moved within the UK. It is not uncommon for 
families to move areas after the birth of a child and some women may have transferred 
to another HIV clinic within the UK, not part of UK CHIC. Women who did not attend 
care after pregnancy, and were therefore not included in analyses, are likely to have 
higher rates of viral rebound than the women who attended care. This selection bias 
may therefore result in an underestimation of post-pregnancy viral rebound. The 
pregnancies included in both of the post-pregnancy analyses were only those of 
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women who had achieved viral suppression during pregnancy. Women with a 
detectable viral load at delivery, are also likely to have detectable viral loads for at least 
some of the period after delivery, particularly as these women may have been having 
adherence problems during pregnancy or entered care late, leaving insufficient time to 
achieve viral suppression by delivery. In addition, only live births were assessed. The 
risk of viral rebound may differ according to pregnancy outcome, something which 
would be difficult to assess using the NSHPC data due to small numbers and 
underreporting of miscarriages and terminations of pregnancy.  
In the first analysis of the post-partum year, viral rebound was examined in four groups: 
women who conceived on life-long ART; women who started life-long ART in the 
pregnancy; women who used short-course ART in the pregnancy; and women who did 
not fit into any of these groups. As anticipated, the risk of post-pregnancy viral rebound 
was highest in women who stopped ART at delivery or shortly after (the short-course 
ART group). When interpreting Figure 8.1 it is important to bear in mind that follow-up 
started at delivery, not when ART was stopped. Women were included in the short-
course ART group if they started ART in pregnancy and stopped ART within 6 months 
of delivery. Although many of the women in this group stopped ART at delivery, some 
remained on ART for a number of weeks or even months after delivery. For some, this 
was a temporary switch (of 4 weeks) to a PI-based regimen – recommended for 
women stopping an NNRTI-containing regimen [84]. For others it may have been an 
unplanned treatment interruption. Whatever the reason, it delayed the viral rebound 
until weeks/months after delivery. It is also important to bear in mind that the data do 
not show the actual timing of when viral rebound occurred. Although a woman’s viral 
load may have rapidly reached detectable levels, this would not be captured in the data 
until the next viral load measurement. Although three-quarters of women who used 
short-course ART had experienced viral rebound by six months post-pregnancy, some 
women had not yet had a viral load measurement by this point, so the actual 
percentage of women who experienced viral rebound was probably higher, closer to 
100%. In view of this limitation, I also examined the percentage of women with 
detectable viral load among women with a viral load measurement reported in any 
given month (Table 8.4 and the same data presented as a graph in Figure 8.2).  
Examining viral rebound in this way showed a steep increase in the percentage of 
women with a detectable viral load in the first 2 months after delivery (to around 80%). 
Again, this percentage would probably be higher, if follow-up was started when ART 
was stopped rather than at delivery.  
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Although the rapid increase in viral load after cessation of cART is expected, it might 
be something best avoided (by remaining on cART), particularly if there is an overshoot 
(a temporary peak) in viral load, as some studies suggest  [197, 378, 380] as this would 
increase the risk of onward transmission. This is an additional benefit of the recent 
changes to ART guidance [86], since all women, whether they start ART in pregnancy 
or conceive on ART, will be advised to remain on ART after pregnancy. For a number 
of reasons it is unlikely that the high viral load post pregnancy resulted in a large 
number of transmissions, as is the case in newly infected individuals who contribute to 
a disproportionate number of transmission events due to a temporary peak in their 
viraemia shortly after HIV infection [488]. Women are unlikely to re-initiate sexual 
activity until around 2-3 months after delivery [489]. Sexually active HIV-positive 
women are strongly advised to have protected sex. Postnatal women living with HIV 
are encouraged to bottle feed rather than breastfeed their infant [169]. Although bottle 
feeding is socially acceptable and is fairly common in the wider population within the 
UK, some women may have chosen to breast feed for social, financial or cultural 
reasons. Cessation of short-course ART after pregnancy does not appear to lead to 
increased morbidity or mortality among women with high CD4 counts i.e. women 
eligible for short-course ART in pregnancy [249]. However, it may have implications for 
the women’s health and future treatment, as examined in Chapter 6. Remaining on 
treatment after pregnancy will likely be beneficial for the woman’s health as well as 
minimising HIV transmission risk in subsequent pregnancies [89, 490]. The PROMISE 
study is currently assessing the benefits, in resource limited settings, of women with 
higher CD4 counts remaining on cART after delivery (Trial reference: NCT01061151). 
In women who remained on ART after delivery, risk of viral rebound was not as high as 
in those who stopped. However, women who started life-long ART in pregnancy had 7 
times the risk of viral rebound compared to women already on life-long ART (aHR 7.2) - 
by six months post-pregnancy, 42% of women who started life-long ART during their 
pregnancy experienced viral rebound compared to only 7% of women who had 
conceived on ART. For the former, the cumulative probability of viral rebound was not 
as high when follow-up was censored if ART was stopped, even for a short time. This 
indicates that some, but not all, of the viral rebounds were a consequence of a short 
treatment interruption (if the interruption had been longer than 30 days then they would 
not have been included in this ART group).  
The analysis comparing women who started life-long ART during pregnancy and 
women who remained on life-long ART (analysis 3) found that the risk of viral rebound 
in the post-pregnancy year was higher than in matched controls – women who had 
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been on ART for a similar duration but who had not recently had a pregnancy. Among 
women who conceived on cART, the risk of viral rebound was 2.6-fold higher in the first 
three months after delivery than among matched controls, but similar in the 3-12 
months after delivery. In contrast, among women who started life-long ART during 
pregnancy, viral rebound risk was 11.7-fold higher than among matched controls during 
the first three months and 3.9-fold higher 3-12 months after delivery. Previous studies 
have reported a high prevalence of viral rebound in post-pregnant women remaining on 
therapy [375, 376, 381], but this is the first to compare the risk of viral rebound in post-
pregnant women with rates seen in a demographically matched group of non-post-
pregnant women.   
Overall, 9% of women who conceived on life-long ART experienced viral rebound 
within six months of delivery, less than in a Brazilian study in which 15% (9/52) of post-
pregnant women, who conceived on and remained on cART after pregnancy, 
developed viral rebound (0.5 log10 increase) at six months post-pregnant [375]. This 
difference may be because women in the Brazilian study had more advanced disease 
and not all had achieved viral suppression during pregnancy. Two further studies [376, 
381] reported that 18% and 19% (respectively) of post-pregnant women who remained 
on cART experienced viral rebound (defined as ≥0.7 log10 increase at 24 weeks post-
pregnant and ≥0.5 log10 increase at 6-12 weeks post-pregnant respectively). However, 
neither of these studies stratified by timing of cART initiation (before or during the 
pregnancy), which limits comparison here. Further analysis is needed to determine the 
proportion of women with viral rebound who subsequently regained virological control 
and whether that was achieved without a regimen change.  
Although physiological changes during pregnancy and at delivery might have 
contributed to the increased incidence of viral rebound in the first three months after 
delivery, this would not explain the ongoing increased risk of viral rebound after three 
months among women who started life-long ART in pregnancy, or the much higher 
incidence in women who started life-long ART in pregnancy than in women conceiving 
on cART. The more likely explanation is reduced adherence to cART following 
pregnancy. Studies have observed a fall in adherence following pregnancy [376, 388, 
389], when the risk of vertical transmission has passed (if breastfeeding is avoided) 
and the demands of looking after the baby are high. Treatment interruptions and 
changes to medication are also more likely in this period [376]. Treatment interruptions 
and regimen alterations are common in the first year of treatment, particularly for 
women [476, 491]. Reduced adherence could also explain, in part, the almost three-
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fold increase in viral rebound observed in the 3-12 months after delivery/pseudo-
delivery in women with a previous live birth at baseline, i.e. women with the additional 
burden of looking after children as well as their new baby. Other studies have found 
that both drug adherence and access to antenatal HIV services fall with an increasing 
number of children in the household [492-494]. Post-pregnancy treatment interruptions 
could be examined further in a future analysis of the combined dataset. 
Adherence is defined by the WHO as ‘the extent to which a person’s behaviour – taking 
medication, following a diet, and/or executing lifestyle changes, corresponds with 
agreed recommendations from a health care provider’ [495]. Adherence is difficult to 
accurately measure and adherence data is not collected by UK CHIC or the NSHPC. 
There are numerous factors known to be associated with adherence. These include 
regimen-related factors such as pill burden [496, 497], dose burden [497, 498], dietary 
restrictions [499] and side-effects [500]. Factors relating to the individual are also 
important predictors of adherence including: age [501, 501, 502, 502, 503, 503]; belief 
systems; forgetfulness [504]; understanding of the importance of adherence [504]; 
disclosure of HIV status [503]; depression [497]; stress; and social support [497]. In 
both analyses of viral load in the postpartum year, a number of factors which are 
known to be predictive of adherence were found to be associated with viral rebound. 
Whereas older age is commonly associated with poorer health, risk of viral rebound 
decreased with increasing age in the first, but not the second analysis. This association 
is likely to be due to behavioural differences and better drug adherence in older 
women. The lack of association between age and viral rebound in the second analysis 
might be because few adolescents and young adults were included.  
In this observational study, data were collected as part of patients’ clinical records and 
can therefore be used as a proxy for HIV clinic attendance. For all groups, the median 
number of viral loads was three in the year following delivery/pseudo-delivery. 
However, for women who recently started cART, there was evidence that post-
pregnant women attended care less often than controls. Previous studies have noted 
low attendance rates in clinical care in the three months following childbirth [505] and a 
delay in seeking HIV care [492] or inability to complete post-pregnant follow-up [506] 
among women with children in the household.  
CD4 count was also associated with viral rebound. In women who started life-long ART 
in pregnancy and their controls, risk of viral rebound in the first three months after 
delivery/pseudo-delivery was lower in women with a low CD4 count than in women with 
a high CD4 count. Despite only including women who, according to the data, remained 
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on cART for at least six months after delivery, some discontinuations may not have 
been recorded in the clinical notes. A woman’s CD4 count at cART initiation could 
indirectly affect adherence; for example, women with a high CD4 count may not 
perceive the need for perfect adherence as much as women starting cART with a low 
CD4 count. A Ugandan study found that a high CD4 count at ART start was not 
associated with adherence (measured using MEMSCap pill bottles) but was associated 
with more treatment interruptions and persistent detectable viraemia [507]. In some 
settings where WHO Option B+ has been implemented, high rates of loss-to-follow-up 
have been observed among pregnant women starting life-long cART with a high CD4 
cell count [508, 509]. We do not know if a similar incidence of post-pregnant viral 
rebound would occur if all pregnant women not yet on ART started life-long treatment 
in pregnancy, as is now the recommendation [510]. There may be a similar reason for 
the association between HBV/HCV co-infection and viral rebound seen in the first, but 
not the second analysis. Women with HBV/HCV were less likely to experience viral 
rebound in adjusted analyses than women without hepatitis, perhaps due to the 
increased contact with their HIV clinician resulting in a better understanding of the 
importance of ART adherence.  
Among women already on life-long ART, women with a lower CD4 count were at 
increased risk of viral rebound in the 3-12 months post-delivery/pseudo-delivery. 
Although all these women were virally suppressed at baseline, a low CD4 count 
indicates that they were having adherence problems or that the regimen was failing 
due to resistance.  
Assessing the CD4 count at which ART was started was not an intended outcome of 
the study. However, it is of interest to note that 62% of the women who started ART 
during pregnancy had a CD4 count below the threshold at the time for treatment 
initiation in the UK (350 cells/µl) [85]. Most of these women were diagnosed with HIV 
during the pregnancy, highlighting the importance of antenatal screening for HIV, 
routine in the UK since 2002  [142].  
For women who started cART in pregnancy and their controls, a quadruple regimen 
was associated with increased risk of viral rebound in the 3-12 months after 
delivery/pseudo-delivery compared to a triple regimen. Since the standard first line 
treatment in the UK during the study period was a triple regimen (where ritonavir use 
as a pharmacological booster is not counted as a component of the regimen) [84], use 
of a quadruple regimen suggests that they were on a subsequent regimen due to 
development of resistance or problems with a previous regimen/s. Adherence could be 
 324 
 
more of an issue for women on a quadruple regimen, since adherence is negatively 
associated with pill burden [63].    
As previously mentioned increased viral load following pregnancy could have a 
detrimental impact on women’s health and future treatment options and increase the 
risk of HIV transmission. Therefore, these findings indicate a need for additional 
support for ART adherence and for maintained engagement with HIV clinical care for 
this group. This could include support from clinicians, specialist nurses and peer 
support (via charities) from women with experience of taking ART during and after 
pregnancy. As the incidence of viral rebound was higher in women who started therapy 
in pregnancy than in women already on therapy, adherence support is particularly 
needed for women starting life-long treatment during pregnancy, especially those who 
already have children. It is encouraging that the risk of viral rebound was lower in later 
years. This may reflect improvements in clinical management of people living with HIV 
including the management of side effects as well as the increased use of fixed-dose 
regimens (FDRs) over the study period. Different ART combinations have different 
thresholds of adherence needed to ensure viral suppression. In other words, some are 
more forgiving to suboptimal adherence than others. Regimens have become more 
forgiving to lapses in adherence; older regimens required very high rates of adherence 
(of around 95%), whilst newer NNRTI combinations require about 85% adherence 
[511]. The UK CHIC study does not collect data on pill burden or use of FDRs, so these 
could not be assessed as potential factors associated with viral rebound. However, 
other studies have found that use of a single-pill regimen can improve adherence [512]. 
For pregnant women starting life-long cART in pregnancy, a once a day FDR may 
promote good adherence. Regimens which are more forgiving to poor adherence could 
also be considered as the initial regimen. Further studies are required to identify the 
most effective strategies for improving post-pregnant ART adherence. 
There are a number of important limitations to bear in mind when interpreting the 
results of these analyses. Whilst several relevant variables were included in the 
adjusted models, not all confounders could be accounted for. Resistance cannot be 
ruled out as the reason for viral rebound. However, in sensitivity analysis excluding 
women with known previous exposure to ART, post-pregnant status remained 
significantly associated with an increased risk of viral rebound.  
To avoid detecting viral blips, viral rebound is often defined on the basis of two 
consecutive HIV-RNA >200/400/1000 copies/ml; I was not able to take this approach 
due to the limited number of viral load measurements reported in this group. This 
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should not have an impact on the outcome when the risk of viral rebound was 
compared between groups.  
ART use in pregnancy was categorised as either ‘conceived on life-long’, ‘started life-
long ART’, or ‘short-course ART’ using data from both studies. The categorisation of 
ART use was not straightforward and there were a sizable number of women whose 
ART use did not fit within the three categories. For the purposes of the first analysis, 
these pregnancies were grouped together as ‘other’. It is difficult to interpret the results 
of this group which included women whose ART use was not known or who, according 
to the data, stopped ART after delivery despite conceiving on ART. This group could 
have been excluded. They were, however, included as it is important to remember that 
there are women whose ART use is not in accordance with treatment guidelines. It is 
therefore not surprising that women in this group were more likely to experience viral 
rebound than women who conceived and remained on life-long ART. Previous studies 
have reported a high rate of women stopping ART after pregnancy, despite intending to 
continue ART postnatally [376].  
The categorisation of ART was compared with the results of the NSHPC reported 
variable ‘reason for ART use in pregnancy’. There were a large number of 
discrepancies between the two and the NSHPC variable was underreported (one-
quarter of pregnancies had no reason reported). Of note, there were 183 pregnancies 
reported to NSHPC as using ART for PMTCT only (i.e. short-course) whilst the ART 
data indicated that the women started life-long ART in pregnancy. This highlights the 
value of using the UK CHIC data from after the pregnancy to validate ART data 
reported to the NSHPC.  
Key points from this chapter 
 In women who were virally suppressed at delivery and remaining on ART after 
pregnancy, the risk of viral rebound in the post pregnancy year was higher in 
women who had started life-long ART in pregnancy than in women who had 
conceived on ART. 
 For post-natal women who started life-long ART during pregnancy, the risk of 
viral rebound was higher than in non-post-natal matched controls who had 
recently started life-long ART. This increase in risk is seen throughout the 12 
months after delivery/pseudo-delivery.    
 For post-pregnant women already on life-long ART, risk of viral rebound is 
higher than in similar women who have been on ART for a similar duration but 
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who did not recently have a pregnancy. This increase in risk is seen in the first 
three months after pregnancy but not in the 3-12 months after pregnancy.    
  
 327 
 
Chapter 9 Concluding remarks 
 
 
The development of antiretroviral drugs for the treatment of HIV is a remarkable 
success story. The use of combination antiretroviral therapy (cART) is the main reason 
why, in the UK, the life expectancy of people living with HIV is now approaching that of 
the general population. The use of ART in pregnancy, alongside appropriate antenatal 
care and clinical management during labour and delivery, mean that the risk of mother-
to-child transmission (MTCT) is now very low; in the UK, only 10 of the 4271 infants 
born to diagnosed women living with HIV were vertically infected with HIV in the 5 
years prior to submission of this work [145]. It is therefore not surprising that, as they 
would have done if they were HIV-negative, many women living with HIV decide to 
have children, anticipating that their infant will not become infected and that they 
themselves will remain in good health throughout their child’s upbringing.  
The broadest aim of this work was to assess the impact of ART use in pregnancy on 
women’s health during and after pregnancy. Initially, the focus was intended to be the 
long-term outcomes following short-course ART use in pregnancy. However, it quickly 
became apparent, from the results of Chapter 5, that a decreasing number of women 
were using short-course cART in pregnancy. This was because most women were 
either already on lifelong therapy when they conceived or initiated life-long therapy 
during pregnancy. As such, the focus of the work was redirected to examine the 
outcomes during and after pregnancy in women who remained on ART as well as in 
women who used short-course ART. Since 2009, when this work was started, there 
have been important changes in the clinical management of people living with HIV. The 
recommendation that everyone living with HIV should start ART as soon as possible 
after diagnosis means that women are no longer recommended short-term ART use in 
pregnancy and therefore some of the results presented in this thesis are no longer 
relevant to current practice. However, the majority of the research remains relevant 
since it examines ART use during or after pregnancy in women starting ART in 
pregnancy and/or remaining on ART following pregnancy. 
The linkage between UK CHIC and the NSHPC provided a unique opportunity to 
identify predictors of pregnancy in a large cohort of women living with HIV in the UK 
and to estimate the incidence of pregnancy in this group. The results presented in 
Chapter 5 are essentially surveillance data. That is, rather than contributing to the 
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evidence base for practice, they are useful for researchers in this area and for 
assessing and planning HIV services. The paper reporting the results of Chapter 5 
[423], published in 2013, has been cited by a number of subsequent research papers.  
The number of pregnancies among women living with HIV reported to the NSHPC has 
plateaued in recent years [145]. Bearing this in mind, as well as changes in immigration 
dynamics within the UK, an update to the analyses in Chapter 5 would be useful in the 
near future. This would assess whether pregnancy incidence has continued to increase 
and whether specific groups of women are following the general trend. 
In Chapter 7, I examined liver enzyme elevation in pregnancy. The results of this 
chapter provide further evidence that women using antiretroviral therapy in pregnancy 
have an increased risk of liver enzyme elevation and, for the first time, show that this 
risk is increased in women who are already on ART when they conceive as well as in 
women who initiate ART use in pregnancy. Whereas many UK based HIV clinics are 
moving to less regular monitoring of liver function tests in pregnancy, the results of 
Chapter 7, highlight the importance of maintaining regular monitoring of liver enzymes 
throughout pregnancy and the importance of monitoring the symptoms of toxicity, such 
as rash, among pregnant women on antiretroviral therapy, including women who have 
been on ART for some time. As with most previous studies examining hepatotoxicity in 
pregnancy, my analysis was fairly simplistic - limited to assessing ALT only. There are, 
however, other biomarkers of synthetic function, in addition to ALT, which can be used 
to distinguish hepatotoxicity from other pregnancy complications and could be 
examined in any future research. Although some of these data are collected in UK 
CHIC, this type of research might be better suited to a single site study with samples 
taken in all women at regular intervals throughout pregnancy therefore avoiding the 
bias introduced when using observational data, where women with a risk profile for 
raised liver enzymes are more likely to have liver function tests. 
In Chapter 8, I examined post-pregnancy viral rebound. The results of this chapter 
show that women are more likely to experience viral rebound in the year after 
pregnancy than at other times outside pregnancy. During this post-pregnancy period, 
among women who remain on ART, women who started life-long ART in their 
pregnancy are more likely to experience viral rebound compared to women who were 
already on ART before their pregnancy. The interpretation of these results are limited 
by the fact that this was an observational study and I only used the quantitative clinical 
data collected by UK CHIC and the NSHPC, a limitation that I discuss further on.  
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Viral rebound not only has implications for the women’s health but increases the risk of 
transmission to the baby if the woman breastfeeds, or to a partner, if the couple have 
unprotected sex. If we assume that the heightened risk of viral rebound is the result of 
reduced ART adherence, the results of Chapter 8 highlight a need for additional 
adherence support for post-partum women. The need for continuous high levels of ART 
drug adherence is well understood by the HIV community. Clinics already provide 
adherence advice and support, particularly when people are starting life-long ART. 
There are numerous on-line resources including websites, online video clips and blogs. 
Charities, such as Positively UK25, provide peer support and short educational/support 
courses. NAM26, a leading HIV information sharing charity in the UK, provides HIV and 
ART information in numerous languages and any website can now be translated into 
almost any language using online translation tools. 
Not everyone will be able to or want to use these services or necessarily find them 
useful. For example, not all women will have access to the internet or live close to a 
peer support programme and not everyone will have the time or the desire to use them. 
There needs to be a variety of interventions for different people as there is unlikely to 
be a one-size-fits-all solution to improving post-partum drug adherence. Where some 
HIV support services are suffering from a lack of funding [513] it is crucial that support 
services are maintained and where possible, research and cost-effective analyses are 
performed to provide evidence to funders and commissioners of the value of the 
service. For service evaluation, services need to collect good quality data about the 
number and type of people attending their services. In addition, in this time of financial 
pressure on the National Health Service (NHS) and local authorities (who commission 
social services and some health services), inexpensive ways of providing adherence 
support need to be developed and assessed. At present there is very little research on 
ART adherence post pregnancy and only one study from the UK has been published 
which examines the use of a specific intervention to promote retention in care after 
pregnancy [514].  
For women who have access to the internet, I would recommend that more resources 
are developed with specific groups of women in mind, for example, young mothers, 
newly diagnosed mothers and mothers who have recently arrived in the UK and where 
possible that online resources are translated into languages reflecting the diverse and 
multilingual mix of people living with HIV in the UK. Having the web page or app 
already translated makes it easier to find and use for non-English speakers and the 
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 www.positivelyUK.org 
26
 www.aidsmap.com 
 330 
 
translation will be more accurate than if the translator is performed by an online 
translation programme.  
There are many drug adherence apps available on smartphones. A recent paper 
identified 461 such apps [515], but few are specifically for ART adherence and none 
are aimed at women living with HIV. The ownership of smartphones has increased and 
the use of apps for monitoring health means that developing an app for very specific 
scenarios can be an effective and inexpensive intervention. NHS England has already 
produced some apps which are free or inexpensive and which are recommended for 
particular patient groups. For example, the NHS developed a pelvic floor exercise app 
for women with urinary incontinence, Squeezy27, costing £2.99 to consumers. An app 
designed to help ART drug adherence could also provide HIV information and could be 
available in multiple languages. These could be developed by BHIVA, NHS England, 
an HIV charity such as NAM, who already have some HIV information apps, by one of 
the pharmaceutical companies which manufacture ART drugs, or by a collaboration of 
these groups. In time, as the databases for storing patient records become more 
sophisticated, such an app could link to a patient’s medical records so that their 
clinician could be alerted to any problems with adherence and the patient could be sent 
updates and reminders of clinic appointments.  
With just over 6000 people diagnosed with HIV each year, the number of people living 
with HIV will continue to increase and so the number of people receiving antiretroviral 
therapy (ART). This means that the overall cost to the NHS of purchasing these drugs 
increases yearly but NHS England is under increasing financial pressure as their drug 
budget does not increase at the same rate. Some antiretroviral drugs have reached the 
end of their patent protection. Generic drugs, i.e. drugs with the same formula but 
manufactured by companies which did not develop the drugs, are considerably 
cheaper. Because ART drugs are purchased in bulk with a negotiated discount, NHS 
England do not publish the purchase price of the drugs. However, it is likely that a 
move to using generic drugs will result in a considerable cost saving. Although HIV 
clinics are being urged to change patient medications to equivalent generics, the 
choice of drug for a particular individual will still be made based on their specific 
circumstances. The results of Chapter 8 highlight the post-pregnancy period as a 
vulnerable time. For many women this would not be an appropriate time to switch 
treatment, particularly to a regimen with a higher pill or dose burden. Any reduction in 
adherence may lead to complications and therefore the need for more clinic visits, 
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 www.squeezyapp.co.uk 
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negating any cost saving achieved by switching to cheaper drugs as well as posing a 
risk to the woman’s health.  
Some regimens are more forgiving to incomplete adherence than others. Long-acting 
injectable antiretroviral therapy is already being trialled. This way of administering 
treatment would negate the need for day-to-day adherence. At the moment it requires 
an injection every one to two months. In this form it would not be suitable for the post-
partum women. However, in the future, developments could mean that it is longer 
acting and administered in a range of formats such is the case with long-acting 
contraception, which can be administered as injections or subdermal implants.  
The interpretation of the findings in Chapter 8 in particular would be greatly enhanced 
by the collection and analysis of qualitative data. Mixed methods research, i.e. the 
combined use of quantitative and qualitative research to answer the same research 
question, is increasingly used in health research [516]. Future research could for 
example include semi-structured interviews with health advisors, HIV clinicians and 
with pregnant and post-partum women living with HIV. Used among pregnant and post-
pregnant women, interview data could provide insights into the barriers to full drug 
adherence, factors affecting adherence and aid the development of effective 
interventions to promote drug adherence which could then be tested in randomised 
control trials.  
For obvious ethical and practical reasons it is not possible to use randomised 
controlled trials (RCT), the gold standard for clinical studies, to investigate the effect of 
pregnancy on disease progression or the impact of antenatal ART use (compared to no 
ART use) on the mother’s health. This means that observation data are heavily relied 
on in this area of study. There are some benefits to using observational data. For 
example, large amounts of data can be collected from multiple locations. This means 
the data reflect clinical practice from across the UK over a long period of time. Data are 
already collected by the clinician for the patient’s clinical notes meaning that no 
additional resources are needed for data collection, only for combining the data from 
across all sites. An important limitation of using observation data is that although it is 
possible to account for measured confounders, such as age and duration of ART 
infection, unmeasured confounders cannot be adjusted for and are unlikely to be 
randomly distributed across the groups examined, as is the case with RCTs. Examples 
of possible confounders here include socioeconomic status, educational level, home 
location, co-morbidities, co-medications, parental responsibilities, work status, diet, 
languages spoken, alcohol consumption, illicit drug use, smoking status and BMI. Many 
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clinics now record patient’s smoking status and BMI and I would recommend that 
where these data are recorded, that UK CHIC start to collect them. Perhaps most 
importantly, no information on drug adherence was available, something which is 
difficult to accurately record.  
The linkage of two datasets introduced its own complexities. Where variables were only 
available from one of the studies, they could not be used in a combined analysis. For 
example, parity (i.e. the number of pregnancies before and after HIV diagnosis) and the 
date of arrival in the UK are collected in NSHPC but not UK CHIC. For variables 
collected by both studies, there were sometimes discrepancies which were either 
impossible or time consuming to reconcile. In many cases it was difficult to assess 
whether discrepancies were due to inaccurate reporting or incorrect linkage even after 
scrutinising the two records. The most problematic and time consuming discrepancies 
were those relating to ART use in pregnancy as described in Chapter 4.  
Whilst the combining of the two datasets resulted in some improvements to data quality 
for the individual studies, for example filling in gaps in missing data, it also required a 
huge amount of work to create harmonised variables. The combining of HIV diagnosis 
data from both studies exposed how inaccurate this variable is, a variable used in 
many of the analyses in this thesis and other UK CHIC analyses. If HIV diagnosis date 
was only available from one of the studies, this date would have been taken as ‘true’ 
unless there was some discrepancy with another variable for the same person. Yet, 
when I examined the variable, it was clear that many of the diagnosis dates reported 
were either estimated dates or the first visit to the clinic; even when NSHPC records 
were linked to UK CHIC records from the same hospital only 27% of pairs had an 
identical HIV diagnosis date in both records. Therefore, care must be taken when 
interpreting ‘duration since HIV diagnosis’, a variable based on HIV diagnosis date.  
There were some improvements in the data quality over time - particularly for the drug 
resistance data - but the amount of data was not consistent at all times and for all 
women. For many variables it is unlikely that missing data were missing completely at 
random – something which must be the case if multiple imputation techniques are to be 
used to impute missing variables.  
Clinical and demographic data on patients seen at a single clinic can be used to 
address some research questions. In some circumstances, this information can be 
used to adapted services at that centre to address local issues or needs. However, the 
collection of data from numerous sites increases the sample size and the heterogeneity 
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of patients included in the cohort. The larger number of individuals included in the 
cohort is particularly important to provide sufficient statistical power when studying rare 
outcomes or if the patient group being examined is relatively small, as was the case in 
Chapter 6. However, because UK CHIC is a large dataset containing many variables 
from numerous sites, it is a complex task for the UK CHIC data manager to collate the 
data and produce a finalised datasets. This results in a considerable delay of around 9 
months between the end of the calendar year and the point at which any analysis of the 
data or data linkage can begin. This delay can be problematic in a field where clinical 
practice can change so rapidly.  
Since the initial development of the NSHPC and UK CHIC linkage (described in 
Chapter 3), which created a dataset containing data to 31st December 2009, the 
linkage has been repeated in each subsequent year. The SAS code which I wrote 
contains the linkage algorithm, creates the combined variables and harmonises 
variables where there are discrepancies. This code can be reused each year but the 
linkage is by no means an automated process, since additional variables are often 
introduced and there is often data cleaning required as well as the need for some 
manual review. In the future, there may be better, faster ways of collecting this data.  
In 2014, Public Health England (PHE) replaced the New HIV Diagnosis dataset and the 
Survey of Prevalent HIV diagnosed (SOPHID) programmes (data from SOPHID) was 
used to estimate the completeness of the UK CHIC - NSHPC linkage in Chapter 3) with 
the new HIV and AIDS reporting system (HARS)[517]. Fully rolled out at the end of 
2014, HARS collects attendance based data quarterly from all HIV clinics in the UK. 
Not only are data collected more regularly than by UK CHIC, sites are motivated to 
report data in accordance with the short deadline set, since their data are required by 
commissioners under the scheme which allows correct reimbursement to sites 
according to the number and type of patients attending their service. This means that 
HARS has a much shorter reporting delay than UK CHIC. However, HARS is a 
surveillance system rather than a research database. Far fewer variables are collected 
compared to UK CHIC, with clinical data limited to CD4 count, viral load, AIDS/other 
complexities and no obstetric data are collected.  
At present, there is no obvious alternative way of collecting data equivalent to that 
collected in UK CHIC, data which, since its inception in 2001, have contributed to 
numerous international collaborations, informed decision-making, led to further 
research and guided policy and practice in the UK and internationally. Since 2004, 
there are been more than 100 research papers published in clinical journals which 
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have arisen from the UK CHIC study and its collaborations. The UK CHIC data have 
been used to estimate the life expectancy of people living with HIV [518] and assess 
the impact of late diagnosis on life expectancy [420]. The late diagnosis findings 
informed the decision to expand HIV testing in the UK to additional clinical settings 
including primary care where the prevalence of diagnosed HIV was above 2 in 1000 
and resulted in numerous auditable outcomes relating to reducing late diagnosis in the 
2013 BHIVA Standards of Care Report [519]. The findings also informed the Halve It 
campaign28, a coalition of national experts aiming to halve the proportion of people 
diagnosed with a CD4 count <350 cells/mm3, and are cited in the Introduction of the 
2014 BHIVA treatment guidelines [420] and the 2014 National AIDS Trust report on 
Commissioning HIV Testing Services in England [520]. An analysis of outcomes in the 
first year of life-long ART, using UK CHIC data, found a similar virological response in 
men and women [459] informing BHIVA’s recommendation that the first line regimen be 
the same for women and men [86]. In the near future, UK CHIC will continue to provide 
important data on patient outcome, response to newer HCV drugs, the transition of 
people from paediatric to adult HIV services, contributing to numerous areas of 
research including HIV and hepatitis co-infection and HIV and ageing. 
Similarly, data collected by the NSHPC have informed HIV testing policy and HIV 
treatment guidelines as well as contributing to numerous collaborations including with 
COHERE and SOPHID [521]. PHE’s HIV New Diagnoses, Treatment and Care in the 
UK Report [9] reports the very low transmission rate using data from the NSHPC [129] 
as does the Halve It Position Paper which uses the success of antenatal screening as 
a positive case study. Two papers from NSHPC [149, 151] were key to informing 
recommendations on when to initiate ART in pregnancy in the 2014 BHIVA Pregnancy 
guidelines [169]. An analysis published in 2014, which used NSHPC data to examine 
viral load at delivery among women having their second pregnancy, showed that 
women who were not on ART at conception were less likely to achieve viral 
suppression by delivery than women who had conceived on ART. This paper 
contributed to the case for lifelong ART [490] instead of short-course cART, which at 
the time was still the recommendation in the UK.  
Both the NSHPC and UK CHIC have well-established protocol. However, it is important 
that the ways in which data are collected are continuously developed, not just to 
improve the efficiency and speed at which data are reported but also in line with 
developments in data security and technology. Whilst the best attempts are currently 
                                               
28
 www.halveit.org.uk 
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made to maintain the security and integrity of the data, regular reassessment of 
security practices are required. As new tools become available for increasing security, 
these must be adopted where appropriate.  
Although neither dataset include any unique identifiers, such as NHS number or 
National Insurance number, both studies collect some demographic data which could 
be used to identify the record of a particularly individual, for example using their 
ethnicity and date of birth, for malicious intent. The chance of being able to identify an 
individual increases after the linkage simply because there are more data variables for 
each individual in the dataset. The transfer of data from one location to another and the 
use of data by a large number of collaborators all increase the risk of a security breach. 
High profile breaches by local government, health clinics, and academic institutes are 
unusual but there have been a number of cases in the past few years. One such 
incident was an email containing a list of 780 clinic patients’ names and email 
addresses sent out incorrectly from the 56 Dean Street clinic in Soho [522]. Not only do 
such breaches cause distress to the patients whose data are exposed, they also cause 
damage to the trust of anyone using or considering using the clinic. Concerns over the 
security of data can be heightened for people with HIV because they may fear stigma 
and discrimination. It is crucial that patients can trust that their clinical and personal 
data will be kept accurate and confidential.   
The NSHPC have for a number of years used a secure data transfer website to transfer 
any study data. They are now piloting the use of a similar encrypted website for sites to 
report their data electronically. This will hopefully improve data security, data quality 
and the timeliness of data reporting. It is unlikely that in the near future the NSHPC 
could automatically collect data from the patients centralised health record but with 
improvements to the way data are stored within the clinic there is potential for the 
reporting of the data to NSHPC by the clinics to be hugely simplified or even 
automated, removing or reducing the burden of data reporting for the clinic staff.  
The NHS attempted to create a national patient database Care.data, potentially the 
biggest patient database in the world. The benefit being that any clinician could review 
a patient’s medical history in whichever health care setting they presented, improve the 
care of that individual, and that the large amounts of data could be used by 
researchers. However, Care.data was halted in February 2012 shortly before it was put 
into use and was officially brought to a close in July 2016 due to concerns over 
confidentiality and the control of access to the data [523] after a review by Dame Fiona 
Caldicott, the national data guardian. Although the work will be taken forward by the 
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National Information Board it is unclear whether we will ever have a fully connected 
database and if we do, to what extent people will opt-out of having their data included.  
Even if Care.data or a similar database were rolled out, it is unlikely that data held 
within an HIV clinic would be part of a patient’s record visible to other health care 
providers. Under the NHS (Venereal Diseases) Regulations 1974 and the NHS Trusts 
and Primary Care Trusts (Sexually Transmitted Diseases) Directions 2000 [390], the 
data held by sexual health services have for a long time been limited in the extent to 
which they are shared with other health professionals. For example, data on HIV 
diagnosis and the use of antiretroviral therapy are not included in a hospital-wide 
database or sent to a patient’s GP, as is standard practice with other specialist care, 
unless the patient consents. Also, patients who do not wish to provide their personal 
data can still use sexual health services. This is due to both to the sensitive nature of 
the information and so that people with concerns over confidentiality are not dissuaded 
from using the service [524]. Even if HIV clinical data were kept separately from other 
clinical data, the developments required to create such a national database will 
hopefully result in improvements to all patient data storage and result in more 
standardisation between clinics in the way that patient data are recorded. This will 
hopefully make the transfer of data for research and surveillance purposes more 
automated as well as improving the data security. It may also increase the public’s 
understanding of the value of using anonymised clinical data for research and 
commissioning – something which can ultimately improve patient outcomes by 
informing service provision and clinical management.  
To summarise, in this work I have developed a linkage between two existing datasets. I 
then used the data available to examine specific questions about hepatotoxicity, viral 
rebound and the outcomes in women starting life-long ART who previously used short-
term ZDVm or cART in pregnancy. Here, I have discussed some of the implications of 
the findings of the work, most importantly, the need for close monitoring of toxicity in 
pregnancy and additional drug adherence support for women following pregnancy. 
There are many other ways in which ART use in pregnancy could impact women’s 
health during and after pregnancy. Although the linked dataset continues to provide a 
valuable resource for investigating clinical outcomes in patients attending care, 
improving the way in which data are collected, stored and transferred would be 
beneficial. Additional sources of data including qualitative data are likely to provide a 
more insightful resource for examining further research questions in this area. 
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Appendix Ia  Search terms 
All searches were undertaken using MeSH (Medical Subject Headings) and free-text terms.  
Pregnancy incidence and predictors of pregnancy 
Search 1: HIV terms 
HIV or “human immunodeficiency virus” or HIV/AIDS or HIV[MeSH] or HIV Infections[MeSH]  
Search 2:  
("predictors of pregnancy") or (pattern* AND pregnan*) or ("pregnancy incidence") 
Final search (#1 AND #2) 
Response to treatment following short-term ART use in pregnancy: 
Search 1: HIV terms 
HIV or “human immunodeficiency virus” or HIV/AIDS or HIV[MeSH] or HIV Infections[MeSH]  
Search 2: Short-term use ART in pregnancy 
(short-course or short-term or PMTCT) and (ART or HAART or “antiretroviral therapy” or “combination ART” or cART or “zidovudine 
monotherapy” or ZDVm or Anti-HIV Agents[MeSH] or Antiretroviral Therapy, Highly Active[MeSH]) and (pregnancy[MeSH] or pregnant) 
3
3
7
 
 338 
 
Search 3: ART 
(previou* and (“treated” or “exposed”)) or Drug Resistance[MeSH] or Retreatment[MeSH] or (response and (treatment or therap* or HAART) 
Final search (#1 AND #2 AND #3) 
Hepatotoxicity: 
Search 1: HIV terms 
HIV or “human immunodeficiency virus” or HIV/AIDS or HIV[MeSH] or HIV Infections[MeSH]  
Search 2: Maternal/pregnancy terms 
Matern* or pregnan* or intrapartum or intra-partum or Pregnancy[MesH] not “in infants” not ((HIV-uninfected or uninfected or HIV-exposed or 
“HIV-exposed breastfed”) and (infant* or newborn* or children)) 
Search 3: ART 
ART or HAART or “antiretroviral therapy” or “combination ART” or cART or Anti-HIV Agents[MeSH] or Antiretroviral Therapy, Highly 
Active[MeSH] or HIV Infections/Drug therapy[MeSH] 
Search 4: Hepatotoxicity 
Hepatotoxicity or toxicity or (liver and enzyme*) or ALT or “alanine transaminase” or Liver[MeSH] 
Final search (#1 AND #2 AND #3 AND #4) 
 
 
 
 
3
3
8
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Postpartum viral rebound: 
Search 1: HIV terms 
HIV or “human immunodeficiency virus” or HIV/AIDS or HIV[MeSH] or HIV Infections[MeSH]  
Search 2: Post-pregnancy terms 
“post pregnancy” or “post pregnant” or post-pregnancy or post-pregnant or postpartum or post-partum 
Search 3: ART 
ART or HAART or “antiretroviral therapy” or “combination ART” or cART or Anti-HIV Agents[MeSH] or Antiretroviral Therapy, Highly 
Active[MeSH] or HIV Infections/Drug therapy[MeSH] 
Search 4: Viral rebound 
“viral rebound” or “viral load” or “detectable viral load”  
Final search (#1 AND #2 AND #3 AND #4) 
  
3
3
9
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Appendix 1b Summary tables for published research 
Table 1. Outcomes and disease progression following pregnancy in the pre-highly active antiretroviral therapy (HAART) era  
Study design and 
setting 
Inclusion group  
(sample size) 
Outcome measures Findings 
French, 1998 [186] 
Systematic review 
and meta-analysis 
Articles published 
1983-1996 
The impact of pregnancy on disease 
progression among women with HIV 
(n=7 studies included in meta-analysis 
including Hocke,1995 [187] and Weisser, 
1998 [182]) 
Death 
HIV disease progression 
Progression to AIDS 
Fall in CD4 count to <200 
cells/mm
3
 
Summary ORs pregnancy vs. no 
pregnancy: 
Death: 1.8 [95% CI 0.99-3.3]  
Disease progression: 1.41 [0.85-2.33] 
Progression to AIDS: 1.63 [1.00-2.67]  
Fall in CD4 to <200: 0.73 [0.17-3.06] 
HIV progression was more common in 
developing countries. 
Summary: there does appear to be an 
association between pregnancy and 
disease progression, but the association is 
weak and further studies are required. 
Alliegro, 1997 [189]  
Prospective study of 
HIV-positive women 
14 HIV clinics in Italy  
1981-1994 
Women with known seroconversion date  
(within a 2 year period)  
(n=331) 
HIV-related diseases 
AIDS 
CD4 count <100 cells/mm
3
 
 11% of women were pregnant at HIV 
diagnosis 
 29% of women had a pregnancy during 
follow-up  
Summary: Pregnant women did not 
experience more rapid disease progression 3
4
0
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Table 1. continued:  Outcomes and disease progression following pregnancy in the pre-HAART era 
Study design and 
setting 
Inclusion group (sample size) Outcome measures Findings 
Buskin, 1998 [188] 
Observational study 
of adults attending 
care 
Seattle, US 
To 1997 
Women attending care  
PW and non-PW were compared  
(n=372) 
AIDS  15% of women were pregnant at HIV 
diagnosis 
 29% of women had a pregnancy during 
follow-up  
Summary: In adjusted analysis, women 
pregnant at baseline were no more likely to 
develop AIDS than women not pregnant at 
baseline. 
Bessinger, 1998 
[190]  
Retrospective study  
New Orleans, US 
1989-1995 
Women aged 15-35 years old attending 
HIV clinical care  
PW (n=192) were compared to non-PW 
(n=164). 
Death 
AIDS  
HIV-related disease 
 
PW were more likely to be African-
American, <22 years old and have a higher 
CD4 count. 
Summary: Pregnancy was not significantly 
associated with any of the outcomes.  
Brettle, 1995 [191] 
Observational study 
Edinburgh, UK 
1985-1992 
Women attending HIV clinical care at the 
city hospital.  
(n=145) 
CD4 cell count 
CD8 cell count 
CD4% 
CD8% 
Pregnancy had no effect on immunological 
markers of HIV 
Pregnancy after sero-conversion was 
associated with an increase in CD4% and 
decrease in CD8% 
3
4
1
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Table 1. continued:  Outcomes and disease progression following pregnancy in the pre-HAART era 
Study design and 
setting 
Inclusion group (sample size) Outcome measures Findings 
Saada, 2000 [192] 
Prospective cohort 
France 
1989- June 1997 
Comparison of women who did not have a 
pregnancy during follow-up (n=124) and 
women who did (n=241) (no ART 
received).  
AIDS Pregnancy was not associated with 
progression to AIDS in adjusted analysis 
accounting for time since seroconversion. 
Weisser, 1998 [182] 
Prospective cohort 
Switzerland 
1986-1993 
PW with 6 months post-pregnancy follow-
up (n=32) were compared to controls with 
no pregnancy matched on age and CD4 
count (n=416) 
Any AIDS-defining event  
Specific AIDS-defining event 
Death 
Cox proportional hazards 
Any AIDS event: RR 1.92 [0.80-4.64] (p-
value 0.15) 
Recurrent bacterial pneumonia: RR 7.98 
[1.73-36.8] p-value 0.01).  
Death: RR 1.14 [0.48-2.72] (p-value 0.8) 
Hocke, 1995 [187] 
Prospective cohort 
France 
Women with a pregnancy (n=57) were 
compared to controls, women with no 
pregnancy (n=114) matched on age, CD4 
count, and year of HIV diagnosis 
Death 
AIDS-defining event 
Fall in CD4 count <200 cells/mm
2
 
 
Pregnancy vs. No-pregnancy 
Death: aHR 0.92 [0.40-2.12] 
AIDS: aHR 1.02 [0.48-2.18] 
CD4 <200: aHR 1.20 [0.63-2.27] 
CI: confidence interval; OR: odds ratio; PW: pregnant women; RR: rate ratio; US: United States of America.  
 
 
 
  
3
4
2
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Table 2. Outcomes and disease progression after ART use in pregnancy 
Study design and 
setting  
Inclusion group (sample size) Outcome measures Findings 
Use of zidovudine monotherapy (ZDVm) in pregnancy 
Bardeguez, 2003 
[193] 
Placebo-controlled 
trial 
US 
Jan 1995 -Aug 1996 
HIV-positive women (asymptomatic and 
with CD4>200) were randomised to receive 
ZDVm or a placebo drug during pregnancy 
(n=226)  
3-6 years follow-up 
 
Disease progression (CDC 
category B clinical event) 
Time to AIDS/death 
Single ZDV resistance mutation 
Risk of AIDS/death was similar for both 
groups (RR 0.73 [90% CI 0.46-1.17] (not 
95% CI) as was disease progression (RR 
0.89 [90% CI 0.58-1.36]) 
Genotypic ZDV resistance found in 9% of 
zidovudine group and 11% of placebo group 
(not statistically significant difference – but 
no p-value given) 
Watts, 2003 [382] 
Phase 3 Clinical trial 
US & Puerto Rico 
1993-1997 
Pregnant women (n=497) using short-
course ZDVm or remaining on ZDVm after 
pregnancy   
Monitored at: 12, 26, 48 & 78 
weeks pp 
VL changes after delivery  
CD4 changes after delivery 
AIDS/death 
Observed a rise in VL at 12 weeks pp in the 
group who remained on ZDVm/cART and 
short-course ART group 
Women on cART had less chance of 
AIDS/death than women on ZDVm who had 
less chance than women not on any ART 
Use of short-course cART in pregnancy 
Pilotto, 2011 [255] 
Brazil 
May 2005-2007 
PW stopping ART after delivery with CD4 
count >200 cells/mm
3
 at start of ART – (the 
CD4 threshold for treatment at the time) 
(n=120).  
 
WHO event 2-3 
Starting ART treatment                    
i.e. CD4<200/WHO event 4 
Event 2-3 - incidence rate 13/100 PY  
Started therapy rate 6/100 PY  
Lower CD4 count at delivery was 
associated with increased risk of both 
outcomes 
  
3
4
3
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Table 2. continued: Outcomes and disease progression after ART use in pregnancy 
Study design and 
setting  
Inclusion group (sample size) Outcome measures Findings 
Comparing regimens used for short-course cART in pregnancy 
Lehman, 2009 [525] Short-course ZDVm/sdNVP compared to cART (See Table 3) 
Watts, 2009 [249] 
Prospective 
observational study 
Multiple US cites  
Jun 1994-Jun 2006 
Pregnant women with CD4 >350 using 
ART in pregnancy (n=206) 
1) short-course ZDVm (n=41) 
2) remained on ZDVm (n=62) 
3) short-course cART (n=18) 
4) remained on cART (n=82) 
Monitored during pregnancy, at 
delivery and for one year pp 
pp CD4 slope, CD4% and VL 
CDC class B/C events 
Biological markers of CVD risk 
No significant differences in CD4 slope was 
observed after pregnancy  
No women developed class C event 
Class B events in women who stopped 
therapy vs. continued HR 2.09. p-value 0.14 
Biomarker data too limited for statistical 
comparison between groups 
Shapiro, 2013 [247] 
Randomised clinical 
trial of HAART used 
for PMTCT 
Botswana 
July 2006 - May 2008 
HIV-positive ART naïve pregnant women 
with CD4>200 choosing to breastfeed  
Women were given ART until earliest of 
end of weaning or 6 months pp  
Randomised to:                                       
NRTI arm: Trizivir (ABC/ZDV/3TC) (n=285)          
PI arm: Kaletra (LPV/r/ZDV/3TC) (n=170) 
24 month maternal outcomes: 
death, CD4<200.  
Also examined infant outcomes 
(i.e. HIV infection and survival) 
Time to death/CD4<200 was shorter in the 
NRTI arm than the PI arm  
CD4 count increase was greater in the PI 
arm than the NRTI arm 
  
3
4
4
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Table 2. continued: Outcomes and disease progression after ART use in pregnancy 
Study design and 
setting  
Inclusion group (sample size) Outcome measures Findings 
Kesho Boro Study 
Group, 2012 [248] 
Randomised control 
trial  
Burkina-Faso, Kenya 
and South Africa 
Jan 2005 – Aug 2008 
HIV-positive ART naïve pregnant women 
with CD4>200 choosing to breastfeed.  
Women were randomised to: 
PI arm: Kaletra (LPV/r/ZDV/3TC) (n=384) 
until earliest of end of weaning or 6 months 
pp 
ZDVm/sdNVP arm: ZDVm until delivery 
and sdNVP at onset of labour (plus 1 pp 
week ZDV+3TC since Dec 2006) (n=405) 
18 months maternal outcomes  
1a: clinical progression to WHO 
clinical stage 4/death 
1b:clinical/immunological 
progression 
(stage4/death/CD4<200) 
2. Among women with baseline 
CD4>350, progression to stage 3 
or CD4<350 
Rates of disease progression were similar in 
both groups after cessation of ART but 
women on cART (PI) had lower progression 
risk whilst on ART (i.e. pp but before 
stopping ART) 
Low progression rates (<5%) in both groups 
among women with baseline CD4 count 
≥350 
Souda, 2013 [469] 
Randomised control 
trial  
Botswana 
July 2006-May 2008 
ART naïve PW (CD4 ≥200) were 
randomised to receive either  
1) NNRTI (ABC/ZDV/3TC)  
2) PI (LPV/r/ZDV/3TC)  
ART was discontinued at 6 months 
postpartum (total=560)       
RNA samples were taken at 7 
months pp and tested for drug 
resistance (total=85; NRTI arm 
n=42; PI arm=43) 
Stanford HIV drug resistance 
database 
No major antiretroviral drug resistance 
mutations were detected in either arm  
Minor mutations were found but similar to 
those found in ART naïve groups  
Kakehasi, 2007 [278] 
Prospective cohort 
Brazil 
Jan-Sept 2004 
PW using cART after 24 weeks pregnancy 
(n=30) (63% on NFV/ZDV/3TC) 
Genotypic resistance test at 24 
weeks gestation (before ART) 
and at ART cessation. 
4/17 women (24%) using NFV regimen had 
new resistance mutations at ART cessation. 
  
3
4
5
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Table 2. continued: Outcomes and disease progression after ART use in pregnancy 
Study design and 
setting  
Inclusion group (sample size) Outcome measures Findings 
Perez, 2008 [468] 
Prospective  
Argentina 
PW who used short-course 3TC/ZDV/NVP 
in pregnancy (n=20) 
Assess mutations associated with 
resistance to 3TC or NVP after 
ART discontinuation using PCR  
35% of pp women had ≤0.01% virus with 
mutation at K103N (associated with NVP 
resistance) 
10% of pp women had ≤0.5% virus with 
mutation at Y181C (associated with NVP 
resistance) 
65% of pp women had <0.9% with mutation 
at M184V (associated with 3TC resistance) 
4 women restarted the same treatment and 
achieved viral suppression 
Comparing use of short-course cART to continued use of cART following pregnancy 
Melekhin, 2010 [250] 
Retrospective cohort  
Nashville, USA 
1997-2008 
Comparison of pp women continuing cART 
(n=69 ) or discontinuing cART (n=54) 
(total=123 women) 
Categorised according to ART use up to 90 
days pp 
AIDS defining event or all-cause 
death;  
non-AIDS defining event or all-
cause death 
 
In adjusted analyses, women who 
discontinued cART had worse outcomes 
than women who continued cART but this 
association was NOT statistically significant 
AIDS event/death HR 0.50 [0.12-2.12]  
Non-AIDS event/death HR 0.69 [0.24-1.95] 
  
3
4
6
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Table 2. continued: Outcomes and disease progression after ART use in pregnancy 
Study design and 
setting  
Inclusion group (sample size) Outcome measures Findings 
Onen, 2008 [251] 
Observational study 
US           
1997-2005 
Women who received ZDVm or cART in 
pregnancy  
Comparison of women who continued on 
ART (n=49) with those who discontinued 
(n=123) after delivery. Total (n=172). 
Risk of opportunistic infection  Number of OI was higher in women who 
discontinued ART after pregnancy (4%) 
than in women who continued ART (9%) as 
was death (0% vs. 2%) but the difference in 
risk was not statistically significant p=0.26  
No cox proportional hazards analysis 
Coria, 2012 [254]  
Retrospective 
observational study 
Haiti 
1999-2005 
 
pp women who stopped ART after delivery 
(n=508 women) with CD4 count >200 at 
start of ART (the CD4 threshold used at 
the time)  
Compared women on cART from delivery 
(n=48) with women on short-course ART, 
stopping at delivery (n=313) 
(ZDV/3TC/NVP regimen) 
Time to cART treatment initiation 
or death  
Time to CD4 count<350  
Time to subsequent pregnancy 
LTFU 
 
Women on cART from delivery:                         
4.0 deaths/100 PY in first 3 years after 
delivery 
Women on short-course ART:                     
4.9 deaths/100 PY in first 3 years after 
delivery 
Median CD4 count at treatment start (after 
pregnancy) was 106 cells/mm
3
 - below 
recommended (CD4 200 cells/mm
3
)  
In cART from delivery group, all deaths 
occurred <100 days after starting ART in 
women with CD4<350 
High rates of LTFU, higher than among 
women remaining on therapy 
  
3
4
7
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Table 2. continued: Outcomes and disease progression after ART use in pregnancy 
Study design and 
setting  
Inclusion group (sample size) Outcome measures Findings 
Giuliano, 2013  [252] 
Observational study 
Malawi  
Feb 2008 – Feb 2009 
PW (n=311) received short-course ART 
(CD4 ≥350) or treatment (CD4<350) (NVP-
based) 
Disease progression at 24 
months pp 
No statistical comparison between groups 
Many of the women who discontinued 
treatment (short-course ART group) 
restarted ART due to a subsequent 
pregnancy or indication to start life-long 
ART i.e. reached CD4 cut off  
Minniear, 2014 [253] 
Prospective, non-
randomised clinical 
trial 
Kenya 
2003-2009 
 
Women started cART at 34 weeks 
pregnancy. They either discontinued at 6 
months postpartum (n=366), or, if they had 
CD4 count <250 or WHO stage 3/4, 
remained on ART (n=82).  
Outcomes at 24 months 
postpartum: maternal TB, 
maternal death, infant death, 
vertical transmission, LTFU. 
In women in the short-course 
ART group: risk of CD4 decline 
following ART cessation 
according to CD4 at initiation, 
discontinuation and viral 
suppression at discontinuation 
Infant death/HIV infection was more 
common in women who discontinued ART 
(n=10.1%) than in women who continued on 
ART (n=2.4%) (unadjusted analysis)  
In women who discontinued ART, the CD4 
count decline was rapid.  
Women who initiated ART with CD4<500 
and discontinued with CD4 350-500 were at 
higher risk of having to start treatment within 
6 months than women who initiated ART 
with CD4>500 or women who initiated ART 
at CD4<500 and discontinued with CD4 
≥500  
3TC: lamivudine; ABC: abacavir; CD4: CD4
+
 cell count (cells/mm
3
); CDC: US Centre for Disease Control; CI: confidence interval; CVD: cardiovascular disease; HR: hazard 
ratio; LPV/r: ritonavir boosted lopinavir; LTFU: lost to follow up; NFV: nelfinavir; NRTI: nucleoside reverse transcriptase inhibitor; OI: opportunistic infections; PCR: polymerase 
chain reaction; PI: protease inhibitor; pp: post pregnancy; RR: risk ratio; sd-NVP: single-dose nevirapine; TB: tuberculosis; US: United States of America; WHO: World Health 
Organization; ZDV: zidovudine; ZDVm: zidovudine monotherapy.  
3
4
8
 
 349 
 
 
 
Table 3. Response to treatment started after use of single dose nevirapine (sdNVP) in pregnancy  
Study design and 
setting  
Inclusion group (sample size) Outcome measures Findings 
Jourdain, 2004 [274] 
Prospective 
observational study  
Thailand (37 sites) 
2002 
Women starting NVP-containing triple 
therapy who had received NVP+ZDV or 
ZDV for PMTCT as part of a double-blind, 
randomized, placebo-controlled trial 
comparing the use of NVP+ZDV with ZDV 
for PMTCT 
(NVP+ZDV=221; ZDV=48; Total=269) 
1: Virological response at 3 
months and 6 months (VL<50) 
2: Among women with NVP 
exposure the association between 
virological failure and resistance 
mutations at 10 weeks pp 
Drug resistance mutations at 10 
days pp among women with 
VL>400. 
34% had VL<50 at 3 months  
49% had VL<50 at 6 months  
NVP exposure and high VL at baseline were 
independently associated with detectable 
VL after 6 months on treatment 
NVP exposure was not independently 
associated with immunological outcome 
(increase in CD4 from baseline to 6 months)  
Lockman, 2007 [280] 
Prospective 
observational study 
Botswana 
Women recruited to 
clinical trial March 
2001-October 2003 
who started 
treatment before 
October 2004  
Women starting NVP-containing triple 
therapy (symptomatic or CD4<200) who 
had received NVP+ZDV or ZDV for 
PMTCT as part of a double-blind, 
randomized, placebo-controlled trial 
comparing the use of NVP+ZDV with ZDV 
for PMTCT 
 
(NVP+ZDV=112; ZDV=106; Total=218) 
1: Virological failure at 6 month 
(VL ≥400) 
2: Virological failure at 12 and 24 
months  
3: Time to virological failure 
NVP exposure was associated with 
virological failure if women started treatment 
within 12 months of NVP exposure, but not 
if women started treatment >12 months after 
NVP exposure  
NVP exposure and baseline CD4 count 
were associated with time to virological 
failure  
NVP exposure was not independently 
associated with immunological outcomes  
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Table 3. continued: Response to treatment started after use of single dose nevirapine (sdNVP) in pregnancy  
Study design and 
setting  
Inclusion group (sample size) Outcome measures Findings 
Coffie, 2008 [220] 
Prospective cohort 
study 
Côte d’Ivoire 
Aug 2003-Sept 2006 
(Related study: 
Ekouevi, 2011 [281]) 
Women starting NNRTI-based treatment 
regimen (with symptoms or CD4<350) 
Group 1: ART naïve  
Group 2: sdNVP or sdNVP + ZDV for 
PMTCT 
Group 3: ZDV and 3TC for PMTCT 
(Group 1=109; Group 2=52; Group 3=86; 
Total=247) 
Outcomes  at 12 months on 
treatment 
1: Immunological failure (30% 
fall from CD4 peak during 
treatment) 
2: Virological failure (VL>500)  
3: Treatment failure (worsening 
disease/death/immunological 
failure/virological failure) 
Resistance test at week 4 pp (in 
groups 2 & 3) and at virological 
failure  
Overall: 11% developed immunological 
failure, 19% developed virological failure 
NVP resistance was not associated with 
virological or immunological failure at 12 
months (21 months median time between 
NVP exposure and ART start) 
3TC resistance (at 4 weeks pp) was 
associated with virological failure but with 
immunological failure  
Virological failure was associated with 
poor adherence, 3TC resistance at 4 
weeks pp and baseline CD4<200   
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Table 3. continued: Response to treatment started after use of single dose nevirapine (sdNVP) in pregnancy  
Study design and 
setting  
Inclusion group (sample size) Outcome measures Findings 
Ekouevi, 2011 [281] 
Prospective cohort 
study 
Côte d’Ivoire 
Aug 2003-Sept 2005 
(Related study:     
Coffie, 2008 [220]) 
Women starting NNRTI-based treatment 
regimen (with symptoms or CD4<350). 
Group 1: ART naïve  
Group 2: sdNVP or sdNVP and short-
course ZDV for PMTCT 
Group 3: short-course ZDV and 3TC for 
PMTCT.  
(Group 1=109; Group 2=50; Group 3=81; 
Total=240) 
 
Outcomes at 36 months on 
treatment 
1: Immunological failure (50% 
fall from CD4 peak during 
treatment) 
2: Treatment failure 
(immunological failure or death 
within 36 months on treatment).  
ART drug adherence 
Censored at last visit, death or 
treatment switch to a PI. 
Resistance test at week 4 pp (in 
groups 2&3) and at virological 
failure. 
Overall, 20% developed immunological 
failure and 26% developed treatment 
failure 
Immunological failure was not associated 
with NVP or 3TC exposure or the 
presence of a NVP or 3TC resistance 
mutation at week 4 pp  
It was associated with poor drug 
adherence (21 months median time 
between NVP exposure and ART start) 
 
 
Kuhn, 2009 [282] 
Zambia 
May 2001- 
September 2004 
Women starting cART after sdNVP 
exposure (n=161). 
Association between viral 
suppression within 6 months 
(VL<400) and the interval 
between sdNVP use and 
starting treatment  
Women with <6 months interval were 
least likely to suppress VL.  
Women with an interval of 6-12 months 
were also less likely to suppress than 
women with an interval of >12 months.   
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Table 3. continued: Response to treatment started after use of single dose nevirapine (sdNVP) in pregnancy  
Study design and 
setting  
Inclusion group (sample size) Outcome measures Findings 
Chi, 2007 [279] 
Prospective 
observational study 
Zambia (26 sites) 
April 2004-July 2006 
(Related study:  
Chintu, 2010 [526]) 
Women starting NVP-containing triple 
therapy with and without previous 
exposure to NVP 
NVP exposed n=229  
NVP-unexposed n=1530 
Total n=1759 
1: CD4 cell count change 
2: Death 
3: Treatment failure at 6 and 12 
months 
NVP exposure was not associated with 
CD4 response at 6 or 12 months or with 
mortality (within 12 months) 
Women with exposure to NVP <6 months 
before starting treatment were more likely 
to experience treatment failure than NVP-
naïve women  
Chintu, 2010 [526] 
Prospective 
observational study 
Zambia 
April 2004-July 2006 
(Related study:        
Chi, 2007 [279]) 
Women starting NNRTI-containing 
treatment with and without previous 
exposure to NVP in pregnancy 
NVP exposed n=596                                 
NVP-unexposed n=4576 
Mortality and treatment failure 
(worsening WHO clinical 
staging/CD4 drop below 95% 
pre-ART CD4/switch of regimen) 
after 12 months 
Adherence data was collected 
Treatment failure was not significantly 
associated with previous NVP exposure  
Women with previous NVP use had better 
survival (p-value 0.07) 
Lehman, 2009 [525] 
Randomized clinical 
trial  
Kenya 
PW with CD4 count 200-500 cells/mm
3
 
Randomised at 34/40 weeks to                       
1) ZDVm and sdNVP in pregnancy or                                 
2) cART (ZDV+NVP+3TC) for last 6 weeks 
of pregnancy plus 6 months breastfeeding   
Detection of NVP resistance at 3 
months after treatment cessation 
(using PCR)  
Women in ZDV/NVP group were more likely 
to have resistance mutation at 3 months 
after ART cessation than women in cART 
group (75% vs. 18%, OR 13.5 p-value 
0.007)  
  3
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Table 3. continued: Response to treatment started after use of single dose nevirapine (sdNVP) in pregnancy  
Study design and 
setting  
Inclusion group (sample size) Outcome measures Findings 
Stringer, 2010 [283] 
Prospective 
observational non-
inferiority study 
Zambia n=509  
Kenya n=152  
Thailand n=217 
June 2006-Jan 2007 
Women starting NNRTI-containing 
treatment with and without previous 
exposure to NVP in pregnancy 
sdNVP exposed n=355                             
NVP-unexposed n=523 
1: Treatment failure at 48 weeks 
(death, regimen switch or VL 
≥400 at 24/48 weeks) 
Overall, 28% of women had treatment 
failure at 48 weeks 
Women with an interval <6 months 
between exposure and treatment:            - 
NVP exposure increased the risk of 
treatment failure  
Women with a 7-12 month interval:                       
NVP exposure increased risk of treatment 
failure but not statistically significant 
Women whose exposure interval was 
>12m - no evidence of increased risk. 
Coovadia, 2009 
[527] 
Prospective 
observational study 
Johannesburg, 
South Africa  
July 2004-May 2006 
Women starting NNRTI-containing 
treatment with and without previous 
exposure to sdNVP (18-36 months 
earlier). 
(sdNVP exposed=94;                                 
NVP-unexposed=60) 
1. Time to viral suppression 
(VL<50) 
2. Viral suppression at 24 weeks 
3. Time to viral rebound (2 
consecutive VL>400 following 
viral suppression)  
4. Viral rebound at 78 weeks 
Viral RNA and proviral DNA 
tested for K103N mutation 
10% sdNVP-exposed women had K103N 
mutation  
15% drug naïve women had K103N 
mutation  
K103N mutation predicted inadequate 
virological response 
A similar % of women in both groups 
achieved viral suppression or developed 
viral rebound (unadjusted analysis).  
3TC: lamivudine; cART: combination antiretroviral therapy; CD4: CD4
+ cell count (cells/mm3); NNRTI: non-nucleoside reverse-transcriptase inhibitor; PI: protease inhibitor; 
PMTCT: prevention of mother-to-child transmission; pp: post-pregnancy; sdNVP: single dose nevirapine; VL: viral load (copes/ml); ZDV: zidovudine.   3
5
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Table 4. Response to treatment started after use of short-course cART in pregnancy 
Study design and 
setting  
Inclusion group  (sample size) Outcome measures Findings 
Vogler, 2014 [286] 
Prospective clinical 
trial 
HIV treatment sites in 
US, Brazil & Peru 
Oct 2007-Dec 2009 
 
Non-PW starting treatment on combination 
of EFV + TDF/FTC with ≥1 previous use of 
short-course ART in pregnancy  
No use of ART in the past 24 weeks 
VL ≥500 copies/ml 
(Brazil=22; Peru=20; US=12; Total=54)  
1: Virological response (VL <400) 
at 24 weeks after ART start 
2: Characterise drug resistance 
mutations among women with 
virological failure (defined as two 
consecutive VL ≥400 at ≥16 
weeks after ART start) 
3: Self-reported drug adherence 
1: 81% women had virological response at 
24 weeks. No characteristics were 
predictive of virological response.  
3. Virological failure was associated with 
poor adherence. 
“Provides further support that virological 
response in HIV-1–infected women to a 
commonly used initial cART regimen is not 
compromised by prior PMTCT with cART”. 
cART: combination antiretroviral therapy; EFV: efavirenz; FTC: emtricitabine; PMTCT: prevention of mother-to-child transmission; PW: pregnant women; TDF: tenofovir; US: 
United States of America; VL: viral load (copies/ml). 
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Table 5. Hepatotoxicity rates among pregnant HIV-positive women  
Study design and 
setting 
Inclusion group             Toxicity measure Regimen used  Findings 
Hitti, 2004 [236] 
Drug trial 
US - Aug 2003 
Women starting ART in 
pregnancy (>late second 
trimester) (hepatitis co-
infected women excluded) 
Treatment limiting 
toxicity 
NVP-containing  29% (5/17) experienced toxicity 
NFV-containing  5% (1/21) experienced toxicity 
Marazzi, 2006 [239] 
Retrospective cohort  
Mozambique 
May 2002 - July 2004 
PW starting ART in 
pregnancy 
Liver enzyme elevation 
(LEE)  
NVP-containing 12.3% (86/703) Grade 2-4 LEE                             
6.5% (46/703) Grade 3-4 LEE 
High CD4 count when starting ART was not 
independently associated with LEE 
João, 2006 [237] 
Retrospective cohort 
Brazil 
Jan 1996- Dec 2003 
PW starting ART in 
pregnancy 
LEE  NVP-containing  5.1% (10/197) Grade 1-4 LEE                              
0.5% (1/197) Grade 3-4 LEE 
HCV co-infection was the only factor 
independently associated with hepatotoxicity. 
CD4 count was only protective if the cut off for 
‘high’ CD4 category was >600 cells/mm3 
Lyons, 2006 [288] 
Retrospective cohort  
3 HIV centres  
Dublin 
Oct 2000 – Feb 2003 
Women prescribed NVP-
containing regimen in 
pregnancy 
LEE  
 
NVP-containing  
 
8.2% (7/85) Grade 1 LEE 
16.4% (14/85) Grade 2 LEE 
9.4% (8/85) Grade 3-4 LEE 
10% discontinued ART in preg due to LEE Pre-
treatment CD4 count was associated with LEE 
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Table 5. continued: Hepatotoxicity rates among pregnant HIV-positive women 
Study design and 
setting 
Inclusion group             Toxicity measure Regimen used  Findings 
Jamisse, 2007 [240] 
Prospective cohort 
Mozambique 
Aug 2004 – Jun 2005 
Women prescribed NVP-
containing regimen in 
pregnancy 
LEE  
 
NVP-containing  7.5% (11/146) Grade 2-4 LEE 
2.7% (4/146) Grade 3-4 LEE 
Baseline CD4 ≥250 was associated with 
increased risk of Grade 3-4 but not Grade 2-4. 
Kondo, 2007 [241] 
Retrospective cohort 
Brazil                          
Jan 2003 – Dec 2006  
PW starting ART LEE  
 
NVP-containing  4.5% (6/133) Grade 1-4 LEE 
1.5% (2/133) Grade 3-4 LEE 
van Schalkwyk, 2008 
[242] 
Retrospective study  
US                              
Jan 1997 – Feb 2004 
PW on ART (starting during 
and before pregnancy) 
Treatment change 
required due to toxicity 
NVP-based (54%) and 
non-NVP-based (46%) 
7% (7/103) changed treatment due to toxicity 
overall 
11% (6/56) NVP-based group 
2.1% (1/47) non-NVP-based group 
Black, 2008 [243] 
Retrospective study  
South Africa  
Aug 2004 – Feb 2007 
Treatment naïve PW 
starting ART 
Treatment change 
required due to toxicity 
HAART (82% using 
NVP+d4T+3TC) 
2.6% women (16/620) switched to a different 
regimen in pregnancy due to toxicity 
3.5% experienced NVP associated rash 
3TC: lamivudine; ALT: alanine transaminase; d4t: stavudine; LEE: liver enzyme elevation; NFV: nelfinavir; NVP: nevirapine; PW: pregnant women; ULN: upper limit of normal; 
US: United States of America.  3
5
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Table 6. Comparing LEE in pregnant women on NVP-containing and non-NPV-containing regimens 
Study design and 
setting 
Inclusion group             Toxicity measure Regimen used  Findings 
Peters, 2012 [352] 
Prospective study 
Kenya 
July 2003-Nov 2006 
PW starting cART at 34 
weeks gestation 
Severe LEE              
(grade 3-4) 
NVP-containing  
NFV-containing  
Overall, 3% (14/522) experienced severe LEE  
Women on NVP-regimen (n=254) had higher 
rates of severe LEE than women on NFV-
regimen (4.6% vs. 1.0%, p-value 0.03)  
Baseline CD4 count ≥250 was not associated 
with severe LEE in women on NVP-regimen 
Ouyang, 2010 [324] 
Multi-centre 
prospective cohort  
US 
July 2002-June 2006 
 
Women using cART in 
pregnancy 
Any LEE            
(grade 1-4) 
Severe LEE             
(grade 3-4) 
 
 
NVP-containing 
(n=218, 18%)  
non-NVP containing 
(n=1011) 
Cox proportional 
hazards regression 
models using time-
dependent covariates 
(pregnancy assessed 
as baseline variable 
but includes 
pregnancies 
conceived on ART)  
Any LEE: 
13% PW on NVP-regimen  
14% PW on non-NVP-regimen  
aRR: 1.00 [0.64-1.57] p-value 0.99 
Severe LEE: 
0.5% PW on NVP-regimen  
1.4% PW on non-NVP-regimen  
In adjusted analysis using a NVP-regimen 
was not associated with LEE or severe LEE   
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Table 6. continued: Comparing LEE in pregnant women on NVP-containing and non-NPV-containing regimens 
Study design and 
setting 
Inclusion group             Toxicity measure Regimen used  Findings 
Timmermans, 2005 
[316] 
Retrospective study 
15 HIV centres 
Netherlands 
Jan 1997-June 2003 
PW and non-PW starting 
NVP-containing or NFV-
containing regimens 
ALT/AST ≥3x ULN NVP-containing & 
NFV-containing  
NVP-containing regimen:  
PW: 19% (11/58) experienced toxicity              
non-PW: 4% (4/95) experienced toxicity 
NFV-containing regimens: 
PW: 4% (5/128) experienced toxicity                                         
non-PW: 4% (4/91) experienced toxicity 
No adjusted analysis performed  
Aaron, 2010 [358] 
Retrospective study 
3 HIV clinics  
US 
Jan 1999-August 2005 
 
 
PW on NVP-regimen 
(n=79) 
PW on non-NVP-regimen 
(n=67) 
Non-PW on NVP-regimen 
(n=61) 
Non-PW on non-NVP-
regimen (n=392) 
LEE (≥grade 2) 
 
NVP-containing 
(n=140) and non-NVP 
containing (n=459) 
NVP-containing regimen: 
PW: 2.5% (2/79) experienced LEE             
non-PW: 6.6% (4/61) experienced LEE 
NFV-containing regimens: 
PW: 0% (0/67) experienced LEE                    
non-PW: 5.4% (21/392) experienced LEE  
Pregnancy status (at baseline), using NVP-
regimen and baseline CD4 >250 were not 
associated with LEE in adjusted analysis. 
ALT: alanine transaminase; AST: aspartate transaminase; aRR: adjusted relative risk; CD4: CD4
+
 cell count (cells/mm
3
); LEE: liver enzyme elevation; NFV: nelfinavir; NVP: 
nevirapine; PW: pregnant women; ULN: upper limit of normal; US: United States of America.  
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Table 7. Summary of studies comparing LEE in pregnant women and non-pregnant women 
Study design and 
setting 
Inclusion group             Toxicity measure Regimen used  Findings 
Phanuphak, 2007 
[320] 
Retrospective study 
Thailand  
1996 onwards 
 
PW (n=244), non-PW 
(n=87) & men (n=78) 
PW started long-term ART 
>14 weeks gestation 
(CD4≤200) or started 
short-course cART >28 
weeks gestation 
(CD4>200). 
Non-PW and men started 
long-term cART with 
CD4≤200 
ALT LEE (grade 1/2 
and grade 3/4) 
Note: ALT 
measurements were 
taken at regular 
intervals 
NVP-containing 
regimens 
LEE: Grade 1-2 
PW on short-course ART 19.5/100PY                     
PW on therapy 12.3/100PY                               
Non-PW on therapy 9.8/100PY                             
Men on therapy 29.8/100PY 
LEE: Grade 3-4 
PW on short-course ART 1.6/100PY                                 
PW on therapy 0.0/100PY                                
Non-PW on therapy 0.0/100PY                           
Men on therapy 2.0/100PY  
LEE: Grade 1-4 
PW on short-course ART 21.1/100PY                 
PW on therapy 12.3/100PY                          
Non-PW 9.8/100PY                                          
Men 31.8/100PY 
Neither pregnancy status or female gender 
were associated with LEE in analysis adjusted 
for baseline characteristics 
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Table 7. continued: Summary of studies comparing LEE in pregnant women and non-pregnant women 
Study design and 
setting 
Inclusion group             Toxicity measure Regimen used  Findings 
Ouyang, 2009 [317] 
2 prospective cohorts  
US 
July 2002-June 2006 
Comparison of PW and 
non-PW (under 45 years 
old) on cART  
Time-dependent variables, 
but pregnancy was a 
baseline characteristic 
only 
Any LEE           
(grade 1-4) 
Severe LEE             
(grade 3-4) 
19% of women were 
on NVP-containing 
regimen (18% of PW 
and 21% of non-PW) 
14% PW experienced LEE                                   
9.1% non-PW experienced LEE 
aRR 4.7 [95% CI 3.4-6.5], p<0.001 
1.2% PW experienced severe LEE                      
0.6% non-PW  experienced severe LEE  
(p=0.17) 
Bersoff-Matcha, 2010 
[359] 
Retrospective cohort  
US  
Jan 1995-May 2007 
PW (n=42) and non-PW 
(n=211) starting ART in 
first or early second 
trimester 
Adverse events 
(rash/LEE) 
NVP-containing 
regimen 
Baseline CD4 did not predict adverse events 
Similar rates of rash and LEE as in other non-
PW cohorts  
In unadjusted analysis PW were less likely to 
experience an adverse event (rash/LEE)  
Coffie, 2010 [220] 
Prospective cohort  
Côte d'Ivoire  
Aug 2003-Oct 2006 
PW and non-PW starting  
cART with CD4<350   
Severe LEE              
(grade 3-4) 
NVP-containing  Overall rate severe LEE: 2.2/100 PY (95% CI 
1.1-4.0) 
Pregnancy status in the first three months of 
ART use was not associated with risk of 
severe LEE (HR 1.22, p=0.82) 
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Table 7. continued: Summary of studies comparing LEE in pregnant women and non-pregnant women 
Study design and 
setting 
Inclusion group             Toxicity measure Regimen used  Findings 
Snijdewind, 2012 [318] 
Retrospective cohort  
Netherlands (Athena 
Study) 
Jan 1997-Feb 2008 
PW and non-PW starting 
cART  
 
Severe LEE             
(grade 3-4) 
23% used NVP-
containing regimen 
(23% PW & 24% non-
PW) 
3.8% PW experienced LEE 
5.4% Non-PW experienced LEE 
Pregnancy was not independently associated 
with severe LEE (aOR 0.70 [0.38-1.28], 
p=0.25) 
HCV co-infection (in non-PW) and NVP use 
were both associated with severe LEE 
Aaron, 2010 [358] (See Table 6) 
Timmermans, 2005 [316] (See Table 6) 
ALT: alanine transaminase; aOR: adjusted odds ratio; cART: combination antiretroviral therapy; HCV: hepatitis C virus; LEE: liver enzyme elevation; NVP: nevirapine; PW: 
pregnant women; aRR: adjusted relative risk; ULN: upper limit of normal; US: United States of America. 
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Table 8. Summary of study comparing LEE in women who conceive on ART with women who start ART in pregnancy  
Study design and 
setting 
Inclusion group             Toxicity measure Regimen used  Findings 
Natarajan, 2007 [321] 
Retrospective study 
5 HIV centres  
London 
PW starting ART in 
pregnancy (>20 weeks) 
compared with PW 
starting ART prior to 
pregnancy 
 
ALT >3 times ULN NVP-containing cART 
regimens 
Either starting in 
pregnancy or 
conceiving on  
Overall, 3% developed toxicity 
PW starting ART in pregnancy: 4.7% (8/170) 
experienced LEE 
PW starting ART before pregnancy: 0% (0/65) 
experienced LEE 
p-value not given but >0.05 
Notes a similar rate of LEE in PW as would be 
expected in non-PW   
ALT: alanine transaminase; cART: combination antiretroviral therapy; LEE: liver enzyme elevation; NVP: nevirapine; PW: pregnant women; ULN: upper limit of normal.  
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Table 9. Summary of studies examining post-pregnancy viral rebound in the pre-HAART era 
Study design and setting Outcome measures (sample size) Findings 
Burns,  1998 [384] 
Mother and infant cohort  
1986-1991 
New York, US 
160 pregnancies (6 used ZDVm in pregnancy) 
VL was assessed at delivery, 2, 12 & 24 months 
pp 
 
No increase in VL at 12 months pp was observed  
VL increase at 2 years pp – probably due to disease 
progression   
Bardeguez, 2003 [193] 
Prospective observational study  
1991-1994 
US & France 
Women randomized to receive either ZDVm 
(n=236) or placebo (n=238) in pregnancy 
VL assessed at 6, 12, 18, 24 and 36 months pp 
6 months pp the median VL had increased in both 
groups – probably due to disease progression 
Cao, 1997 [132] 
1993-1996 
US 
204 pregnant women receiving long-term ZDVm, 
short-term ZDVm or no ART 
5 fold elevation in VL assessed at 2 and 6 
months postpartum 
Increased VL and lower CD4 count at 2 and 6 months 
pp among women in all three groups (no statistical 
comparison between groups) 
Watts, 2003 [382] 
Phase 3 clinical trial 
1993-1997 
US & Puerto Rico 
Pregnant women (n=497) using short-course 
ZDVm or remaining on ZDVm after pregnancy   
Rise in VL from delivery to 12 weeks pp 
assessed  
Observed a rise in VL at 12 weeks pp in group who 
remained on ZDVm/cART and short-course ART group 
Ekpini, 2002 [197] 
1996-Feb 98 
Côte d’Ivoire 
Short-course ZDVm=34 women 
Placebo = 15 women 
2 & 4 weeks pp 
Increase in viral load from baseline at 2-4 weeks pp in 
both groups 
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Table 9. continued: Summary of studies examining post-pregnancy viral rebound in the pre-HAART era 
Study design and setting Outcome measures (sample size) Findings 
Truong, 2010 [385] 
Secondary data analysis of 
prospectively enrolled HIV 
transmission study  
1989-2003 
US  
VL at delivery and 2-8 weeks pp  
Group 1: n=11, no ART 
Group 2: n=12, short-course-ZDVm 
Group 3: n=37, continuous ZDVm 
Group 4: n=36, continuous cART 
VL increased from delivery to pp 2-8 weeks in all 
groups 
cART: combination antiretroviral therapy; pp: post-pregnancy; US: United States of America; VL: viral load; ZDVm: zidovudine monotherapy. 
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Table 10. Summary of studies examining post-pregnancy viral load in the HAART era 
Study design and setting Outcome measures (sample size) Findings 
Bryson, 2008 [374] 
Phase 1 study of NFV safety and 
pharmacokinetics of NFV in 
pregnancy 
1997-2002         US 
33 women on short-term cART (NFV,ZDV+3TC) 
12 weeks pp 
Proportion with HIV-1 RNA <400 copies/ml 
At delivery, 81% (25/31) had undetectable VL  
At 12 weeks pp, 52% (15/29) had undetectable VL 
Tungsiripat, 2007 [383] 
Retrospective study 
1999-2003 
US 
60 women using short-course ART in pregnancy 
VL at 12-24 weeks pp compared to pre-
pregnancy levels 
pp VL was similar to pre-pregnancy levels 
Sha, 2011 [376] 
Prospective study 
2002-2005 
US 
63 pregnancies – women on cART in pregnancy 
and remaining on cART afterwards (29 different 
regimens represented) 
VL measured at 6, 12 & 24 weeks pp 
≥0.7 log10 (5-fold) increase in VL or ≥500 
copies/ml from 34/36 weeks gestation   
29% (18/63) women remaining on ART pp experienced 
viral rebound at 24 weeks pp  
(14% (10/74) at 6 weeks pp) 
Drug adherence reduced after pregnancy 
Melo, 2011 [381] 
Prospective cohort 
1119 pregnancies 
2002-2007 
Latin America & Caribbean  
Increase VL ≥1.5 log10   
6-12 weeks postpartum 
START defined as women who did not conceive 
on ART and stopped before 6-12 week pp check 
60% women on START experienced pp viral rebound 
19% women on long-term ART experienced pp viral 
rebound 
  
3
6
5
 
 366 
 
Table 10. continued: Summary of studies examining post-pregnancy viral load in the HAART era 
Study design and setting Outcome measures (sample size) Findings 
Cavallo, 2010 [375] 
Prospective cohort study  
2003-2007 
Brazil 
112 women on short-course or continuous ART 
in pregnancy 
Viral rebound defined as a 0.5 log10 increase in 
VL at 6 months pp compared to VL at delivery 
VL assessed at 6-12 weeks pp & 6 months pp 
pp viral rebound was more likely to occur in women 
using short-course ART in pregnancy (85% 50/60) 
compared to women on continuous ART (15% 9/52)  
(p-value <0.001) 
 
Watts, 2009 [249] 
Prospective observational study 
Multiple US cites  
Jun 1994-Jun 2006 
Pregnant women with CD4 >350 using ART in 
pregnancy (n=206) 
1) short-course ZDVm (n=41) 
2) remained on ZDVm (n=62) 
3) short-course cART (n=18) 
4) remained on cART (n=82) 
VL and biomarkers at 2, 6 and 12 months pp  
Did not compare VL at delivery with VL at 2 months pp  
VL between 2 months pp and 12 months pp did not 
significantly change  
Studies examining biomarkers  
Hoffman, 2013 [387] 
Biomarker study  
US & Puerto Rico 
≥2002 
Biomarkers (C-reactive protein, D-dimer, 
interleukin-6) levels measured at delivery and 6 
weeks pp 
Continuers; n=65 women staying on ART pp 
Discontinuers: n=63 women stopping ART <6 
weeks pp 
Biomarkers were decreased at 6 weeks pp 
The continuers had a steeper decrease in D-dimer than 
the discontinuers 
3TC: lamivudine; cART: combination antiretroviral therapy; NFV: nelfinavir; US: United States of America; VL: Viral load; pp: post-pregnancy; ZDVm: zidovudine monotherapy.3
6
6
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Appendix IIIa NSHPC pregnancy notification form 
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Appendix IIIb NSHPC pregnancy outcome form 
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Appendix IV  UK CHIC Coding Frame (November 2008) 
General points: 
 Data to be provided on all patients seen at your HIV centre  
 All data can be provided as access tables, excel spreadsheets or text files with the 
variables comma or tab delimited  
 All dates should be provided in dd/mm/yyyy format, including leading zeros 
 All files should include the clinic ID and date of birth for each patient so that the files 
can be easily merged 
 Important: Please submit data files by FTP method. When you are ready to send 
data please contact or email t.hill@pcps.ucl.ac.uk for FTP details 
 Important: If possible encrypt data using Axcrypt which is free open source software 
available from www.axantum.com/AxCrypt. Please password protect data files or 
folder with a strong password or phrase (not ‘ukchic’, or the clinic name)  
 Variables in bold in the data tables (Files 1 – 11) have codes listed in the data 
specifications. Data must be coded using UK CHIC codes otherwise it will not 
be accepted. If you need help in coding any data please contact us 
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File 1 – PATIENTCENTRE table 
Field Name Description Type 
ClinicNo HIV Clinic’s unique patient identifier  text (12) 
DOB Date of birth dd/mm/yyyy 
Soundex Soundex code text (4) 
Initial Patient initial/s text (2) 
SexID Patient sex code integer 
HIVPos Date of first known positive HIV 
antibody test 
dd/mm/yyyy 
HIVNeg Date of last negative HIV antibody test dd/mm/yyyy 
Firstseen Date of first HIV attendance at centre dd/mm/yyyy 
Lastseen Date when last seen by a clinician at 
the centre 
dd/mm/yyyy 
ExposureID HIV exposure category  integer 
EthnicityID Ethnicity code integer 
CountryID Country of birth code text (30) 
DiedID Is patient known to have died code integer 
DDeath Date of death dd/mm/yyyy 
Cause Cause of death (where known) text (60+) 
TransferFr Transfer from centre text (50) 
TransferFrDate Transfer from centre date dd/mm/yyyy 
TransferTo Transfer to centre text(50) 
TransferToDate Transfer to centre date dd/mm/yyyy 
 
File 2 – AIDSEVENT  table 
Field Name Description Type 
ClinicNo HIV Clinic’s unique patient identifier  text (12) 
DOB Date of birth dd/mm/yyyy 
DAIDS Date of AIDS event dd/mm/yyyy 
AIDSID AIDS event code  integer 
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File 3 – ANTIRETRO table 
Field Name Description Type 
ClinicNo HIV Clinic’s unique patient identifier  text (12) 
DOB Date of birth dd/mm/yyyy 
DStart Date started taking drug dd/mm/yyyy 
DStop Date stopped taking drug dd/mm/yyyy 
DrugID Drug code integer (15) 
ReasonStopID1 Reason for stopping drug integer 
ReasonStopID2 Reason for stopping drug (if multiple 
codes) 
integer 
ReasonstopID3 Reason for stopping drug (if multiple 
codes) 
integer 
File 4 – CD4 table 
Field Name Description Type 
ClinicNo HIV Clinic’s unique patient identifier  text (12) 
DOB Date of birth dd/mm/yyyy 
Dlab Date of lab measurement dd/mm/yyyy 
CD4A Absolute CD4 count in cells/mm3 integer 
CD4P CD4 percentage number (1dp) 
CD8A Absolute CD8 count in cells/mm3 integer 
CD8P CD8 percentage number (1dp) 
File 5 – RNA/Viral Load table 
Field Name Description Type 
ClinicNo HIV Clinic’s unique patient identifier  text (12) 
DOB Date of birth dd/mm/yyyy 
Dlab Date of lab measurement dd/mm/yyyy 
RNA HIV Viral Load level in copies/ml  long integer 
UndetID Status of HIV RNA measurement 
code 
integer 
AssayID HIV RNA assay code  integer 
File 6 – Hepatitis  table   
Field Name Description Type 
ClinicNo HIV Clinic’s unique patient identifier  text (12) 
DOB Date of birth dd/mm/yyyy 
DHeptest Date of hepatitis test dd/mm/yyyy 
HepTestID Hep test code  integer 
HepResultID test result (-/+/indet) integer 
Hepvalue test result value, if appropriate long integer 
UndetID please ignore this  
Hepassay please ignore this  
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File  7 – ADHERENCE  table 
Field Name Description Type 
ClinicNo HIV Clinic’s unique patient identifier  text (12) 
DOB Date of birth dd/mm/yyyy 
DAdherence Date of clinic visit dd/mm/yyyy 
AdherPeriodID Adherence period codes  integer 
AdherPerOther Adherence period other text (50) 
DosesMiss No / % of doses missed  integer 
ReasonMissID  Reason for missing treatment code integer 
File 8 – PCPPROP  table  
Field Name Description Type 
ClinicNo HIV Clinic’s unique patient identifier  text (12) 
DOB Date of birth dd/mm/yyyy 
PCPpDrugID PCP Drug code  integer 
PCPpStart Date of starting PCP prophylaxis dd/mm/yyyy 
PCPpStop Date of stopping PCP prophylaxis dd/mm/yyyy 
File 9 – Toxicity table  
Field Name Description Type 
ClinicNo HIV Clinic’s unique patient identifier  text (12) 
DOB Date of birth dd/mm/yyyy 
DToxtest Date of toxicity test dd/mm/yyyy 
ToxTestID Tox test code  integer 
ToxResult Test result value integer 
ToxUnitID Test results units text (10) 
 
File 10 – HLA-B57 table 
Field Name Description Type 
ClinicNo HIV Clinic’s unique patient identifier  text (12) 
DOB Date of birth dd/mm/yyyy 
DHLAB57 Date of HLA-B57 test dd/mm/yyyy 
HLAB57ResultID test result (-/+/indet) integer 
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File 11 – Attendance table 
Field Name Description Type 
ClinicNo HIV Clinic’s unique patient identifier  text (12) 
DOB Date of birth dd/mm/yyyy 
DAttend Date of attendance dd/mm/yyyy 
AttSeenBy Who patient is seen by eg. Dr, nurse, 
dietician, psychologist, other etc 
integer 
AttType Attendance: scheduled, walk-in, 
virtual,   in-patient, other 
integer 
Ddischarge Date of discharge if in-patient dd/mm/yyyy  
 
Reference Tables 
 Table Name 
Variable1 Variable2 
AdherPeriodID AdherPeriod 
1 No in last 3 days   
2 No in last 14 days  
3 No in last 30 days   
4 % in last 30 days  
98 Other 
99 Not known 
AIDSID AIDS 
1 Bacterial infections (multiple or recurrent) at age < 13 years 
2 Candidiasis, oesophageal 
3 Candidiasis, trachea/bronchi/lungs  
4 Candidiasis, site unknown  
5 Cervical cancer, invasive  
6 Coccidioidomycosis, extrapulmonary  
7 Cryptococcosis, extrapulmonary  
8 Cryptosporidiosis, duration > 1 month  
9 Cytomegalovirus retinitis   
10 Cytomegalovirus disease, other  
11 Cytomegalovirus, site unknown  
12 Herpes simplex disease, duration > 1 month  
13 Histoplasmosis, extrapulmonary and/or disseminated  
14 HIV Encephalopathy   
15 Isosporiasis, duration > 1 month  
16 Kasposi’s sarcoma  
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17 Lymphoid interstitial pneumonia or pulmonary lymphoid 
hyperplasia at age <13 years  
18 Lymphoma, Burkitt’s, immunoblastic or equivalent   
19 Lymphoma, primary in brain  
20 Mycobacterium avium, extrapulmonary (MAI/MAC) 
21 Mycobacterium tuberculosis, pulmonary  
22 Mycobacterium tuberculosis, extrapulmonary  
23 Mycobacterium, other (disseminated)  
24 Pneumoncystis carinii pneumonia (P. jiroveci) 
25 Pneumonia, recurrent in a 12-month period  
26 Progressive multifocal leukoencephalopathy  
27 Salmonella Septicaemia, recurrent  
28 Toxoplasmosis, cerebral  
29 HIV wasting syndrome  
31 Lymphoma Site Unknown 
51 Mycobacterium tuberculosis, Site Unknown 
98 AIDS disease, not specified  
99 Not Known 
AssayID Assay 
1 Roche v1.0 (<400) 
2 Roche non-B (<400) 
3 Roche v1.5 (<400) 
4 Roche v1.5 US (<50) 
5 Roche – version unknown 
6 Cobas v1.5 (<400) 
7 Cobas v1.5 US (<50) 
9 Cobas – version unknown 
10 NASBA (<400) 
11 NASBA US 
12 NASBA – version unknown 
13 Chiron b-DNA v1.0    
14 Chiron b-DNA v2.0 (<500) 
15 Chiron b-DNA v3.0 US (<50)    (also known as Bayer?) 
16 Chiron – version unknown 
17 Nuclisens (<400) 
18 Nuclisens US (<50?) 
19 Nuclisens – version unknown 
21 Cobas<10 copy assay 
98 Other 
 429 
 
99 Not known 
AttSeenBy Attendance 
1 Clinician 
2 Nurse 
3 Health advisor 
4 Pharmacy/Pharmacist 
5 Dietician 
6 Psychologist / Counsellor 
98 Other 
99 Not known 
AttType Type of attendance 
1 Scheduled or booked 
2 Walk-In 
3 Virtual – telephone or email contact 
4 In-patient 
98 Other 
99 Not known 
DiedID Died 
0 No 
1 Yes 
99 Not known 
DrugID Drug 
1 Zidovudine (AZT)  
2 Zalcitabine (ddC)  
3 Didanosine (ddI)  
4 Stavudine (d4T) 
5 Lamivudine (3TC) 
6 Abacavir  
7 Combivir (AZT+3TC)  
8 Lodenosine 
9  Trizivir (AZT + 3TC + abacavir) 
10 Tenofovir (TDF) 
11  Emtricitabine (FTC) 
12 Kivexa (3TC + Abacavir) 
13 Truvada (Tenofovir/TDF + emtricitabine /FTC) 
19 Other NRTI 
20 Nevirapine  
21 Efavirenz  
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22 Loviride  
23 Delavirdine  
24 Etravirine / TMC125 
39 Other NNRTI  
40 Saquinavir hard gel (invirase)  
41 Indinavir  
42 Ritonavir – any dose  
43 Nelfinavir  
44 Saquinavir soft gel (fortovase)  
45 Amprenavir  
46 Lopinavir (ABT 378) (kaletra) 
47 Saquinavir (form unknown)  
48 Atazanavir  
49 Other PI  
50 Hydroxyurea / hydroxycarbamide 
51 IL-2 
60 Acyclovir 
61 Fos amprenavir 
62 Tipranavir 
63 Darunavir / TMC114 
70 Enfuvirtide / T20  
80 Adefovir 
90 Blinded treatment in clinical trial  
95 Maraviroc 
96 Vicriviroc 
98 Other drug  
99 Not known 
110 Raltegravir / MK-0518 
120 Atripla (Efavirenz/Tenofovir/Emtricitabine) 
EthnicityID Ethnicity 
1 White 
2 Black-Caribbean 
3 Black-African 
4 Black – unspecified/black-other 
5 Indian/Pakistani/Bangladeshi 
6 Other Asian/Oriental 
7 Other/mixed 
98 Other 
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99 Not known 
ExposureID Exposure 
1 Homosexual/bisexual (including homo / bi sex who also 
injected drugs) 
2 Injecting drug use  
3 Heterosexual 
4 Blood/blood products recipient 
5 Mother-to-child transmission 
98 Other 
99 Not Known 
HepResultID HepResult 
0 Negative 
1 Positive 
2 Indeterminate /weakly reactive/equivocal 
HepTestID HepTest 
1 Hep A antibody (total) 
2 Hep B surface antigen         (HbsAg) 
3 Hep B surface antibody       (anti-HBs) 
4 Hep B core antibody            (anti-HBc) 
5 Hep B e antigen 
6 Hep B e antibody 
7 Hep C antibody 
8 Hep C virus PCR/bDNA 
9 Hep B core antibody (IgM) 
10 Hep A antibody (IgM) 
11 Hep B DNA (Type unknown) 
12 Hep D antibody (total) 
13 Hep B surface antigen (titre) 
14 Hep D antibody (IgM) 
98 Other  
99  Not known 
HLAB57ResultI
D 
HLAB57Result 
0 Negative 
1 Positive 
2 Indeterminate /weakly reactive/equivocal 
PCPpDrugID PCPpDrug 
1 Co-trimoxazole/septrin 
2 Dapsone  
 432 
 
3 Pentamidine  
4 Atovaquone  
5 Azithromycin  
6 Clarithromycin  
7 Clindamycin  
8 Fansidar (=pyrimethamine + sulphadoxine) 
9 Primaquine  
10 Pyrimethamine 
11 Sulphadiazine 
12 Sulphadimidine 
13 Sulfametopyrazine 
14 Trimetrexate 
15 Trimethoprim 
16 Sulfadoxine 
17 Maloprim (pyrimethamine + dapsone)  
18 Eflornithine 
98 Other 
99 Not known 
ReasonMissID ReasonMiss 
1 Forgot 
2 Ran out of medicaiton 
3 Wanted a short break 
4 Side effects 
5 Away from home/supply  
6 In company 
7 Treatment holiday 
98 Other 
99 Not known 
ReasonStopID ReasonStop 
10 Failure-cause unknown  
11 Virological  
12 Immunological   
13 Clinical 
14 VL / CD4 
20 Toxicity-type unknown  
30 Skin  
31 Hypersensisity – Abacavir  
32 Rash  
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40 GI  
41 Nausea/Vomiting 
42 Diarrhoea  
43 Pancreatitis  
44 Abnormal LFT  
50 Neuro  
51 CNS Disturbance  
52 Peripheral Neuropathy  
53 Headache  
60 Metabolic  
61 Lipids  
62 Glucose Intolerance  
63 Hyperlactataemia  
64 Osteopaenia  
70 Lipodystrophy  
80 Myelotoxicity  
81 Anaemia  
82 Neutropenia  
83 Thrombocytopenia  
91 Myotoxicity  
92 Nephrolithiasis/Renal Dysfunction   
100 Patient Choice 
110 Clinician decision 
120 Interaction  
130 Simplification  
140 Poor Adherence  
150 Joined clinical trial  
160 Study/Trial End  
170 New drug available  
180 Known treatment interruption  
190 Protocol amendment  
200 Pregnancy  
201 At start/during pregnancy  
202 End of short-course ART  
210 Intercurrent illness, not HIV/ drug related  
220 VL sufficiently low  
230 CD4 sufficiently high  
240 Regimen change 
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250 Transfer of care 
260 Drug Experience / Resistance 
998 Other   
999 Not Known 
SexID Sex 
1 Male 
2 Female 
99 Not known 
ToxTestID ToxTest 
1 ALT 
2 Albumin 
3 Alkaline phosphatase 
4 Amylase 
5 AST 
6 Bilirubin 
7 Cholesterol total (non fasting or unknown) 
8 CPK (creatine phosphokinase) 
9 Creatinine 
10 Glucose 
11 GGT(g-glutamyl transferase) 
12 Haemoglobin 
13 HDL 
14 Lactate 
15 LDL 
16 Triglycerides 
17 Urea 
18 Lactate dehydrogenase  
19 Cholesterol (fasting) 
98 Other 
99 Not known 
ToxUnitID ToxUnit 
1 IU/L 
2 g/L 
3 U/L 
4 mol/L  
5 mol/L(plasma) 
6 mmol/L 
7 mmol/L(urine) 
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8 g/dL  
9 mg/L 
98 Other 
99 Not known 
UndetID Undet  
-1  < Below lower limit of detectability  
0 Any value that is detectable but below the upper limit of 
quantification 
1 > Above upper limit of quantification 
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Appendix V  Summary of matching  
Figure 1. Matching records for women reported to NSHPC and UK CHIC to create a 
combined 2011 dataset  
 
 
 
 
 
 
 
 
  
NSHPC 
♀ 9501 
UK CHIC a 
♀ 11,302 
Identical DOB 
14,170 pairs b 
(6896 UK CHIC records) 
(7031 NSHPC records) 
 
No DOB match 
♀ 4406 
 
No DOB match 
♀ 2470 
 
Exact CD4 date 
match 
2165 
 
CD4 count ±10 
1995 pairs 
 
1977 
(1977) 
Pairs confirmed 
as a match 
(cumulative) 
Ethnic discrepancy 8 - rejected: 0 
COB discrepancy 6 - rejected: 0 
Drug naive 8 - rejected: 0 
Death date - 0 rejected: 0 
 
 
 
4655 pairs  
removed c 
 n=7479 
NSHPC 
♀ 9564 
Did not attend 
care at a HIV 
clinical in UK 
♀ 60 
No DOB 
reported 
♀ 3 
 
UK CHIC 
♀ 12,517 
No data in 1995-2010 
♀ 1215 
18 had no data >1995 
16 had no data <2010 
1181 had no data  
No DOB 
reported 
♀ 4 
 
18 duplicates removed 
 
HIV- date/site  
61 pairs 
 
CD4>50 discrepant 40 –rejected: 1 
Ethnic discrepancy 0 - rejected: 0 
COB discrepancy 4 - rejected: 0 
Drug naive 9 - rejected: 0 
Death date - 0 rejected: 0 
 
1 duplicate removed 
59 
(2036) 
 n=14,170 
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CD4 ±30 days 
1767 
CD4 count ±10 
335 pairs 
 
295 
(2331) 
Pairs confirmed 
as a match 
(cumulative) 
Ethnic discrepancy 13 - rejected: 12 
COB discrepancy 28 - rejected: 15 
Drug naive 20 - rejected: 1 
Death date 0 - rejected: 0 
 
 
 
12 duplicates removed 
 
HIV- date/site  
82 pairs 
 
CD4>50 discrepant 58 – rejected: 3 
Ethnic discrepancy 2 - rejected: 1 
COB discrepancy 4 - rejected: 0 
Drug naive 8 - rejected: 0 
Death date 0 - rejected: 0 
 
2 duplicates removed 
 
821 pairs  
removed c 
76 
(2407) 
 n=6287 
Drug dates 
Exact start/stop dates (106) 
Start & Stop & Drug = 13 
Start/Stop & Drug = 80 (78) 
Start & Stop only = 0 
Start/Stop & Site = 1  
Start/Stop & Diagnosis date = 12 
  
104 (2511) 
Ethnic discrepancy 1 - rejected: 0 
COB discrepancy 6 - rejected: 1 
Death date 0 - rejected: 0 
 
 
 
1 duplicate removed 
 
Dates ± 7 days (66) 
Start & Stop & Drug = 0 
Start/Stop & Drug = 59 (55) 
Start & Stop only = 0 
Start/Stop & Site = 3 
Start/Stop & Diag date = 4 (2) 
  
Ethnic discrepancy 3 - rejected: 3 
COB discrepancy 8 - rejected: 2 
Death date 0 - rejected: 0 
 
 
 
1 duplicate removed d 
 
60 (2571) 
 n=7479 
317 pairs  
removed c 
 n=5806 
Figure 1 
cont. 
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 Linked pairs not 
identified as a match 
5185 pairs 
3207 UK CHIC records  
3345 NSHPC records  
 
 n=5806 
Site match (307) 
 
 
 
 
HIV diagnosis date & site = 
43  
  
Ethnic discrepancy 0 - rejected: 0 
COB discrepancy 0 - rejected: 0 
Drug naive 4 - rejected: 0 
Death date 0 - rejected: 0 
 
 
 
0 duplicates removed 
 
43      
(2614) 
Pairs confirmed 
as a match 
(cumulative) 
42 pairs  
removed c 
n=5721 
Manual Matching e  
(2631 fit at least one of these criteria) 
HIV diagnosis dates 
1. Exact match (16) 
2. Date v proxy date in same month (81) 
3. ±30 days (117) 
4. Date v proxy date in same year (175) 
5. Matching year only (277) 
9. Date missing from one or both (792) 
 
 Drug dates 
1. Start match (4) 
2. Stop match (1) 
3. Drug match (1) 
4. Start match ± 7 (20) 
5. Stop match ± 7 (1) 
6. Drug match ± 7 (3) 
 
 Soundex (264 ♀ in linked dataset have 
Soundex in NSHPC and UK CHIC) 
 
 ART profile indicates pregnancy 
Reason code = pregnancy (69) 
Started ART during pregnancy (623) 
Started ART during preg CD4 >350 (181) 
Started ZDVm during preg (14) 
 
Viral load 
Exact date and VL match (19) 
Exact date but ≠ VL (44) 
Date±7 and VL match (188) 
Date±7 but ≠ VL (918) 
 
 
 
215 (2829) 
358 pairs  
removed c 
Total matched records = 2823 (pregs = 4229) 
Pregnancies after which HIV was diagnosed were 
excluded (n=14), 6 were among women who only 
had 1 pregnancy so these women were excluded 
Figure 1 cont. 
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Figure 1 footnotes:  
a
  Women older than childbearing age were not excluded at this stage. 
b
  The maximum number of pairs with the same DOB was 88 where DOB  was 1
st
 January and 48 where 
DOB was not 1
st
 January.
  
c  
Pairs were removed as one or both records in the pair were confirmed as a match in a different pair.  
d  
These linked to multiple UK CHIC records which on examination were two records for the same woman. 
e
  The manual matching categories are not exclusive; they are categories which allow the reviewer to select 
records which can be manually assessed using multiple fields including site, HIV-diagnosis date, ethnicity, 
viral load dates and viral loads, COB, date of UK arrival and so on.  
Note that the discrepancy checks are hierarchical; if a woman had discrepant ethnicity and country of birth 
(COB), she would be excluded based on discrepant ethnicity and would therefore not be included in the 
COB discrepancies.  
 
After the creation of the final matched dataset it is cleaned and new variables are created.  
1. Creating variables using combined data  
HIV-diagnosis date 
Ethnicity 
Exposure 
2. Data cleaning 
Removing all pregnancies where HIV-diagnosed occurred after delivery 
(n=6) 
3. Deriving new variables (for each pregnancy) 
Timing of diagnosis before/during pregnancy  
ART use during pregnancy 
ART use prior to pregnancy  
ART experience at conception 
ART status at conception 
4. All women in UK CHIC – includes antenatal data from NSHPC for those with a 
pregnancy 
Date of starting ART for women’s own health 
Boolean variable indicating if they have started ART by the end of follow-up 
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Appendix VI  NSHPC and UK CHIC criteria used to assess ART use 
Table 1. Criteria used to assess ART use at conception 
Dataset Criteria n 
NSHPC Yes if PRETRT = Yes  531  
 
or PRETRT = No/NK  
P_DRUG_CON=Yes 
1 
 
or PRETRT=No/NK  
P_DRUGSTART<EDC  
P_DRUGSTOP≥EDC/null  
498 
No if PRETRT=No   1571 
NK if PRETRT=NK   19 
UK CHIC Yes if DSTART < EDC 
DSTOP ≥ EDC /null 
996 
NK if EARLIEST_DATE ≥ EDC                         
HIV diagnosis date < EDC 
123 
 
or  EARLIEST_DATE = null        
HIV diagnosis date < EDC 
0 
 
or SEEN_12MB4 = No                                 
Date HIV diagnosis < EDC
1
 
113
No  DSTART=Null/> EDC  1388 
DSTART: ART drug start date; DSTOP: ART drug stop date; EDC: Estimated date of conception; PRETRT: 
ART use at conception (Yes/No/NK); P_DRUG_CON: on specific ART drug at conception (Yes/No); 
SEEN_12MB4: Attended care at a UK CHIC site during the 12 months before conception (Yes/No).                    
1
Although these women were HIV diagnosed, there were no data in UK CHIC during the year prior to the 
pregnancy, it was not clear from the UK CHIC data whether or not they started ART during that period.  
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Table 2. Criteria used to assess ART status at 6 months before conception 
Dataset Criteria n 
NSHPC  Yes if P_DRUGSTART <EDC-6 months 
P_DRUGSTOP >EDC-6 months/null 
387 
 No if HIV diagnosis date > EDC-6 months                     862 
 NK   1371 
UK CHIC Yes  if DSTART <EDC-6 months 
DSTOP >EDC-6 months/null 
903 
 NK if 
or  
or  
EARLIEST_DATE > EDC-6months/null 
EARLIEST_date = null 
SEEN_12MB4 = No  
1061 
1 
170 
 No    485 
DSTART: ART drug start date (UK CHIC); DSTOP: ART drug stop date (UK CHIC); EDC-6 months: 6 
months before the estimated date of conception; P_DRUGSTART: ART drug start date (NSHPC); 
P_DRUGSTOP: ART drug stop date (NSHPC). SEEN_12MB4: attended care at a UK CHIC site during the 
12 months before conception (Yes/No). 
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Table 3. UK CHIC criteria used to assess ART status at 6 and 12 months after delivery  
Criteria Months after delivery 
 6 months 
n  
12 months 
n 
Yes if 
 
DSTART <6/12m post-delivery 
DSTOP ≥6/12m post-delivery 
660 588 
 
or DSTART <6/12m post-delivery 
DSTOP = null 
SEEN_12MB4 = Yes  
588 587 
NK if EARLIEST_DATE >6/12m post-delivery 56 46 
 or 6/12m post-delivery year ≥ 2010  324 469 
 or EARLIEST_DATE >6/12m post-delivery 
DSTART1 = null  
TRT = Yes or PRETRT = Yes 
58 53 
 or DSTART <6/12m post-delivery 
DSTOP = null  
SEEN_12MB4 = yes 
124 110 
No   810 767 
DSTART: ART drug start date; DSTOP: ART drug stop date; 6/12m post-delivery: the date 6/12 months 
after delivery; PRETRT: ART use at conception (Yes/No/NK); SEEN_12MB4: attended care at a UK CHIC 
site during the 12 months before conception (Yes/No); TRT: ART use during pregnancy (Yes/No).  
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Table 4. Criteria used to assess ART status during pregnancy 
Dataset Criteria n 
NSHPC Yes if P_DRUGSTART < EDC 
P_DRUGSTOP > EDC/null  
2421 
  or TRT=Yes  4 
  or TRT=null/NK  
NSHPC indicates ART use at 
conception 
28 
 No
1
 if  TRT=No  86 
 NK if  TRT=NK  81 
UK CHIC Yes  if DSTART<DELIVERY 
DSTOP=null/>DELIVERY  
2248 
 NK if  EARLIEST_DATE≥DELIVERY  79 
  or SEEN_6MB4=No 
SEEN_PREG=No  
49 
  or CHIC_on_ART_at_conc=No 
SEEN_PREG=No 
29 
 No   215 
CHIC_on_ART_at_conc: ART status at conception according to the UK CHIC data; P_DRUGSTART: ART 
drug start date; P_DRUGSTOP: ART drug stop date; TRT: ART use during pregnancy (Yes/No); 
SEEN_6MB4: attended care at a UK CHIC site in the 6 months prior to pregnancy (Yes/No); 
SEEN_PREG: attended HIV care at a UK CHIC site during the pregnancy (Yes/No).  
1
The outcomes for these pregnancies were: miscarriage (n=39); termination (n=16); and live birth (n=31). 
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Table 5. Criteria used for categorising ART use for each pregnancy (n=2620) 
 
ART use 
 
Category                  
of ART use 
 
n 
6 months 
before 
conception 
At 
conception 
During 
pregnancy 
6 months 
after 
delivery 
12 months 
after delivery 
- Yes Yes Yes Yes 
Long-term use 
623 
- Yes Yes NK Yes 0 
- Yes Yes Yes NK 81 
Yes NK Yes Yes Yes 1 
Yes Yes Yes
a
 NK NK 183 
- No/NK No - - No ART use 103 
No No Yes No No 
Short-course 
ART 
543 
NK No Yes No No 5 
No NK Yes No No 2 
No No Yes No NK 9 
No No Yes NK No 3 
Yes*/No/NK No/NK Yes
b
 Yes*/No Yes*/No 22 
Yes*/No/NK No/NK Yes
b
 Yes*/NK Yes*/NK 196 
Yes*/No/NK No/NK Yes
c
 No Yes 27 
Yes*/No/NK No/NK Yes
b
 Yes No 16 
No/NK No Yes Yes** Yes** 
Start long-term 
use 
382 
No No Yes NK Yes** 3 
No No Yes Yes** NK 20 
No/NK No/NK Yes
d
 NK NK/No 37 
No/NK No/NK Yes
d
 NK/No NK/Yes 6 
No/NK No/NK Yes
d
 Yes (preg) Yes (preg) 33 
No/NK No/NK Yes
d
 Yes No 12 
Yes/NK Yes Yes No No 
Long-term use 
(but interrupts 
after pregnancy) 
46 
Yes/NK Yes Yes No NK 4 
Yes/NK Yes Yes NK No 1 
Yes/NK Yes Yes No Yes 12 
Yes/NK Yes Yes Yes No 14 
Yes/NK Yes/NK Yes
a 
No/NK No/NK 15 
No Yes Yes
e
 No/NK No/NK 17 
Yes* No Yes
a
 - - 
Long-term use
 f
 
18 
No Yes Yes
a
 - - 8 
- - NK - - 
 
Not known 
67 
- - Yes NK NK 83 
All other combinations 28 
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Footnotes for Table 5 
Categories are hierarchical 
a
 Where start date for long-term ART use is before the pregnancy
 
b
 Where start date for long-term ART use is after the pregnancy or start_treatment=0 (i.e. they have not 
started long-term ART yet) 
c 
Where start date for long-term ART use is within 12 months after the pregnancy 
d 
Where start date for long-term ART use is during the pregnancy  
e 
Where start date for long-term ART use is within 6 months before the pregnancy 
f
 but interrupts before pregnancy – or there is no record of that ART use in UK CHIC  
* Woman does not have a pregnancy at this time  
** Woman does not have a pregnancy at this time or start date for ART during pregnancy 
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Steering Committee  
Jonathan Ainsworth, Sris Allan, Jane Anderson, Abdel Babiker, David Chadwick, 
Duncan Churchill, Valerie Delpech, David Dunn, Brian Gazzard, Richard Gilson, Mark 
Gompels, Phillip Hay, Teresa Hill, Margaret Johnson, Sophie Jose, Stephen Kegg, 
Clifford Leen, Dushyant Mital, Mark Nelson, Chloe Orkin, Adrian Palfreeman, Andrew 
Phillips, Deenan Pillay, Frank Post, Jillian Pritchard, Caroline Sabin, Achim Schwenk, 
Anjum Tariq, Roy Trevelion, Andy Ustianowski, John Walsh. 
Central Co-ordination 
University College London (Teresa Hill, Susie Huntington, Sophie Jose, Andrew 
Phillips, Caroline Sabin, Alicia Thornton); Medical Research Council Clinical Trials Unit 
at UCL (MRC CTU at UCL), London (David Dunn, Adam Glabay).  
Current collaborating sites 
Barts Health NHS Trust, London (Chloe Orkin, Janet Lynch, James Hand, Carl de 
Souza); Brighton and Sussex University Hospitals NHS Trust (Duncan Churchill, Nicky 
Perry, Stuart Tilbury, Elaney Youssef, Duncan Churchill); Chelsea and Westminster 
Hospital NHS Foundation Trust, London (Brian Gazzard, Mark Nelson, Rhiannon 
Everett, David Asboe, Sundhiya Mandalia); Homerton University Hospital NHS Trust, 
London (Jane Anderson, Sajid Munshi); King’s College Hospital NHS Foundation Trust, 
London (Frank Post, Ade Adefisan, Chris Taylor, Zachary Gleisner, Fowzia Ibrahim, 
Lucy Campbell); Medical Research Council Clinical Trials Unit (MRC CTU), London 
(Abdel Babiker, David Dunn, Adam Glabay); Middlesbrough, South Tees Hospitals 
NHS Foundation Trust, (David Chadwick, Kirsty Baillie); Mortimer Market Centre, 
University College London (Richard Gilson, Nataliya Brima, Ian Williams); North 
Middlesex University Hospital NHS Trust, London (Jonathan Ainsworth, Achim 
Schwenk, Sheila Miller, Chris Wood); Royal Free NHS Foundation Trust/University 
College London (Margaret Johnson, Mike Youle, Fiona Lampe, Colette Smith, Rob 
Tsintas, Clinton Chaloner, Samantha Hutchinson, Caroline Sabin, Andrew Phillips 
Teresa Hill, Sophie Jose, Alicia Thornton, Susie Huntington); Imperial College 
Healthcare NHS Trust, London (John Walsh, Nicky Mackie, Alan Winston, Jonathan 
Weber, Farhan Ramzan, Mark Carder); The Lothian University Hospitals NHS Trust, 
Edinburgh (Clifford Leen, Alan Wilson, Sheila Morris); North Bristol NHS Trust (Mark 
Gompels, Sue Allan); Leicester, University Hospitals of Leicester NHS Trust (Adrian 
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Palfreeman, Khurram Memon, Adam Lewszuk); Woolwich, Lewisham and Greenwich 
NHS Trust (Stephen Kegg, Akin Faleye, Dr Mitchell, Dr Hunter), St. George’s 
Healthcare NHS Trust (Phillip Hay, Mandip Dhillon, Christian Kemble); York Teaching 
Hospital NHS Foundation Trust (Fabiola Martin, Sarah Russell-Sharpe, Janet Gravely);  
Coventry, University Hospitals Coventry and Warwickshire NHS Trust (Sris Allan, 
Andrew Harte, Stephen Clay); Wolverhampton, The Royal Wolverhampton Hospitals 
NHS Trust (Anjum Tariq, Hazel Spencer, Ron Jones); Chertsey, Ashford and St.Peter’s 
Hospitals NHS Foundation Trust (Jillian Pritchard, Shirley Cumming, Claire Atkinson);  
Milton Keynes Hospital NHS Foundation Trust (Dushyant Mital, Veronica Edgell, Julie 
Allen); The Pennine Acute Hospitals NHS Trust (Andy Ustianowski, Cynthia Murphy, 
Ilise Gunder); Public Health England, London (Valerie Delpech); i-Base, London (Roy 
Trevelion). 
Funding  
From 2001 to 2014 the UK CHIC study received funding from the UK Medical 
Research Council (MRC) (Grant numbers G0000199, G0600337 and G0900274) and 
in August 2014, the MRC jointly awarded the UK CHIC study and the UK HDRD a 
further 5 years funding. I received a UCL studentship, funded by the MRC, for 
postgraduate work.  
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Appendix VIII The NSHPC collaborators 
Steering Committee  
M Cortina-Borja, A Brown, A de Ruiter, S Donaghy, S Farthing, K Harding, A Judd, L 
Logan, H Lyall, A Namiba, F Ncube, C Peckham (chair), L Primrose, C Thorne, P 
Tookey (PI), S Webb.  
Funding 
The NSHPC receives core funding from PHE (grant number GHP/003/013/003). The 
study was previously funded by the National Screening Committee (2011-2013) and 
the Welton Foundation (2011-2013). Data are collated at the UCL Institute of Child 
Health which receives a proportion of funding from the Department of Health’s National 
Institute for Health Research Biomedical Research Centres funding scheme.  
We gratefully acknowledge the contribution of the midwives, obstetricians, 
genitourinary physicians, paediatricians, clinical nurse specialists and all other 
colleagues who report to the NSHPC through the British Paediatric Surveillance Unit of 
the Royal College of Paediatrics and Child Health, and the obstetric reporting scheme 
run under the auspices of the Royal College of Obstetricians and Gynaecologists. 
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Appendix IX  Major drug resistance mutations in women who were ART-naïve or ART-experienced prior to 
starting life-long ART 
Major NRTI resistance mutations  
 Non-TAMS TAMS Additional 
 M184V M184I K65R K70E K70R L74V Y115F M41L D67N L210W T215F T215Y K219E V108I P225H 
Before starting treatment 
Naïve 4 1 2 1 2 - - 3 2 3 2 1 1 6 - 
Experienced a - - - - - 1 - - - - - - - - - 
Experienced b - - - - 1 - - 1 1 - 1 - - 1 - 
On treatment -  failed to achieve viral suppression within 6 months 
Naïve 3 2 - - - - - - - - - - - - - 
Experienced 1 - - - - - - - - - - - - - - 
On treatment – viral rebound following viral suppression  
Naïve 2 1 - - - - - - - - - - - - - 
Experienced 1 - - - - 1 - - - - - - - - - 
 
In women who start life-long ART with some prior use of ART experience, ‘Experienced a’ refers to a resistance test when ART naïve (prior to any reported ART use), 
‘Experienced b’ refers to a resistance test in the 12 months prior to starting life-long ART. Non-TAMS: Non-Thymidine analog mutations; TAMS: Thymidine analog mutations; 
Additional refers to Additional Accessory mutations. ‘Major mutations’ refers to mutations which are generally selected for f irst under drug pressure and which reduce drug 
susceptibility.   
 
4
4
9
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Major NNRTI resistance mutations 
 L100I K101E K103N K103S V106A V106M E138A E138G E138K E138Q Y181C Y188H Y188L G190A H221Y 
Before starting treatment 
Naïve 2 2 12 1 - 2 32 1 - 1 1 - 1 1 - 
Experienced a - - - - - - 1 - - - - - - - - 
Experienced b - - - - 1 - 2 - - - - - - - 1 
On treatment -  failed to achieve viral suppression within 6 months 
Naïve - 1 1 - - - 2 - - - 1 - - 2 2 
Experienced - - - - - - - - - - 1 - - - 1 
On treatment – viral rebound following viral suppression 
Naïve - - - - - 1 1 - - - - - - - - 
Experienced - - 1 - - - - - - - 2 - - 1 - 
 
Major Protease resistance mutations 
 D30N V32I M46L M46I Q58E L76V V82A V82S I84V N88S L90M 
Before starting treatment 
Naïve - - 2 - 5 - 1 - - 1 1 
Experienced a - - - - 1 - - - - - - 
Experienced b - - - - - - - - - - - 
On treatment -  failed to achieve viral suppression within 6 months 
Naïve  - - - - 1 - - - - - - 
Experienced  - - - - - - - - - - - 
On treatment - viral rebound following viral suppression 
Naïve - - 1 - - - - - - - - 
Experienced - - - - - - - - - - - 
 
4
5
0
 
 451 
 
Appendix X Mutations associated with resistance to ART drugs  
 
 
Source: Wensing et al. [102] 
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Source: Wensing et al. [102] 
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